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ABSTRACT 
 
Self-care is considered a means of meeting the challenge of providing care to 
patients with long-term conditions. However this has not achieved widespread 
penetration in the UK, the reasons for which are unclear. 
 
This research examined one area of self-care in depth - self-monitoring of oral 
anticoagulation therapy. The aim was to derive the requirements for an 
anticoagulation patient self-monitoring service from an analysis of the drivers for, 
the benefits of, the barriers to, and the challenges of establishing this service from 
the perspectives of key stakeholders – patients, healthcare professionals and 
healthcare managers.   
 
Qualitative and quantitative techniques - interviews, semi-structured questionnaire 
survey and focus groups  – were used to gain an in-depth understanding of their 
views. From triangulated results, the candidate requirements for an anticoagulation 
self-monitoring service were derived, presented in Donabedian’s framework: 
structure, process and outcome. Most of these requirements were then validated 
through a pilot self-monitoring service.   
 
All stakeholder groups supported anticoagulation self-monitoring. However, 
financial, clinical and legal barriers were identified. 
 
53% of surveyed patients were willing to undertake self-monitoring. However, only 
17% of respondents felt able to purchase a coagulometer, a significant barrier. Lack 
of confidence in the ability to self-test was also demonstrated. 
 
Healthcare staff welcomed self-monitoring as a way to increase capacity and support 
evolution in the healthcare landscape. There were concerns about affordability to all 
stakeholders, the potential for increased clinical risk through sharing care with 
patients, and a fear of litigation compounded by a lack of clarity in the medicolegal 
position.   
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Patient education and support were essential requirements, to prepare the patient, 
and on an ongoing basis. Primary care professionals felt expert support was 
essential for them to deliver this service. 
 
A definitive set of service requirements is proposed, and the implications of this 
research for other long term conditions discussed. 
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1. CHAPTER ONE: INTRODUCTION  
 
1.1. The case for patient self-care 
 
Providing care for people with long-term conditions is one of the greatest 
challenges facing healthcare providers. This is a large and growing group. Around 
15 million people in England – almost a third of the population - suffer from a 
long-term condition, and it is predicted that this number will rise by 23% over the 
next 25 years.1 
 
This predicted increase is largely due to people living longer. However, the rising 
incidence of some long-term conditions amongst younger people, related in part to 
lifestyle and obesity (e.g. diabetes), is a contributory factor. Because of increasingly 
sophisticated treatments, more illnesses are, in effect, becoming long-term 
conditions (e.g. HIV). The expected growth in this health burden will, therefore, be 
due to a larger number of people with one (or more) long-term conditions, but also 
partly due to the greater complexity of the care delivery and treatment of each 
condition.    
 
Not least of the challenges facing the National Health Service (NHS) is the financial 
one. It was estimated in 2008 that the treatment and care of those with those with 
long-term conditions accounts for 69% of the primary and acute care budget in 
England.1 A consequence of an ageing population is the changing balance between 
the number of persons working and the number of those who are in retirement, 
decreasing the number of people contributing financially to healthcare provision for 
an increasing number of those no longer working. 
 
The challenge of providing care to those with a long-term condition has prompted 
healthcare providers to re-assess how services are designed and delivered. The NHS 
has focused on altering the ‘delivery system’, targeting the level of care according to 
need. Supporting those with long-term conditions can be conceptualised as a three-
level delivery system: case management, disease management and supporting self-
care.2 This builds on what is known as the Kaiser Permanente chronic disease 
management triangle and is shown below.  
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              Figure 1: Kaiser Permanente Chronic Disease Management Triangle3  
 
Level 3 of this model, case management, focuses attention on those high intensity 
users of the service for whom a lead case manager in the community will be 
nominated to better co-ordinate health and social care services, to anticipate and 
hopefully to prevent disease escalation. 
 
Level 2 involves the alignment of multi-professional teams through National Service 
Frameworks to provide optimally effective care to patients needing regular health 
professional involvement, that follows evidence based guidelines and efficient care 
pathways. 
 
Level 1, embracing patient self-care or self-management, is perhaps the most 
innovative, and involves “helping individuals and their carers to develop the 
knowledge, skills and confidence to care for themselves and their condition 
effectively”. This level of the triangle has the potential to make the greatest 
difference to chronic condition management, as it covers 70-80% of the long-term 
condition population (as estimated by the Department of Health3). Even small 
increases in the number of people self-caring could therefore have a huge impact on 
the demand for (and cost of) healthcare services. It is also, arguably, the least well 
developed level thus far, and might require significant learning and innovation in 
order to identify optimal ways to foster good quality and well-accepted self-care 
services. 
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Self-care has been enshrined in health policy in the UK since the 1999 White Paper 
Saving lives: our healthier nation,4 which set out the then newly elected Labour 
government’s public health strategy. This was swiftly followed by the establishment 
of the Expert Patients Programme (EPP), which was largely based on the work of 
Kate Lorig, head of the Chronic Disease Self-Management Program in California. 
By 2005, self-care was a major component of British health policy.5 
 
Aside from the predicted benefit of reduced use of health services, self-care may 
also bring benefits to the patient. These include improved quality of life and well-
being,  increased life expectancy and greater independence and symptom control.5 
For example, diabetes self-management has been shown to improve glycaemic 
control and dietary habits.6 
 
However, despite being enshrined in government policy, and the benefits it may 
bring to healthcare providers and patients, services to support patient self-care are 
not widespread. The reasons for this are not clear and warrant further investigation. 
Focusing on one area of self-care in depth - patient self-monitoring of oral 
anticoagulation therapy – this research will investigate why its rate of adoption 
remains low in the UK, despite it being technically feasible for many years. It will 
aim to identify the drivers for, the benefits of, the barriers to, and the challenges of 
establishing and delivering an oral anticoagulation patient self-monitoring service 
from a multi-stakeholder perspective. From these perspectives, a set of 
requirements of a service designed to support patient self-monitoring of oral 
anticoagulation will be derived. Finally, a patient self-testing pilot will be developed, 
implemented and evaluated to test these requirements.  
 
The focus of the research will be to identify the factors that will ensure the quality 
and the acceptability of oral anticoagulation patient self-monitoring to the key 
stakeholders. Although any emerging issues will be discussed in the thesis, a detailed 
examination of the legal issues and the cost-effectiveness of an oral anticoagulation 
patient self-monitoring service is beyond the scope of this investigation.  
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It is not clear if an identical set of drivers, benefits, barriers and challenges will be 
applicable to other long-term conditions. Many of these conditions will require 
some form of daily treatment; will require the frequent monitoring of one or more 
physiological parameters to maintain stability and optimal functional capability; may 
require the monitoring of other parameters to detect complications; may be 
influenced by lifestyle behaviours as well as by treatments; and will have outcomes 
that are influenced by the quality of care provided. The configuration of self -
monitoring services might plausibly have some common features. The research 
therefore proposes to examine these issues for one condition in detail, and then to 
discuss if some of the findings may be generalised to other conditions. 
 
1.2. The case for patient self-monitoring of oral anticoagulation 
 
Some long-term conditions (e.g. atrial fibrillation) require the person to take lifelong 
oral anticoagulation therapy (OAT), usually warfarin. Managing oral anticoagulation 
entails many of the facets of managing a long-term condition as mentioned above. 
Treatment is often lifelong. Patients need to adjust their diet and lifestyle to 
minimise the risk of adverse effects from treatment. There is normally some input 
from healthcare professionals, and this is often focused on patient education – for 
example, monitoring of disease indicators and skills development – and ongoing 
support.  
  
Warfarin’s narrow therapeutic range and unpredictable patient response means that 
a fixed dose cannot be given to every patient and clinical expertise is needed to 
titrate the dose to response. Because of this narrow range, treatment monitoring by 
measurement of the patient’s International Normalised Ratio (INR) from a small 
sample of blood is mandatory.  INR monitoring is usually done by a healthcare 
professional. However, self-monitoring of oral anticoagulation treatment – where 
the patient measures their own blood INR on a small hand-held machine – is an 
alternative model of care for patients taking OAT. After measuring their INR, the 
patient can either seek dosing advice from a healthcare professional or they can 
decide on the appropriate dose of warfarin on the basis of personal experience, or 
supported by written or computerised guidance.  
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In Germany, this model of monitoring has been better adopted, with 160,000 
patients self-monitoring their oral anticoagulation as of 2010.7 However, the UK has 
not widely embraced this model of care.  
 
On the face of it, the lack of interest in OAT patient self-monitoring in the UK is 
surprising. In addition to the widespread interest in promoting general patient self-
care, there are other, more specific drivers for patient self-monitoring of OAT: the 
technology to facilitate patient self-monitoring is available; published evidence is 
available to support its safety; there is widespread support for shared decision-
making and there are models of successful self-care for other long-term conditions. 
Thus, one would expect the NHS to pursue a model of care whereby patients 
assume responsibility for testing their INR.  
 
Research is needed to investigate how this form of monitoring may be more widely 
adopted and to specify the requirements for a patient self-monitoring service which 
would be acceptable to patients, clinicians and managers. Until the drivers for, the 
benefits of, the barriers to, and challenges of, setting up an OAT patient self-
monitoring service are established, including its factors influencing acceptability to 
patients and healthcare professionals, it is difficult to find the best way of migrating 
from the current model of care (where clinicians carry out the monitoring) to a self-
monitoring service where patients take responsibility for self-testing and perhaps 
self-management (i.e. adjusting their dosage). 
 
1.3. A framework for specifying a patient self-monitoring service 
 
The requirements for a patient self-monitoring service need to be formally 
organised. A framework to specify a patient self-monitoring service, that 
accommodates the perspectives and needs of the major stakeholders, is required at 
the outset for a number of reasons: 
 
i. To support the design of the service  
ii. To specify the processes that will support implementation of the service 
iii. To establish the measures used to assess the quality of the service  
iv. To cultivate a shared view of the service across these stakeholder groups 
v. To define and connect components of the service 
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As a successful patient self-monitoring service for anticoagulation will need to be of 
demonstrably high quality as well as empowering patients, the quest for a high 
quality service lies at the heart of specifying this framework.  
 
The goal of the NHS in adopting the three level Kaiser Permanente Triangle is to 
improve the quality of care for patients with long-term conditions. (Although 
reduced cost is probably an additional desired outcome, this is not presented as a 
driver behind its strategy to enhance self-care.) However, quality is multi-
dimensional and defining it is problematic. Although stressing the goal of improving 
quality, the Department of Health does not define what it means by quality in either 
the NHS Improvement Plan or in the report Supporting People with Long Term Conditions. 
There is no single, universally accepted definition and, in an effort to elucidate the 
concept, experts have developed broad conceptual frameworks to describe it in a 
systematic way. 
 
1.3.1. Conceptual frameworks for describing quality 
 
In 1998, the Institute of Medicine (IOM) in the USA launched an initiative to assess 
and improve the nation's quality of healthcare with the formation of the Committee 
on Quality of Health Care in America. Its seminal report, Crossing the Quality Chasm: 
A New Health System for the 21st Century, outlined a strategy to improve the quality of 
care over ten years.8  
 
This report defines the following six broad aims for improvement earmarked for 
21st century health care systems: 
 
i. Safety 
ii. Effectiveness 
iii. Patient centeredness 
iv. Timeliness 
v. Efficiency 
vi. Equity 
 
The chasm in the title of the report refers to the one that exists between the current 
and future healthcare system, and the framework described in the report is a set of 
recommendations aimed at bridging this gap to build a stronger healthcare system. 
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These aims describe the major quality categories for describing a good health 
service, but could they be applied to describe a specific clinical service?  
Considering these aims from the perspective of oral anticoagulation patient self-
monitoring, five of these six quality considerations can be readily mapped to this 
service: 
 
Safety: optimising the time each patient spends within the therapeutic range, to 
maximise the benefits of anticoagulation and to minimise the risks of treatment.  
Effectiveness: ensuring that care is based on systematically acquired evidence and 
will result in better outcomes than alternative models 
Patient centeredness: ensuring that the service meets the needs of patients  
Efficiency: ensuring that the service is cost effective compared with current service 
models. 
Equity: enabling all patients to take advantage of self-monitoring if their clinical 
situation permits, regardless of cultural background or financial circumstance. 
 
The remaining aim – timeliness, defined in the report as relating to patient waiting 
times – is not readily applicable. A successful patient self-monitoring service will 
eliminate the need to wait for a service to be provided. This quality aim is therefore 
not directly applicable to this research, except to note that it can be met. 
 
In 2002, the Nuffield Trust commissioned an appraisal of the quality agenda in the 
NHS in the UK as set out by the Labour Government in their policy documents.9 
As part of this appraisal, a conceptual framework was developed to provide a basis 
for the evaluation. This framework comprises of four levels, described in Table 1. 
 
 Functional level of 
healthcare system 
Generic function 
TIER 1 National Policy formulation and infrastructure 
TIER 2 Regional Performance monitoring and management 
TIER 3 Institutional Operations management 
TIER 4 Individual Clinical service provision and individual 
accountability 
 
Table 1: Conceptual model for the NHS Quality Agenda 
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A patient self-monitoring service maps to Tier 4 of this model. The authors of this 
report do not single out specific quality characteristics of this tier that might be used 
in this research. They do, however, review definitional models of quality and 
conclude proposing a set of six domains that closely resemble the IOM six aims 
quoted above: 
 
i. Access 
ii. Effectiveness 
iii. Equity 
iv. Responsiveness and patient centeredness 
v. Safety  
vi. System capacity 
 
On an international level, the Organisation for Economic Co-operation and 
Development (OECD) has set out a conceptual framework for their Health Care 
Quality Indicator (HCQI) project.10 The aim of the HCQI project was to develop a 
set of indicators for comparing the quality of health care across the 23 participating 
OECD countries, including UK, USA, Canada and Australia. To do this, a 
conceptual framework outlining the dimensions of quality to be measured, was 
developed from quality indicators already developed in member countries. This 
framework is shown in Figure 2. 
 
From the perspective of patient self-monitoring, the closest corresponding 
healthcare need in the HQI model is “Living with illness or disability”. The three 
quality dimensions of healthcare performance: effectiveness, safety and patient-
centeredness, map to three of the six IOM domains. 
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Figure 2: Conceptual framework for the OECD HQI project 
 
In conclusion, the quality domains in the conceptual model for the NHS quality 
agenda and the OECD framework are largely based on those used by the IOM. 
Although these aims were informative on quality, they were unlikely to map fully to 
the envisaged anticoagulant self-monitoring service, and would have been less useful 
to categorise and connect these service requirements. Two of the domains – 
timeliness and effectiveness – were likely to be redundant categories. Establishing a 
self-monitoring service eliminates the need to wait in clinic, and thus obviates the 
need to formally measure timeliness. And although, the effectiveness of the service 
is considered, in terms of its evidence base, when establishing a service, it is less 
helpful in assessing a service once it is operational. Additionally, if the IOM 
framework was used, some of the service categories could have conceiveably  
straddled multiple categories. 
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1.3.2. Using Donabedian’s framework to specify a patient self-monitoring 
service 
 
All of these quality frameworks - the NHS Quality Agenda, the IOM’s Crossing the 
Quality Chasm and the OECD’s Health Care Quality Indicator (HCQI) project - are 
explicitly underpinned by the use of the Donabedian triad, which is widely used in 
healthcare research to measure the quality of services. Avedis Donabedian, regarded 
as the father of assessing quality, developed the structure-process-outcomes triad11 
that classifies measures of quality into three broad categories:  
 
i. Structure – measuring service elements 
ii. Process – measuring service activities 
iii. Outcome – measuring health and system status 
 
Each component has a direct influence on the next: for example in anticoagulation 
monitoring, clinicians (structure) monitoring OAT effectively (process) will result in 
good INR control (outcome). Donabedian’s triad was adopted in this research as a 
framework to define the requirements of a service model for OAT patient self-
monitoring for the following reasons. 
 
Firstly, this framework would not only guide the development of, but would also 
provide a framework to evaluate the patient self-monitoring service. 
 
Secondly, it was felt that a framework based on Donabedian’s triad would be 
dynamic and adaptive to change, providing scope for fine-tuning if necessary – for 
example, the addition of sub-classes. 
 
Thirdly, there was evidence of its use in defining the characteristics of other service 
models. As an example, Canadian researchers have used this framework to develop 
a service model of primary health care (PHC) rehabilitation for arthritis.12 Using 
Donabedian’s triad as a framework for their literature review, they described the 
best practice approaches for PHC rehabilitation and from this, and from interviews 
with key informants (healthcare professionals who had a role in caring for this 
group of patients), developed a conceptual model for the delivery of PHC 
rehabilitation services for those with arthritis. 
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Finally, the author was familiar with the model, having used it to define the quality 
standards for a community pharmacy-led anticoagulation monitoring service.13 
 
 The elements of this triad – structure, process and outcome –are described in Table 
2, with some examples of how these elements might be applied to specifying OAT 
patient self-monitoring. 
 
Element Description Examples 
Structure Resources required to deliver the 
service. Include healthcare staff, 
patients and carers and 
organisational resources. 
- Healthcare staff supporting 
patient self-monitoring 
- Patients undertaking self-
monitoring 
- The coagulometers used by 
patients to measure the INR 
Process Activities undertaken to provide 
care to patients 
- Management of an OAT 
patient self-monitoring 
service 
- Educating self-monitoring 
patients 
- Referral procedures when 
patients become unstable 
Outcome Desired states resulting from the 
care process. Can be sub-divided 
into technical and interpersonal 
outcomes 
- Self-monitoring patients 
achieved good therapeutic 
control 
- Patients are satisfied with 
the service 
- The service is cost-effective 
 
Table 2: Description of Donabedian's framework and its application to OAT 
patient self-monitoring 
 
The success of this framework for presenting the requirements for the OAT patient 
self-monitoring service will be discussed in Chapter 9.  
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1.4. Setting the scene - a personal history 
 
I set out on this journey at the start of 2006. As a pharmacist working in a hospital-
based anticoagulation service, my interest was to understand the long-term future of 
this service and the steps the Trust needed to take to ensure it was responsive to 
changing patient expectations, government initiatives and technological innovations. 
My starting point was to explore the area of patient self-monitoring, which, though 
not currently provided by the Trust, fits in with the direction of travel of the 
Anticoagulation Monitoring and Stroke Prevention Service. I reviewed the literature 
on patient self-monitoring of oral anticoagulation and then broadened my reading 
to include government policy documents on patient self-care, along with literature 
on self-care initiatives for a range of chronic conditions. 
 
My initial plan was to set up a pilot patient self-monitoring project at the Trust, 
which would provide a basis for redesigning our service to support patients who 
elect to self-monitor. It quickly became clear that this would be more difficult than 
it first appeared. Self-monitoring for those on OAT poses issues which have not 
been highlighted or addressed for other chronic conditions. A service which caters 
for OAT patient self-monitoring would necessarily entail changes in clinical roles, 
relationships between clinicians and patients, and methods of organising workflows. 
Although there was a body of evidence to demonstrate the safety of an oral 
anticoagulation patient self-monitoring service, there was very little in the literature 
to help in the redesign of service delivery. I realised that in order to derive the 
requirements for an oral anticoagulation patient self-monitoring service, empirical 
research exploring the perspectives of the key stakeholders was needed. 
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1.5. Explanation of terms used in this thesis 
 
It was felt that it was important from the outset to define the key terms and 
abbreviations used in this thesis. These are as follows. 
 
Oral anticoagulant treatment (OAT). A group of drugs which slow down the 
rate of blood clotting by antagonising vitamin K. The most common OAT used in 
the UK is warfarin. 
 
International normalised ratio (INR). A test that measures how long it takes 
blood to clot. It is used to monitor warfarin treatment. 
 
Patient self-monitoring. An all-embracing term suggesting that the patient 
measures their INR with a portable device. When self-monitoring, the patient can 
then either self-test or self-manage. 
 
Patient self-testing (PST). The patient measures their INR, but the dose is 
decided by a healthcare professional.  
 
Patient self-management (PSM). Analogous to diabetic self-care, PSM involves 
the patient measuring their INR at a convenient location, then interpreting the 
result, and altering their warfarin dose as appropriate. 
 
Near-patient testing (NPT). Diagnostic testing performed near, or at, point of 
care. Also known as point-of-care testing (POCT). 
 
National Health Service (NHS).  The publicly funded healthcare system in the 
UK, which provides treatment free at the point of care. 
 
General practitioner (GP). A primary-care physician whose practice covers a 
variety of medical problems in patients of all ages. 
 
Primary Care Trust (PCT). Organisation within the NHS that commissions 
primary, community and secondary care from providers. 
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1.6. Content of this thesis 
 
The chapters in this thesis are set out in Table 3: Thesis chapters and a description 
of their content, along with a brief description of the contents of each chapter. 
 
 Chapter heading Description 
1 Introduction Introduces the subject area, and the need 
for the research to be undertaken. 
2 Background Provides the context for the research and 
defines the research problem. 
3 Literature review Summarises and critically evaluates the 
relevant bodies of literature, to identify 
where gaps exist and provide justification 
for the research. 
4 Materials and methods Sets out the aims and objectives of the 
research. Defines the methodological 
approach taken, instruments used and the 
environment in which the research was 
conducted. 
5 Patients’ perspectives of self-
monitoring of oral 
anticoagulation 
Describes how patients’ perspectives 
were evaluated and analysed, and 
presents the results. 
6 Healthcare personnel’s 
perspectives of patient self-
monitoring of oral 
anticoagulation 
Describes how the views of those 
delivering and commissioning oral 
anticoagulant monitoring were evaluated 
and analysed, and presents the results. 
7 A validation of a set of 
candidate requirements for an 
OAT patient self-monitoring 
service 
Describes how a PST pilot service was 
developed, implemented and evaluated to 
validate a set of candidate service 
requirements derived from the empirical 
work. 
8 Requirements for an oral 
anticoagulation patient self-
monitoring service 
Presents the validated requirements as an 
OAT patient self-monitoring service 
blueprint. 
9 Discussion Summarises the key findings from the 
empirical work undertaken, describes any 
limitations and makes recommendations 
for future work. 
10 Conclusion Provides a final short summary of the key 
messages from the thesis 
 
Table 3: Thesis chapters and a description of their content 
 
The next chapter sets out the context for this investigation and defines the research 
problem. 
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2. CHAPTER TWO: BACKGROUND  
 
The last chapter set out the case for patient self-care, with a focus on patient self-
monitoring of oral anticoagulation.   
 
This chapter takes a closer look at patient self-monitoring of OAT. It will consider 
the clinical management issues relating to OAT, and how the challenges of 
monitoring treatment, and technological, economic and Governmental policy 
drivers have led to the development of alternative models of service delivery, 
including patient self-monitoring. 
 
2.1. An overview of the Clinical Management Issues Relating to 
Oral Anticoagulant Treatment 
 
2.1.1. Introduction 
 
Oral anticoagulants have been the mainstay of prevention and treatment of 
thromboembolic disease for over 50 years. This class of drugs acts by slowing down 
the blood clotting process, preventing clots from forming.14 The most commonly 
used oral anticoagulant in the UK, and worldwide, is warfarin. Other less commonly 
prescribed oral anticoagulants include phenindione and nicoumalone 
(acenocoumarol).  
 
Oral anticoagulant treatment (OAT) is used to reduce the risk of thromboembolism 
in a wide variety of clinical conditions. Since the first clinical use of these agents in 
the 1950s, indications for therapy have been subject to changes in medical 
knowledge and attitudes. An overview of current indications, as recommended by 
the British Committee for Standards in Haematology, is shown in Table 4.15 
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Pulmonary embolus 
Proximal deep vein thrombosis 
Calf vein thrombosis 
Recurrence of venous thromboembolism 
Symptomatic inherited thrombophilia 
Antiphospholipid syndrome 
Non-rheumatic atrial fibrillation 
Atrial fibrillation due to rheumatic heart disease, congenital heart disease and 
thyrotoxicosis 
Cardioversion 
Mural thrombus 
Cardiomyopathy 
Mechanical prosthetic heart valve – aortic 
Mechanical prosthetic heart valve – mitral 
Bioprosthetic heart valve 
Arterial grafts 
Coronary artery thrombosis 
 
Table 4: British Committee for Standards in Haematology: Indications for oral 
anticoagulation 
 
2.1.2. The challenges of OAT monitoring 
 
The management of patients on long term OAT poses clinical challenges for 
healthcare providers.  
 
Although warfarin is a highly effective drug, it has a narrow therapeutic range - i.e. 
there is a relatively small margin between efficacy and toxicity - and there is huge 
variation in response to a given dose both between individuals and within the same 
individual. This means that a fixed dose cannot be given to every patient and, 
instead, the dose must be titrated to response, to achieve a balance between the risk 
of stroke or venous thrombosis (under-treatment) and risk of bleeding (over-
treatment).  
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Adverse effects associated with warfarin are listed in Table 5. 
Haemorrhage 
Hypersensitivity 
Rash 
Alopecia 
Diarrhoea 
Skin and soft tissue necrosis 
Cholestatic liver damage 
Priapism 
Nausea and vomiting 
Pancreatitis 
 
Table 5: Adverse affects associated with warfarin16 
 
Bleeding is the most serious complication of treatment. Although numerous studies 
have demonstrated that the risk of bleeding is directly related to the INR, 
determining the true incidence of bleeding complications associated with OAT has 
been difficult. Definitions of the occurrence and severity of bleeding have differed 
between studies, and there has been a lack of consistency in anticoagulant initiation 
doses used.  
 
A review of bleeding complications associated with oral anticoagulant treatment 
reported bleeding rates of 0 – 4.8% for fatal bleeding and 2.4 to 8.1% for major 
bleeding.17 In another review of observational studies, the average annual rates of 
fatal and major bleeding were 0.8% and 4.9% respectively.18 A meta-analysis of 33 
studies involving patients receiving OAT for the treatment of venous 
thromboembolism with more than six months of follow-up reported a rate of fatal 
major bleeding as 13.4%.19 
 
Although rare, patients can demonstrate a resistance to warfarin and may require 
doses 5 – 20 times greater than usual achieve a therapeutic effect.20An ongoing 
study is attempting to define the genetic and environmental factors that determine 
variability in response to warfarin.21 The proposed outcome would be the 
development of an algorithm, accounting for genetic and environmental factors, 
which would help clinicians to better individualise anticoagulant therapy.  
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Variations in vitamin K availability – for example, as a result of low vitamin K diet 
or malabsorption - can also cause individuals to respond differently to OAT. 
However, the most common cause of inter-individual variation in response is due to 
pharmacokinetic differences, particularly the extent of plasma protein binding of 
warfarin and variations in liver enzyme activity.22 This is explained further below. 
 
Warfarin has complex pharmacokinetics, which complicate its management. It is 
completely and rapidly absorbed from the GI tract. However, there are considerable 
variations in the rate and extent of absorption between different commercially 
available tablets.23 Although warfarin reaches a peak concentration in the blood 
stream within one hour, there is a marked delay in it exerting its effect. This is 
because whilst oral anticoagulants inhibit the synthesis of clotting factors in the 
liver, they have no effect until existing clotting factors are catabolised, a process that 
can take several days to complete.24 As the effects of a single dose of warfarin are 
not observed until some time after that dose is ingested, dose titration can be 
problematic. 
 
Many other factors can affect a patient’s response to warfarin, including interacting 
drugs, diet, concurrent diseases and age. 
 
Warfarin is very highly bound to plasma proteins – up to 99.5%. When other drugs 
are introduced which are also highly bound to plasma proteins – for example non-
steroidal anti-inflammatory drugs (e.g. ibuprofen, aspirin) – these drugs can 
compete for the binding sites and displace warfarin, making more warfarin available 
in the circulation, resulting in an increase in the INR. 
 
Warfarin is extensively metabolised in the liver by the enzyme cytochrome 
P4502C9.25 Metabolism is very important for removing drugs from the body. If this 
process did not occur, warfarin would not be removed and its effects would persist 
for a very long time. However, certain drugs can “induce” cytochrome P450 by 
enhancing its rate of synthesis or reducing its rate of degradation. Conversely, other 
agents can “inhibit” cytochrome P450. Therefore when warfarin is administered 
with drugs that either induce or inhibit this enzyme, its effects can be reduced or 
enhanced respectively. 
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Alcohol consumption also affects anticoagulant control. Whilst a regular modest 
intake is unlikely to cause any problems, acute excessive intake enhances the effect 
of warfarin. Conversely, regular heavy drinking reduces the effects of warfarin. 
 
Oral anticoagulants act by antagonising the effect of vitamin K, which plays a 
crucial role in the formation of clotting factors. Therefore, any changes to dietary 
vitamin K content are likely to affect its action. Foods that are high in vitamin K, 
including broccoli, spinach, liver and cabbage, can reduce or negate the effects of 
warfarin. Nutritional supplements containing vitamin K can also reduce the effect 
of warfarin. 
 
Concurrent disease also affects response to warfarin. Congestive cardiac failure, 
hyperthyroidism, cholestasis and renal impairment may all increase its effects.26 
 
Finally, individuals demonstrate increasing sensitivity to warfarin with age, and a 
reduced dose may be required.25  
 
Therefore, monitoring treatment by regular measurement of the patient’s 
International Normalised Ratio (INR) from a small sample of blood is mandatory. 
 
2.1.3. Monitoring oral anticoagulant treatment 
 
The INR is a measurement of how long it takes for the blood to clot, and each 
patient’s treatment plan states the INR at which they should be maintained. A 
healthy person who is not taking warfarin should have an INR of around 1.0. The 
target INR for those on warfarin is most commonly 2.5 or 3.5 depending on the 
indication. The British Committee for Standards in Haematology makes 
recommendations on these target INRs15, and some of the common indications and 
target INRs are shown in Table 6. It should be noted though that these target INRs 
are only recommendations, and they may be tailored to the patient; for example, the 
target may be reduced if the patient has frequent nosebleeds. 
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Indication Target INR 
Pulmonary embolus 2.5 
Deep vein thrombosis 2.5 
Recurrence of venous thromboembolism whilst taking warfarin 3.5 
Symptomatic inherited thrombophilia 2.5 
Antiphospholipid syndrome 2.5 
Atrial fibrillation 2.5  
Mechanical prosthetic heart valve - aortic 2.5 or 3.0 
Mechanical prosthetic heart valve - mitral 3.0 or 3.5 
 
Table 6: British Committee for Standards in Haematology: Recommended target 
INRs for common indications for oral anticoagulation15 
 
2.2. Current model for monitoring oral anticoagulation 
 
In the UK the need for frequent monitoring and close patient follow-up has been 
met by dedicated anticoagulant clinics. Despite policy initiatives to foster shared 
care with patients, the predominant model of care for patients receiving warfarin is 
still a paternalistic one.  
 
In a paternalistic model the clinician holds the knowledge and decides on the 
treatment choice. Characteristically, there is little or no discussion of alternative 
options with the patient complying with this clinician-directed standard, assuming a 
largely passive role.  It is assumed that the clinician will make the best treatment 
decision for the patient without involving them in the decision making process. This 
is in stark contrast to a more contemporary, collaborative model, where decision-
making is shared, grounded in the expertise and experience of both patient and 
clinician.27 
 
The monitoring process for OAT is summarised in Figure 3. The patient attends an 
anticoagulation monitoring service at an outpatient hospital clinic, where the INR is 
measured using capillary or venous citrated blood samples. Dosing 
recommendations are made by a healthcare professional -  doctors, nurses, and 
pharmacists - and the patient is given a date for the next appointment. 
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Patient attends 
appointment 
antcoagulation 
monitoring service
INR measured using 
capillary or venous 
citrated blood sample
Dosing 
recommendation 
made by healthcare 
professional
Patient given date 
for next 
appointment
 
 
 
 
Figure 3: The general process for anticoagulation monitoring 
 
How frequently a patient attends clinic for anticoagulation monitoring depends on 
the stability of their INR blood result – i.e. if their INR is within their target range a 
longer time interval to their next appointment is acceptable. Time intervals between 
clinic appointments range from one to twelve weeks. 
 
The challenge of providing anticoagulation monitoring services in secondary care, 
both in terms of meeting demand and organisationally, is considerable. It has been 
estimated just under a million people in the UK are taking warfarin, and this 
number is predicted to increase still further.28 The main driver behind the increase in 
the number of patients prescribed warfarin is published trial data proving the 
effectiveness of the drug in preventing stroke in those with atrial fibrillation (AF). 
 
Atrial fibrillation is associated with an increased risk of thrombotic stroke and 
increased mortality. The substantially increased use of warfarin in the 1990s was 
predicated on robust evidence for the use of adjusted dose warfarin to reduce the 
risk of stroke. A pooled analysis of five randomised controlled trials (RCTs) 
demonstrated a stroke risk reduction of 68%, compared to aspirin, when warfarin 
was used.29  
 
AF is predominantly a disease of the elderly; its prevalence increases from 0.5% in 
those 50 – 59 years, to approximately 9% in those aged over 70 years.30 With an 
increasingly elderly population, the need for warfarin for stroke prevention 
increases.  
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In a UK survey conducted in 2005 nearly three quarters of anticoagulant clinics 
surveyed stated that their patient numbers had increased by up to 25% in the 
preceding two years.31 Eighty-six per cent of the clinics expected demand to increase 
still further over the next year, and 17% of clinics surveyed were considering 
limiting the number of new patients to cope with the increase in demand. 
 
In addition to burgeoning numbers, from an organisational point of view, 
traditional management of OAT is far from ideal. OAT management is a distributed 
service:  patients are not necessarily hospitalised at the start of therapy, and the 
planning, implementation and monitoring of care take place at different places and 
at different times. Patients on OAT frequently have concurrent diseases, again 
managed by different people at different places, and it is easy for care to become 
fragmented, leading to sub-optimal care.32 
 
A consequence of fragmentation of care is fragmentation of knowledge amongst the 
different healthcare professionals caring for that patient. Potentially, this may lead to 
an individual clinician having a relatively narrow understanding about a patient’s 
total health care.  Good communication is a vital component of any anticoagulation 
monitoring service, and breakdowns in communication can occur.  
 
Distributed care also raises questions as to where liability rests when things go 
wrong.  
 
2.3. Drivers for the development of INR monitoring services in 
primary care 
 
These two issues – the need to increase INR monitoring capacity and the existing 
fragmented care -  have raised questions about how, and where, warfarin monitoring 
should be undertaken. Consequently, new models of service delivery have been 
developed. 
 
Increasingly, INR monitoring clinics are being held in primary care. Two factors 
have made this a feasible option; reforms in the National Health Service (NHS) 
financial system and the development of reliable & portable near patient testing 
(NPT) devices. These factors will now be considered. 
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2.3.1. Reforms in the NHS financial system  
 
Payment by Results (PbR), which was fully implemented in England in 2008/9, has 
been a key driver in NHS financial system reform, and has also been instrumental in 
commissioning of anticoagulant monitoring services in primary care. Under PbR, 
hospitals are paid a fixed price for each treatment carried out. The Department of 
Health has drawn up a list of procedures, each with its own Healthcare Resource 
Groups (HRG) code. The price of each HRG procedure or treatment is fixed in 
relation to a national tariff, based on its average cost across the NHS. 
 
When PbR was first introduced, a hospital anticoagulation monitoring service was 
considered expensive, costing the commissioning Primary Care Trust (PCT)  £207 
for a first appointment and £110 for each subsequent visit (June 2007). This made 
primary care monitoring financially attractive to PCTs. However, the hospital tariff 
price for anticoagulation monitoring service has fallen significantly over the last 
three years, challenging the economic basis for the shift to primary care monitoring.  
 
2.3.2. The technology supporting monitoring INR in primary care 
 
Point-of-care testing (POCT), or near-patient testing (NPT), is “diagnostic testing 
performed at or near the point of patient care”.33 The development of portable, 
accurate, affordable NPT devices – coagulometers - for measuring INR has meant 
that it is no longer necessary to bring the patient to the hospital for anticoagulation 
monitoring. 
 
Coagulometers are small lightweight devices that use freeze-dried thromboplastin 
reagents incorporated in strips or cuvettes. When a drop of fresh capillary blood is 
applied to a pre-warmed reaction chamber, the thromboplastin starts to aid 
formation of a blood clot. The instrument then detects the formation of the clot. 
The clotting time, the time from the beginning of the reaction to clot detection, is 
then converted to an INR by a microprocessor.34  
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Lucas35 established the validity of measuring prothrombin time from a whole-blood 
capillary blood sample, kick-starting the development of NPT machines for 
monitoring oral anticoagulation. The prototype machine, the Protime Monitor 1000, 
was launched in the late 1980s, and was swiftly followed by other models based on 
the same technology, the models evolving as they acquired additional 
functionalities.36 The Biotrak 512 coagulometer™  (Ciba) evolved from the 
Protime™ machine, and was launched for patient use in Germany in 1991. Roche 
launched CoaguChek™ in Germany in 1993, and the following year bought the 
Biotrak machine which they marketed as CoaguChek Plus™.  
 
However, the development of reliable NPT coagulometers has not only made 
monitoring by healthcare professionals outside of the hospital setting possible. It is 
now also feasible for patients to use them in their own homes to monitor their INR. 
 
2.4. Patient self-monitoring of oral anticoagulation: a brief 
history 
 
Patient self-monitoring of anticoagulation, where the patient measures his or her 
own INR on a NPT coagulometer, has been feasible since the 1980s.The evolution 
of research evidence relating to patient self-monitoring of oral anticoagulation is 
summarised in Table 7. 
 
In 1974, Israeli patients with mechanical heart valves were trained to manage their 
OAT based on INR measured by the lab, which still therefore required patients to 
attend the hospital. No further reports of patient self-monitoring were published 
until the mid-1980s when, with the emergence of near patient testing technology, a 
case report of a young German student taking the initiative to monitor her OAT 
was published.37  
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The first published data indicating that both patient self-testing and self-
management are feasible models of anticoagulation emerged from the USA in the 
late 1980s. White38 demonstrated concordance between home measured and 
laboratory INRs, and that the anticoagulation control achieved by those self-testing 
was better compared with those receiving standard anticoagulation clinic care. In the 
same year, Jack Ansell published a study demonstrating that patients could make 
safe dose adjustments based on home-measured INRs.39 Ansell and colleagues then 
followed up this work with a larger scale case-control study.40  
 
However, much of the supporting evidence has emerged from Germany. Angelika 
Bernardo provided the impetus towards the large-scale use of PSM in Germany. 
Her descriptive study followed up 600 patients over 6 years (1986 – 1992), and 
provided 205 patient-years of PSM follow-up.41 In the same year the results of the 
first randomised controlled trial (RCT) to demonstrate that PSM of OAT produces 
at least as good control of anticoagulation, as measured by the time spent by the 
patient at a therapeutic INR, as “conventional” care became available.42 Other RCTs 
emerged from Germany43 and Holland44;45 supporting these results.  
 
The first UK patient started self-testing in 1994, with the first UK controlled study 
published in 2001.46 Since 2002, the INR test strips have been prescribable by 
general practitioners (GPs) i.e. patients can obtain a supply of these strips at no 
charge or at minimal charge (depending upon their income). 
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 Israel Germany USA UK 
1974 First published paper 
on PSM using lab-
measured INRs 
 
  
1985  A student takes the initiative to manage her 
own INR after purchasing a NPT machine   
1989  
 
White et al publish the seminal PST 
study, demonstrating that PST leads 
to significantly better control  
1989  
 
Seminal PSM pilot study published by 
Jack Ansell & colleagues  
1994    First UK patient starts self-monitoring 
1995  
 
Ansell et al follow up their pilot study 
with a retrospective matched case-
control study. Demonstrated feasibility 
of this approach.  
1996  Six year retrospective analysis of PSM 
published by Bernado et al. Leads to large-
scale adoption of PSM in Germany   
  First prospective RCT comparing PSM by 
Horskotte & colleagues showing modest 
improvement in control with PSM  compared 
with routine care (published only as abstract 
in 1996 - fuller publication in 1998)   
2001   
 
First prospective RCT from UK comparing 
PSM with routine care showing 
improvement in control with PSM. 
2002   
 
Strips become prescribable by GPs 
 
Table 7: Milestones in the evolution of anticoagulant patient self-management 
  
39  
2.5. Patient self-monitoring of oral anticoagulation – an 
international perspective 
 
As of June 2011, patients in 55 countries are self-monitoring their oral 
anticoagulation treatment.47 But, this is uncommon in the UK, with an estimated 
20,000 of approximately 1 million patients self-monitoring, representing just 2% of 
this population.  
 
Reimbursement of the costs of testing strips, meters and patient education varies 
from country to country, and may have an impact on the uptake of patient self-
monitoring. The key differences between the UK and the two countries where there 
has been greater uptake of patient self-monitoring  – USA and Germany - are 
summarised in Table 8.  
 
 UK Germany  USA 
Health system funding  Publicly 
funded by 
taxation 
Contributory 
state health 
insurance 
plans 
Private health insurance 
plans. Government 
health insurance 
(Medicare™) for less 
well off. 
Reimbursement of 
machines 
X √ √a 
Reimbursement of 
consumables 
√ √ √a 
Reimbursement of 
training 
X √ √a 
National training 
program 
X √ X 
Encouragement to 
self-test from start of 
treatment 
X √ X 
Strong patient 
advocacy movement 
X √ X 
a = via Medicare™ 
Table 8: Key differences in OAT patient self-monitoring in the UK, USA and 
Germany 
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2.5.1. Patient self-monitoring in the USA 
 
Although many Americans have health insurance through their employers, 
Medicare™, a government sponsored health insurance program, pays some medical 
benefits on behalf of qualified disabled and elderly people. Coverage is available 
under Medicare™ for prescription drugs, wheelchairs, and for the cost of certain 
medical supplies. In July 2002, Medicare™ started to cover the cost of both NPT 
devices and consumables for patients self-testing.34 For reimbursement by 
Medicare™, the following conditions needed to be met:  
 
i. The machine and home testing must be prescribed by the patient’s doctor 
ii. Patient must have a mechanical heart valve. (Some private insurers may 
cover other indications) 
iii. Patient must have been anticoagulated for at least 3 months 
iv. Patient must have undergone an educational programme before use 
v. Use of the device is limited to once a week 
 
The patient does not purchase the machine or supplies directly. The physician or 
Independent Diagnostic Testing Facility (IDTF) purchases them, and is then 
reimbursed by Medicare™. The physician (or IDTF) is also paid a one-off fee for 
training the patient on how to use the device, and for reviewing and interpreting the 
INRs the patient measures.  
 
In March 2008 the Centers for Medicare™ & Medicaid™ Services (CMS) expanded 
Medicare™ coverage for self-testing to those taking oral anticoagulants for atrial 
fibrillation and venous thromboembolism.48 This has resulted in a sharp increase in 
uptake of patient self-monitoring in the USA.7 Under the new Medicare™ B policy, 
the patient portion of costs for self- testing is expected to be about $30 a month 
(based on a national average) for the use of the coagulometer meter and test strips, 
and about $35 for the initial training. Patients with supplemental insurance coverage 
could potentially have little or no out-of-pocket expenses. 
 
There is no national training schemein the USA. 
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2.5.2. Patient self-monitoring in Germany 
 
Although enthusiasm for patient self-monitoring is growing in the USA, no other 
country has achieved the level of OAT self-monitoring uptake seen in Germany. It 
has over 20 years of experience with patient self-monitoring, and currently 
approximately 160,000 German patients are using the CoaguChek™ machine, by far 
the largest market.7 If eligible for self-monitoring, patients are encouraged to self-
test as soon as warfarin is initiated. They then graduate to self-management if 
appropriate.  
 
Insurance companies heavily influence the German health system. Most Germans 
receive health care coverage through state health insurance plans, funded by 
contributions. Employers subsidise these contributions for those on low earnings. 
Germans can opt to pay for private insurance instead of the state insurance plan.49 
 
The Association of Self-Management of Anticoagulation (ASA) has established 
nationally approved training centres across Germany to train both healthcare 
professionals and patients. The patient receives a certificate of competency when 
they have completed this training, which is required for them to obtain a NPT 
machine. Patients are then reimbursed for the first machine that they purchase and 
for consumables thereafter.  
 
The system of rehabilitation following valve replacement surgery may have a part to 
play in the rapid uptake of patient self-monitoring of OAT in Germany.37 Patients 
are provided with 4 – 6 weeks of mandatory inpatient rehabilitation which offers an 
excellent opportunity for the necessary education. The strong voice of the ASA may 
be another contributory factor. 
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2.5.3. Patient self-monitoring in the UK 
 
Healthcare in the UK is publicly funded by the National Health Service (NHS) 
which provides the majority of healthcare in the UK. NHS services are largely free 
at the point of delivery, paid for by taxes. Although private health care has 
continued parallel to the NHS, paid for largely by private insurance, it is used only 
by a small percentage of the population and, unlike Germany and the USA, 
insurance companies do not currently play a large role in the British Health Care 
System. However, this may change in the future. Equity and excellence: Liberating the 
NHS, the White Paper setting out the Government's long-term vision for the future 
of the NHS, envisages increasing roles for the medical insurance industry.50 
Patients need to buy their own machines (and quality control solutions if required). 
Testing strips for available machines have been prescribable by the patient’s GP 
since 2002.  
 
However, matters are not always that straightforward. Anticoagulation Europe, a 
patient advocacy group for warfarinised patients, has received reports of GPs 
refusing to supply test strips. There appears to be an element of buck-passing; while 
GPs were blaming Primary Care Trusts (PCTs), the PCTs would say that it was the 
GP’s decision leaving the patient firmly in the middle.  
 
There is no established approved national syllabus for educating those who wish to 
self-monitor their OAT, or a national training scheme. This is discussed further in 
3.12.1. In addition, the cost and effort associated with preparing this group of 
patients to assume a greater role in their OAT are not reflected in the current 
funding model within our internal commissioning market for healthcare services. 
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2.6. Drivers for OAT patient self-monitoring 
 
For the purposes of this thesis, a driver is considered to be factor that allows, or 
provides impetus for, uptake of patient self-monitoring of OAT. Despite the patchy 
uptake in the UK, there are OAT monitoring-specific drivers in place that may 
facilitate the adoption of OAT patient self-monitoring. These are the availability of 
portable, reliable NPT machines that allow the patient to monitor their INR at 
home, and the financial incentives available to practitioners to support self-
monitoring patients. These will now be described. 
 
2.6.1. Near patient testing (NPT) coagulometers for patient self-monitoring 
 
As of October 2011, there were three NPT coagulometers suitable for patient use 
on the UK market; CoaguChek™ XS (Roche Diagnostics), INRatio (Hemosense, 
distributed in UK by Sysmex UK) and the ProTime 3 machine (ITC, distributed in 
UK by Instrumentation Laboratory Ltd). Some key features are summarised in 
Table 9. 
 
Machine Manufacturer 
 
MHRA* 
evaluation 
Published 
evidence 
Testing 
strips 
available on 
prescription 
Cost of 
machine 
– 
October 
2011 (£) 
CoaguChek™ 
XS 
Roche 
Diagnostics 
Yes +++ Yes 299** 
INRatio Allere Yes + Yes 399 
ProTime ITC Yes ++ Yes 840 
* MHRA = Medicines and Healthcare Products  Regulatory Agency 
** Promotional price until 31st December,  2011 
 
Table 9: NPT coagulometers currently on UK market 
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Home coagulation monitoring is a growing and highly profitable market. Roche 
dominates the global market. Its CoaguChek™ machine has been extensively used 
in published clinical trials, and has gone through many iterations with the launch of 
the CoaguChek™ XS machine in May 2006. The CoaguChek™ XS machine was 
one of Roche’s biggest sellers in 2010, generating global sales of 330 million Swiss 
francs (approximately £264 million) and demonstrating a 19% year-on-year 
growth.51 Expansion in Medicare™ coverage for home coagulation testing, as 
described earlier, was a key factor contributing to this growth. 
  
UK consensus guidelines, produced by the British Society for Haematology, 
recommend that NPT coagulometers should be thoroughly evaluated prior to use.52 
However, the NHS decommissioned the organisation responsible for assessing 
these devices -  the Centre for Evidence-based Purchasing (formerly the Medicines 
and Healthcare Products  Regulatory Agency’s  (MHRA) Device Evaluation Service) 
-  in 2011. Therefore, at the time of writing this thesis it was not known which body 
would be undertaking these evaluations in future. 
 
2.6.2. Financial drivers for OAT patient self-monitoring 
 
Supporting patients who are self-testing may qualify general practitioners for extra 
payment. Since March 2006, anticoagulation monitoring has been one of the 
national enhanced services (NES) under the new GP contract.53 These are services 
that were negotiated into the General Medical Services (GMS) contract as a key tool 
to help Primary Care Trusts (PCTs) reduce demand on secondary care, and are 
commissioned to meet local need to national specifications and benchmark pricing. 
Under the terms of the Department of Health’s national specification for this 
service, providers would be responsible for sampling, testing and dosing patients 
according to locally agreed protocols approved by the PCT.  
 
There are financial rewards for practices choosing to offer an anticoagulation 
monitoring NES, the magnitude of which is dependent on the level of service 
offered. An illustration of the remuneration for provision of anticoagulation 
monitoring service levels is provided in Table 10. 
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Level Responsibility  Summary Payment  
(per patient 
per year) 
 
Level 1 Prescribing Practice prescribing 
following laboratory 
sampling, testing and 
dosing. 
£10.63
Level 2 Dosing & 
prescribing 
Practice dosing and 
prescribing following 
appropriate external 
sampling and testing.  
£116.34
Level 3 Sample, dosing 
& prescribing 
Practice sampling, 
dosing and prescribing 
with laboratory testing.  
£126.30
Level 4 Sampling, 
testing, dosing 
& prescribing.  
Practice sampling, 
testing, dosing and 
prescribing.  
 
£144.79
 
Table 10: Service agreement for anticoagulant monitoring 2011-12: financial 
details. NHS Hertfordshire NHS Trust54 
 
Practices offering a level 4 service agree to offer a comprehensive package with near 
patient testing and dosing by practice staff, for which they can command over £140 
per year per warfarinised patient. Feasibly, the patient could undertake the INR 
measurement. The challenge is to identify why this change has not yet widely 
occurred, and how it might be enabled. 
 
Thus, patient self-monitoring of oral anticoagulation is the latest stage in the 
evolution of OAT monitoring services, driven largely by a need to increase to build 
capacity and reduce fragmentation of care, and the availability of reliable NPT 
devices has made this model of care possible.  However, patient self-monitoring of 
oral anticoagulation forms part of the broader agenda of self-management of long-
term conditions, for which there are other, more general, drivers. These will now be 
considered. 
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2.7. Drivers for patient self-management of long-term 
conditions 
 
2.7.1. Societal drivers 
 
There has been a paradigm shift in how the patient-clinician relationship is 
conceptualised. A paternalistic approach to healthcare, as described earlier, is not 
acceptable to many patients who are better educated, and have greater access to 
health information through the mass media and the Internet.55  
 
Self-management, described in more detail in the next chapter, is one, but not the 
only, way in which patients can play a more active role. A number of ways of 
increasing patient involvement in their healthcare have been developed and 
evaluated.56 These include the following: 
 
¾ Improving health literacy (e.g. providing health information tailored to an 
individual’s needs) to improve patients’ confidence and ability to be 
involved in decisions 
¾ Involving patients in shared decision-making, where they patients are 
involved as active partners to clarify medical options and choose treatments. 
¾ Providing patient coaching to empower patients to participate in making 
treatment decisions 
¾ Providing patients with decision aids to increase their level of involvement 
in treatment decisions 
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2.7.2. National Health Service policy drivers 
 
As described in the last chapter, the NHS direction of travel supports the redesign 
of clinical services that involve the patient taking more responsibility for their care. 
 
Since the founding of the NHS in 1948, the focus has been on elective care – for 
example, reducing waiting lists and increasing productivity. However, by 2030, the 
incidence of long-term conditions is expected to double.5 A long-term medical 
condition is usually incurable and, whilst usually not immediately life-threatening, 
can have a considerable impact on the patient. In addition to the health & economic 
burdens, they may experience disruption to daily life, social exclusion and reduced 
mobility, and are more likely to be unemployed and reduced educational 
achievements.5;57  
 
2.8. The research problem 
 
There is a need to meet the challenges of providing services to monitor oral 
anticoagulation, and patient self-monitoring presents an alternative method of 
service delivery. It is in keeping with societal and policy drivers for patient self-
management, and the technology exists to make it possible. 
 
However, it is unclear how an oral anticoagulation monitoring service model would 
be redesigned to successfully incorporate patient self-monitoring. Successful OAT 
patient self-monitoring models exist elsewhere, but although OAT self-monitoring 
is well established in Germany, and gaining in momentum in the USA, it is unclear 
if these models are transferable to other countries. The lack of uptake in the UK 
suggests that existing established models are not directly transferable, and there is 
insufficient detail to allow the requirements of a service model that encourages 
OAT patient self-monitoring to be defined. 
 
To define the requirements of this new service model, it is necessary to have an 
understanding of the drivers for, the benefits of, the barriers to, and the challenges 
of establishing and delivering an oral anticoagulation patient self-monitoring service 
from the perspectives of the key stakeholders. The challenge of this research is to 
better understand what these drivers, benefits, barriers and challenges are.  
  
48  
 
Some of these factors may be derived from the published literature on patient self-
monitoring of oral anticoagulation. Lessons may be also learnt from experiences in 
self-management of other long-term conditions – for example, diabetes – where this 
model of care is more established. The next chapter takes a critical look at this 
literature, and describes how it was identified and analysed. 
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3. CHAPTER THREE: LITERATURE REVIEW 
 
The last chapter proposed patient self-monitoring of oral anticoagulation as a way 
of redesigning services to meet the challenges of OAT monitoring, and some 
drivers for this model of service delivery were described. However, for a successful 
scalable adoption, it is also necessary to understand the benefits of, the barriers to, 
and the challenges of this model of care. 
 
These elements were synthesised below into a diagrammatic representation (Figure 
4), which helped to structure the literature review and subsequent method of 
investigation. 
 
Drivers
OAT Self-
monitoring
Barriers BenefitsChallenges  
Service requirements 
for  scalable adoption 
of OAT self-
monitoring
 
Figure 4. A conceptual framework for deriving the requirements for migration to 
an OAT self-monitoring service 
 
Each element within this framework will now be defined. 
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i. Driver – A factor that will allow, or provide impetus for, uptake of 
patient self-monitoring of OAT. 
 
ii. Barrier – A factor that may prevent or limit adoption of OAT patient 
self-monitoring 
 
iii. Challenge – A task that needs to be undertaken to enable successful 
adoption of OAT patient self-monitoring. May be derived from the 
barriers to OAT patient self-monitoring. 
 
iv. Benefit – An advantage that may arise from OAT patient self-monitoring 
 
v. Scalable adoption of OAT patient self-monitoring – The introduction 
os an OAT patient self-monitoring service that can be changed in size or 
scale with minimal effort 
 
vi. Requirement – A condition that needs to be met to enable successful 
adoption of OAT patient self-monitoring 
 
The requirements will be identified from the drivers for, benefits of, barriers to, and 
challenges of OAT patient self-monitoring. The main drivers for OAT patient self-
monitoring were discussed in the last chapter. This chapter will focus on identifying 
the benefits of, the barriers to, and the challenges of OAT patient self-monitoring 
service.  
 
Some of these elements may be derived from published research. It was important 
to appraise the available literature not only to establish the strength of the evidence, 
but also to identify where gaps in knowledge existed. In a broader context, lessons 
may also be learnt from experiences in self-care of long-term conditions, especially 
those where dose adjustment is central to clinical care, and relevant literature from 
this domain was included. 
 
As this research aims to establish these factors from a multi-stakeholder perspective, 
it was essential at an early stage to identify the key stakeholders, their role in OAT 
patient self-monitoring, and predict what their expectations might be, and the 
potential challenges they may face in establishing an OAT patient self-monitoring 
service (Table 11).  This exercise served two purposes. Firstly, it informed the scope 
of the literature review. Secondly, as each of the elements in the conceptual 
framework (Figure 4) was to be considered from each stakeholder’s perspective, it 
also informed the direction of the empirical work.  
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Stakeholder 
Patient / carer Clinician (hospital or primary care) Hospital manager PCT commissioner 
Role 
¾ Assumes more 
responsibility for monitoring 
OAT by measuring INR at 
home + / - adjusting own dose 
of warfarin 
¾ Provides initial patient education and 
ongoing support and review, including 
dosing advice for those self-testing 
 
¾ Monitors the service to ensure that it 
is safe 
¾ Manages the budget for 
OAT monitoring services 
¾ Commissions OAT 
monitoring services both in 
primary and secondary care 
Expectations 
¾ Patient self-monitoring is 
integrated into everyday life 
 
¾ INR control is good and 
there are no OAT-related 
adverse effects 
¾ INR control is good and there are no 
OAT-related adverse effects 
 
¾ Patients contact clinic at the 
appointed times for review and dosing 
advice 
 
¾ Clinic capacity is increased 
¾ OAT patient self-
monitoring is cost-
effective, and generates 
income for the 
organisation 
 
¾ Clinic capacity is 
increased 
¾ OAT patient self-
monitoring is cost-effective 
compared with other 
methods of service delivery 
Potential challenges 
¾ Education provided prepares 
them for self-monitoring 
¾ Patient selection criteria accurately 
predicts those who will be successful in 
self-monitoring  
 
¾ Clinical staff will be able to support 
those who are self-monitoring 
 
¾ Development of a patient self-
monitoring service does not introduce 
new clinical risks 
¾ Introduction of patient 
self-monitoring does not 
result in loss of revenue or 
extra cost for the 
organisation 
¾ Introduction of patient 
self-monitoring is not a 
financial risk 
 
Table 11: Key stakeholders in the development of an OAT patient self-monitoring service
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The next section of this chapter describes the purpose and scope of the literature 
review, and how this review was conducted. 
 
3.1. Purpose of the literature review 
 
The purpose of this literature review was three-fold: 
 
i. To synthesise and interpret previous research on patient self-monitoring of 
OAT and patient self-management of other long-term conditions 
ii. To identify gaps in knowledge and understanding of patient self-monitoring of 
OAT 
iii. To guide the empirical work described in subsequent chapters 
 
 
3.2. Scope of the literature review 
 
The concept areas covered by this literature review are described in Table 12 below.  
 
These concept areas were directly derived from the aim of the research, or were 
included to understand relevant context, informed by the author’s own experience 
in developing innovative anticoagulation monitoring services in north London. The 
author contributed to establishing a hospital based anticoagulation service led by 
pharmacists and specialist nurses in 1998, and to establishing a community led 
service involving general practitioners and community pharmacists from 2001. 
These service developments involved consideration of several elements, including 
patient selection, education, cost-effectiveness and accountability, and these would 
be expected also to apply to developing a patient self-monitoring service. They also 
reflect the challenges that may face the key stakeholders, described in Table 11. 
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 Concept area Derivation or 
rationale 
1. Safety of patient self-care 
2. Safety of patient self-monitoring of OAT 
 
To provide context 
 
3. Benefits of patient self-monitoring of OAT 
 
4. Barriers to patient self-monitoring of OAT 
5. Patients’ and healthcare professionals’ views of self-care 
6. Successful approaches to patient self-monitoring of OAT 
7. Design of clinical service models 
Derived from aim 
of the research 
 
 
8. Patient selection for self-monitoring of OAT 
9. Educational support for patients wishing to self-monitor 
OAT 
10. Educational support for healthcare professionals 
supporting patients self-monitoring OAT 
11. Financial implications of patient self-monitoring of OAT 
12. Accountability in patient self-monitoring of OAT 
Derived from 
author’s 
experiences in 
developing 
anticoagulation 
monitoring 
services 
 
Table 12: Derivation of concept areas for the literature review 
 
3.3. Sources used for literature review 
 
Material was initially identified and then reviewed periodically during the course of 
the research up to August 2011. Both qualitative and quantitative research were 
included. Material was confined to that published in the English language.   
 
The sources used for the literature review are described below. 
 
3.3.1. Published literature (print media) 
 
Published literature on all core concepts was identified by searching the following 
computerised bibliographic databases;  
 
Medline (Dialog Datastar, 1951 to present day) 
Embase (Dialog Datastar, 1974 to present day)  
CINAHL (Dialog Datastar, 1982 to present day)  
Kings Fund database  (Dialog Datastar, 1979 to present day) 
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MeSH terms were used if available, using Boolean operators to combine terms 
where desirable. Expert input from a medical librarian was sought to refine 
searches. The following search terms were used (all are MeSH terms unless stated): 
 
Anticoagulants; Warfarin; Oral anticoag$ (non MeSH); Anticoagulant therapy 
(EMBASE only); Anticoagulant agent (EMBASE only); Coumadin (non MeSH) 
 
Patient education; Patient education (free text search); Patient information (non 
MeSH); Consumer information (non-MeSH); Information dissemination; 
Information (non MeSH); Information needs; Needs assessment 
 
Self care; Self administration; Self management (Kings Fund only); Self 
monitoring (EMBASE only) 
 
Health knowledge attitudes practice; Attitude to health; Quality of life; Patient 
satisfaction; Patient acceptance of health care; Attitude of health personnel 
 
Disease management; Chronic disease 
 
Costs; Costs analysis; Cost (EMBASE); Cost utility analysis (EMBASE); Cost 
benefit analysis (EMBASE); Cost effectiveness analysis (EMBASE) 
 
 
Bibliographies of retrieved papers were hand-searched and relevant citations 
reviewed. 
 
A citation search using ISI Web of Science citation index was performed for oral 
anticoagulant education using selected citations:58-61 
All searches were conducted until saturation was reached and nothing new of 
relevance was found. 
 
3.3.2. Email discussion lists 
 
JSIC Consumer Health Informatics email list archives  
www.jiscmail.ac.uk/lists/CONSUMER-HEALTH-INFORMATICS.html 
In December 2005, the author subscribed to this discussion list for 
developers/evaluators of computerised info for patients/public. The archive 
content prior to subscription was searched using the following search terms:  
Anticoag$; Warfarin;  Chronic disease management; Self-management; Decision 
support; Electronic health record  
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3.3.3. Research registers 
 
Research registers provide early access to information about early stage studies. This 
can be a useful indicator of present research priorities, and a pointer to future areas 
of research results 
 
The National Research Register (NRR; www.nihr.ac.uk) is a database of ongoing 
and recently completed research projects funded by, or of interest to, the United 
Kingdom's National Health Service (NHS). Information is provided by NHS 
Trusts, national and regional funding programmes, universities and charities in 
England, Scotland and Wales. Unpublished anticoagulant-related research was 
identified from this database using the following search terms: 
Anticoagulants; Self management; Self administration 
 
3.3.4. Anticoagulation specialist websites 
 
The following sites were checked for relevant information: 
 
Anticoagulation forum (www.acforum.org) 
Conceived in 1991, the Anticoagulation Forum is a network of anticoagulant clinics 
and promotes professional development and is committed to enhancing the quality 
of anticoagulation care. It currently has 3300 members representing over 1300 
anticoagulation clinics throughout the world. 
 
Anticoagulation Europe (www.anticoagulationeurope.org) 
Anticoagulation Europe is a UK-based charity providing information and advice to   
communication and education on anticoagulation therapy. 
 
Anticoagulation.org (www.anticoagulation.org.uk/main.html) 
This website is produced by the University of Birmingham (UK) and is a source of 
information, links & references. It is aimed mainly at healthcare professionals. 
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ClotUK (www.clotuk.com) 
CLOT -  Clinical Leaders Of Thrombosis - is an anticoagulation and deep vein 
thrombosis special interest group for health care professionals in the UK. The site is 
designed as a resource for professionals in anticoagulant care. 
 
Anticoagulation Specialist Association (ASA) (www.the-asa.org.uk) 
This UK-based body acts  as an “advocate for specialists working within the field of 
anticoagulation, and their patients to encourage and promote high standards of care 
within the speciality through evidence-based practice.”  
 
ClotCare (www.clotcare.com) 
ClotCare is aimed at both patients and healthcare professionals and aims to provide 
current information and expert insight on optimal use of oral anticoagulants. Its 
multidisciplinary editorial board are all from the US. 
 
International Self-Monitoring Association for oral Anticoagulation (ISMAA) 
(www.ismaa-int.org) 
The ISMAA’s website is aimed at healthcare professionals who manage patients on 
oral anticoagulant therapy, with the aim of improving the quality of  treatment 
through patient self-testing. Its executive committee is international and includes 
UK representation. 
 
The International Self-Monitoring Association of oral Anticoagulated 
Patients (ISMAAP) (www.ismaap.org) 
Representatives of National Associations of patients on oral anticoagulation therapy 
founded ISMAAP. The site acts as a resource to support patients on oral 
anticoagulation therapy and to motivate them to carry out self-monitoring. Its 
executive committee comprises mainly European patient members. 
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3.3.5. Other resources 
 
Department of Health website (www.dh.gov.uk) 
At the start of the literature review in December 2005, and periodically through the 
course of the research, relevant policy documents were identified by entering the 
following terms into the website’s search engine: 
Self care; Self management; Long term conditions; Chronic disease management 
 
The Cochrane Collaboration (www.cochrane.org) 
The Cochrane Collaboration produces and disseminates systematic reviews of 
healthcare interventions. Its major product is the Cochrane Database of Systematic 
Review, published in the Cochrane Library 
(www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_articles_fs.html) 
 
At the start of the literature review in December 2005, and again towards the end of 
the research in July 2011, reviews of patient self-management were identified by 
searching The Cochrane Library’s alphabetical index. 
 
Health Technology Appraisals (NHS HTA) website (www.hta.org) 
The HTA programme ensures that high quality research information on the costs, 
effectiveness and broader impact of health technologies is produced in the most 
effective way for those who use, manage and provide care in the NHS. The 
National Coordinating Centre for HTA  coordinates the HTA programme on 
behalf of the Department of Health's Research and Development Division. Every 
year the HTA programme commissions research, and the results of this research are 
published as reports in the HTA monograph series.  
 
The HTA website was searched for relevant research by inputting the following 
terms into the website’s search engine: 
Anticoagulants; Self management 
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Google (www.google.com) 
Throughout the course of the research, the search engine Google™ was used to 
search for information on topics that was difficult to search for using standard 
medical bibliographic databases (e.g. locus of control, patient pathways, history of 
discovery of warfarin) 
 
Websites of manufacturers of near-patient testing coagulometers 
 
The following websites were searched for product information and shareholders’ 
reports: 
www.protimetest.com 
www.roche.com 
www.hemosense.com 
www.invernessmedical.com 
 
The author also contacted representatives of Roche, Hemosense and Inverness 
Medical for additional information 
 
Websites of professional bodies: BMA, RCGP, RPSGB, Royal College of 
Physicians, GMC and Royal College of Nursing 
The following websites were searched for policies or position statements on patient 
self-management. 
www.rcgp.org.uk 
www.bma.org.uk 
www.rpsgb.org 
www.gmc-uk.org 
www.rcn.org.uk 
www.rcplondon.ac.uk 
 
3.4. The growth and size of the literature 
 
The literature supporting this thesis is diverse. It includes not only clinical data to 
support the safety of both general self-care of long-term conditions and oral 
anticoagulation, but also embraces organisational change, economic and medico-
legal literature. 
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It is also a vast field of study: the volume of published literature to support self-care 
of long-term conditions and oral anticoagulation has grown hugely since the 1990s 
(Figure 5).  
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Figure 5: The growth of published self-care literature: 1960-2010 
* Hits were papers with keywords “self-care” and therapeutic area (e.g. 
“asthma”) 
 
This literature review examines the available evidence on patient self-monitoring of 
oral anticoagulation and also, in a broader sense, self-care of long-term conditions. 
Firstly, the evidence supporting patient self-monitoring will be critically reviewed. 
Then the benefits of, the barriers to, and challenges of introducing this model of 
care will be discussed. 
 
3.5. Evidence for the safety of patient self-management of long-
term conditions 
 
3.5.1. Introduction 
 
Historically, individuals and families have always taken care of their own health. 
With the growth of organised healthcare systems, affordable or free access to these 
services, and increasing sophistication of healthcare interventions, personal 
autonomy and responsibility for self-care has diminished in favour of professionally 
directed and delivered care.  
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One of the first times that the term ‘self-management’ appeared in print was in a 
book written by Thomas Creer on the rehabilitation of asthmatic children.62 Since 
the mid 1960s, Creer and his colleagues at the Children’s Asthma Research Institute 
in Denver had used this term to indicate that the patient was an active participant in 
treatment.63 Randomised trials examining the effectiveness of self-management 
interventions started appearing from the late 1970s, with the publication of a trial 
exploring the effects of relaxation therapy and patient self-monitoring on the 
management of hypertension.64 
  
3.5.2. Describing self-management 
 
The definition of self-management is problematic. There is a lack of consensus 
about its meaning, and that of the closely related concept of self-care. Self-
management and self-care are defined as one entry in the glossary of the NHS Care 
Records Service, as how “many people can learn to be active participants in their own health 
and social care, living with and managing their conditions/needs”.65  
 
However, self-care can be thought of as an overarching concept; it embraces the 
spectrum of activities undertaken by a person to stay well or to manage a chronic 
illness, with or without support from a healthcare professional.66 This care can be 
extended to children, family, friends and others in neighbourhoods and local 
communities.  
 
Self-management can be thought of as a sub-category of self-care, and relates to the 
tasks that an individual must undertake to live well with one or more chronic 
conditions. Barlow & colleagues defined self-management as:  
 
“the individual’s ability to manage the symptoms, treatment, physical and psychosocial consequences 
and lifestyle changes inherent in living with a chronic condition”67  
 
Self-management will normally include some input from healthcare professionals, 
which is often focused on education, monitoring of disease indicators and skills 
development.  
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However, for self-management to be considered feasible it must result in disease 
control that is as least as good as conventional care. The evidence to support the 
clinical effectiveness of self-management of long-term conditions will now be 
considered. 
 
3.5.3. Evidence to support self-management intervention programmes 
 
There is a small body of evidence to show that self-management of chronic disease 
may improve patients’ quality of life and health, increase patient satisfaction & life 
expectancy and lead to less reliance on healthcare services.68 However, the evidence 
is by no means unequivocal. 
 
Three comprehensive reviews of self-management of long-term conditions have 
been published 
 
Warsi69 located 71 trials of self-management education, mostly in arthritis, asthma, 
diabetes and hypertension. The programs resulted only in a small to moderate 
overall effect. Also, there was evidence of publication bias which may overestimate 
the benefits of these programmes. Additionally, the author concluded that the 
methodology between studies was not consistent and was often sub-optimal.  
 
Results were not consistent across all diseases. Whilst diabetic and asthmatic 
patients benefited from the education, this success was not reported with respect to 
those with hypertension & arthritis. Few researchers referenced behavioural science 
frameworks in developing these educational programmes. 
 
Chodosh70conducted a meta-analysis of self-management programs for diabetes, 
hypertension and osteoarthritis and concluded that these programs had a beneficial 
effect for diabetes and hypertension, but not for osteoarthritis. The trials did not 
provide evidence about the essential elements of self-management programs, 
limiting the ability to design such programs. There was some evidence that the 
beneficial effects reported might have been in part achieved by increased adherence 
to prescribed medicines. The author also noted that publication bias was evident.
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Newman71 adopted a more discursive approach. This review of 63 studies 
examining self-management interventions for asthma, diabetes and arthritis found 
that the content and intensity of the programmes differed substantially even within 
the three illnesses. The objectives of the interventions reflected the complexity of 
the issues that they were attempting to tackle. For example: for diabetes and asthma, 
there were clear strategies to achieve underlying control of the condition. However, 
strategies to deal with symptoms of pain and the consequences of disability in 
arthritis were more complex. 
 
The Cochrane Collaboration, an independent international organisation that 
produces and disseminates systematic reviews of healthcare interventions, has 
published reviews of self-management of, chronic obstructive pulmonary disease 
(COPD)72, asthma73 and non-insulin treated type II diabetes.74 Its findings are 
summarised in Table 13. 
 
Therapeutic 
area 
Selection criteria Number 
of trials 
Main conclusions 
Asthma Randomised controlled 
trials (RCTs) of asthma 
self-management in 
adults > 16 years 
15 Self-adjustment of 
medication using a written 
action plan is as effective as 
adjustment by a doctor 
Reducing the intensity of 
self-management education 
may reduce its effectiveness 
COPD Controlled trials of 
self-management 
education in those with 
COPD 
9 Insufficient evidence to 
determine whether self-
management of COPD is 
effective. 
Type II DM 
(non insulin 
dependent) 
RCTs comparing self-
management of type II 
DM with usual care 
+/or self-monitoring of 
urine glucose. 
6 Self-monitoring of blood 
glucose might be effective 
at improving glycaemic 
control. Methodological 
quality of studies poor and 
well-designed RCT is 
needed 
 
Table 13: Cochrane Reviews of self-management interventions in chronic disease 
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From the published evidence, it is difficult to draw firm conclusions as to the 
effectiveness and optimal content of programmes to support patient self-
management of long-term conditions. There is evidence of publication bias, 
exaggerating the actual effect of these programmes, and methodological flaws. 
There may be a small to moderate beneficial effect derived from programmes to 
support patient self-management of asthma, diabetes and possibly hypertension, but 
there is no evidence of benefit in such programmes for either osteoarthritis or 
rheumatoid arthritis.  
 
Therefore, patient self-management may be effective only for some long-term 
conditions, and these may be where goals are clearly defined and 
progress/attainment easily measured – i.e. blood glucose, systolic blood pressure. 
OAT patient self-monitoring, where keeping the INR within a defined range, is in 
keeping with these conditions. Conversely, the goals of arthritis are not so clearly 
defined, nor is progress easy to measure. 
 
The next section will consider the evolution of patient self-monitoring of oral 
anticoagulation and the evidence supporting it. 
 
3.6. Evidence for the safety of patient self-monitoring of oral 
anticoagulation 
 
3.6.1. Assessing the safety of patient self-monitoring of oral anticoagulation 
 
For patient self-monitoring of OAT to be considered feasible, it must be at least as 
safe as conventional care. Most studies have used the percentage of time in 
therapeutic range or the number of INR readings in therapeutic range as the 
primary endpoint. These are calculated as follows: 
 
Time in therapeutic range (TRR): involves linear interpolation of the observed INR 
values to extrapolate daily INR values, then defining the TTR as the number of 
patient days spent in therapeutic range divided by the total number of patient days 
in the follow-up period 
 
Percentage of time in therapeutic range: derived by dividing the number of INR values in 
therapeutic range by the number of INR tests (x100) 
   
64 
 
 
Of the two, time in therapeutic range is considered to be the outcome of choice.75 
The percentage of INR tests in therapeutic range, although far more simple to 
calculate, is more easily influenced by the frequency of monitoring, which might 
itself be subject to bias. 
 
3.6.2. The safety of patient self-testing (PST) 
 
From the available limited data, PST is at least as safe as usual control45;76;77or 
better.38;78-80  
 
In the UK, the team at University College London has been instrumental in 
assessing the feasibility of PST in the UK. Their study showed that PST is a reliable 
method of anticoagulation monitoring, in that good correlation between laboratory 
values and those measured by the coagulometer was demonstrated.76 Secondly, in 
terms of INR control, weekly PST was equivalent to usual care. However, dosing in 
the PST group was based on laboratory values and the median age of both study 
groups was lower than the average of their clinic population. 
 
3.6.3. The safety of patient self-management (PSM) 
 
More data are available to support the safety of PSM. INR control has been shown 
to be as good as usual care44;45;81 or better.40;43;46;82;83 In a handful of other studies, 
although INR control appeared to be better with PSM it was impossible to tell if 
this was statistically significant, either because the trial report was only available as 
an abstract42;78 or no statistical analysis was applied.84 Although earlier studies used 
the percentage of INRs in therapeutic range as the primary endpoint,40;42;44;78;84 later 
studies,45;83;85 including those from the UK,46 86;49;81used the preferred time in 
therapeutic range. 
 
The Birmingham group, led by Professor David Fitzmaurice, has identified the need 
for robust data from the UK, and has led the way in this research in the UK. Their 
last (2005) study demonstrated that PSM results in similar INR control to routine 
care.49 
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The seminal studies assessing the safety of patient self-monitoring or oral 
anticoagulation are summarised in Table 14. 
 
Numbers 
analysed 
Main author, 
year and 
country PST 
/PSM 
Control 
Duration 
of study 
(months) 
Description Significance 
White 1989, 
USA38 
26 24 2 Comparison of 
home INR testing 
with management 
by specialist 
nurses in an 
anticoagulant 
clinic 
The first published RCT 
to demonstrate that INR 
control achieved by self 
testing was as good as 
clinic care 
Ansell, 1995, 
USA40 
20 20 90 Retrospective 
cohort study of 
self-managing 
patients with 
matched control 
subjects 
monitored at an 
anticoagulation 
clinic. 
The first published study 
to demonstrate that 
patients can safely self-
manage their OAT . 
Horskotte, 
1998, 
Germany42 
75 75 18 RCT comparing 
PSM with 
management by a 
home physician 
The first published RCT 
to demonstrate that PSM 
produces INR control 
equal to conventional 
care 
Sawicki, 
1999, 
Germany43 
82 83 6 RCT comparing 
PSM with 
management by 
family doctor 
This study included a 
structured educational 
programme which has 
subsequently been used 
by other researchers. 
Fitzmaurice, 
2005, UK49 
337 280 12 RCT comparing 
PSM with 
management by 
family doctor or 
hospital clinic. 
This study (SMART 
study) is the largest 
published trial from the 
UK demonstrating the 
safety of PSM. The use 
of broad inclusion criteria 
demonstrated that PSM 
could be done by ‘non-
selected’ patients 
 
Table 14: Seminal studies assessing the safety of patient self-monitoring of oral 
anticoagulation 
 
3.6.4. Comparing oral anticoagulation patient self-testing with self-
management 
 
In terms of INR control, there appear to be no advantages of patient self-
management over self- testing. However, direct comparisons are few and make it 
difficult to draw firm conclusions. 
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Gadisseur87 compared PSM with PST; no significant difference in INR control was 
found between patients dosing themselves and those who are self-testing only.  
 
Gardiner,88 at University College London, has compared the safety of patient self-
management and self-testing. Both groups measured their INR once every two 
weeks for 6 months; there were no significant difference between the time in 
therapeutic range for PSM (70%) or PST (72%).  
 
3.6.5. Clinical outcomes data 
 
Although INR control is an indicator of anticoagulant safety, it is a surrogate 
endpoint. Improved clinical outcomes are demonstrated by reductions in mortality 
and in  thromboembolic and bleeding episodes, and few trials have these as the 
primary outcome measure.89 This is because it is more difficult to demonstrate 
clinical effectiveness in terms of hard clinical endpoints as large numbers of patients 
and longer follow-up periods would be needed to power a study to demonstrate 
differences in incidence. If these data were available, the evidence would be far 
more robust. 
 
However, meta-analyses have been conducted to determine if PSM and PST are 
better than standard care in terms of these definitive endpoints. The three largest, 
most recent ones will now be considered. 
 
In 2006, a meta-analysis of 14 OAT patient self-monitoring trials (both PST and 
PSM) was conducted by a team at Centre for Evidence Based Medicine at Oxford 
and the Iberian Cochrane Centre in Barcelona.90 Thromboembolic events were 
halved in those self-monitoring, probably due to the increased frequency of INR 
testing. However, there was not a compelling case for patient self-monitoring in 
terms of mortality and bleeding. Although there was a 36% reduction in death from 
all causes, this result was influenced by the single study that demonstrated a 
significant reduction. There was a non-significant (13%) reduction in major 
haemorrhage and although there was a significant reduction in minor haemorrhage, 
the results varied considerably.   
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When the patient self-testing trials were pooled, benefits in terms of clinical 
outcomes were minimal. There was no significant reduction in major bleeds and 
mortality and considerable variance in results in terms of minor haemorrhage. 
Although still significant, there was less impact on thromboembolic events 
compared with both patient self-management and self-testing trials. 
 
This meta analysis was updated to form part of a Cochrane review in 2010.91 
Although four additional controlled trials were identified, the outcomes were the 
same. 
 
More recently (2011), the U.S. Department of Veterans Affairs (VA) Evidence-
based Synthesis Program, in conjunction with the VA's Office of Quality and 
Performance, commissioned a review to determine whether OAT patient self-
monitoring was more effective and safer than usual care.92 22 trials were identified, 
four more than the Cochrane Review a year previous. Thromboembolic events were 
reduced by 42% in patients randomly assigned to PST or PSM. Although there was 
a significant 26% lower risk for death, this evidence was considered low strength 
because of inconsistency among studies. There was a non-significant reduction in 
major bleeding events.   
 
This VA analysis included the largest PST study to date, THINRS, published in 
2010.77 THINRS randomly assigned 2,922 people receiving warfarin therapy for 
either mechanical heart valves or atrial fibrillation to PST or to receive care at a 
high-quality anticoagulation clinic. They were then followed up for an average of 3 
years, giving the study sufficient power to yield hard endpoints in terms of strokes, 
bleeding and deaths Although PST produced a small but significant improvement in 
INR control, the self-testing group reported more minor bleeding events and there 
was no significant difference in the time to the first major bleeding or 
thromboembolic event between the two groups (the primary endpoint). 
 
In summary, patient self-monitoring results in fewer thromboembolic events than 
usual care, without causing bleeding. Although meta-analyses have demonstrated 
that patient self-monitoring reduces mortality, there is inconsistency amongst the 
studies reviewed. These benefits appear to be largely confined to patient self-
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management. There is no evidence that patient self-testing has a positive effect on 
clinical events, reflected in outcome of these meta-analyses and THINRS study. 
David Matchar, the THINRS co-leader, remarked that any extra benefit of PST was 
“modest at best”.93 
 
3.6.6. Confounding factors 
 
It is important to note that there are potential confounding factors that limit the 
generalisability of these trial results to a UK clinic population.  
 
It is not entirely clear if the potential benefits of PST / PSM stem solely from the 
act of self-monitoring, or are modified by other factors. These factors include the 
education and training given to patients undertaking self-monitoring, increased 
frequency of testing, positive effects on compliance and greater patient 
empowerment. 
 
Additionally, a randomised controlled trial (RCT) is the gold standard in terms of 
robustness of clinical evidence. Although it is not possible to totally blind the results 
of trials of OAT patient self-monitoring, it would be possible to blind the 
investigators to the results. As only one group of researchers has partially blinded 
their trial,45 it is impossible to say that bias has been properly eliminated. 
 
In the vast majority of self-monitoring trials, education and training have been given 
to patients randomised to the self-monitoring group to equip them with the 
necessary skills and knowledge to take responsibility for their own anticoagulation 
therapy. Generally, no such education has been provided for the control group, 
placing them at an immediate potential disadvantage.  
Although there have been a few attempts to account for the effects of these 
educational programmes, no firm conclusions can be drawn from the results. Dutch 
researchers randomised 341 patients to four groups: weekly PST (trained patients); 
weekly PSM (trained patients); usual care (trained patients); usual care (untrained 
patients).45 There were no significant differences in the time in therapeutic range 
between the four groups; education alone was at least as good as education plus 
self-monitoring. 
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Similarly, Khan80 compared the effects of providing anticoagulation education, 
education plus weekly PST and usual care over a six-month period. Although 
education alone increased the percentage  time in range from 61% to 70% 
(compared with the previous six-month’s results), this result barely reached 
statistical significance (p=0.05) and greater benefits were derived from education 
plus PST (% time in range increased from 57% to 71%, p<0.001). 
 
Although there is small body of published evidence examining the safety of 
anticoagulation patient self-monitoring, most of these studies originate from outside 
the UK, where the routine care that self-monitoring is being compared against may 
not be as good as that usually achieved in the UK. Therefore, generalisability and 
interpretation of this evidence in a British context is difficult. 
 
Finally, as with trials evaluating self-management of long-term conditions, there is 
some suggestion of publication bias, which may lead to an overestimation of the 
benefits of patient self-monitoring 
 
3.7. Patient benefits of self-monitoring of oral anticoagulation 
 
From the limited body of evidence it appears then that patient self-monitoring is at 
least as safe as routine care, resulting in fewer thromboembolic events without 
causing bleeding,  and may reduce mortality. However, the evidence is not 
compelling and raises the question that if there is no clear advantage in terms of 
clinical endpoints, are there other patient benefits that could augment the case for 
self-monitoring of OAT?  
 
Four published studies, including one from the UK, have explored patient views of 
self-management of OAT: the results are mixed.  
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Sawicki43 developed a 40-point structured questionnaire, with the assistance of a 
national self-help group, to assess the effect of an anticoagulation education 
program, which included self-management of OAT, on treatment-related quality of 
life. This questionnaire was used also in two subsequent studies to assess the impact 
of patient self-management and patient self-testing.44;45 The questionnaire included 5 
treatment-related topics; general treatment satisfaction, self-efficacy, strained social 
network, daily hassles and distress. 
 
All three of these OAT patient self-management studies reported benefits in terms 
of reduction in “daily hassles”. Daily hassles reflected minor, stressful events that 
were thought to add to the burden of having to cope with a long-term condition.  
 
Improvements in distress and self-efficacy were also reported. The theory of self-
efficacy proposes that people avoid activities that they perceive as more than they 
can manage.94 Self-efficacy is important in self-management behaviour then, in both 
initiating and maintaining this behaviour.  
 
Only one of the studies reported a reduction in the strain on the patient’s social 
network.  
 
Gadisseur45 examined the effects of both patient self-testing and self-management 
on quality of life. Patient self-testing conferred significant benefits in terms of self-
efficacy. However, there was a trend towards an increased distress score, which may 
have been caused by an increase in patient awareness.  
 
However, the reliability and validity of the questionnaire used in all three of these 
studies has been questioned, especially with respect to its low Cronbach alpha 
values. Also, patient numbers were small. 
 
The sole published UK study examining this area is of limited value.81 It merely 
reported the five main themes arising from patient interviews: knowledge & 
management of condition & self-empowerment; increased anxiety & obsession with 
health; self-efficacy; relationship with health professionals; societal and economic 
cost.  
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3.8. Healthcare professionals’ perspectives on OAT patient self-
monitoring  
 
From the patient perspective, self-monitoring appears at least as good as 
conventional management and may confer benefits such as a reduction in “daily 
hassles” and increased self-efficacy. However, for an OAT patient self-monitoring 
service to be successful, the support of the other key stakeholders – clinical staff, 
healthcare managers and commissioners - is essential.  
 
No studies were found describing the views of healthcare managers or 
commissioners on self-monitoring of OAT. 
 
One published study of the views of healthcare professionals on patient self-
monitoring of oral anticoagulation was located. Wittkowsky95surveyed American 
anticoagulation practitioners to identify the main barriers to self-monitoring. The 
main barriers were financial ones, relating both to the cost of the machine and 
consumables. However, these conclusions should be considered with caution. The 
results are not representative, even from a US perspective, as the study did not 
address the use of self-testing by patients whose anticoagulation is not monitored by 
anticoagulation clinics, which is more often the case. Additionally, the UK patient 
will not usually pay for INR testing strips as they are available on prescription. 
 
Although not supported by evidence, these authors did offer some thoughts on why 
PSM has been so successful in Germany, which are summarised below: 
 
¾ Sufficient reimbursement for coagulometers & testing strips 
¾ Physician ‘champions’ who have promoted self-management nationally 
¾ Healthcare system provides resources for extensive patient training 
¾ Marketing by coagulometer manufacturers  
 
Whilst the published literature exploring the views of healthcare staff on self-
management of long-term conditions is minimal, it may give an additional 
perspective on OAT patient self-monitoring. This evidence is now described. 
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3.9. Healthcare professionals’ views of patient self-management 
of long-term conditions 
 
One of the key challenges of self-management is changing the mindset of healthcare 
professionals. Traditionally, healthcare professionals are trained to treat acute illness 
and, to a much lesser extent, to manage long term conditions strategically – but still 
directing that management.  A self-management model of care represents a new way 
of working with patients. Self-management requires changes in the traditional 
relationships and roles that health professionals assume with their patients. 
 
Clinicians may be reluctant to relinquish control of management. Jones96 reported 
that asthma nurses and GPs were not enthusiastic about asthma self-management 
plans. Both professional groups questioned their relevance and usefulness. Nurses 
felt that they were in the best position to provide the necessary education and 
monitoring that these patients needed. The group of GPs involved in the study 
agreed that these patients needed continuing education and dialogue and doubted 
patients’ ability to self-manage.  
 
‘Public Attitudes to Self Care,’ a 2005 survey commissioned by the Department of 
Health, found that engagement from healthcare professionals was essential.97 Over 
half (55%) of patients surveyed said that they had not often received encouragement 
to self-care and a third said that they had never been encouraged to do so. A fifth of 
those questioned in this survey said that more advice and guidance from healthcare 
professionals would enable them to self-care better, and 13% said that more 
encouragement was important. 
 
This supports the findings of a report compiled by the Kings Fund; support from 
healthcare professionals was found to be one of the key influences on compliance 
with self-management advice.65  
 
3.9.1. Views on patient self-management from healthcare professional 
bodies 
 
Some of the main professional bodies have issued position statements on patient 
self-management. 
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General Medical Council 
The update to the General Medical Council's 'Good Medical Practice' says that 
doctors should 'encourage patients and the public to take an interest in their health and to take 
action to improve and maintain it. This may include advising patients on the effects of their life 
choices on their health and well-being and the possible outcomes of their treatments'.98 It 
continues to ask that doctors support 'patients in caring for themselves to improve 
and maintain their health' and encourage 'patients who have knowledge about their condition 
to use this when making decisions about their care.' 
 
British Medical Association 
The Patient Liaison Group and General Practitioners Committee of the British 
Medical Association (BMA) published a policy document for self-management of 
long-term conditions in 2007.99 This document describes the BMA’s aspiration to 
see self-care through self-management education become central to the patient 
involvement agenda. The BMA has also developed a web resource for GPs with 
information on the types of self-management education programmes available.100  
 
Royal College of General Practitioners  
Self-care is a strategic element in the Royal College of General Practitioners’ 2007 
report ‘The Future Direction of General Practice. A roadmap’.101 
 “Patients should be increasingly involved in planning health services, self-care, demand 
management, quality assessment, and in self-management and group education” 
 
Royal Pharmaceutical Society of Great Britain (RPSGB) 
The Royal Pharmaceutical Society of Great Britain has been pro-active in its 
recommendations to support self-care. In March 2006, it launched a strategy 
document aiming to maximise the potential of pharmacy in self-care.102 One of its 
key messages was to highlight the opportunities that exist for pharmacists to 
improve the care of long-term conditions, including delivery of high quality 
information, allowing more medicines to be purchased without a prescription (more 
“POM-to-P” switches) to enable self-treatment and offering point-of-care testing.  
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Royal College of Nursing 
As of September 2011, a policy or position statement relating to self-management 
of long-term conditions was not available from the Royal College of Nursing.  
 
In summary, the support of healthcare professionals in enabling patient self-
management is essential and this move away from the more traditional, paternalistic 
model of care is broadly embraced by most of the professional bodies. However, 
there may be a reluctance to relinquish control, which may be a barrier to overcome 
in establishing an OAT patient self-monitoring service. There may also be 
reluctance amongst patients to embrace patient self-monitoring, and the next 
section considers the potential patient-centred barriers.   
 
3.10. Patient-centred barriers to self-management  
 
There is little point in setting up an OAT self-monitoring service if patients are not 
willing to participate. Therefore, it is essential to establish the barriers that need to 
be overcome before introducing such a service.  
 
3.10.1. Patient-centred barriers of patient self-monitoring of oral 
anticoagulation 
 
Bungard103conducted a telephone survey of Canadian patients to assess their 
preferred method of OAT management. Only 24% of the 50 respondents chose 
PST or PSM (12% for each method) as their first choice of management. This 
survey was published only as a letter, which provides only limited detail on why the 
potential uptake of self-monitoring was so low. (This study was published after the 
empirical work with patients in this research was conducted) 
 
Recruitment and attrition rates cited in published trials of patient self-monitoring 
programmes also provide some indication of the proportion of patients who would 
be willing and able to undertake self-testing. These data have been analysed in three 
systematic reviews and are summarised in Table 15. 
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Systematic review Number 
of trials 
included 
in analysis 
Averages from pooled trial data 
Connock (2007) 28 
All data 
 
 
 
 
 
UK specific data 
 
12  
 
 
 
 
 
2 
 
33% of eligible patients agreed to participate 
80% of those randomised to self-monitoring  
were successfully trained and able to self-
monitor 
87% of these continued to end of trial 
 
24% eligible patients agreed to participate 
70% of those randomised to self-monitoring  
were successfully trained and able to self-
monitor  
80% of these continued to end of trial 
 (14% of total) 
Heneghan (2006)90 8  62 % could or would not participate 
78 % of those enrolled continued to end of 
trial 
Garcia-Alamino 
(2010)91 
14  68 % could or would not participate 
75 % of those enrolled continued to end of 
trial 
 
Table 15: Average recruitment and attrition rates from pooled published trials of 
patient self-monitoring of oral anticoagulation 
 
Analysis of UK-specific data suggests that an average 14% of those on oral 
anticoagulation would be willing and able to self-monitor their oral anticoagulation. 
An audit conducted at University College London suggests that, outside of trial 
conditions, 44% of eligible patients would choose to self-monitor from the start of 
treatment, with 86% of these patients successfully completing training (38% of the 
eligible patients).86  
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The reasons for dropouts in OAT patient self-monitoring trials may give an 
indication of potential barriers to successfully implementing and sustaining a self-
monitoring service. In common with published studies on self-management of long-
term conditions, the study authors have not always stated the underlying reasons for 
attrition. However, the authors of the reviews cited in Table 15, and a retrospective 
analysis of attrition rates in OAT patient self-monitoring trials by Carl Heneghan’s 
team at Oxford,104 have attempted to understand the reasons behind drop-outs in 
these studies. These include the following: 
 
¾ Problems with monitoring device 
¾ Physical limitations 
¾ Problems attending training 
¾ Failing training 
¾ Stopping OAT 
¾ A preference for other method of monitoring 
¾ Loss of confidence in self-monitoring 
¾ Adverse events 
¾ Moving out of the area 
¾ Poor compliance 
 
3.10.2. Patient-centred barriers of patient self-management of long-term 
conditions 
 
Few studies have explored the potential barriers to patients self-managing long-term 
conditions.105-109 Emotional factors – for example, depression, anxiety and stress - 
can pose difficulties, as can physical factors such as fatigue and pain, both in terms 
of active involvement and in limiting the mobility needed to access self-management 
education programmes. Lack of family support, financial concerns, time constraints 
and lack of information or knowledge emerged as common problems. A barrier 
cited by patients in all studies was poor communication with physicians or 
physicians’ poor attitudes to self-management. 
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To help assess the impact of recent initiatives and to inform care policy, the 
Department of Health commissioned MORI to survey the English public on their 
attitudes and behaviours on the following aspects of self care:   
 
i. Leading a healthy lifestyle (including diet, exercise and lifestyle choices) 
ii. Self care of minor ailments 
iii. Self care of long-term conditions 
iv. Self care of acute illness after discharge from hospital 
 
Over 3000 people were surveyed in two stages between August 2004 and January 
2005, and the results published in the document ‘Public Attitudes to Self Care - Baseline 
Survey’, previously discussed in 3.9. Among other topics, the survey explored overall 
attitudes to self-care, barriers and facilitators to self-care and knowledge & 
information.97 
 
The results were promising in that 82% of those surveyed who had a long-term 
condition claimed that they played an active role in caring for their condition. 
However, levels of self-care activity were not consistent across all demographic 
groups; younger people, those aged above 85 years, less affluent deprived groups 
and those from ethnic minorities were less active. 87% of those with a long-term 
condition stated that they were interested or very interested in taking a greater role 
in their management. 
 
In summary, there may be potential significant patient-centred barriers to the 
introduction of patient self-monitoring of OAT, as evidenced by the low 
recruitment and high attrition rates in published clinical trials. However, these 
barriers have not been systematically studied. The long-term conditions literature 
suggests that emotional factors, co-morbidity and a lack of support from their 
clinician can be barriers to self-management.  
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In addition to overcoming these potential barriers, there may be clinical, financial 
and service challenges to be overcome when introducing a patient self-monitoring 
service. Earlier in this chapter, the generation of concept areas based on the author’s 
experience of developing innovative anticoagulation monitoring services was 
described (Table 12). These concept areas were as follows: 
 
i. Patient selection 
ii. Patient education  
iii. Clinical staff education 
iv. Financial implication 
v. Accountability  
 
These may also mirror the challenges facing key stakeholders in establishing an 
OAT patient self-monitoring service, and will now be discussed. 
 
3.11. Patient Selection 
 
Not everybody will be willing, or able, to monitor their oral anticoagulation. There 
are no clearly defined selection criteria for OAT patient self-monitoring and no 
reliable way to predict who will be suitable for PST or PSM. Most of the published 
trials used highly selected groups of patients; the inclusion and exclusion criteria for 
these studies are summarised in Table 16.  
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Study Inclusion criteria Exclusion criteria 
Self-testing 
White, 1989, USA38 Ability to use a coagulometer 
Home telephone 
<150 miles from hospital 
Long-term treatment plan (> 8 weeks) 
Previous treatment with  warfarin  
Non-compliance 
Alcoholism 
Memory impairment 
Beyth, 2000, USA79 Inpatients aged > 65 years 
Treatment plan of > 10 days 
Treatment with  warfarin in previous 6 
months 
Did not speak English 
 
Gardiner, 2004, UK76 Treated with warfarin for >8/12 
Record of good compliance 
None stated 
Self-management 
Sawicki, Germany, 199943 
 
Long-term treatment 
Willing to participate 
None stated 
Cromheecke, Holland, 200044 Long-term treatment 
Taken warfarin for >6/12 
 
None stated 
Sidhu, UK, 2001110 Mechanical heart valve 
Lifelong treatment  
> 85 years 
Visual difficulties 
Fitzmaurice, UK, 200281 Long-term treatment 
Treated with warfarin for >6/12 
Sufficient vision 
Manual dexterity 
Good control within last 12/12 (60% within 0.5 
units of target) 
Compliant with treatment 
Physically well 
Not anxious 
Sufficient cognitive ability 
None stated 
Gadisseur, Holland, 200345 Long-term treatment 
Taken warfarin for >3/12 
 
Antiphospholipid syndrome 
Life-threatening illness 
Life expectancy < 1 year 
Diminished understanding 
Physical limitations (e.g. dementia, tremors) 
Sunderji, 2004, Canada85 Taken warfarin for >1/12 
Clinicians then selected patients for inclusion based 
on an assessment of their competency, compliance 
and willingness 
Mental incompetence 
Language barrier 
Hypercoaguble disorder 
Unable to  
attend training 
Voller, Germany, 2004111 Long-term treatment 
Capable of reading & writing German 
Not stated 
Fitzmaurice, UK, 200549 Long-term treatment 
Taken warfarin for >6/12 
None stated 
Koertke,Germany, 2005 112 Willingness to perform PSM Chronic alcoholism 
Menendez-Jandula, Spain, 
200583 
Long-term treatment 
Taken warfarin for >3/12 
Ambulatory 
Severe mental or physical illness without 
caregiver 
Unable to understand Spanish 
 
Table 16: Inclusion and exclusion criteria used in key studies of patient self-
monitoring of oral anticoagulation 
 
 
UK consensus guidelines, issued by the British Society for Haematology, state that 
the individual should be on long-term treatment (because it can take up to three 
months for the patient to become used to managing their treatment), and that 
previous INR stability is not a prerequisite to home testing as previously unstable 
patients may benefit from increased frequency of testing and greater autonomy.52  
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International consensus guidelines, compiled by representatives from the USA, UK, 
Germany and Denmark, recommend that patient self-management should be 
considered as an option for those on long-term anticoagulation, irrespective of 
educational background and social status. However, the patient (or carer) must be 
able to understand the concept of OAT and its potential risks.36 In Germany, the 
patient is deemed suitable for PSM if they have sufficient manual skills and eyesight, 
an indication for long-term anticoagulation and are willing and motivated to accept 
responsibility for self-management.113 
 
The UK guideline considers previous non-adherence as a contraindication for 
patient self-testing or self-management. However, a history of non-adherence either 
in terms in attendance at the anticoagulant clinic or taking warfarin, is an area of 
contention. Medication adherence is a complex construct, a full consideration of 
which is outside the scope of this literature review. Non-adherence can be 
considered as the extent to which a patient’s behaviour differs from that expected 
by the prescriber.114 In broad terms, non-adherence can be viewed as two types: 
intentional and non-intentional. Unintentional non-adherence is usually associated 
with financial, physical or cognitive barriers to using medication. For example; the 
patient wants to follow the treatment plan but is prevented from doing so because 
they cannot afford the prescription charges or cannot open the medication 
packaging or cannot understand the instructions.  As the name suggests, intentional 
non-adherence results from the patient actively deciding not to take the medicine as 
recommended.  
 
However, although not yet explored, it is possible that poor adherence with OAT or 
clinic attendance may be improved with self-management.  
 
Through a review of the literature and patient interviews, researchers from the 
King’s Fund have identified factors that determine the likelihood that a patient with 
a long-term condition will self-manage.65 These findings are summarised in Table 
17. 
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Factor Comments 
Length of time since diagnosis Involvement in self-management is likely to 
fluctuate over time. It may increase but, 
equally, may also decrease. 
Stage of life when diagnosed For example, being a parent + / - in full-time 
employment will influence the time 
commitment to, and importance placed on, 
self-management 
Severity of disease Increasing severity of disease decreases 
confidence to self-manage 
Age Participants are more likely to be younger 
Support services Support from parents, healthcare 
professionals and peers may influence 
compliance with self-management advice. 
Healthcare services need to be flexible 
enough to support self-management 
Gender Women are more likely to participate in self-
management. 
Social class Participants are more likely to be middle-
class 
Level of education Participants are more likely to be better 
educated. Lack of basic literacy skills, or for 
those whom English is not their first 
language, may be less likely to self-manage 
well 
 
Table 17: Factors affecting people’s ability to self-manage identified from a 
literature review conducted by the King’s Fund. 
 
From this research, a young, female, middle class, well-educated patient is most 
likely to be motivated to manage her disease. This does not describe most of the 
patients attending the Whittington Anticoagulation & Stroke Prevention Service. 
Although the local population are relatively young compared to the rest of England, 
with more residents in the 20-44 year age group, patients attending the anticoagulant 
are, on average, considerably older than this. The local population is very mixed, 
both in terms of socio-economic status and ethnic origins. Within both Islington & 
Haringey there is considerable social and economic deprivation.115  
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3.12. Patient Education and Training 
 
Once it has been decided that a patient is suitable for self-monitoring of OAT, they 
will have to be educated how to do so safely. 
  
Deciding on the content of an educational programme for those wishing to self-
monitor their oral anticoagulation will be challenging. There is no standardisation of 
training, no nationally endorsed programme for patients in the UK and the 
educational needs of anticoagulated patients, including those willing to undertake 
self-monitoring of OAT, are not known.  
 
The next section will review the published work on educating those who are self-
monitoring their oral anticoagulation. 
 
3.12.1. Educating patients who are self-monitoring oral anticoagulation 
 
Most of the work in educating patients self-monitoring their oral anticoagulation 
emerged from Germany in the late 1990’s.  
 
The first account of a training programme for patients undertaking self-
management of OAT emerged from Angelika Bernardo’s 1996 account of her 10-
year experience in training patients in self-management of OAT.41 Nurses and 
physicians delivered an educational programme comprising three one-hour sessions 
to familiarise patients with the coagulometer and five hours of theory. 
 
Stefan Morsdorf, another German physician, developed a training programme for 
patient self-management that gained only very limited popularity.59 It was a very 
intensive course and, consequently, costly to deliver. A physician and “other 
qualified personnel” delivered a programme usually comprising four 1.5-hour theory 
sessions and between two and six 1.5-hour practical sessions using multimedia, 
video and flipcharts. Older participants needed significantly more theoretical 
sessions. Trainees undertook an examination, which is not described. 
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In the late 1990s, Peter Sawicki & colleagues developed their seminal program, 
which has achieved far greater popularity.43 This programme takes the form of 
didactic teaching supplemented with practical dosing exercises, and a nurse and 
physician deliver it to groups of between three and six patients over three weekly 
sessions of 60 to 90 minutes.  
 
The content of the programme is well-described and it has been adapted and used 
by many researchers,44;83;111 including the Birmingham group in the UK group who 
have adopted a “train the trainer” approach where trained healthcare professionals 
train patients.81;116;117 However, it is not clear how the Sawicki program was 
developed, and there was no attention paid to behavioural interventions to improve 
patients’ motivation and confidence.  
 
The training programmes described in the literature share common elements. These 
are described below: 
 
¾ Delivered to small groups of usually between 3 and 6 patients. This is 
distinct from traditional anticoagulant training which is delivered on a one-
to-one basis. 
¾ Where stated, delivered by a physician and / or nurse 
¾ Involve more than one session of varying duration (1 – 3 hours) 
¾ Theoretical content of course broadly similar 
 
Although the content of the PSM education programmes are well described, none 
of them have formally established patient education needs.  
 
It is unclear if a lower intensity of training is required for self-testing, compared with 
self-management. There is a very small body of literature describing educational 
programmes for patient self-testing of OAT. Where patients were provided with 
education, this is not described in any detail76;80 and other researchers provided 
instruction on how to use the coagulometer only.118-120 A group of Italian researchers 
demonstrated that patient self-testing could produce acceptable INR control in the 
absence of specific education.121 However, this group of patients were highly 
selected in that they had to pass the Hodkinson Abbreviated Mental Test (AMT) – a 
measure of concentration and memory levels – to be included in the study. 
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UK consensus guidelines for PSM / PST of oral anticoagulation acknowledge that 
standardisation of training is a “pressing requirement.”52 
 
However, providing educational support is, in itself, not enough; assurance that 
patients can self-monitor safely is also necessary. A few of the programmes used a 
form of examination, including a simple examination of ten questions with one or 
two-word answers46 and a multiple-choice performance test at six-months.122 Of 
particular interest, is the study by Voller, as this included an assessment of 
knowledge, using a questionnaire, before, during and after the training 
programme.111 The percentage of correctly answered questions was twice as high 
directly after the end of training and remained at least 90% of this level 6 weeks 
after completing training.  
 
Retention of knowledge was further assessed by Voller two years later.123 Using a 
questionnaire to assess a training programme developed for users of the ProTime 
coagulometer, in addition to statistically significant improvements in knowledge 
immediately post-training, they determined that knowledge was retained at six 
months. 
 
3.12.2. Self-management education and long-term conditions 
 
Despite a growing body of literature, the optimal content of a patient educational 
programme to support self-management is still unclear, largely due to 
methodological issues associated with the published trials. The content of 
interventions has not been described in sufficient detail to allow a thorough 
understanding, small sample sizes and short follow-up periods have been used and 
there is very little information regarding the stage of disease at which the 
intervention should be implemented. 
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Behaviourally oriented programmes to support self-management produce better 
results than more didactic programs, particularly in diabetes.71 In addition to disease 
specific information and technical skills – in the case of anticoagulation  patient self-
monitoring, how to measure blood INR -  patients also need other skills to enable 
them to self-manage. Problem-solving skills are essential; the patient needs to be 
able to both identify & solve problems related to their condition. Additionally they 
need to develop self-efficacy and build effective partnerships with clinicians.  
 
3.13. Education and Training for Staff 
 
The patient is not the only individual who may need education and support. 
Information and knowledge, and support from healthcare professionals are likely to 
be key factors in increasing uptake of patient self-management.124 Healthcare 
professionals will require the skills to enable patient empowerment and facilitate 
effective self-management. Most professionals are skilled at managing patients’ 
acute conditions, with treatment provided by clinicians and little contribution 
expected from the patient. However, they may not possess the communication skills 
that could improve patients’ self-management. 125 
 
There is currently very little evidence on how to educate healthcare professionals on 
how to support patients who wish to self-manage. Healthcare professionals may 
need training in skills such as group facilitation, goal setting, problem solving and 
cognitive behavioural techniques. Encouragingly, the new GP curriculum focuses 
on self-care.74 
 
3.14. Financial implications of patient self-monitoring of oral 
anticoagulant therapy 
 
At this time (2011) of limited resources for healthcare, careful attention has to be 
paid to the cost of any new service development.  Cost data are complex and there 
are no established standards for assessing the economics of point-of-care testing.126 
Test strips cost in the region of £2.50 to £2.70 per test and can be prescribed on the 
NHS. In 2010, the NHS in England spent over £2 million on INR testing strips 
prescribed on GP prescriptions.127 
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The need for the patient to purchase the coagulometer adds further complexity, and 
it is unclear how willing, or able, UK patients are to buy a coagulometer.  
Two UK analyses, described below, have assessed the financial implications of 
patient self-monitoring of OAT. There is also cost associated with training and 
assessing patients, and this was included in both analyses. Neither analyses support 
the cost-effectiveness of patient self-monitoring. 
 
A cost-utility analysis was conducted alongside the SMART trial, the largest UK 
PSM trial.128 Costs were estimated not only from a National Health Service 
perspective, but also from also from a wider societal perspective, accounting for 
costs borne by a random sub-sample of patients. This analysis not only factored in 
patients’ time associated with clinic visits, but also considered activities that the 
patient had to forego to attend clinic appointments. 
 
Costs of each model of care were estimated in two ways: the costs over 12 months 
to the NHS and the patient; and by a cost-effectiveness analysis using the outcome 
data generated by the SMART trial and results from quality of life questionnaires 
sent to study participants. 
 
In terms of annual costs, patient self-management was more expensive than routine 
care, costing the NHS £417 per patient per year, compared with £122 for routine 
care. However, the mean costs to the patient were more in the control arm (£57) 
than in the PSM arm (£46). 
 
Cost effectiveness was measured by the cost of monitoring per quality of life 
adjusted year – £ per QALY. The quality of life adjusted year is an internationally 
recognised method to measure the clinical effectiveness.129 The QALY method uses 
health outcomes, including side effects, and quality of life measures to calculate how 
many extra months or years of life of a reasonable quality a person might gain as a 
result of treatment. The cost-effectiveness of a treatment is then assessed by 
considering how much the treatment costs per QALY. This is the cost of using the 
treatment to provide a year of the best quality of life available and is expressed as ‘£ 
per QALY'. The National Institute for Health and Clinical Excellence (NICE) is the 
body that makes recommendations to the NHS on medicines, treatments and 
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procedures, and it uses QALYs to measure the cost-effectiveness of these 
interventions. It considers interventions that cost more than £20,000-30,000 per 
QALY not to be cost effective. 
 
Using this cost-effectiveness criterion applied by NICE, PSM did not fare well. At a 
cost-effectiveness threshold of £20,000 per QALY, PSM had a probability of only 
30% of being cost-effective, and 46% at £30,000 per QALY.  
 
In 2007, the NHS Health Technology Assessment (HTA) Programme 
commissioned the West Midlands HTA Collaboration to examine the cost-
effectiveness of patient self-monitoring of anticoagulation treatment.28 They 
estimated that wide adoption of PSM of OAT (one quarter of eligible patients, 
estimated at 0.6% of general population) would cost the NHS an additional £8 – 
14.3 million per year. It is important to note that the cost of the machine was 
included in the costs to the NHS. By excluding this cost, the costs to the NHS are 
reduced considerably (by £4.6 – 6.8 million).  
 
Aside from the cost of machines and testing strips, and that of training and 
assessing patients, the lack of adequate reimbursement may represent a barrier to 
potential uptake in the UK. Hospitals are paid for each outpatient clinic 
appointment, instead of receiving an en bloc payment as has been the case in the past. 
Therefore, the movement of patients away from the traditional outpatient setting 
could represent a substantial loss of revenue for the acute hospital Trust. It is quite 
feasible that whilst commissioners may embrace an OAT self-monitoring model, 
hospital managers may be opposed to patient self-testing. 
 
There have also been published cost-effectiveness analyses from USA, Germany 
and Canada.130-132 However, these are not transferable to the UK due to differences 
in the healthcare systems and estimation of costs. 
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In broader terms, although trials are ongoing, the current evidence base does not 
support the cost effectiveness of self-management of long-term conditions.133 
Consequently, as commissioners may not wish to fund a service with unproven 
cost-benefits, this may represent a barrier to the uptake of OAT patient self-
monitoring. Part of this research will seek the views of commissioners to establish if 
this is the case. 
 
3.15. Accountability in patient self-monitoring of oral 
anticoagulant therapy 
 
 
Accountability sits at the heart of clinical governance, the framework for 
maintaining and improving the quality of healthcare in the NHS.134 Accountability is 
a complex construct, and a comprehensive consideration of it is outside the scope 
of this literature review. However, in a broad context, accountability refers to 
individuals’ responsibilities for a set of actions.135  
 
Traditionally, in paternalistic care models, accountability has focused on the 
clinician’s competence and ethical and legal conduct. But the emergence of shared 
decision-making, with the patient playing an active role in their treatment decisions, 
challenges the clinician’s ability to be wholly accountable for the care provided. UK 
law, predicated on the assumption that the clinician solely has the training and skills 
to make treatment choices, does not reflect this shifting relationship, and has been 
static for many years.136 
  
Thus, it is not clear where accountability for patients self-monitoring their OAT 
rests. From a legal liability perspective there are two key questions. Firstly, if 
something goes wrong is there a basis for legal action against the clinician? 
Secondly, by discharging more responsibility to the patient, has he / she taken on 
new risks of liability for the mistakes made by the patient? This is important to 
consider for the following reasons: 
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¾ As discussed above, the patient is taking over historically medical functions 
¾ Patient self-monitoring of OAT is a new, innovative service. It represents a 
change from previous practice and medical advances are often imperfect 
when first applied.8  
¾ Patient self-monitoring is an emerging method of monitoring OAT. As 
discussed earlier, its benefits remain to be conclusively proven.  
 
As of October 2011, there had been no test cases associated with patient self-
monitoring of OAT (similarly, there have been no cases associated with self-
monitoring of blood glucose).  
 
Accountability can also be considered in ethical terms. Empowering patients to self-
monitor should not be viewed as a ‘responsibility dump’, and patients need support 
to preserve and develop their autonomy.137 For this model of care to be ethical it 
should improve benefits, decrease harm and be equitable. Whilst patient self-
monitoring is at least as safe as routine care and may reduce mortality and 
thromboembolic events without an increase in major bleeding, the evidence is not 
compelling. Although published trials do not suggest that patient self-monitoring of 
OAT causes excess harm, again, the evidence base is relatively small. Also, harm is 
not confined to mortality and bleeding events. Educational preparation is necessary 
for OAT patient self-monitoring, and there is a risk that this could invoke fear, 
depression, confusion and loss of confidence.  
 
In terms of equity, patient access to self-management programmes for long-term 
conditions appears skewed in favour of higher socioeconomic groups.138 There is, 
therefore, the risk of widening the gap between the ‘haves’ and the ‘have-nots’. 
 
In summary, there is a lack of clarity as to where accountability sits with OAT 
patient self-monitoring, both in clinical and liability terms. Healthcare professionals’ 
views are required to establish if this is barrier to uptake of this model of care. In 
ethical terms, establishing an OAT patient self-monitoring service may present 
challenges. Patient participation in this model of care is predicated on their ability to 
purchase a coagulometer, which may exclude some of less affluent members of the 
clinic population.  
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3.16. Successful approaches to OAT patient self-monitoring 
 
It is difficult to tease out the successful approaches to establishing and delivering an 
OAT patient self-monitoring service. In the last chapter, the position of self-
monitoring in two countries that have achieved a greater uptake – Germany and 
USA – was contrasted with the UK. There are factors in these countries that may 
have facilitated this model of care, and these are listed below: 
 
i. Initiation of self-monitoring early in treatment 
ii. Nationally approved training scheme for both patients and healthcare 
professionals 
iii. Reimbursement to patient for coagulometers and consumables 
iv. Reimbursement to healthcare professionals for training and monitoring 
v. Strong advocacy 
 
However, it is not known if these factors are transferable to the UK. 
 
3.17. The information gap 
 
In this chapter, the evidence supporting patient self-monitoring of OAT has been 
critically appraised, and any literature highlighting benefits, barriers, and challenges 
has been identified.  
 
One of the aims of this literature review was to identify gaps in knowledge and 
understanding. What has been learnt and, more importantly, what is still to be 
understood is summarised in Table 18. 
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Topic area What is known What is not known 
Benefits of OAT patient 
self-monitoring 
In terms of INR control, OAT patient 
self-monitoring is at least as safe as 
standard management. It results in 
fewer deaths and thromboembolic 
events without causing any more 
bleeding 
 
It may increase patient self-efficacy and 
reduce “daily hassles” 
Does OAT patient self-monitoring 
increase patient empowerment, increase 
satisfaction or reduce reliance on 
healthcare services.  
 
 
 
The benefits of OAT patient self-
monitoring to healthcare staff and 
healthcare system. 
Can lessons be learnt 
from patient self-
management of long-
term conditions? 
Evidence from self-management of long-term conditions is equivocal. It may be 
more effective where the goals of treatment are clearly defined (e.g. blood glucose) 
 
Barriers to OAT patient 
self-monitoring 
Published trials of PSM / PST of OAT 
have low recruitment and high attrition 
rates. Pooled trial data found that 68% 
of those eligible could or would not 
take part. 
 
The reasons behind these rates have not 
been systematically documented. 
 
There are no prospective data to indicate 
the UK uptake of OAT patient self-
monitoring outside of trial conditions 
Can lessons be learnt 
from patient self-
management of long-
term conditions? 
Barriers to self-management of long-term conditions include emotional factors, 
physical limitations, lack of support from family and clinicians, financial concerns 
and a lack of time and knowledge. 
 
There may be reluctance amongst clinicians to relinquish control. Clinicians’ poor 
attitude is a barrier to self-management. 
Successful approaches 
to OAT patient self-
monitoring 
 Successful approaches to patient self-
monitoring of OAT are not known 
Can lessons be learnt 
from patient self-
management of long-
term conditions? 
The support of healthcare staff is key to success in self-management of long-term 
conditions 
Challenges of OAT 
patient self-monitoring 
OAT patient self-monitoring is unlikely 
to be cost effective 
It is unclear how many patients would be 
prepared to buy a coagulometer 
 
There are no clearly defined patient 
selection criteria 
 
There is no standardised educational 
programme for those wishing to self-
monitor OAT 
 
There is no evidence on how to educate 
healthcare professionals on how to 
support self-monitoring patients 
 
It is unclear where accountability lies if 
something goes wrong 
Can lessons be learnt 
from patient self-
management of long-
term conditions? 
A young, female, middle class, well-educated patient is most likely to be motivated 
to manage her disease 
 
 
 
Table 18: OAT patient self-monitoring – gaps in knowledge and understanding 
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3.18. The research problem 
 
It is estimated that just under a million people in the UK take oral anticoagulation 
therapy.28 The vast majority of patients are monitored through dedicated 
anticoagulant clinics, in primary or secondary care. With the development of 
coagulometers from the late 1980’s, there has been growing interest in patients self-
monitoring their INR. OAT patient self-monitoring appears to be a promising, 
innovative way of using available technology to reshape service delivery in the UK. 
It is in keeping with changing patient expectations; it has the potential to increase 
capacity; it is in line with Governmental policy; the technology is robust and there is 
published evidence to support its safety. Whilst there have been small pockets of 
interest in the UK, (the Birmingham primary care service, North Middlesex 
Hospital, and Barts and The London for example), there has not been widespread 
adoption of this form of service delivery.  
 
My view is that we are unlikely to see widespread adoption of OAT patient self-
monitoring until service providers have a clear understanding of the requirements of 
such a service. With clear requirements from the key stakeholders, providers would 
be in better position to design a service that would ensure that self-testing would 
gain the endorsement of patients, clinicians and managers.   
 
In the absence of support from key stakeholders – patients, clinicians and healthcare 
managers - successful migration to a self-monitoring service is unlikely. The 
literature review has revealed that the views of key stakeholders – patients, clinicians 
and healthcare managers -– have not been systematically studied. This leaves 
significant gaps in our knowledge of the requirements for an OAT service aimed at 
supporting patient self-monitoring. The focus of published work has been 
evaluating the safety of OAT patient self-monitoring, there has been very little work 
done on the how this type of shared care is perceived by patients, clinicians and 
service managers. 
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Therefore, there is a need to understand from patients, healthcare professionals and 
managers the drivers for, the benefits of, the barriers to, and challenges of, 
establishing an OAT patient self-monitoring service to derive these requirements. 
The next chapter describes the methodological approach taken to investigate the 
views of these stakeholder groups. 
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4. CHAPTER FOUR: MATERIALS AND METHODS 
 
A review of the literature, described in the last chapter, established the following: 
 
¾ That the drivers, benefits, barriers and challenges to adoption of patient self-
monitoring of oral anticoagulation have not been well investigated, resulting 
in significant gaps in knowledge (Table 18) 
¾ That the views of the key stakeholders in an oral anticoagulation patient 
self-monitoring service have not been systematically studied.  
 
Therefore, the purpose of this research was to investigate key stakeholders’ 
perspectives of the drivers, benefits, barriers and challenges to adoption of patient 
self-monitoring of oral anticoagulation. By involving these stakeholders, it was 
hoped to gain a more comprehensive understanding of the feasibility and impact of 
introducing a patient self-monitoring service, and to derive a set of requirements for 
a service model that encourages OAT patient self-monitoring.  
 
The first part of this chapter will discuss the purpose and aims of this research and 
the methodological approach taken. Then, the design of the research, the methods 
used and the data analysis process will be given. Finally, the setting in which this 
research took place will be described.  
 
4.1. Purpose and aims of the research 
 
The purpose of this research was to establish the requirements of a service designed 
to support OAT patient self-monitoring. 
 
The specific aims are as follows: 
 
i. To understand, from patients who are already self-testing, the key drivers, 
benefits and challenges 
 
ii. To explore the perspectives of different stakeholders (patients, clinicians, 
managers) on warfarin patient self-testing and self-management, including 
drivers, benefits, barriers and challenges 
 
iii. To define the requirements of a service model to support OAT patient self-
monitoring  
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4.2. Methodological approach 
 
A combination of qualitative and quantitative techniques was used for this research.  
 
Qualitative research, traditionally used in social sciences, is used to gain an in-depth 
understanding of the meanings that people attach to their behaviour, how they 
interpret situations, and what their perspectives are on particular issues. The most 
common qualitative methods are interviews, unstructured or semi-structured 
surveys and focus groups. The resulting unstructured data – for example, interview 
transcripts, open-ended survey responses - are then usually analysed by 
categorisation.  
 
By contrast, quantitative research ‘measures’. It refers to a systematic investigation, 
in which findings are expressed numerically to summarise and describe variables, 
and to examine the relationships among variables. Examples of quantitative research 
are randomised controlled trials and structured surveys. 
 
The main focus of this research was to investigate key stakeholders’ perspectives of 
the drivers, barriers, benefits and challenges to adoption of patient self-monitoring 
of oral anticoagulation. As an in-depth understanding of the views of these key 
stakeholders was desired, a largely qualitative approach was adopted using 
interviews, semi-structured questionnaires and focus groups. 
 
However, for the purposes of this investigation, an exclusively qualitative approach 
would not be sufficient. Quantitative analysis was desirable for two main reasons. 
Firstly to estimate the prevalence and strength of opinion – particularly of patients - 
uncovered through the qualitative studies. Secondly, it was desirable to see which 
patient characteristics – for example; age, duration of treatment with OAT -  were 
associated with a willingness to self-monitor their OAT, and a qualitative 
quantitative analysis would test the relationship between variables with greater 
precision than a purely qualitative analysis. Therefore, a semi-structured 
questionnaire survey, which would yield data for quantitative analysis, was included. 
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Additionally, to ensure that self-testing was a safe option in the local patient 
population, a numerical analysis of INR control during the PST pilot was required, 
which is also a quantitative analysis. 
 
In summary, qualitative methods were used to explore topics and identify and 
understand in detail the potential drivers, benefits, barriers and challenges, inevitably 
using small numbers of stakeholders. A quantitative analysis was applied to assess 
the prevalence and distribution of these viewpoints across a wider patient 
community, and also to assess the effectiveness and safety of a patient self-testing 
pilot study.  
 
4.3. Research design 
 
Redesigning an anticoagulation monitoring service model to embrace patient self-
monitoring must result in high quality care, be acceptable to commissioners, service 
managers, patients, carers and staff, and have no adverse budgetary implications. To 
ensure that a redesigned service aimed at patients who self-monitor met their needs 
and at the same time identified and mitigated any potential risks to the health 
service, a set of requirements needed to be elaborated. Donabedian’s triad of 
structure, process and outcome was used as a framework to analyse the 
requirements of a service model for patient self-monitoring of OAT, and this has 
been described in Chapter 1.  
 
This research entailed eliciting from key stakeholders the drivers, benefits, barriers 
and challenges to warfarin patient self-testing and self-management  were perceived 
to be. From these perspectives, the candidate requirements for a service that 
supports OAT patient self-monitoring were derived, in terms of the structure, 
process and desired outcomes. These candidate requirements were then tested by 
implementing and evaluating a PST pilot. The research design is summarised in 
Figure 6. 
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Patients’ perspectives on self-monitoring of OAT were determined through three 
studies. Firstly, a small group of patients who were already self-monitoring their 
OAT were interviewed to provide an insight into the potential drivers, benefits and 
challenges to self-monitoring. Their views informed the next study; interviews 
conducted with a cohort of anticoagulated patients who were not self-monitoring to 
elicit their perspectives on OAT patient self-monitoring. These interviews were then 
used to develop an instrument to explore the perspectives of a larger group of 
patients on OAT patient self-monitoring, the final patient-centered study. The 
results of these three studies were then triangulated to produce a set of patient-
centred candidate requirements for an OAT patient self-monitoring service 
 
The perspectives of healthcare personnel – clinicians, commissioners and hospital 
managers - were gained through two focus group meetings. Through this 
exploration of the drivers, benefits, barriers and challenges of OAT patient self-
monitoring, a second set of candidate requirements for an OAT patient self-
monitoring service was derived, this time from a healthcare personnel point-of-
view. 
 
Lastly, these two sets of candidate requirements were combined and validated 
through a patient self-testing pilot. The safety and acceptability of this pilot service 
was evaluated through auditing the INR control of participants, and through the 
views of clinicians and patients. 
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Figure 6: Research design for the investigation
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In this investigation, the results from one study helped to develop and inform 
subsequent studies – for example, the patient interviews were used to develop and 
pilot the final patient questionnaire. But equally importantly, the results were 
complimentary - ‘hard data’ from the patient survey with patients’ views and 
experiences from both the survey narrative and the in-depth interviews.  
 
The detailed method of each study is described in the relevant later chapter, along 
with the results obtained, and how these were then used to inform the subsequent 
studies. The next section discusses in general terms the  methods used in this 
investigation .  
 
4.4. Methods  
 
There were three main stages to this research: eliciting patient views; exploring the 
perspectives of clinicians, healthcare hospital managers and commissioners; and 
testing a draft candidate service model requirements through a PST pilot. This 
research used patient questionnaires, one-to-one interviews and focus groups, which 
were applied across the main stakeholder groups: 
 
Patients’ views assessed through - interviews 
 - questionnaires 
Clinicians’ views assessed through - focus groups 
 - interviews 
Healthcare managers’ views assessed through - focus groups 
Commissioners’ views assessed through - focus groups 
 
In addition, the following were undertaken during the PST pilot: 
 
i. Audit of INR results  
ii. Analysis of clinicians’ narrative in patients’ electronic health records. 
 
This section discusses these methods, the reasons for their selection, their 
advantages, threats to validity and reliability and the steps taken to minimise 
potential biases.  
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Biases in the design, sampling and the process of a study can threaten its validity 
and reliability. Much of the debate over the quality and usefulness of qualitative 
research centres on the concepts of validity and, to a lesser extent, reliability.139 
Validity refers to whether a data collection instrument measures what it aims to 
measure and how credible the findings are. Reliability refers to the consistency of 
the measurement, or the extent to which an instrument measures the same way each 
time it is used under the same condition with the same subjects. 
 
4.4.1. Interviews 
 
Patient interviews were used three times in this research: 
 
i. In a preliminary exploration of self-testing patients’ motivations for, and 
experiences of, undertaking OAT self-monitoring.  
ii. To pilot the patient questionnaire (the design of which was informed by the 
above exploration) 
iii. To elicit the views of staff managing the PST pilot  
 
Interviews were used for the following reasons. Low literacy is not an issue, 
response rates are higher and inconsistencies and misinterpretations can be checked. 
But, importantly, they allow more detailed questions to be asked and complex issues 
can be probed more deeply, which allows a more in-depth understanding of the 
phenomenon being evaluated. The data yielded are often good and rich.   
 
Reflective diaries were considered for recording clinic staff’s experiences and 
perspectives during the PST pilot. Although these had the potential to produce rich 
data, this approach was rejected for two reasons. Firstly, there was a desire not to 
add to the staff’s already heavy work burden associated with establishing and 
supporting a new service. Secondly, there was concern that the enthusiasm for 
recording entries would tail off over the six-month pilot period.  
 
Instead, the author had regular – at least two-weekly – oral progress updates with 
staff supporting the service; for the purposes of methodological approach, these will 
be considered as interviews. 
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However, interviews are more time-consuming and can be subject to interviewer 
bias. Interviewers can, knowingly or unknowingly, influence the responses to 
questions by asking leading questions, or even by their tone of voice, threatening 
validity. Bias can also be introduced through the eagerness of the respondent to 
please the interviewer, or from a tendency by the interviewer to seek out answers 
that support preconceived notions. In an attempt to reduce bias, an interview guide 
was used for each interview. Care also had to be taken that probing did not become 
intrusive.  
 
To increase reliability, two researchers analysed the interview results independently. 
 
4.4.2. Focus groups 
 
Two focus groups were convened to explore the perspectives of healthcare staff; 
one for clinicians and another for healthcare managers (including hospital managers 
and commissioners).  
 
Focus groups are “unstructured interviews with small groups of people who interact 
with each other and the group leader”.139 In addition to being a quick and 
convenient way to collect data from several people simultaneously, group dynamics 
are used to stimulate discussion. This interaction not only highlights respondents’ 
attitudes and framework of understanding, but also may encourage participants to 
raise their own questions and issues. 
 
However, focus groups carry the risk of bias. The composition of the focus group 
has to be carefully considered or more vocal members may inhibit those who more 
retiring. Most the participants were known to the author and, to minimise bias, the 
groups were balanced as much as possible in terms of age, sex and seniority and a 
relaxed setting was aimed for to establish the right atmosphere.   
 
There are also opportunities for interviewer bias. To minimise this, a discussion 
guide was used to ensure questions were posed consistently, and to maximise 
consistency between groups, the same interviewer interviewed both groups.  
 
 102  
4.4.3. Analysis of clinicians’ narrative in patients’ electronic healthcare 
records 
 
As discussed earlier, interviews were conducted with anticoagulant clinic staff 
supporting the PST pilot to gain an insight into their experiences and perspectives 
of this draft service model. Additionally, the electronic anticoagulant record of each 
patient participating in the pilot was reviewed, and narrative from clinic staff 
recorded. This was done for two reasons: 
 
i. To capture perspectives that staff omitted to convey during the interviews 
ii. To capture information on patient adverse events 
 
4.4.4. Patient questionnaires 
 
Patient questionnaires were used three times in this investigation. Firstly, to explore 
the perspectives of patients on long-term warfarin on self-testing and self-
management. Then again, later in the investigation, they were used to explore both 
the expectations and experiences of those participating in the PST pilot. These uses 
will now be explained. 
 
4.4.4.1 Patient questionnaires used to explore the perspectives of patients 
on long-term warfarin on self-testing and self-management 
 
A semi-structured questionnaire was used to explore the perspectives of those on 
long-term OAT because it would allow a large number of people to be sampled and 
would yield unambiguous answers, allowing quantitative analysis. This would allow 
associations between patient characteristics and views of self-monitoring to be 
tested. This method of data collection is also relatively cheap. 
 
Although interviews or focus groups would have allowed more in-depth probing, 
they were not felt to be suitable for this investigation as large patient numbers were 
involved, and a quantitative analysis was desired. 
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However, questionnaires have disadvantages. The main weakness is that the pre-
coded responses may not accommodate all possible answers. This may force 
respondents to select pre-coded responses that do not fully represent their views, 
threatening validity. To try to mitigate this, although the questionnaire was largely 
structured, it also contained some optional questions requiring a free text response. 
 
The wording of a questionnaire is fundamental to both the validity and reliability of 
a study. Extensive piloting of this questionnaire was undertaken to minimise these 
biases. This was to ensure that the questions were clear and unambiguous, and that 
questions yielding unusable data were eliminated.  
 
Although a self-administered postal questionnaire eliminates interviewer bias, it is 
less suitable for complex issues, for those with low literacy levels and, unless 
resources are put into translating the questionnaire, for those speaking the default 
language (English, in this case). As the interviewer is not there to clarify questions 
and responses, the data are generally less reliable than face-to-face interviews. 
 
Non-response is a major source of potential bias in postal questionnaires. Not only 
does it reduce the effective sample size, the characteristics of responders and non-
responders may be different which may introduce bias into the results. Careful 
design and testing were undertaken in order to optimise the response rate. Other 
steps were also taken to increase the response rate, including sending a covering 
letter and a postal reminder. 
 
The development of this questionnaire is described in Chapter 5. 
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4.4.4.2 Patient questionnaires used to explore the expectations and 
experiences of those participating in the PST pilot 
 
A questionnaire was also used to explore both the expectations and the experiences 
of those participating in the PST pilot. 
 
Focus groups or one-to-one interviews would have allowed in-depth probing, 
permitting a greater understanding of the perspectives of this patient cohort. 
However, they would have been time consuming, in terms of both conducting the 
interviews and their analysis. Also, although there is no consensus on the optimal 
way to measure patients’ expectations,140 the majority of published evaluations of 
patient expectations have used self-administered questionnaires.141 Therefore, 
questionnaires were used in this investigation to measure patients’ expectations of 
PST. 
 
Questionnaires are also routinely used to measure patient experiences, particularly 
whilst they are in hospital.142 Therefore, questionnaires were also used in this 
investigation to measure patients’ experiences of PST. 
 
In contrast to the earlier survey, less structured instruments were used. These have 
the advantage of accommodating more patients’ views, increasing validity.  As they 
were shorter questionnaires sent to a smaller group of people, it was felt patients 
would be more likely to complete them, and that it would be feasible to analyse 
them.  
 
To ensure that the questions were clear and unambiguous, and to eliminate 
questions yielding unusable data, these questionnaires were sent to experts for 
comments before administering. Again, a covering letter was used. 
 
The development of these instruments is described in the relevant chapter.  
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4.4.5. Audit of INR results 
 
Audit is conducted to ensure that quality in healthcare is achieved and maintained.139 
For patient self-testing to be viable, INR control must be at least as good as that 
achieved by routine (clinic) management. Although this has been demonstrated 
under trial conditions, as has been discussed earlier (3.6), it was also important to 
determine that self-testing is safe for patients outside of trial conditions. Therefore, 
at the end of the pilot period, the INR results for each patient were audited. 
 
The process of data analysis for each of these three research methods used – 
questionnaires, interviews and focus groups - will now be considered. 
 
4.5 The plan for analysis of empirical data  
 
Although questionnaires, interviews and focus groups tell us what participants said, 
they do not provide explanations. A meaning has to be attached to these data by 
sifting and interpreting them. 
 
The overall aim of the analysis of the empirical data generated in these studies was 
to describe the drivers for, benefits of, barriers to, and challenges of, patient self-
monitoring of oral anticoagulation. From this, it was hoped to derive a set of 
requirements for an OAT patient self-monitoring service.  The data analysis process 
is summarised in  
Figure 7.
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Figure 7: The data analysis plan for the investigation
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4.5.1 Analysis of interview and focus group data 
 
Thematic analysis was used to analyse the interview and focus group data. It is the 
most common type of qualitative analysis used in health care research.143 This 
method was selected because it is of value in describing the important issues for a 
group of people.144  
 
An alternative method of data analysis would have been grounded theory. This is a 
process that results in a detailed account of the data, as opposed to describing 
themes. Practical constraints of time and funding meant that this type of analysis 
was not feasible. Grounded theory is an iterative approach: data are collected, 
analysed and coded, and then this cycle is repeated until the point of ‘saturation’ is 
reached, that is, no new constructs identified.145 As this research was conducted 
within a deadline, it could not be guaranteed that saturation would happen.  
 
However, although this was not a grounded theory research, a grounded theory 
approach was used. Open coding, a feature of grounded theory, is a line-by-line 
analysis to ‘open up’ the data, to generate as many themes as possible.144 Although 
broad themes had already been defined from the research objectives – for example, 
the challenges and benefits of OAT patient self-monitoring – open coding was used 
to analyse the early data from the patient interviews to generate further themes. The 
iterative approach taken with grounded theory was adopted, in that the themes 
identified in earlier studies were verified in the later work.  
 
4.5.2 Analysis of questionnaire data 
 
A mixture of deductive and inductive analyses was applied to the questionnaires 
used to explore the perspectives of patients on long-term warfarin on self-testing 
and self-management. In induction, ideas are built from a set of observations which 
can be further tested. With deduction, there are general ideas to start with which are 
then tested.139  
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Most of the questionnaire comprised questions for which there was a fixed 
response. Coding was mostly deductive in that previous knowledge and theory were 
used to construct the response categories. Descriptive statistics and bivariate 
analyses were then applied to pre-coded fixed questions. Descriptive statistics were 
used to summarise data; for example, the proportion of those willing to self-test. 
Bivariate analyses were used to determine the relationship between two variables; 
for example, if women were more likely to be willing to self-test than men.  By 
contrast, inductive coding was used to categorise the responses to the open 
questions into themes. 
 
The questionnaires used in the PST pilot comprised mostly open questions, the 
responses to which were categorised into themes. Descriptive statistics were applied 
to the few fixed-response questions. 
  
4.5.3 Analysis of INR control from PST pilot 
 
As described earlier, the PST pilot was evaluated by multiple methods: audit, patient 
questionnaires, unstructured interviews and document analysis. The analysis of 
questionnaires and interviews in this research has been described above. 
 
The safety of the pilot service was evaluated by retrospective audit of the 
participants’ INR results. Options for assessing the safety of anticoagulation control 
have been discussed previously (3.6.1). It was decided to use percentage time in 
therapeutic range (TIR) to assess INR control in this study, calculated using the 
method of linear interpolation described by Rosendaal et al.146 Although it is more 
labour intensive to perform the calculations, it is subject to less bias and the 
relatively small patient numbers make it feasible.   
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However, this method is not without limitations. This calculation assumes a linear 
relationship between individual INR results, and the reality is that the INR will 
fluctuate between tests. In addition, small departures from the target range are 
treated exactly the same as larger deviations. Whilst the former will have little 
impact on event rates (i.e. thromboembolism / bleeding), the latter have a 
potentially greater impact. In an attempt to compensate for this, the proportion of 
tests above and below the therapeutic range were also recorded, as were the number 
of INRs <1.5 and >5.0, as the risk of thrombosis and bleeding are known to 
increase exponentially at these values.147 
 
Patients acted their own controls; INR values for the self-testing period were 
compared with the values recorded for the same set of patients in the six-months 
prior to the pilot. Inferential statistical tests were used to describe the differences 
between these two sets of values. 
 
The narrative content recorded by anticoagulant clinic staff in the participants’ 
electronic health record was analysed by thematic analysis. There are other 
techniques for analysing documents, including content analysis and semiotics.139 
Both of these techniques focus on the social and cultural context of the document, 
resulting in a highly structured and detailed report. As this part of the research was 
concerned largely with verifying themes that had emerged in the earlier studies, a 
thematic analysis was felt to be more suitable. 
 
4.5.4 Triangulation of research data 
 
Triangulation involves comparing the results from two or more methods of data 
collection (e.g. surveys and interviews) or from different data sources (e.g. patients 
and healthcare professionals).143 This was carried out for the following reasons: 
 
i. It could offset any weaknesses of individual methods  
ii. It used the different perspectives to ensure that findings were as rich as 
possible. 
iii. It linked the qualitative and quantitative analysis  
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Triangulation of analysed data was conducted throughout this research: 
i. To compare and combine the results of the three patient studies 
ii. To compare and combine the results of the two focus groups 
iii. To compare and combine the results of the patient and healthcare 
professionals studies to produce a draft service model 
 
 
Triangulated data are presented at the end of each relevant chapter. The draft 
service model – the candidate service requirements - is presented in a separate 
chapter. A framework based on the aims and objectives of the research, with each 
derived service requirement anchored to the relevant element of Donabedian’s triad, 
is used to present these results. Using the example of patients’ perspectives on the 
drivers for OAT patient self-monitoring, the template for this framework is shown 
below (Figure 8). 
 
Patient perspectives Drivers 
Exploratory 
interviews 
with self-
monitoring 
patients 
Interviews 
with local 
anticoagulant 
clinic 
patients 
Survey of 
with local 
anticoagulant 
clinic 
patients 
Derived 
service 
requirement 
Donabedian 
framework 
element 
Convenience Convenience 
cited as a 
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motivating 
factor for 
starting 
OAT self-
monitoring 
Convenience 
identified as a 
potential 
benefit  
Patients were 
significantly 
more willing 
to self-
monitor if 
clinic visits 
were 
disrupting 
their life 
Self-
monitoring 
service is 
acceptable to 
patients 
Outcome 
Theme (i.e. 
driver 2) etc.
     
 
Figure 8: The framework for presenting triangulated research results  
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4.6 Materials 
 
4.6.1 The setting: The Whittington Hospital 
 
The Whittington Hospital employs over 2,000 staff and has 470 beds.148 It is one of 
the teaching hospitals of University College London, providing clinical placements 
and training for doctors. 
 
The Whittington is located in North London and predominantly serves the 
population of North Islington and West Haringey, which gives a combined total 
population of approximately 300,000. However, there may be significant under 
recording of population numbers in both Haringey and Islington due to the 
transient nature of the population and the large numbers of refugees and asylum 
seekers arriving in the area who have not yet registered in national statistics.  
 
4.6.2 The research subjects 
 
The local population is very mixed, both in terms of socio-economic status and 
ethnic origins. Within Islington and Haringey, there is considerable deprivation. 
Based on the borough average of the ward level scores for the DTLR (Department 
for Transport, Local Government and the Regions) Index of Multiple Deprivation 
2000, which include a wide range of income, health and other deprivation 
indicators, both Islington and Haringey rank amongst the worst ten per cent 
nationally with very high average ward deprivation scores.149 This has been proven 
to increase the risks of heart disease through smoking, hypertension, raised 
cholesterol, diabetes, physical inactivity and poor nutrition. Almost 17% (65,000) of 
those in Islington and Haringey have a limiting long-term illness.  
 
30% of the population of Haringey and Islington are from ethnic minority groups, 
predominantly black Afro-Caribbean, Indian and Bangladeshi.150 These figures are 
significant compared to a national (England and Wales) proportion of ethnic 
minorities of less than 9 %. This poses an increased specific health risk; deaths from 
heart disease are more common in people from the Indian subcontinent and deaths 
from stroke are more common in African and Caribbean people.  
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4.6.3 The service: The Whittington Hospital Anticoagulation Monitoring 
and Stroke Prevention Service 
 
The Whittington Hospital has an Anticoagulation Monitoring and Stroke 
Prevention Service which provides INR monitoring, in the hospital or primary care 
setting, for those taking oral anticoagulants. Although the service offers traditional 
secondary care anticoagulation monitoring service as described above, it has been 
innovative in the development of other models of monitoring. The service’s 
approach is a collaborative one; the Whittington service works closely with that at 
the North Middlesex Hospital and also with local PCTs to create a patient-centred, 
seamless service to their shared population.  
 
At the time of starting this research, the next step in its development was 
establishing a patient self-monitoring service. This is the context and the setting in 
which this investigation takes place.   
 
The Whittington Anticoagulation Monitoring & Stroke Prevention Service is 
managed by a full-time Anticoagulant Nurse Specialist, under the clinical direction 
of a Consultant Cardiologist. She is supported by two part-time pharmacists, a 
senior pharmacist with a responsibility for education and service development, a 
clinic care co-ordinator and phlebotomy services. 
 
Additional staff provide a contracted outreach service to Barnet PCT. This service is 
led by a senior pharmacist, who also leads on clinical governance for this service and 
for the clinics operating within Haringey PCT, and he is supported by a junior 
pharmacist and an administrator. 
 
Another pharmacist has responsibility for the clinical governance arrangements for 
clinics operating in Camden and Islington PCTs and leads on education and training 
for practitioners working in the service. 
 
Finally, a senior pharmacist (the author) has management responsibility for the 
pharmacists working in the service and undertakes research and development. 
 
The staffing for the service is summarised in Table 19. 
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Staff Hours per week 
Whittington service  
Consultant Cardiologist 7 
Anticoagulant Nurse Specialist 35 
Cardiology Pharmacist 11 
Anticoagulation Support Pharmacist 18 
Senior pharmacist 7 
Clinic Care Co-ordinator 26 
Phlebotomist / Laboratory MLSO 20 
Barnet PCT  
Project lead (senior pharmacist) 28 
Anticoagulant practitioner (junior pharmacist) 35 
Clinic administrator 35 
Camden PCT  
Clinical governance and education pharmacist 35 
  
Total  292  
 
Table 19: Person-hours at the Whittington Anticoagulant & Stroke Prevention 
Service (October 2010) 
 
With the exception of the extra personnel required to support the Barnet service, 
staffing for the service has remained static during the total data collection period.  
As new patients are constantly received into the Whittington service and others 
discontinue warfarin, patient numbers are never static. As of December 2010, there 
were 1,250 patients under the care of this service. A total of 13,494 visits to the 
Whittington clinic occurred in 2010, and clinic numbers continue to grow, reflecting 
national trends.31 With the exception of an unexplained downward blip in 2007, the 
increasing workload at the Whittington anticoagulant clinic is has increased between 
2006 and 2010 (illustrated in Figure 9). 
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Figure 9: Number of patient visits to the Whittington anticoagulant clinic: 2006-10 
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Up to 300 patients attend the clinic each week, and there is an average of 7 new 
patients each week. Approximately 25% of clinic patients will wait to see one of the 
clinic staff. The remainder will travel home after phlebotomy and will be telephoned 
later the same day by the clinic staff with their INR and warfarin dose. Clinics are 
held on Monday – Thursday, with Friday reserved for emergencies only.  
 
With the clinic operating to nearly full capacity and anticipated further increases in 
patient numbers, increasing pressure was being placed on both service premises and 
costs. The Whittington therefore actively encouraged the author to explore 
alternative models of service delivery for OAT monitoring. These will now be 
discussed. 
 
4.6.3.1 Development of alternative models of service delivery 
 
As discussed in Chapter 2, with the development of reliable & portable near patient 
testing (NPT) devices (coagulometers), it is no longer necessary to bring patients to 
the hospital for anticoagulation monitoring. Therefore, with appropriate support, it 
is now possible for the monitoring to take place in primary care and the Trust has 
been innovative in its developing its service to bring anticoagulation closer to the 
patient.13;151;152 This distributed service is summarised in Figure 10. 
 
A successful nurse / pharmacist-led outreach service to two local GP surgeries has 
been running from the Whittington for the past 15 years. Approximately 80 patients 
attend these clinics. The anticoagulant nurse specialist or pharmacist visits these 
clinics every two weeks. Patients have timed appointments when their INR is 
measured by a NPT device from a capillary blood sample. The healthcare 
professional can then advise on the subsequent dose of warfarin from this test 
result. Approximately 15-20 patients are seen at each clinic (three-hour session). The 
travelling and waiting times for patients are negligible. Patient views of this service 
have not been formally assessed. 
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Figure 10: Distributed clinics of the Whittington Anticoagulation Monitoring 
Stroke Prevention and Service 
 
  
A weekly community pharmacy service started in Islington in 2002, and Haringey in 
2005. Patient views of the Islington service were formally assessed in 2003.151 
Patient satisfaction was high with those interviewed found the service less disruptive 
compared to the hospital clinic. 
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As of March 2006, anticoagulation monitoring is one of the potential national 
enhanced services (NES) under the new GP contract.53 These are services that were 
negotiated into the General Medical Services (GMS) contract as a key tool to help 
PCTs reduce demand on secondary care, and are commissioned to meet local need 
to national specifications and benchmark pricing. Under the terms of the 
Department of Health’s national specification for this service, providers would be 
responsible for sampling, testing and dosing patients according to locally agreed 
protocols approved by the Primary Care Trust (PCT).  
 
As discussed in Chapter 2, when PbR was first introduced, a hospital commissioned 
anticoagulation monitoring service was considered expensive, resulting in local 
PCTs commissioning primary care anticoagulation monitoring services. The 
Whittington Hospital has worked closely with PCTs to facilitate the migration of 
anticoagulation monitoring  service into the community.  
 
Primary care anticoagulation monitoring services that have been commissioned 
locally are summarised in Table 20. 
 
Year of 
starting 
PCT Service model Number of sites 
(2010) 
2002 Islington Community Pharmacy 
(independent) 
1 
2005 Haringey Community Pharmacy (Boots) 
GP practices 
7 
2007 Enfield Community Pharmacy 
(Independent) 
1 
2008 Barnet Outreach service from 
Whittington Hospital 
2 
2009 Camden GP Practices 8 
 
Table 20: Commissioned Primary Care Anticoagulation Monitoring Services in 
North London 
 
This distributed service is supported by a robust clinical governance framework, 
which is underpinned by an electronic information management and advisory 
system and a structured education and accreditation programme. These components 
will now be considered. 
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4.6.3.2 Clinical governance framework of the Whittington Hospital 
Anticoagulation Monitoring and Stroke Prevention Service 
 
The service has established a strong Clinical Governance Board for the North 
Central London Community based service. Membership of this Board includes 
patients; hospital consultants (haematology and cardiovascular); anticoagulant 
practitioners from each PCT; senior pharmacists with educational remit; senior 
pharmacists with governance remit; a commissioner from each PCT; a clinical GP 
lead from each PCT; an academic health informatist; an academic behavioural 
scientist and statistician; an academic legal advisor; an IT representative from 
Whittington Hospital. 
 
The Clinical Governance Board reports both to the Clinical Governance Boards in 
the Hospitals as well as the Medicines Management Boards within the PCTs.  
 
The clinical governance support offered to all clinic sites includes the following: 
 
i. Advice on complying with NPSA guidance in a community setting together 
with audit. 
ii. Access to INR result information by site, by INR range across the whole of 
North Central London Community sites. The Board receives anonymised 
INR data across all delivery sites in NC London – this forms a rich 
perspective of the anticoagulant and stroke prevention service by site, by 
dose range and by total service. It helps the declared intent that the service 
standards should aspire to be the same high quality for the whole of North 
Central London. 
iii. Access to collated information relating to NEQAS results and other quality 
measures 
iv. Access to quality measure of the educational processes 
v. Involvement in novel techniques to explore quality in service delivery and 
benefit from the learning that accrues; these techniques include “Root Cause 
Analysis”, “Cognitive Work Analysis”. 
vi. Access to our Clinical Standard Operating Procedures (CSOP) and Site 
Specific Operating procedures (SSOP). 
vii. Optional central clinical monitoring service, for audit and governance, by 
our anticoagulation experts 
viii. Optional clinical support telephone/email service. 
 
The information management system and education and accreditation programme 
play key roles in supporting the service’s clinical governance framework. These will 
now be discussed. 
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4.6.3.3 The information management system 
 
The service is supported by an electronic management and advisory system for 
anticoagulation and stroke prevention, which is a module of the underlying 
Electronic Health Record (EHR). It is a secure, web-enabled system available to any 
authorised clinician wherever they are situated, whether this is in the hospital 
environment or in primary care.  
 
It has been developed by CHIME (UCL Centre of Health Informatics and 
Multiprofessional Education) and draws on experience of over a decade of 
European work.  It plays a key role in the delivery of the clinical governance agenda, 
and also has modules for the management of patients with heart failure and 
coronary artery disease. The system has the following key features: 
 
i. Comprehensive electronic health record server 
ii. Consolidates all disease information into a whole-person record 
iii. Demographics service for patients and staff users 
iv. User authentication and role-based access policies 
v. Rigorous medico-legal and information governance of clinical data 
vi. Auditing of data entry, changes and of all accesses 
vii. Viewable audit log, to support security policy management 
viii. Standards based architecture (EN 13606), optimised for interoperability 
ix. Easy integration of other systems and data feeds 
x. Easy generation of messages in other standard formats 
 
The anticoagulant module has the following key features: 
 
i. Trial-validated anticoagulation dosing and monitoring algorithms153;154;154 
ii. Anticoagulant treatment plan management 
iii. Advisory system offers warfarin dosing and recommended monitoring 
interval 
iv. Ability to record adverse events 
v. Access to INR result information is offered in a confidential and 
customisable form. It can be accessed on a daily, weekly or other chosen 
interval at different levels; at a practitioner level; at a site level; at a PCT 
level; at a North Central London level; at a total service level 
vi. The INR data can be explored by therapeutic range level; by age; by date 
range 
vii. The INR data has the ability to be contrasted with INR results over the past 
20 years. 
 
This electronic management and advisory system was used by clinic staff to support 
the PST pilot.  
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4.6.3.4 Education and accreditation programme 
 
The author has played a leading role in developing and delivering an education and 
accreditation programme for practitioners managing warfarin treatment. The 
education and accreditation programme has been created and designed in a flexible 
manner to enable safe practice in dealing with fundamental and more complex 
problems of oral anticoagulation and stroke prevention management in the 
outpatient or community settings. It aims to impart an understanding of the theory 
underpinning anticoagulation management together with training in the practical 
competencies that are required.  
 
The course consists of one full day devoted to the required knowledge base and 
training in the use of the coagulometer and the electronic management and advisory 
system. This is followed by two half days of small group attendance at an 
anticoagulant and stroke prevention clinic, in which the knowledge and skills 
acquired can be practised in a supervised environment. All prospective 
anticoagulant practitioners will sit an OSCE (Objective Structured Clinical 
Examination) which comprises six “stations” which test the knowledge and 
competencies required to safely anticoagulate patients.  
 
All practitioners are re-accredited every two years. The knowledge components 
include:   
i. An understanding of the pharmacology of vitamin K antagonists and the 
relevant medications 
ii. Blood coagulation, INR, Pharmacokinetics, Indications for anticoagulation  
iii. Side effects 
iv. Warfarin drug interactions 
v. Clinical governance 
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The skill components include: 
i. Using the coagulometer and the techniques of finger prick sampling of 
blood 
ii. Electronic management and advisory system demonstration 
iii. Patient counseling 
iv. Warfarin monitoring and dose adjustment together with case scenarios 
 
Example pages from the educational workbook used in this programme can be 
found in Appendix 1. 
 
4.6.3.5 The future direction of the Whittington Hospital Anticoagulation 
Monitoring and Stroke Prevention Service 
 
The strategy of the service is to move, at a safe rate, towards a distributed service 
where the more complex patients have their anticoagulant control managed in the 
hospital setting (10-15%). The remainder will be managed in the following settings: 
 
i. The GP setting delivered by a practice nurse or the GP   
ii. An outreach service from the hospital to the GP practice   
iii. The Community Pharmacy       
iv. The patient self-testing  
v. The patient self-managing   
 
A pilot self-testing service forms part of this strategy. 
 
The service is conceptualised in Figure 11. 
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Figure 11: Conceptual model for The Whittington Hospital Anticoagulation 
Monitoring and Stroke Prevention Service 
 
The Whittington cardiovascular service, of which the Whittington Hospital 
Anticoagulation Monitoring and Stroke Prevention Service forms a part, has been 
awarded the Government’s highly prestigious Customer Service Excellence 
standard, in recognition of the high level of customer care it provides. It is the only 
clinical cardiovascular department in the UK to have achieved this standard. 
Moreover, the anticoagulation monitoring and stroke prevention service has been 
singled out for an additional accolade; a recommendation has gone to the Cabinet 
Office to recognise the service as an example of transformational practice. 
 
4.7 Endnote 
 
This chapter has described the methodological approach, the research design, the 
methods used in this investigation, the data analysis process and the setting in which 
the research was conducted. The following three chapters will report on the results 
of this empirical work. 
 122  
CHAPTER 5: PATIENTS’ PERSPECTIVES ON SELF-
MONITORING OF ORAL ANTICOAGULATION 
 
Although the literature indicates some of the potential barriers and challenges to the 
adoption of patient self-monitoring, the views of patients have not been 
systematically studied.  The work described in this chapter aims to fill that gap in 
knowledge. 
 
The purpose of the work described in this chapter was to explore the perspectives 
of patients on warfarin self-testing and self-management. From establishing the 
patient-centred drivers, benefits, barriers and challenges of OAT patient self-
monitoring, it was hoped to derive a set of suggested, or ‘candidate’, requirements 
of a service designed to support OAT patient self-monitoring. 
 
Patients’ perspectives on self-monitoring of OAT were determined through three 
studies. These studies were: 
 
i. An exploration of the experiences of self-monitoring patients 
ii. In-depth interviews with local patients who were not self-monitoring 
iii. A survey of a larger population of local patients who were not self-
monitoring 
 
These three studies were undertaken in a deliberately sequential fashion, with the 
results of one study informing the next (Figure 12). 
 
Firstly, a small group of patients who were already self-monitoring their OAT were 
interviewed to provide an insight into the potential drivers, benefits and challenges 
to self-monitoring. Their views informed the next study - interviews conducted with 
a cohort of anticoagulated patients who were not self-monitoring to elicit their 
perspectives on OAT patient self-monitoring. However, the primary aim of these 
interviews was to develop an instrument to explore the perspectives of a larger 
group of patients on OAT self-monitoring, the final patient-centered study.  
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The approach to analysis of these studies, including triangulation of results, has 
been previously described (4.5). Once the data from all three studies had been 
analysed, these results were triangulated and a summary of these results is provided 
at the end of the chapter. 
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Figure 12: Study design for evaluating patients’ perspectives on OAT self-
monitoring 
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5.1 Patient study 1: An exploration of the experiences of self-
monitoring patients 
 
As an exploratory first step, it was felt that it would be useful to engage with those 
who were already self-monitoring to understand their motivations for undertaking 
anticoagulant self-monitoring, what type of support they had required and any 
difficulties experienced along the way. Although there are data to support the safety 
of OAT patient self-monitoring, no published work exploring patients’ experiences 
of this could be found. 
 
5.1.1 Aims and Objectives 
 
The aim of this part of the research was to explore the perspectives of patients on 
warfarin self-testing and self-management (OAT patient self-monitoring). Within 
this aim, the objective was to identify the key drivers, benefits, and challenges of 
OAT patient self-monitoring.  . 
 
5.1.2 Recruitment of sample 
 
Five patients were invited to take part in this study in May 2007.  
 
As this work was exploratory, with a view to exploring the main issues around 
patient self-monitoring, small numbers were chosen. A mixture of purposive and 
convenience sampling was used. Purposive sampling in that the participants were 
self-monitoring patients who were thought to be able to articulate their experiences. 
Convenience sampling as these participants were near to hand, were known to the 
author or colleagues and were easy to recruit. One of the patients was known to the 
author, two were known to staff in the anticoagulant clinic at the Whittington and 
the remaining two were known to a colleague (JL) at a neighbouring Trust. JL 
sought obtained permission from his patients before they were approached by the 
author. Prior to staring the study, the author consulted with the Chair of the Local 
Research and Ethics Committee (LREC), who felt that formal ethical approval was 
not required for this set of informal interviews. 
 
The methodological and data analysis approach to this study is summarised in 
Figure 13. 
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Figure 13: Patient Study 1: Methodological and data analysis approach 
 
5.1.3 Method 
 
Semi-structured interviews were used, with questions covering the following broad 
topics identified from the published literature and the research objectives: 
 
i. Introductory questions (method of management, length of time self-
monitoring, duration of  warfarin treatment and indication) 
ii. Starting self-monitoring (including drivers and potential barriers) 
iii. Information needs for OAT patient self-monitoring 
iv. Support for OAT patient self-monitoring 
v. The patient’s self-monitoring journey (including challenges faced) 
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These exploratory topics only were served as ‘starting points’ only. Although some 
questions were pre-prepared, these were intended as a series of themes and prompts 
rather than a rigid interview script, to allow the subject to talk freely about his or her 
experience. Interviews were not audiotaped to allow participants to express their 
views more freely. Field-notes were taken at the time of interview.  
 
Interview question prompts can be found Appendix 2. 
 
5.1.4 Analysis 
 
After the interview, the field-notes were read by the researcher and the data coded 
into themes. As this work was exploratory, it was felt appropriate just to describe 
identify thematic groupings only at a high level at this stage. 
 
5.1.5 Results 
 
5.1.5.1 Sample 
 
Three people agreed to be interviewed; two men (M1 & M2) and one woman (F1). 
Their background information is shown in Table 21. 
 
 M1 F1 M2 
Age 62 58 36 
Duration of 
treatment with 
warfarin 
7 years 11 years 2 years 
Indication for 
warfarin 
Heart valve 
replacement 
Dilated 
cardiomyopathy 
Anti-
phospholipid 
syndrome 
Length of time self-
monitoring 
4 years 10 years 18 months 
Self-managing or 
self-testing? 
Self-managing Self-managing Self-testing 
 
Table 21: Patient study 1: Demographic details of patients interviewed 
 
5.1.5.2 Data collection 
 
Two participants (M1 and F1) were interviewed by the author for between 30 and 
45 minutes. Because of work patterns, it was difficult to schedule an interview with 
the third participant (M2). At the participant’s suggestion, questions were submitted 
by email.  
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5.1.5.3 Themes 
 
Six main themes emerged from the interviews: 
 
i. Convenience 
ii. Independence 
iii. Warfarin dose adjustment 
iv. INR testing 
v. Coagulometer & consumables 
vi. Support for OAT patient self-monitoring 
 
These will now be discussed. Selective quotations are used to illustrate pertinent 
comments. 
Theme 1: Convenience 
 
All participants cited convenience as a major motivating factor for starting OAT 
self-monitoring. This was both from the point of view of the freedom to schedule 
INR tests when convenient, and also with respect to avoiding busy, overcrowded 
hospital clinics.  
 
"When travelling for either business or pleasure… to avoid the need to 
negotiate going to hospital should any of my symptoms change. It's hard to fit 
hospital blood tests with a busy job" (M2) 
 
Theme 2: Independence 
 
In addition to being more convenient, anticoagulation patient self-monitoring may 
bring more independence and empowerment.  
 
“I want to be independent …. I want to have more control”(F1) 
 
One interviewee (M2) viewed self-monitoring as a way of establishing ‘normality’ in 
his life; his main motivating factor for starting self-testing was the desire "to live as 
normal a life as possible". 
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Theme 3: Warfarin dose adjustment 
 
The two participants who were self-managing their oral anticoagulation had 
different views on how to adjust their dose of warfarin to achieve INR control. 
Whilst F1 had her “own way of doing it”, M1 felt that having a dosing algorithm was 
essential: 
 
“Having the proforma is critical ….. gives me confidence”(M1) 
 
In the early days of self-management, out of range INRs caused M1 some anxieties. 
However, this improved as he became more experienced at managing his treatment 
and he now felt that his INR was good.  
 
“I am now confident that an INR of 2.9 is not a disaster” (M1) 
 
However, M2 felt that he did not yet have the confidence to adjust his dose of 
warfarin, and phoned the anticoagulant clinic if his INR was too high or too low. 
 
Theme 4: INR testing 
 
Initially, one participant (M1) had difficulties in obtaining and testing an adequate 
blood sample. However, he became more proficient at using the coagulometer as 
time progressed. He felt that greater clarity on how to test his INR would have been 
helpful; for example, blood sampling techniques and alternative lancets available. 
 
Although another participant (F1) did not indicate any difficulties with INR testing, 
she voiced a concern that it may not be suitable for all: 
 
“Some people may not be able to do it …. the elderly for example” (F1) 
 
Whilst the third participant (M2) found INR testing easy, with the coagulometer 
“simple to use from day 1”, he conceded that there may be issues with the 
dexterity required. 
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Theme 5: Coagulometer and consumables 
 
The participants had slightly different approaches to assuring the accuracy of their 
machines. M1 and F1 periodically compared their INR results with the results 
obtained from an identical, externally quality assured machine. M2 had a venous 
blood sample tested at the Whittington alongside a simultaneous capillary blood test 
on his CoaguChek™ machine.  
 
The CoaguChek™ machine is not 100% accurate when testing the INR of those, 
like M2, with anti-phospholipid syndrome. This proved to be both an obstacle at 
the start of self-testing, but also a factor that ensures his continued contact with the 
hospital anticoagulant clinic. M2 has found that the INR results are consistently 
20% higher than those generated from reading a venous blood sample at the 
hospital. Although with hindsight he felt that this information would have been 
useful at the outset, he has devised his own system to deal with this: 
 
“I have drawn up a table in Microsoft Excel to enable me to calculate my 'true' 
INR from the machine reading. Really this is the only factor in continuing with 
the warfarin clinic - to make doubly sure my INR readings are accurate" (M2) 
 
M2 & F1 had concerns over the cost of the coagulometer. M2 claimed that the 
coagulometer is "very expensive" and that this initially deterred him from self-
testing. The need to purchase lancets also adds to the cost. F1 felt that the cost may 
deter many people from self-monitoring anticoagulation. She considered the cost 
very carefully before proceeding. 
Theme 6: Support for OAT patient self-monitoring 
 
Support is an essential ingredient of the success of patient self-management.104 
Healthcare professionals at their respective hospitals were very supportive of F1 and 
M1 self-managing their oral anticoagulation. This support was especially valuable 
when they were starting self-management.  
 
However, support was not just confined to healthcare professionals. Both spouses 
provided help along the way; from agreeing to fund the machine and setting it up 
(F1), to getting a blood sample (M1).  
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F1 felt that it could be valuable for those starting self-testing to speak to those 
already doing it: 
 
"Some people might want support or to be able to talk to someone already 
doing it" (F1) 
 
The manufacturer of the coagulometer (Roche) provided support to all participants, 
through their dedicated helpline and CoaguChek™ manual. 
 
5.1.6 Limitations 
 
This study in a small group of self-monitoring patients identified some drivers – 
convenience in INR testing and the need for independence – and also some 
challenges to OAT patient self-monitoring, which centred on INR testing and 
warfarin dose adjustment. It also highlighted the need for the patient to purchase 
the coagulometer as a potential barrier to uptake, and that support from healthcare 
professionals and family may be valuable when starting self-monitoring. 
 
As this was a small, exploratory study, it was not possible to draw any firm 
conclusions from its findings. However, the results of this study informed the next 
two studies, which involved interviewing and surveying Whittington patients who 
were not self-monitoring. These were larger studies and form the bulk of the 
patient-centred part of this thesis. The remainder of this chapter discusses these 
studies. 
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5.2 Patient Study 2: Interviews with local anticoagulant clinic 
patients  
 
The initial interviews with patients who were already self-monitoring provided some 
insight into some of the factors that might influence the uptake of OAT patient 
self-monitoring. However, this was a very small study with a cohort of patients who 
would not be representative of the general anticoagulant clinic population.  
 
This section describes how in-depth interviews with a larger, more representative 
group of patients attending the anticoagulant clinic were conducted. 
 
5.2.1 Aims and Objectives 
 
The main aim of this study was to develop a questionnaire to elicit the views of a 
larger group of patients.  
 
A secondary aim was to yield narrative data for qualitative analysis in order to 
explore the perspectives of patients on long-term warfarin on self-testing and self-
management, including drivers, benefits, barriers and challenges.  
 
5.2.2 Recruitment of sample 
 
Invitation letters, accompanied by a study information sheet, were sent out to 23 
patients attending the Whittington Anticoagulation Monitoring and Stroke 
Prevention Service in July and August 2007. These can be found in Appendix 3. 
 
The sampling frame was the patient list of the Whittington Hospital Anticoagulation 
Monitoring and Stroke Prevention Service. These patients were attending either the 
Whittington Hospital clinic or one of its primary care outreach clinics for 
anticoagulation monitoring. At the time of sampling (June 2007), the size of this list 
was 912 patients.   
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A mixture of purposive and convenience sampling was used. Purposive sampling in 
that the sample was selected to represent a spread of ages, indications, duration of 
treatment and gender. Equally importantly, those selected were thought likely to be 
able to articulate their experience of being on warfarin. Convenience sampling as 
these participants were near to hand, were known to the author, were easy to recruit 
and were likely to respond. As the main aim of this study was to test, refine and 
extend the ideas and topics identified from the initial interviews, ultimately to 
develop a patient questionnaire, statistical representativeness was not sought. 
 
There are no set rules governing sample sizes for interviews. Instead, they are 
determined by other factors such as the likely depth and duration of the interview 
and the number feasible for a single researcher to undertake.143 Large qualitative 
studies rarely interview more than 50 or 60 people. Therefore, the sample size was 
largely determined by how many interviews a single researcher would be able to 
conduct and analyse; it was decided that nine interviews would be feasible. 
 
The methodological and data analysis approach to this study is described in Figure 
14. 
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Figure 14: Patient Study 2: Methodological and data analysis approach 
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5.2.3 Method 
 
The perspectives of this group of patients were collected through face-to-face 
interviews. This section describes how this was carried out, and how the data 
collection tool for this study was developed. 
 
Local Research and Ethics approval was granted for this study. Relevant 
correspondence is in Appendix 4. 
 
5.2.3.1 Development of the data collection tools – the interview guide and 
survey instrument 
 
This developmental work took place over a period of six months, from June to 
December 2007, and is summarised in Table 22.  
 
Activity Outcome Resulting Data 
Collection Tool 
Examined existing 
questionnaires exploring 
attitudes and perspectives of 
anticoagulated patients described 
in published literature and from 
the emergent themes from the 
patient interviews in Patient 
Study 1. 
 
¾ Salient issues 
identified 
¾ Questions 
written 
 
Preliminary set of 
questions 
Preliminary set of questions sent 
to two experts for comments 
¾ Minor 
modifications 
made 
Interview guide 
First interview guide used for 
first 4 interviewees 
¾ 40 
amendments 
made to guide 
Prototype 
questionnaire 
Prototype questionnaire used for 
final 6 interviewees 
¾ 32 
amendments 
made to guide 
Amended prototype 
questionnaire 
Discussions with supervisor ¾ 31 
amendments 
made 
Final questionnaire 
 
Table 22: Overview of stages of developing the patient interview guide and 
questionnaire 
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Development of the interview guide 
 
A preliminary set of questions was developed from two sources. 
 
Firstly, emergent themes from the interviews with self-monitoring patients were 
used to construct the responses to some of the questions. The construction of these 
questions and response options is summarised in Table 23. 
 
Secondly, patient questionnaires described in the published literature were reviewed. 
Studies exploring the perspectives of patients who were self-monitoring their 
OAT43;44;81;87 have previously been described in Chapter 3. Additionally, surveys 
exploring the attitudes and perspectives of anticoagulated patients (not self-
monitoring) were reviewed.155-158  
 
Salient issues were identified from these studies, particularly relating to perceived 
benefits and concerns about warfarin patient self-monitoring. In addition, questions 
to determine subjects’ warfarin information needs were included and, in order to 
explore the feasibility of making this information available electronically, their 
experiences with computers. 
 
This preliminary set of items was sent to two experts – an academic with an 
expertise in qualitative research and a lead pharmacist in anticoagulation - for 
comments. Some minor modifications were made. This resultant set of questions 
was used as the first interview guide, and can be found in Appendix 5.
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Interview question  Mapping to 
emergent theme 
Now think about what you would like to change about your warfarin 
treatment & monitoring.  
Please tick a box to show which of these options are most attractive. You 
may tick more than one box. 
 
 
¾ Less frequent clinic visits Convenience 
¾ Testing my INR (blood level) at home and phoning the clinic for 
advice on my dose 
¾ Testing my INR (blood level) at home and adjusting the dose of 
Warfarin myself 
Independence 
 
Independence 
Now think about testing your own INR (“self-testing”). 
Please tick a box to show how much you agree with each of the following 
statements. 
 
 
¾ I would like to have more control over my warfarin treatment Independence 
¾ I would be able to prick my finger to get a blood sample 
¾ I would be able to test my blood on the machine 
INR testing 
INR testing 
¾ I would be able to buy a machine 
 
¾ I would be happy to buy a machine 
Coagulometer and 
consumables 
Coagulometer and 
consumables 
Now think about testing your own INR and adjusting the Warfarin dose 
yourself (“self-managing”).  
Please tick a box to show how much you agree with each of the following 
statements. 
 
 
¾ I would like to have more control over my warfarin treatment Independence 
¾ I would be able to adjust my dose of Warfarin Adjusting warfarin 
dose 
¾ I would be able to prick my finger to get a blood sample 
¾ I would be able to test my blood on the machine 
INR testing 
INR testing 
¾ I would be able to buy a machine 
 
¾ I would be happy to buy a machine 
Coagulometer and 
consumables 
Coagulometer and 
consumables 
If we were to set up these “self-testing” and “self-management” 
programmes, there are a number of ways we could support you. 
We have listed some of these below. Please could you indicate how 
important these would be if you were self-testing or self-managing your 
warfarin treatment. 
 
 
¾ Provide the machine to measure your blood INR Coagulometer and 
consumables 
¾ Give you more information / education 
¾ Make it easy for you to contact the clinic if you have any concerns 
¾ Check up on you regularly 
Support 
Support 
Support 
There may be other ways that the clinic could support patients who 
decide to self-test or self-manage their Warfarin treatment. If you can 
think of any, please write your suggestions in the space below. (Open 
question) 
Support 
 
Table 23: Construction of patient interview questions and response options from 
emergent themes from Patient Study 1 
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Development and piloting the questionnaire 
 
This first interview guide was used to conduct the first four patient interviews. 
 
The rationale behind careful design and piloting of survey instruments has been 
previously described in Chapter 4. The following checks were conducted during the 
course of the patient interviews: 
 
i. That questions were unambiguous 
ii. That none of the questions caused offence or discomfort 
iii. For the closed questions that all possible responses were included 
iv. That each question measured what it was intended to measure 
v. That all relevant issues had been included 
vi. How the patient feels about the questions 
 
After these four interviews, 40 amendments were made. Half of these amendments 
were suggested by the interviewees; the remaining 20 were initiated by the author 
based on the experience of conducting the interviews and the kinds of response 
elicited. The majority of changes were rewordings of questions for clarity, or 
formatting amendments.  
 
The resulting prototype questionnaire was then piloted on the remaining six 
patients. 
 
Further amendments were made after the remaining six interviews and through 
discussion with the academic supervisor. The final questionnaire was a 66-point 
instrument, to be used for the patient survey (section 5.3), which was divided into 
six sections: 
 
i. Warfarin treatment and current health 
ii. Attending the warfarin clinic 
iii. Self-monitoring warfarin 
iv. Education and support for those self-monitoring warfarin 
v. Experiences with using computers 
vi. Demographic data 
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5.2.3.2 Interview methodology 
 
Each participant was interviewed by the author face-to-face. Signed informed 
consent was obtained before each interview was conducted. Participants were asked 
permission for the interview to be audiotaped. Additional relevant field notes were 
also taken with observations and reflections added after the interview. 
 
As the primary aim of this part of the study was to develop and pilot the survey 
instrument to be sent out to a larger patient population, the interview was largely a 
“talk-through” of the interview guide. However, as a more qualitative analysis was 
also desired in order to obtain additional results (patient perspectives), through the 
course of the interview each participant was given opportunities to expand on 
comments and to raise issues that had not been addressed. 
 
Additional information on warfarin PST and PSM was provided, using patient 
information leaflets, to allow the interviewee to reach a more informed view of 
OAT patient self-monitoring. These leaflets can be found in Appendix 6. 
 
5.2.4 Analysis 
 
The main purpose of the pilot study was to gain an insight into the experiences of 
patients who were on long-term warfarin, with the goal of using these data to 
develop and pilot a questionnaire to be used in the second phase of the study. The 
use of the interviews to develop and pilot the questionnaire has been described in 
5.2.3.1.  A secondary purpose was to yield narrative data for qualitative analysis. 
 
As soon as possible after the interview, the author transcribed the audiotapes 
verbatim. Once the interviews were transcribed, the audiotapes were destroyed. 
These transcripts were then subjected to a thematic analysis. All of the interview 
transcripts were read and then re-read by the author, who then identified broad 
themes and also sub-themes within these broad themes. A master list of major 
themes and sub-themes – the coding frame - was compiled, and phrases in the 
interview transcripts were marked with different coloured pens to identify the 
different themes. Notes were also made in the margin to denote these themes and 
also any sub-themes.   
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Using the same methodology, another researcher conducted (JM) independently 
coded the interview data. The author and JM then compared their coding frames 
and, after discussion, a consensus was reached on a common coding frame. The 
interview transcripts were then re-coded using this consensus coding frame. 
 
 Data were tagged with participants’ sex and identifying number (e.g. M1 refers to 
the first male participant to be interviewed). 
 
5.2.5 Results 
 
5.2.5.1 Sample  
 
Ten patients agreed to be interviewed. Their demographic details are shown in 
Table 24. The majority of these participants were on lifetime treatment with 
warfarin, and had already been on it for more than 10 years.  
 
 No. of patients 
Age at time of interview (years)  
40 – 49  1 
50 – 59 2 
60 – 69 6 
70 - 79 1 
Sex  
Women 5 
Men 5 
Indication for warfarin  
Venous thromboembolism 2 
Mitral stenosis 2 
Heart valve replacement 3 
Atrial fibrillation 2 
Post-partum dilated cardiomyopathy with apical 
thrombosis 
1 
Duration of treatment at time of interview  
> 10 years 7 
1 – 5 years 2 
< 1 year 1 
Planned total treatment length  
Lifetime 9 
Six months 1 
 
Table 24: Patient study 2: Demographic details of patients interviewed 
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One participant (M1) was also diabetic and tested his blood glucose at home. Three 
participants had tested their INR at home in the past. One (M3) of these had 
participated in a self-testing clinical trial conducted at UCLH; two (F2 & F5) had 
purchased coagulometers, although they rarely used them. 
 
5.2.5.2 Data collection 
 
Each participant was interviewed face-to-face with interviews taking between 40 and 
90 minutes. Nine people were interviewed at the Whittington; one person was 
interviewed in her own home. One participant was accompanied by her husband, 
whose views were also included in the analysis. All participants granted permission 
for the interview to be audiotaped.  
 
5.2.5.3 Themes 
 
Seven main themes emerged from analysis of these interviews. These are 
summarised in Figure 15 and are discussed below. As before, selective quotations 
are used to illustrate pertinent comments. 
 
However, three of these themes – impact of warfarin on everyday life, experiences 
of INR monitoring and the expert patient – are not included in the discussion 
because they were felt not to have a direct bearing on the shift to self-monitoring. 
Although an in–depth analysis of these themes would not have made a significant 
contribution to the research, the rich narrative generated will form the focus of a 
separate academic publication.  
 
Instead, more value was attached to examining the relationship of variables within 
these themes with willingness to self-monitor in a quantitative manner. To this end, 
for the patient survey, described later in this chapter, statistical analysis will be used 
to correlate these factors with a willingness to self-monitor – for example, the 
relationship between willingness to self-monitor and how disruptive clinic visits 
were to the individual. 
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Figure 15: Patient study 2: Themes from interviews  
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Theme 1: Perceived benefits of patient self-testing 
 
Potential benefits of anticoagulation self- monitoring cited in the literature include 
increased patient empowerment, improved patient - healthcare professional 
relationship, greater patient convenience and avoidance of damage to the veins 
through capillary sampling. 
 
Participants’ views of self-monitoring were largely positive. Most of the comments 
on the potential benefits of patient self-monitoring centred on increased 
convenience for them, particularly in terms of allowing freedom to travel. Some 
respondents felt that the ability to test their INR more frequently would be 
reassuring and might also result in fewer erratic INR results. These sub-themes of 
convenience and reassurance will now be considered. 
 
Sub-theme 1: Convenience of patient self-monitoring 
 
Most of the participants’ comments on the potential benefits of patient self-
monitoring centred on increased convenience for them, particularly in terms of 
travel. 
 
“If you’re on holiday it’s … it could be useful then … or of you’re away in out 
of the way places …in the wilds of Scotland where you don’t have local access 
to the major facilities”(M3) 
 
But another dimension to greater convenience with self-monitoring was the ability 
to test INR when and where desired. In the words of participant M4: 
 
“…in the comfort of your own home” (M4) 
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Sub-theme 2: Reassurance provided by patient self-monitoring 
 
As discussed earlier, patient self-monitoring of oral anticoagulation is at least as safe 
as usual management. Increased frequency of testing may improve INR control in 
its own right and has been cited as a possible confounding factor in these trials.78  
 
Two participants felt that the ability to test their INR more frequently would be 
reassuring and may also result in fewer erratic INR results. 
 
“Occasionally, you know, when you don’t have your appointments perhaps for 
maybe 3 or 4 weeks, you know, you …I mean I personally tend to wonder if it’s 
actually at the right level or …. And again, I think that’s where this self-
monitoring comes in. Because if you do get a little bit worried say within in a 
week or … you could actually do it yourself and you would know, put your mind 
at rest.” (M3) 
 
“Yeah. I … I mean, I think that’s good that you can test your blood if you have 
any concerns about it, you know, rather than think, you know, I’ll go to the 
clinic in 3 weeks time I’ll test it then. Because my warfarin … my INR’s been 
quite erratic. If I have a feeling I should be testing it that’s when I want to test 
it. I don’t want to wait 2 weeks because, you know. I could end up with a 
situation I was on holiday where I came back and it was 6.7. My other half 
laughed. He said ‘Oh well at least there’s no chance of you getting a blood clot 
on the plane’ (laughs)”(F5) 
 
Theme 2: Concerns about patient self-testing 
 
As well as the perceived benefits, it was equally important to tease out any concerns 
that participants may have about self-monitoring their INR. Potential disadvantages 
of patient self-monitoring cited in the published literature include increased anxiety 
and obsession with health, reduced access to healthcare professional, the cost of the 
coagulometer and the training & support that will be required. Our sample’s 
comments partially reflected these potential disadvantages - in that they had 
concerns about the support that would be provided for those self-testing and there 
was much discussion about purchasing the coagulometer - but they had additional 
concerns, including eligibility of patients to self-test, introduction of self-monitoring 
and adjustment of the warfarin dose. These will now be discussed, with the 
exception of the coagulometer which is discussed separately in this chapter.  
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Sub-theme 1: Support for patient self-monitoring 
 
Support for patients who self-monitor was felt to be essential and two-dimensional. 
Firstly, a need for advice and support on an ad-hoc basis was identified. The ability to 
access this advice in a timely manner was also important. An alternative to a 
telephone helpline would be delivering support to those self-monitoring via email or 
a website. However, this was felt to have its limitations: 
 
“I’d rather speak directly to somebody …. Without really speaking to you, you 
can’t … well you can put words in speech what you can’t put on an email, put it 
that way … You can say a lot in a matter of just one little sentence and get the 
right advice back.” (M5) 
 
One participant felt that this support should be at least equal to the current 
satisfactory clinic support: 
 
“And I guess that the other .. the other point is that you do feel confident too in 
the clinic because you realise that you can ring and can say  “I’m doing this” 
or “Can I change the day?” as you … as I’ve had to do on odd occasions over 
the past year.  So having that back-up is quite helpful that if,  you know, one … 
if  there is uncertainty then being able to contact or phone somebody is quite 
helpful. And the staff have been very helpful and reassuring about making plans 
where it might be a bit complex like, you know, for work or going away on an 
overseas trip and getting some advice about timescales for adjusting taking 
medication. So one or two times when it’s really been very, kind of  reassuring 
to sit down and just talk through exactly what the plan is. This doesn’t happen 
too regularly but it is .. it is helpful in that circumstance.” (M2) 
 
The ability to access this advice in a timely manner was also important.  
 
“But then you can’t always get through to the clinic. Sometimes you can. I’m 
not saying always. But sometimes it is … it’s like ‘Oh leave a message’ Like all 
these places. You ring, ring and leave a message and they don’t always come 
back. So really, you’d need to be …. I suppose if you were doing something like 
that you’d need then to be assured that you’d be guaranteed to get through to 
somebody.” (F3) 
 
But helpline-type advice is only one aspect of support. Some participants were 
reluctant to completely lose contact with the existing specialist service and felt that 
regular follow-up sessions with their anticoagulant practitioners would be necessary 
to check on progress.  
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“It’s no good sort of just giving somebody a machine and saying ‘Well there 
you go. You know how to prick your finger and  it’s up to you now’ sort of thing 
You know. There has to be  some sort of monitoring or follow-up … I would 
have thought something on the idea, as I say, of after an operation  when you 
had perhaps a six-monthly check-up and then perhaps a yearly one. And even if 
you did that for the first sort of 2 years after, or 3 years after someone’s had the 
machine perhaps you could incorporate it in … I mean, I don’t know how many 
have sort of yearly check-ups with warfarin. I mean, I actually come up every 
year to have like the heart checked and that and whether they could incorporate 
just a check.” (M4) 
 
Views on the frequency of such clinic follow-up visits for self-testing patients 
varied, but one participant felt that the time interval between these visits should be 
not be prescriptive but instead meet the needs of individual patients. 
I think it’s [clinic support] very important because if you have any concerns it’s 
like you say, it’s your health. It’s your health so it’s very important. (M5) 
 
Sub-theme 2: Eligibility for patient self-monitoring 
 
Some participants had doubts as to the ability of some patients to cope with self-
monitoring, particularly the elderly and those with complex medical problems. 
 
“I mean not being funny, perhaps not for sort of somebody like me who is again 
able, you know, to do these sort of things. But when you’re looking at people 
who are a bit older  and as I say - I’ll reiterate it again - they don’t even know if 
they’ve taken their warfarin or, you know, forget that they’ve posted a letter 
and, you know, that would be to my mind a very hard thing to try to get across 
to somebody like that. Do you put a sort of an age limit on it or …?. How do 
you define who is actually fully capable of doing … you know, it is very difficult, 
I’ll admit. Very difficult. Because you’ve got people who are, you know I mean, 
they’re perhaps sort of in their 80’s but they, you know, they got minds of a 50 
yr-old. I mean, so how do you, again, put a dividing line on it? I don’t think you 
could.” (M4) 
 
Sub-theme 3: Introduction of patient self-monitoring 
 
Views on the best way to introduce self-monitoring varied, with some participants 
favoured a ‘softly softly’ approach, with a slow introduction to self-monitoring to 
instil confidence. 
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“What I was thinking about was that this system [self-monitoring] should be 
introduced slowly – not given to them at the first instance when they come to the 
warfarin clinic… Perhaps within 3 or 6 months … You should have them … 
Perhaps you could get the lab people when they .. to take a set of readings here 
and then ask to use the machine to show its accuracy.” (M1) 
 
Each person has a unique approach to self-management, and this approach may 
change over time. Patients’ perspectives shift over the course of their illness, due to 
changes in disease severity but also due to psychological factors.159 This was 
reflected in the following comment: 
 
“I guess one preliminary point I’d like is that I think your capacity to decide on 
(dosing) changes as you become more familiar with the process as it were, and 
really with what the warfarin is doing. And so in this sort of context you need to 
find out a bit more about the heart and the consultant (…) and that gives you 
greater confidence in a way in understanding what the Warfarin is doing and 
why the anticlotting agent is kicking in.  So I think my confidence has grown as 
I’ve understood the problem a little more and in a little more detail. Having … 
once you achieve that level, I … I would certainly be happy to contemplate 
doing it at home and adjusting the dose myself.” (M2) 
 
Sub-theme 4: Dose adjustment for self-management 
 
There was some anxiety at the prospect of adjusting the dose of warfarin in the 
event of self-management: 
 
“It’s …I mean from my point of view, I mean I don’t know how many other 
people experience it but, you know, sometimes …  I mean I can go for a few 
months and it’s … it’s quite level and it’s good. And then all of a sudden, for 
some reason, it will all, you know, just decide to play it’s own game and … and, 
you know, if you get a situation like that then obviously people who find 
themselves in that situation have got to be able or to sort of regulate their own 
doses and manage, you know, because … As I said to you just earlier on, … I 
mean I’ve been on it for 14 years and even now I don’t know how to … if my 
INR is high or …  I don’t actually know how to regulate my dose. It’s only 
because I come to the clinic. They then tell me it’s high, they then regulate it. So 
from that point you are, or I am at the moment, solely in their hands.” (M4) 
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Theme 3: Information requirements to support patients who are self-testing 
 
The patient’s knowledge and understanding of OAT is perceived to play an 
important part in the success of this treatment, and part of these interviews focused 
on the information needs of those self-testing oral anticoagulation.  
Sub-theme 1: The importance of information  
 
There were polarised views on the importance of providing information. 
 
One interviewee was particularly vocal in his view that education was pivotal to any 
warfarin patient self-monitoring programme. 
 
“I think if it’s … if it’s going to be done, I think it’s got to be a sort of a full 
educational programme more than just getting people to just take their own 
blood. Basically, what I’m saying at the end of it is I feel by doing this it’s the 
educating of people that I think is the most important point.” (M4) 
 
However, another interviewee felt that education would be of benefit only when 
new information had become available: 
 
“You know, but if it’s still in the same light that it was years ago, you know, I 
don’t see … I don’t see the point of me learning it when you already know it.” 
(M5) 
 
Some participants felt that they would need information on warfarin irrespective of 
whether they were self-monitoring their treatment.  
 
“How to deal with bleeding? Well I’d need to know that anyway … a lot of this 
would apply even if you weren’t testing yourself? It still applies whether you’re 
coming up here and having it done.” (F1) 
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Sub-theme 2: Types of information needed 
 
There were contrasting views on the importance of different types of information. 
Information on diet and drug interactions in particular was thought to be important.  
 
“It comes back to things like foods, what you’re allowed to eat and what you’re 
not. And another important point I would think from … from that point of view 
is, again, it all comes down to educating people into it, is what other medication 
must you can actually take, you know, with warfarin.” (M4) 
 
Other participants focused on the more ‘hands-on’ skills that they felt they would 
need to self-manage their oral anticoagulation testing and dosages, including an 
awareness of when to seek further help, an ability to recognise when the INR was 
too high and how to adjust their dose of warfarin. 
 
“If you had access to the algorithm, I’m reasonably confident that you could 
actually kind of chart that [dose adjustments] yourself. That could be … 
potentially the table that you would have in front of you and then potentially 
doing that on a weekly basis. One could do it more regularly but I think there is 
then kind of fluctuations and you would be forever changing your dose. So I 
think good advice about the degree of regularity of the checks and the nature of 
the sensitivity to the drug and the way in which you can manage that on a 
weekly basis I think would enable one to do it quite easily.” (M2) 
 
“How warfarin works is a common skill, although I don’t really think I’d 
wanna know how that …well, I don’t know … maybe I would … I mean I do .. 
but would I want to know?… Side effects … that’s the same isn’t it? I don‘t 
really need to know all this do I … well I do actually because I would wanna 
know why … if my INR was particularly high.” (F1) 
 
Sub-theme 3: Differing information needs 
 
People have varying information needs, both in the type and level of information 
and in the way in which it is delivered. This was observed by one participant:  
 
“People are different in different ways aren’t they. Some people like a lot of 
instructions and things to read and others don’t … they’d rather been shown 
and … and a demonstration.” (F1) 
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Another participant felt that detailed information on anticoagulation would be 
beyond the capacity of some patients: 
 
“[Detailed information is] too much for a normal patient to deal with. It 
depends on your medication and how educated they are.” (M1) 
 
It is unclear if a lower intensity of training is needed for those self-testing compared 
to those who are self-managing. Some felt that those who were self-managing may 
need more intense education than those who were only self-testing: 
 
“For self-testing all you need is to how to prick the finger or how to use the 
machine. For self-dosing you will need everything.” (M1) 
 
Instilling confidence by offering a staged education programme was favoured by 
one participant: 
 
“…a sort of progressive education into it, instead of just saying, ‘well, you 
know, there’s your machine, that’s how you use it, get on with it’ basically. 
‘We’ll see you, sort of, you know, if you think we need to’…I think the basis of 
this I think is more education for people. It’s not so much the machines and 
getting people to do it and that. I think people would be quite, you know, willing 
to do it. Or a lot of people, I would think, would be quite willing to do it. But I 
think a lot of it would be that the … they would be a bit apprehensive of, you 
know, as I said to you earlier, on how they would if their dose wasn’t right, how 
they would manage it and …. That would be, to my mind, where the 
apprehension would come in.” (M4) 
 
Sub-theme 4: Delivery of information 
 
Computer-based learning offers many potential advantages to patients wishing to 
self-monitor their oral anticoagulation. It allows the patient access to educational 
material in private when, and where, convenient. It has the potential to individualise 
material according to the patient’s needs, to reinforce learning and provide feedback 
on educational goals, and the ability to simulate life experiences.  
 
When participants were asked for their opinions on delivery of warfarin information 
by information technology views were mixed. For example: 
 
“I’d personally find it a very accessible way of obtaining information and 
interacting with the clinic.” (F1) 
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Versus … 
 
“I just … I just …. paper form me, yeah. You’ve always got it there with you to 
mind, hadn’t you?” (M5) 
 
Although one participant did not consider himself to be computer-literate, he would 
be happy to ask his partner to access warfarin information on the Internet: 
 
“I’d get somebody to print it off for me… I could stick it in my health file then.” 
(M3) 
 
A large number of patients attending the Whittington Anticoagulation Monitoring 
& Stroke Prevention Service are elderly, a group that is consistently under-
represented in terms of Internet usage. This was highlighted as a potential barrier to 
delivery of electronic information by one participant: 
 
“I may be being ageist but I don’t know if all of the older people may be …I 
mean just thinking about my parents I mean they’re not on-
line…thankfully.(laughs) Goodness knows what would happen if they were but 
yeah, I mean from my point of view that would be fantastic … an email resource 
… I mean I tend not to think of that because I’m kind of old-fashioned really 
(laughs) But having said that you might well say OK the people who are 
familiar with the Internet  and there are a lot of older people as well who are 
fantastic with it. I think that’s actually very easy because if I was … when I’m 
back at work picking up the phone and trying to get through to a clinic might be 
quite difficult whereas banging off an email or something or logging into a sort 
of chat thing would be much, much easier.” (F1) 
 
Theme 4: The technology itself – Coagulometers 
 
The technology itself – the coagulometer – stimulated much discussion through the 
course of these interviews. This can be considered as four sub-themes; cost, 
motivation for buying the machine, confidence in the machine and training. 
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Sub-theme 1: Cost 
 
In order for a patient to self-test of self-manage their warfarin, they first need to 
purchase a coagulometer (current price of £400) on which to measure their blood 
INR. This is a very different economic model than that adopted for other forms of 
self-monitoring such as blood glucose (SMBG). The blood glucose testing machines 
are given out free to patients, often through diabetes clinics, and the diagnostics 
manufacturers make their money through the sale of consumables. This difference 
was not lost on some of the interviewees: 
 
“Obviously £400 isn’t available to a lot of people to spend on something like 
that and  diabetics get them free don’t they?”(F5) 
 
“If they charged for the strips they would probably make more money anyway.  
So over a period of time, I mean, how many strips are you going to use 
compared to the machine? I mean, you know, you’re gonna use the machine 
once when you need it, obviously, and your strips. But you’ve only got one 
machine, but you’ll be using maybe hundreds of strips throughout your lifetime.  
It doesn’t really make a lot of sense actually.” (M4) 
 
Many participants commented on the cost of this machine, with some taking the 
view that this represented a barrier to the uptake of INR self-testing. 
 
“I think that’s going to be the biggest stumbling bloc. Now that is [the ability to 
buy a machine], again, a number one fly in the ointment for a lot of people, I 
would think. I mean I just looked at this sheet - £399 is a lot of money.” (M4)  
 
It was felt that the cost of the machine would represent a barrier in certain sectors 
of the population, particularly the elderly: 
 
“You know, when you’re talking about pensioners and things like that. You 
know £399 is probably a year’s electric bill or a year’s gas bill. Yes, that is a 
lot of for people to find.” (M4) 
 
There were several suggestions as to how to alleviate this financial burden. These 
included part payment by the hospital: 
 
“Well yeah. Even if they sort of said ‘ Well you can have it for this price’ 
whatever. You know, if you put something towards it.” (F4) 
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The husband of one interviewee felt that a hire purchase scheme may help some 
people in spreading the financial burden: 
 
“You’d have to do it over alternate months of paying for it, I think. Really.” 
(HF4) 
 
Roche Diagnostics, the manufacturer of the global market leader (CoaguChek™) 
operates a similar scheme where the user pays the company in instalments. 
 
One gentleman who had participated in a self-testing trial in the past suggested 
having a bank of loan machines available: 
 
“The ones that I’ve had in the past have always been on loan – I sign for them – 
and  I then I just give it back and they sign it off and I watch and make sure that 
they do sign it off and then I won’t get charged for it should they say that I lose 
it.” (M3) 
 
One solution proposed was to make a machine publicly available, for example in a 
community pharmacy. However, when one of the participants was questioned about 
this he argued that this proposal negated one of the big advantages of patient self-
testing: 
 
“But that to me … that in effect would be the same as going to a pharmacy to 
have your warfarin taken, wouldn’t it? There wouldn’t be a lot of difference. I 
mean, the idea or … the actual sort of proposal is … is to actually do it at 
home, in the comfort of your own home, when you want to do it sort of thing.” 
(M4) 
 
There were concerns that if the person was unable to use the machine, either 
through lack of dexterity or through medical limitations, that purchasing it would be 
a waste of money. These fears are not ungrounded. A meta-analysis, led by Carl 
Heneghan at Oxford, has analysed the reasons behind dropouts in trials of OAT 
self-monitoring.104 Difficulty measuring INR and lack of manual dexterity were cited 
by authors as reasons for patients dropping out of the study. 
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There were also concerns about the robustness of the machine: 
 
“And also is there a guarantee with the machine that if – ‘cos you’ve got a have 
some sort of guarantee on it – that if it goes in a certain time then somebody 
hasn’t got to go and pay another £400 for a machine… You know, well £400, 
what backing am I going to get with it.” (HF4) 
 
On a more philosophical level, there were some patients who adhered to the 
principle that the National Health Service (NHS) should pay for the machine since 
self-testing would ultimately be cost-effective for the NHS: 
 
“Cos I think some of the answers you’re going to be given to your questions is 
‘Well it’s the NHS. Why should I have to pay for it?” (F4) 
 
Sub-theme 2: Motivation for buying a coagulometer 
 
Despite the significant financial outlay required, if there are perceived benefits 
people may be persuaded to purchase a coagulometer. However, in the absence of a 
specific reason, people may not be prepared to accept this financial commitment: 
 
“If they’re going down the option to come to the clinic or buy a machine – it’s 
nearly £400 – so would you choose the clinic or the machine? If you’re not 
going abroad for any length of time … I would … I would … I would not have 
bought that machine had I not a mother who was living abroad and I had to go 
and visit her. Because I wouldn’t be going abroad for longer than 2 weeks.  So 
if I go abroad to long distance like that I go for 4 or 5 weeks. So you do need 
machine because it’s inconvenient to get your blood tested.” (F2) 
 
One participant felt that if anticoagulation was only short-term, it was not worth 
purchasing a coagulometer: 
 
“Well … yeah … let’s say agree because I don’t see why I’d want to 
particularly. If I was on it for life probably yes but let’s hope I’m not.” (F1) 
 
This comment is consistent with both UK and international consensus guidelines, 
which recommend patient self-testing is only appropriate for those on long-term 
treatment.36  
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Sub-theme 3: Confidence & trust in the machine 
 
Quality assurance of near-patient testing machines is essential to ensure that results 
are reliable.52 Reassurance about the accuracy of the coagulometer was important to 
some participants. 
 
Past experiences may affect the level of trust patients place in coagulometers. For 
example, one participant felt that a machine to measure blood INR would be prone 
to the same inaccuracies as a glucometer: 
 
“And I know that every machine has a tolerance … Because I have this problem 
… I used to have the problem in Trinidad and there was … with the machines 
and when I went to the distributors and they didn’t want to admit that there was 
a tolerance when all the literature shows that there is a tolerance, plus or 
minus.” (M1) 
 
Two participants had had their blood tested on a portable coagulometer in the past, 
either through an outreach clinic in their GP’s surgery (M5) or in the course of a 
self-testing trial (M3). Both of their experiences highlighted a potential limitation of 
portable coagulometers, namely their loss of sensitivity at high INR values.  
 
“So I done the training course and I proved that I could prick me finger, put the 
blood on the unit, it measured it and it always came up “Seek immediate 
medical advice” (laughs) And they couldn’t believe that their machine wouldn’t 
give a true reading. They took it … pricked me finger as they took the blood out 
of the arm and they all went off to do their thing – get the results and so on. And 
I sat outside and wait and the lab result is what we would expect and their 
result was “help”!” (laughs) (M3) 
 
But for some patients their views on using a coagulometer could be distilled down 
to basic trust and a perception that only something ordained or provided by the 
hospital is ‘good’: 
 
“Well, I think that … well I wouldn’t … you see if I wasn’t just looking at it I 
wouldn’t trust it. I’d think ‘oh that’s a gadget’. I wouldn’t trust anything that 
wasn’t given to me by the hospital I have to say. But then that’s me.” (F1)  
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Sub-theme 4: Training in using the coagulometer 
 
Many participants stated that instruction on using the coagulometer was a 
prerequisite for its use. However, one gentleman was almost blasé about capillary 
blood testing: 
 
“I mean, really, to be honest, once you’ve been shown the machine - and 
actually sort of taking your blood is not hard is it as such?… If it’s  … if it’s a 
prick in the finger. Alright it might be if you were trying to go through into sort 
of arms and veins and things like that, that’s a different story. But if it is a 
proper machine that just does a finger prick, there can’t be anything really 
drastically hard about that. So I should think a lot a people will say ‘Yes. That’s 
fine. That’s no problem’.” (M4) 
 
Those participants who had previously self-tested (F2, F5 and M3) were able to add 
valuable insights based on their experiences. Although F2 had purchased a machine, 
she did not feel confident enough to use it.  
 
“I gave up with it. Because I thought I’m not going abroad so I don’t have to 
bother about it. So I have it but I must try and find it. But I have it and I have all 
the literature but it didn’t make a blindest difference to me because when I did 
test it didn’t come out right and I thought ‘I can’t be bothered with this’ and I 
put it down. So if you’re not having it up and the patient is not fully (confident) 
with it it’s a waste of time... The thing is, honestly, if I hadn’t used it I would 
have shipped it back to them.” (F2) 
 
The manufacturer of the market-leading machine provides educational material on 
how to use the monitor in the form of written information and a video DVD. There 
were conflicting views on how useful this information was. Two participants felt 
that this was not sufficient in itself: 
 
“I would have to be shown how to use my machine. Because, actually, 
physically reading the papers with didn’t make one bit of difference at all. (F2) 
 
And the information sheet that you got with the piece of equipment was about 
an A (dot) size piece of paper with very small print – it was like rice paper – 
with all the information. I sat and read the whole lot … (laughs) … it took a 
while actually and-and it was quite small font, and …?”(M3) 
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However, the third participant felt that the video was beneficial: 
 
“You get a video with it which is pretty informative. I mean that’s quite good. 
Well you can watch it over and over again. If there’s a point you’re not happy 
about at least you’ve got that video. Whereas if you go to the clinic, like any 
visit to the doctor, you come out and you’ve forgotten what he’s said to you.” 
(F5) 
 
 
5.2.6 Limitations 
 
This study, interviewing a larger group of patients who were not self-monitoring, 
identified some potential benefits of patient self-monitoring, namely increased 
convenience and reassurance, and better INR control. Challenges centred on patient 
selection, educational support. As with the group of self-monitoring patients, the 
need for the patient to purchase a coagulometer was identified as a barrier to 
establishing a patient self-monitoring service.  
 
The mixture of purposive and convenience sampling used in this study is a non-
random method of selection and, as such, lacks external validity. However, the aim 
of this part of the study was to test ideas and topics to used in a larger study, rather 
than apply the findings to a wider population. 
 
The next study – a survey of local anticoagulant clinic patients – aimed to explore 
the views of a wider population. 
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5.3 Patient Study 3: A survey of local anticoagulant clinic 
patients 
 
The in depth discussions that took place during the interviews reported in the 
previous section allowed the important themes relevant to patient acceptance of 
self-monitoring to emerge in an open, uncontrolled unconstrained way, and for 
these issues to be explored in some detail. However, as non-randomised sampling 
method used, it could not be inferred that the views of this group were 
representative of anticoagulated patients at the Whittington in general. It was 
therefore important firstly to validate the themes with a wider sample of patients. 
Secondly, it was also desirable  to obtain information on the proportion of patients 
who would be willing to self-monitor, and which patient characteristics were 
associated with a willingness, or not, to self-monitor. In contrast to the purely 
qualitative method of the previous section, it was therefore decided that a semi-
structured questionnaire survey, which would yield data for quantitative analysis, 
would be the most appropriate method to use here.  
 
This next section describes a survey of local anticoagulant clinic patients. 
 
5.3.1 Aims and Objectives 
 
The main aim of this study was to explore the perspectives of patients on long-term 
warfarin on patient self-testing and self-management, including drivers, benefits, 
barriers and challenges.  
 
Within this aim there were two objectives: 
 
i. To establish the proportion of the clinic population who would be willing to 
self-monitor their OAT 
 
ii. To identify the patient characteristics associated with a willingness to self-
monitor OAT 
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5.3.2 Recruitment of sample 
 
Questionnaires were posted to 672 patients in August 2007. 
 
5.3.2.1 Inclusion and exclusion criteria 
 
The aim of this survey was to obtain the views of a cross section of the population 
who currently used the existing service.  The sampling frame was the patient list of 
the Whittington Anticoagulant Monitoring and Stroke Prevention Service. The 
population of interest was adult patients attending one of the clinics of the 
Whittington Hospital Anticoagulation and Stroke Prevention Service, who met the 
following criteria:  
 
i. A long-term indication for warfarin  
ii. A good grasp of the English language 
 
Both UK and international consensus guidelines agree that only patients who are on 
long-term treatment with oral anticoagulation should be considered for self-
monitoring. The reasons behind this are largely pragmatic; by the time a person on 
short-term treatment is trained and proficient in self-monitoring, warfarin may have 
been discontinued.  
 
Although it is acknowledged that excluding those who do not speak English is 
potentially discriminatory, including this group of patients would have created 
practical difficulties. If the questionnaire was completed by those who have very 
little command of English, this could have led to false information and error. 
Although a relative or carer could assist with this task there is no way of 
guaranteeing the reliability of the person they seek help from. Within the current 
funding constraints, it was not possible to translate the questionnaire and 
supporting material into other languages. Also, the dominant coagulometer used in 
the UK is driven by an on-screen menu in English. 
 
Patients’ command of the English language was assessed by clinic staff before 
randomisation. A patient list was presented to them and they were asked to identify 
patients for whom completing the questionnaire might present problems. These 
patients were excluded from the sampling frame.
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Exclusion criteria were as follows: 
 
i. Those who were on an alternative oral anticoagulation agent 
ii. Those who were out of the country long-term 
iii. Those who had been interviewed during the pilot study  
 
The overwhelming majority of Whittington patients take warfarin, and an alternative 
anticoagulant agent is only prescribed if a person develops intolerance to warfarin. 
As all of the clinic dosing algorithms relate to warfarin, it was felt that if a patient 
was taking an another oral anticoagulant the clinic staff would not be able to offer 
sufficient support if they wished to self-monitor. 
 
5.3.2.2 Sample size 
 
The final questionnaire was a mostly structured instrument, pre-coded for ease of 
analysis, and included several questions with a binary or categorical response format. 
Advice from a statistician was sought, and a precision (width of confidence interval) 
of +/- 6% was deemed sufficient. The required sample size varies by the proportion 
answering "yes" to a question. The primary objective of the survey was to find out 
how many of our clinic population would be willing to self-test. This proportion - a 
“worst case scenario” for statistical purposes – was assumed to be 30%. Pooling of 
data from UK trials suggest that only 24% of eligible patients would agree to 
conduct self-monitoring.28  On this basis, the sample size required to achieve the 
aforementioned precision for a true proportion of 30% was calculated. The required 
sample size was 224. Assuming a 30% response rate, this required 672 
questionnaires to be sent out. 
 
5.3.2.3 Sampling method 
 
Systematic random sampling was applied until a total of 672 patients had been 
sampled. This was done using Excel™. All eligible patients were put into an 
Excel™ spreadsheet and, using the random worksheet function, each entry was 
assigned a random number. These entries were then re-ordered according to this 
random number and the first 672 entries selected. 
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The methodological and data analysis approach to this study is summarised 
below. 
 
Descriptive and inferential 
statistical analysis applied 
to fixed response questions
All coded data from 
questionnaires entered on 
SPSS 14.0
Consensus reached 
between two sets of themes 
and a code assigned to each 
theme. These codes added 
to coding frame.
Questionnaire posted to random sample
Answers to fixed response 
questions coded using the coding 
frame
Themes from open 
questions identified by a 
second reseracher 
Themes from open 
questions identified by 
author
All questionnaires coded 
using coding frame
Open questions reported as 
themes
Codes assigned to fixed 
response questions in 
questionnaire and coding 
frame developed 
Reminder letter sent if 
necessary
Sub-sample of 30 
questionnaires selected
  
Figure 16: Patient Study 3: Methodological and data analysis approach 
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5.3.3 Method 
 
The final questionnaire, covering letter, study information sheet and a postage-paid 
envelope for return were posted to 672 subjects. Assuming that the majority of 
participants would not be familiar with warfarin patient self-monitoring, an 
information sheet about self-monitoring was also provided to allow them to reach a 
more informed view of this method of monitoring. Following feedback from the 
previous study (Patient Study 2), the existing information sheets A and B were 
merged into one. A reminder letter was sent a month later to those who had not 
returned a questionnaire. 
 
Respondents were given the opportunity to remain anonymous. However, they 
were asked if they would be willing to include their name with a view to 
participation in later stages of the study. Respondents were assured of the 
confidentiality of their responses. 
 
The study invitation letter, study information sheet and reminder letter can be found 
in Appendix 7. 
 
The questionnaire and information sheet on warfarin patient self-monitoring sent to 
patients can be found in Appendix 8. 
 
Local Research and Ethics approval was granted for this study (as part of the same 
application for Patient Study 2). The relevant correspondence can be found in 
Appendix 4. 
 
 
5.3.4 Analysis 
 
Data from the returned questionnaires were coded and entered into SPSS 14.0, 
which was then used to generate statistical analyses. The coding process and 
subsequent statistical analyses will now be described. 
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5.3.4.1 Coding 
 
Coding was used to conceptualise the responses to the survey and to classify these 
data into meaningful categories. Most of the questionnaire was made up of fixed 
responses, which were one of three types: 
 
i. Dichotomised (e.g. yes / no response choices) 
ii. Multiple choice (offering three or more choices. For some of these 
questions, there was no restriction on the number of responses which could 
be selected) 
iii. Scaled (one response code per response frame allowed. Likert scales were 
used to measure level of agreement) 
 
A number – the ‘code’ - was assigned to each category, and from this a coding 
frame was developed. The coding frame comprised the responses to each question 
along with their unique numerical code.  
 
The same numerical codes were assigned to the following response categories 
throughout the questionnaire: 
 
Yes 1 
No 0 
Do not know 7 
Does not apply 8 
Missing response 9 
 
For other response categories, a unique single or double-digit code was assigned to 
each response within each question. For ordinal data, higher numbers were used to 
indicate higher rank or more magnitude.  For nominal data, sequential numbers 
were used.  
 
But there was the possibility that such closed questions will miss some unanticipated 
patient concerns or perspectives. Therefore, some open-ended free-text questions 
were included. Here inductive coding was used, using a sample of data to develop a 
scheme, and then applying this to the whole. To develop codes for the open 
questions a sub-sample of 30 questionnaires was selected and the author transcribed 
responses to these questions together with a patient identifier number. From these 
responses, the main themes were identified by the author, who then coded the data 
into categories assigning a unique code to each category.  
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During the coding process a few problems were encountered. The first difficulty 
was where participants had supplied an ambiguous response, with their answer 
straddling two response categories. A record of these responses was made and 
answers evenly attributed to each category. The second problem was where one 
response to a question was requested, but the respondent answered with more than 
one response. In these instances, the responses were combined into pair and coded 
as a separate entity. 
 
A second researcher (JM) then independently identified the main themes of the 
responses to open questions. Concordance between two sets of themes was 
achieved and these themes were then coded. Both researchers agreed on the 
approach for handling the response problems referred to above. 
 
This coding frame was then tested on another batch of 30 questionnaires and some 
minor adjustments made. From the coding frame, a codebook was prepared. This 
was a master copy of the questionnaire, with the full range of valid codes and a 
unique variable label assigned to each question for the purposes of computer entry. 
Additionally, a coding transfer sheet was developed to facilitate transfer the 
responses from each questionnaire prior to computer data entry. Finally, all coded 
responses were entered on SPSS™. 
 
5.3.4.2 Statistical analyses 
 
All statistical analyses were performed using SPSS 14.0™. Advice from a statistician 
was sought. 
 
Descriptive statistics were used to provide summaries about the sample. Frequency 
was expressed as a percentage with confidence intervals applied to indicate the 
spread of results where appropriate. The median value, with its associated 
interquartile range, was used to measure the central tendency where necessary. 
 
Inferential statistics were used to examine the relationship of one variable with 
another. The test used depended on the type of data analysed. The tests used are 
summarised in Table 25. 
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Variable 2  
Binary Nominal Ordinal 
Binary Chi-square / 
Fisher’s Exact Test 
Chi-square / 
Fisher’s Exact Test 
Mann-
Whitney 
Nominal Chi-square / 
Fisher’s Exact Test 
Chi-square / 
Fisher’s Exact Test 
Kruskal-
Wallis 
 
Variable 
1 
Ordinal Mann-Whitney Kruskal-Wallis Kendalls Tb 
 
Table 25: Patient study 3: Statistical approach used to correlate patient survey data 
 
Where a there was a choice of using Chi-Square or Fisher’s Exact Test, the latter 
was used as it is considered to be more accurate and better suited for smaller data 
sets. 
 
5.3.4.3 Assessing non-response bias 
 
With mail surveys low response rates are the rule rather than the exception, and this 
can introduce a risk of bias. Those who do not respond may be very different from 
those who did respond. If substantial response bias is present, generalisability of the 
survey findings could be limited. 
 
The following characteristics were available for both respondents and non-
respondents: 
 
i. Age 
ii. Gender 
iii. Indication for warfarin 
iv. Clinic location 
 
To assess bias for this survey these characteristics were compared for respondents 
and non-respondents. To determine if bias was statistically significant with respect 
to gender, indication and clinic location (nominal variables), Chi-square tests were 
conducted. When age was plotted on a histogram, it did not have a normal 
distribution. Using a t-test, a parametric test, would not have been appropriate and a 
Mann-Whitney test (non-parametric test) was performed instead. 
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5.3.5 Results 
 
5.3.5.1 Sample 
Of the 672 questionnaires that were sent 297 were returned, representing a response 
rate of 44 %. 158 of these questionnaires (53% of returns) were received after the 
reminder letter was sent out. The demographics of the survey respondents are 
summarised in Table 26. 
 Number (n=297) 
Gender  
Male 173 
Female 121 
Missing response 3 
Age  
Older than 65 years 196 
56 - 65 years 49 
41 - 55 years 39 
18 - 40 years 11 
Missing response 2 
Indication for anticoagulation  
Atrial fibrillation 145 
Artificial heart valve 55 
Venous thromboembolism 51 
Mixed indication 21 
Other 12 
CVA or TIA 9 
Missing response 4 
Duration of anticoagulant treatment  
More than 5 years 134 
1 year - 5 years 131 
7 months - 11 months 18 
1 - 6 months 6 
Missing response 8 
Ethnicity  
White British 185 
White Irish 41 
White Other 34 
Black / Black British 18 
Asian  / Asian British 10 
Mixed race 4 
Other 1 
Missing response 4 
Education  
No formal qualifications 114 
GCSE level 32 
A level 17 
Diploma / NVQ 20 
Degree level 82 
Unwilling to say 32 
 
Table 26: Patent study 3- Demographics of survey respondents 
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Respondents were predominantly elderly, with 41% female and 58% male (3 
respondents did not state which sex they were). The age range of respondents is 
shown below. 
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Number of respondents
 
 
Figure 17: Patient study 3: Age of survey respondents 
 
The majority of respondents (62%) were White British, with a further 25% from 
other white ethnic groups. English was the first language for 83% of those who 
responded to this question. There were nineteen different first languages cited. 
There was a wide variation in the educational level of respondents.  
 
Nearly half of all respondents were taking warfarin for stroke prevention. Nearly all 
of the respondents (99%) had been on warfarin for at least one year, with over a 
half (134 patients) taking the drug for more than 5 years. 
 
Approximately two-thirds of respondents (67%) were monitored by the 
anticoagulant clinic at the Whittington, with the remainder attending a primary care 
clinic. Most of the patients attending the Whittington clinic (94%) were on the 
‘mailing list.’ 
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5.3.5.2 Assessing non-response bias 
 
No significant non-response bias was detected with respect to age (p=0.92), gender 
(p=0.09) and clinic location (p =0.49). However, there was a significant difference 
between responders and non-responders with respect to the indication for OAT 
(p=0.04). These results are summarised in Table 27. 
 
Responded to survey 
No Yes 
Indication for OAT 
n % n % 
Total 
Other 39 80% 10 20% 49 
CVA 11 64% 6 36% 17 
Valve replacement 60 54% 52 56% 112 
VTE 74 64% 42 36% 116 
Atrial fibrillation / atrial 
flutter 
223 63% 131 37% 354 
Total 407 66% 241 34%  
648 
 
Table 27: Patient study 3: A comparison of responders and non-responders to the 
survey with respect to indication for oral anticoagulation 
 
The indication of OAT was verified from the patient’s electronic anticoagulant 
health record. Twenty-four respondents chose to remain anonymous and, therefore, 
their indication for OAT could not be determined. Consequently, they had to be 
excluded from this particular analysis.  
 
5.3.5.3 Results 
 
The questionnaire was split into five sections, with a final (sixth) section requesting 
demographic information to place responses in context: 
 
i. Warfarin treatment and current health 
ii. Attending the warfarin clinic 
iii. Self-monitoring warfarin 
iv. Education and support for those self-monitoring warfarin 
v. Experiences with using computers 
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Similar to some of the emergent themes from the patient interviews, discussed 
earlier in 5.2.5.3, the results from some sections of this questionnaire - warfarin 
treatment and current health, attending the warfarin clinic and experiences with 
using computers- did not make a significant contribution to the research as they do 
not have a direct bearing on self-monitoring. Consequently, these results are not 
presented here but will form the focus of a separate clinical academic publication. 
Instead, more value was attached to examining the relationship of these variables 
with willingness to self-monitor in a quantitative manner. Therefore, statistical 
analysis will be used to correlate these factors – for example, the relationship 
between willingness to self-monitor and current health. 
 
The remaining two topics (sections) will now be discussed. Where appropriate, 
selective quotations are used to illustrate pertinent comments. 
Self-monitoring warfarin 
 
This section of the questionnaire explored attitudes towards warfarin self-
monitoring. It aimed to establish what proportion of the study sample would be 
willing to self-test or self-manage their oral anticoagulation therapy. It also aimed to 
establish which aspects of self-monitoring were potential barriers to uptake of self-
monitoring and, conversely, any factors associated with a willingness to self-
monitor. 
 
53% of respondents (150) said that they would be interested in self-testing their 
warfarin treatment if the Whittington clinic set up a programme to support them. 
[95% CI: 0.47 - 0.58]  When asked the same question of self-management, this 
proportion did not differ.  
 
Subjects were presented with a series of statements relating to factors that might 
influence their decision to self-test or self-manage their warfarin, and asked to 
indicate their strength of agreement on a scale from 2 – 6, with 6 being the most 
positive score and 2 the most negative score (negatively worded questions were 
reverse coded). 
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The median values for these responses are listed in Table 28, with the associated 
interquartile range to indicate the dispersion of results. 
 
Strength of agreement with statement  
Median value Interquartile range 
Able to prick finger 5 4 – 6 
Able to test blood 5 4 – 6 
Able to adjust dose of warfarin 5 4 - 5 
Miss other patients attending clinic 5 5 – 6 
Like more control over warfarin 4 3 – 5 
Miss staff at warfarin clinic 4 3 – 5 
Able to buy machine 3 2 – 4 
Happy to buy machine 3 2 – 4 
 
Table 28: Patient study 3: Factors that might effect the decision of patients to self-
monitor warfarin 
 
Patient factors associated with a willingness to self-test  
 
The patient sample willing to self-test was the same as those who were willing to 
self-manage. Therefore, for this analysis, all associations are made with those who 
were willing to self-test; two separate analyses – for patient self-testing and self-
management – were not performed. 
 
A variety of patient factors were found to have a significant positive correlation with 
a willingness to self-test are shown in Table 29. 
 
Factor Level of significance  
Younger age (those < 65 years) p < 0.001 
Educated to a higher level (those educated to GCSE 
level and above) 
p < 0.001 
Clinic visits causing disruption to life p=  0.002, p = 0.015 
Good health (those with perceived “good” or 
“excellent” current health status) 
p = 0.016 
Fewer concomitant medicines p = 0.037 
Prior awareness of self-testing p < 0.001 
Ability to sample & test blood,  p < 0.001, p < 0.001 
Ability & willingness to purchase coagulometer p < 0.001, p < 0.001 
 
Table 29: Patient study 3: Patient factors associated with willingness to self-test 
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Younger respondents (z = -4.33, p < 0.001) or those educated to a higher level (z = 
-4.60, p < 0.001) were significantly more likely to be interested in warfarin self-
testing. The respondent’s gender (Fisher’s Exact Test, p = 0.23), whether English 
was their first language (Fisher’s Exact Test, p = 0.53) or their ethnicity did not 
significantly affect whether they were interested in self-testing (Χ2 – test, Χ2 (5) = 
8.31, p = 0.14).  
 
Where respondents had their warfarin treatment monitored (i.e. hospital or in 
primary care) did not significantly affect their willingness to self-test (Χ2 – test, Χ2 
(2) = 2.89, p = 0.24). Also, the frequency of warfarin monitoring (Z = -.55, p = 
0.58) and the time commitment needed for these visits (both in terms of travel time 
(Z = -1.83, p = 0.068) and time spent in the clinic (Z = -0.17, p = 0.86) did not 
significantly affect respondents’ willingness to self-test. 
 
However, how easily the clinic visits fitted into respondents’ lives significantly 
affected whether they were interested in self-testing, as assessed by the response to 
two attitudinal statements; “I find it easy to plan my life around my Warfarin clinic visits” ( 
Z = -3.01, p = 0.002), and “I find my Warfarin clinic visits disrupt my life” ( Z = -2.44, p 
= 0.015). Levels of satisfaction with the current service did not have a significant 
effect on the potential willingness to self-test in this study population. (Z = -0.33, p 
= 0.74) 
 
Whether respondents required assistance with warfarin management at home did 
not significantly affect whether they would be willing to consider self-testing 
(Fisher’s Exact Test, p = 0.069). Although there was a trend towards a willingness 
to self-test if the respondent considered that warfarin had had an impact on their 
life (Fisher’s Exact Test, p = 0.052) or if they had experienced bleeding during 
treatment (Fisher’s Exact Test, p = 0.056) this was not statistically significant. 
 
If the respondent considered himself to be in good health, they were significantly 
more likely to be willing to self-test their warfarin treatment (Z = -2.41, p = -0.016). 
Similarly, the less concomitant medication the patient was taking, the more likely 
they were to be willing to self-test (Z = -2.08, p = 0.037).  
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Ninety-six respondents (33%) had heard of patients self-testing or self-managing 
their warfarin treatment before receiving the questionnaire. If respondents were 
aware of self-testing before the survey, they were more likely to be willing to do it 
(Fisher’s Exact Test, p = <0.001). 
 
A perceived ability to both obtain and test a blood sample was highly significantly 
associated with the likelihood of the patient self-testing. If a respondent felt that 
they would be unable to obtain a capillary blood sample, they were not likely to be 
interested in self-testing (Z = -8.82, p < 0.001). Similarly, if they thought that they 
would not be able to use the coagulometer they were also not likely to be interested 
in self-testing (Z = -10.18, p < 0.001). An ability to purchase the coagulometer was 
significantly associated with a willingness to self-test (Z = -5.40, p < 0.001) as was a 
willingness to buy the machine (Z = -6.54, p < 0.001). 
 
Finally, there were two statements included in the questionnaire relating specifically 
to self-management of oral anticoagulation; whether patients would miss the clinic 
staff and if they felt they would be able to adjust their dose of warfarin. Those who 
felt that they would not miss the clinic staff were significantly more likely to want to 
self-manage their Warfarin (Z = -5.28, p < 0.001).  
 
The association between the confidence of the respondent to adjust their dose and a 
willingness to undertake self-management was even more striking. Of the 61 
respondents who ‘disagreed’ or ‘strongly disagreed’ that they would be able to adjust 
their dose of warfarin, only two felt they would like to self-manage.  
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Education and support for those self-monitoring Warfarin 
 
Support for OAT self-monitoring 
 
Respondents were asked to indicate how important the following elements of 
support for self-monitoring OAT were on a scale from 2 – 5, with 5 being the most 
positive score (very important) and 2 the most negative score (not important).  
 
i. Being provided with warfarin education 
ii. Making it easy for them to contact the warfarin clinic 
iii. Clinic providing coagulometer 
iv. Receiving regular clinic check-ups 
 
The median score for all four elements was identical at 5 (very important). These 
results are presented graphically in Figure 18. 
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Figure 18: Patient study 3: Patients’ views of the importance of elements of self-
monitoring support 
 
 
Respondents were then asked to suggest other ways that the clinic could support 
them if they were to self-monitor their oral anticoagulation. This generated 
suggestions from 56 respondents which are summarised in Table 30. 
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Support element Number of 
respondents 
Further information 
Support from clinic staff 16 ¾ Domiciliary visits 
¾ Telephone support 
¾ Email support 
¾ A dedicated 
website 
¾ Sending INR by 
computer to clinic for 
remote monitoring 
Lack of confidence in ability to 
self-monitor  
12  
Clinic to provide coagulometer 9  
Other 7 ¾ Peer support 
¾ Request to view 
evidence to support 
self-monitoring 
Prefer to continue attending 
clinic 
6  
Concerns about QC of 
coagulometer 
6  
 
Table 30: Patient study 3: Survey respondents’ suggestions for self-monitoring 
support 
 
However, not all of these comments related to ways that support could be offered, 
but instead respondents used the question as an opportunity to voice concerns 
about self-testing. An overarching concern was the ability to access the clinic for 
advice when required, echoing comments from the pilot interviews group. 
 
Six patients stated a strong preference for continuing to have their INR monitored 
at an anticoagulant clinic. 
 
“No own test. Leave it to the expert.” (Respondent 264) 
 
Closely linked to this were respondents’ concerns about their ability to self-test: 
 
“I prefer to have my blood test done by a professional person. I think I would 
find the strip difficult to use, although I have no problem testing my blood sugar 
with the monitor.” (Respondent 21) 
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Educational requirements for patient self-monitoring 
 
Respondents were also presented with a list of potential educational requirements 
for OAT patient self-monitoring, and were asked to indicate which option would be 
useful. The results are represented in Figure 19 below. 
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Figure 19: Patient study 3: Survey respondents’’ requirements for individual 
educational elements to prepare them for anticoagulation self-monitoring 
 
The more ‘practical’ skills were the most popular options – how to use the 
coagulometer, deciding why the INR is out of range and warfarin dose adjustment 
skills – although being taught finger-prick technique was less popular. This could be 
because some patients were also diabetic and were therefore familiar with this 
technique, or that simply respondents felt that it was straightforward and they did 
not require formal teaching. 
 
Subjects were then asked to suggest other types of information or skills that might 
help them take a greater role in managing their warfarin treatment. A total of 25 
respondents provided comments. As before, many of these respondents (n=13) 
expressed a preference to remain with the clinic or a lack of confidence to 
undertake self-monitoring.  
 
“At 91, I do not want to be expected to do tests on myself. It is enough to 
manage myself from day to day without any extra responsibilities. I feel happier 
with trained hospital staff doing the testing.” (Respondent 159) 
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Seven patients requested a ‘higher’ level of warfarin information, supported by 
written information. Again, assistance with quality assurance of the coagulometer 
was important to some patients. 
 
5.3.6 Limitations 
 
Steps were taken during this study to increase its validity. Face, content and 
construct validity were increased by extensive piloting of the questionnaire, initially 
through expert review and then by using the instrument to conduct face-to-face 
interviews with ten patients. This piloting ensured that the questions were 
unambiguous and were likely to yield accurate information, that all possible 
responses were were included, that questions would measure what they were 
intended to measure and that the questionnaire would included all relevant issues.  
 
The main weakness of pre-coded responses may not accommodate all possible 
answers. This may force respondents to select pre-coded responses that do not fully 
represent their views, threatening validity. To try to mitigate this, although the 
questionnaire was largely structured, it also contained some optional questions 
requiring a free text response, accommodating more patients’ views.   
 
Biases can affect both the validity and reliability of an instrument. Although postal 
self-completion surveys eliminate interviewer bias, response bias can be accentuated. 
Therefore, reminders and second questionnaires were used to increase the response 
rate and non-response bias was measured. Response style (‘yes-saying’) bias was 
guarded against by including both positively and negatively-worded questions. 
Sampling bias was guarded against by using a randomised sampling. 
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Reliability in questionnaire studies relates to their reproducibility; that is ability of 
the instrument to produce the same results if it were tested it many times over. 
However, this is difficult to demonstrate in practice. If time had permitted, test-
retest, a statistical method used to determine an instrument’s reliability, could have 
been performed.139 This would have entailed testing the questionnaire on a small 
number of the study sample twice, several weeks apart, and performing statistical; 
tests to measure correlation. Although opinion is divided on which statistical tests 
are the best measure of correlation, Cohen’s kappa coefficient (nominal data), 
weighted kappa (ordinal data) or Pearson’s coefficient (interval data) are generally 
used. 
 
This chapter has described three studies exploring patients’ perspectives of OAT 
patient self-monitoring. The final section of this chapter consolidates and 
summarises these results and places them in the context of published work.   
 
5.4 Summary of patients’ perspectives on OAT self-monitoring 
 
The findings from these three studies are summarised in Table 31. No weighting 
was applied to the results from the three individual studies; the first two studies 
recruited far smaller patient numbers. However, a different set of results was 
generated from each study. Therefore, to ensure a comprehensive set of findings, 
the results from all three studies are presented.  
 
There are four distinct sections to this table – drivers, benefits, barriers and 
challenges to OAT patient self-monitoring - derived from the perspectives of 
anticoagulated patients. Sub-themes within these broad themes are described, with a 
summary of supporting evidence from each of the studies where available. Finally, 
these sub-themes are mapped to a suggested, or ‘candidate’, service requirement 
from a patient perspective and where it fits within the Donabedian framework. 
 
These results will be triangulated with the findings from the next chapter, which will 
explore the perspectives of healthcare personnel.
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Table 31: Summary of patients' perceptions of OAT self-monitoring (drivers) 
 
Patient perspectives Drivers 
Exploratory 
interviews with self-
monitoring patients 
Interviews with local 
anticoagulant clinic 
patients 
Survey of with local 
anticoagulant clinic 
patients 
Derived candidate 
service requirement 
Donabedian 
framework 
element 
Convenience Convenience cited as a 
major motivating 
factor for starting OAT 
self-monitoring 
Convenience identified 
as a potential benefit  
Patients were 
significantly more 
willing to self-monitor 
if clinic visits were 
disrupting their life 
Self-monitoring service 
is acceptable to patients 
Outcome 
Independence The need for more 
independence was a 
driver for starting 
OAT self-monitoring 
  Self-monitoring service 
is acceptable to patients 
Outcome 
Availability of 
support for patients 
The support of 
healthcare 
professionals and 
family were important 
when starting to self-
monitor. 
Ability to access advice 
and for the clinic to 
provide regular reviews 
was important 
Support from the 
clinic was considered 
very important if self-
monitoring OAT. The 
availability of timely 
advice was a concern. 
Provide ongoing 
support for patients 
(regular review and 
ad-hoc support) 
Process 
Awareness of OAT 
self-monitoring 
  Patients who were 
aware of self-testing 
before the survey were 
significantly more 
willing to self-monitor 
Promote the self-
monitoring service to 
patients 
Structure 
 
 
 178  
Table 31 (cont): Summary of patients' perceptions of OAT self-monitoring (benefits) 
 
Patient perspectives Benefits 
Exploratory 
interviews with self-
monitoring patients 
Interviews with local 
anticoagulant clinic 
patients 
Survey of with local 
anticoagulant clinic 
patients 
Derived candidate 
service requirement  
Donabedian 
framework 
element 
Convenience Convenience cited as 
a major motivating 
factor for starting 
OAT self-monitoring 
Convenience identified 
as a potential benefit  
Patients were 
significantly more 
willing to self-monitor 
if clinic visits were 
disrupting their life 
Self-monitoring service 
is acceptable to patients 
Outcome 
Reassurance  The ability of test INR 
at home might be 
reassuring 
 Self-monitoring service 
is acceptable to patients 
Outcome 
Improved INR 
control 
 Self-monitoring may 
improve INR control 
 Self-monitoring 
service will be /is safe 
Outcome 
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Table 31 (cont): Summary of patients' perceptions of OAT self-monitoring (barriers) 
 
Patient perspectives Barriers 
Exploratory 
interviews with self-
monitoring patients 
Interviews with local 
anticoagulant clinic 
patients 
Survey of with local 
anticoagulant clinic 
patients 
Derived candidate 
service requirement 
Donabedian 
framework 
element 
Provision of the 
coagulometer 
The need to purchase 
the coagulometer 
almost deterred two the 
patients interviewed 
from self-monitoring 
Many participants felt 
that the cost of the 
machine was a barrier to 
the uptake of INR self-
testing 
Patients were significantly 
more willing to self-monitor 
if they were willing and able 
to buy a coagulometer 
Facilitate provision 
of the coagulometer 
Structure 
Lack of 
confidence in 
testing INR 
One participant had 
initial difficulties in 
testing INR 
Many participants stated 
that instruction on using 
the coagulometer was a 
prerequisite for its use 
Patients were significantly 
more willing to self-monitor 
if they were confident in 
their ability to test their INR 
Provide patient 
training in self-
testing and using the 
coagulometer 
Process 
Patient eligibility One participant felt that 
not all patients would 
be able to self-monitor 
Participants had doubts 
as to the ability of some 
patients to cope with 
self-monitoring 
 Construct patient 
eligibility and 
assessment criteria 
Structure 
Confidence in the 
accuracy of the 
coagulometer 
 Reassurance about the 
accuracy of the 
coagulometer was 
important to some 
participants 
Concerns about QA of the 
coagulometer expressed 
Establish process for 
quality assurance 
(QA) of  
coagulometer 
Structure 
Patient preference 
for alternative 
models of care 
  53% of sample willing to 
self-test. Six respondents 
expressed a wish to continue 
with current service model 
Gauge patient 
demand 
 
Conduct options 
appraisal 
Structure 
 
 
Structure 
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Table 31 (cont): Summary of patients' perceptions of OAT self-monitoring (challenges) 
 
Patient perspectives Challenges 
Exploratory 
interviews with self-
monitoring patients 
Interviews with local 
anticoagulant clinic 
patients 
Survey of with local 
anticoagulant clinic 
patients 
Derived candidate 
service requirement  
Donabedian 
framework 
element 
Adjusting dose of 
warfarin 
Self-managing patients 
had different ways of 
adjusting warfarin 
doses 
Anxiety expressed at the 
prospect of adjusting the 
dose of his warfarin in 
PSM 
 Provide education and 
support for dose 
adjustment by patients 
(PSM) 
Process 
Educating self-
monitoring patients
  Being provided with 
warfarin information 
was very important to 
survey respondents 
(median score) 
Develop and deliver 
an educational 
programme for 
patients 
Structure 
 
Process 
Support for self-
testing patients 
Support was valuable 
to self-monitoring 
patients 
Support required in 
terms of regular review 
and ad-hoc advice 
Regular clinic check-
ups were very 
important to survey 
respondents (median 
score). Other means of 
support also identified. 
Provide on-going 
support to self-
monitoring patients 
Process 
 
 
 181  
5.4.1 Summary list of candidate service requirements from studies with 
patients taking oral anticoagulation 
 
 
STRUCTURE 
¾ Gauge patient demand for OAT self-monitoring 
¾ Promote the self-monitoring service to patients 
¾ Facilitate the provision of coagulometers (e.g. by funding coagulometer) 
¾ Construct patient eligibility and assessment criteria 
¾ Develop an educational programme for patients 
¾ Establish a process for quality assurance (QA) of coagulometers 
 
PROCESS 
¾ Provide patient training in self-testing and using the coagulometer 
¾ Deliver an educational programme to patients 
¾ Provide education and support for dose adjustment by patients (PSM) 
¾ Provide ongoing support to self-monitoring patients (regular review and ad-
hoc support) 
 
OUTCOME 
¾ Self-monitoring service is safe 
¾ Self-monitoring service is acceptable to patients 
 
5.5 Discussion 
 
This series of studies has explored how patients view self-monitoring of oral 
anticoagulation. Over half of our clinic population surveyed (53%) stated that they 
would be interested in self-testing or self-managing their warfarin treatment if the 
Whittington clinic set up a programme to support them. This is greater than would 
be expected from published data; pooling of data from UK trials suggest that only 
24% of eligible patients would agree to conduct self-monitoring.28  
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However, this observed difference may reflect the difference between trial 
conditions and real life, and the results of this survey are more consistent with two 
recently published studies assessing the potential uptake of OAT patient self-
monitoring. In an American study led by Jacquelyn Quin, 211 anticoagulated 
patients from two clinics, the anticoagulation clinic service (ASC) and vascular 
service clinic (VSC), participated in a 15 minute telephone survey to assess their 
interest in self-testing.160 61% of those in the ASC group and 49% in the VSC group 
indicated that they would be interested in self-testing (non-significant difference). 
Closer to home, 44% of eligible patients audited at UCH agreed to self-monitor.86  
 
Whilst it is useful to know the level of potential uptake of OAT patient self-
monitoring, one of the aims of this body of work was to gain a better understanding 
of how patients view self-monitoring of oral anticoagulation therapy. The focus in 
the literature has been on the societal, economic and technological drivers for OAT 
patient self-monitoring, but with little attention paid to the factors that what 
motivate patients to self-monitor, or the barriers and challenges that they may face. 
 
The patient drivers, barriers and challenges to OAT self-monitoring identified in 
this body of work will now be summarised, together with the service requirements 
for an OAT self-monitoring service derived from the views of these patients. 
 
5.5.1 Drivers for OAT patient self-monitoring 
 
As the initial study of self-monitoring patients is limited by its size, it is impossible 
to draw any firm conclusions. However, these interviews may provide a little insight 
into some of the characteristics of these “early-adopters.” Relatively easy access to 
an informed healthcare professional played a big role in starting these patients on 
their self-management journey, and a  “local champion” can be instrumental in 
offering patients a self-monitoring model of care.  
 
Across the three studies, these drivers for self-monitoring translate into patient 
acceptability as an outcome measure for the service. Acceptability was characterised 
as providing the reassurance brought about by the ability to test the INR at home, 
the independence resulting from self-monitoring  but, predominantly, in terms of 
providing a more convenient service. 
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The overwhelming motivation for all of these participants to start self-managing 
was convenience, providing them the flexibility to perform INR tests when and 
where convenient, especially for those with demanding jobs or who travelled 
frequently. This view was echoed by those not self-monitoring their OAT. From the 
point of view of the service provider, the need to cope with increasing volumes of 
patients coming through anticoagulation monitoring services has been cited as a 
driver for development of a patient self-monitoring model. But for the patient, busy 
clinics and associated long waiting times in clinic are potentially inconvenient, and 
those survey respondents who found clinic visits disruptive were significantly more 
likely to be willing to self-monitor. 
 
Contrary to the author’s expectations, the clinical setting where respondents had 
their warfarin treatment monitored did not significantly affect their willingness to 
self-test. The Whittington Stroke Prevention and Anticoagulation Monitoring 
Service is committed to moving the service nearer to the patient, and a third of this 
population sample had their oral anticoagulation monitored in primary care.  It was 
possible that this patient cohort would be more willing to undertake self-testing, 
having already broken the ‘umbilical cord’ with the hospital clinic. This was not the 
case. However, because the patient is attending a service more convenient to them 
this may “balance out” a potentially increased willingness to assume more 
responsibility for their care. 
 
5.5.2 Barriers to OAT patient self-monitoring 
 
To establish the requirements for migration to a self-monitoring service, it is 
essential also to establish, and address, potential barriers. The main barriers 
identified were patient acceptance of self-monitoring, confidence in testing the INR, 
the need for the patient to purchase the coagulometer, and a preference for the 
current monitoring service. From these barriers, the following service requirements 
were derived: 
 
STRUCTURE –  Gauge patient demand; Facilitate provision of the coagulometer 
PROCESS – Provide training in self-testing and in using the coagulometer 
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Making self-monitoring acceptable to patients is likely to be a considerable barrier to 
its uptake. From this survey, younger (less than 65 years), better-educated patients 
were more likely to be willing to self-monitor their oral anticoagulation. Relative 
youth as a predictor of uptake of PSM has also been reported in other studies.86;160  
Carl Heneghan’s meta-analysis suggested that patients who are new to warfarin 
treatment might be more willing to self-test.104 Also, audit work conducted at UCH 
suggested that increased uptake was likely if patients were offered PSM from the 
start of treatment.86 The results of this survey were not consistent with these earlier 
findings; the length of warfarin treatment did not significantly affect whether the 
respondents were interested in self-testing. In common with the UCH study, there 
was no gender-related difference in potential uptake. 
 
Patients’ confidence in their own skills and abilities to cope with self-testing was a 
recurrent theme throughout these studies. Confidence is a complex construct and is 
difficult to measure. People’s beliefs that they can motivate themselves and regulate 
their own behaviour may play a vital role in their confidence to initiate and maintain 
self-management. Various psychological features affect health behaviour, but two 
are of particular interest in analysing the behaviour of those participating in self-
care; locus of control and self-efficacy.  
 
Locus of control is a psychological concept referring to an individual's expectations 
of who or what is responsible for what happens. There are three modifiable beliefs 
that a person may hold:161 
 
i. They have control over the illness & outcome (‘Internal’) 
ii. Healthcare professionals are responsible for managing their illness 
(‘External’) – this may be linked to the public image of healthcare services 
iii. The outcome of their illness is a matter of pure chance (‘External’)  - may be 
determined by religious or socio-cultural views 
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If a person has an internal locus of control then they interpret events as being 
dependent on their own behaviour, as opposed to being contingent on luck, fate or 
the influence of others (external locus of control). Applying this theory to the health 
setting, those who have a strong internal locus of control may be more likely to take 
a more active role in managing their health, as they may feel that they have control 
over their own health and are more likely to pursue health-promoting behaviours. 
Results from diabetes locus of control research are conflicting; no published studies 
were found relating locus of control with oral anticoagulation management. 
 
Self-efficacy is important for self-management behaviour, in both initiating and 
maintaining this behaviour. The theory of self-efficacy proposes that people avoid 
activities that they perceive as more than they can manage.94 Two studies have 
reported improvements in self-efficacy in those who were self-managing their oral 
anticoagulation.43 
 
Whilst locus of control and self-efficacy provide a basis for analysing the behaviour 
of those engaging in self-care, Ajzen's theory of planned behaviour affords a more 
comprehensive view of self-care behaviour by identifying other possible important 
predictors of self-care behaviour. This widely-used social cognition model, asserts 
that health-related behaviour can be predicted by intention which is influenced by 
three factors: attitude, subjective norm and perceived behavioural control.162  
 
Attitude relates to the person's beliefs about the outcome of the health-related 
behaviour; that is, whether this will be good or bad, harmful or beneficial, pleasant 
or unpleasant. Subjective norm refers to the person’s beliefs about the expectations 
of the key people in their life. Perceived behavioural control relates to the person’s 
perceived control over the ability to perform the behaviour. The concept of 
behavioural control includes the concept of self-efficacy. 
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According to this theory, the stronger the behavioural intention to engage in a self-
care behaviour, the more effort the individual is likely to put into performing self-
care. A study of predictors of self-care behaviour in those with type 2 diabetes 
suggest that relationship exists between attitudes, perceived behavioural control, 
subjective norm and intent to perform self-care behaviour.163 Of these, perceived 
behavioural control was the most predictive of behavioural intentions and actual 
performance of self-care behaviour. 
 
In this study, those who felt that they would be able to test their own INR and 
adjust their dose of warfarin were significantly more likely to be willing to self-
monitor. This is consistent with published data. Pooling of data from UK trials 
suggest that one of the main reasons for refusing to participate in self-monitoring 
trials was a fear of blood sampling.28 Carl Heneghan also identified difficulty 
measuring INR, visual impairment and lack of manual dexterity as reasons cited by 
authors for patients dropping out of the study.104 Two out of three of the self-
monitoring patients interviewed admitted to initial difficulties in testing their INR, 
and it will be interesting to see if these experiences are replicated on a slightly larger 
scale through the patient self-testing pilot. These data suggest the inclusion of 
patient training on self-testing and using the coagulometer as a process element in 
the requirements framework is essential. 
 
A ‘leave it to the expert’ dimension emerged through the study, with a small number 
of patients expressing a strong preference to continue to have their INR monitored 
at an anticoagulant clinic. Jacqueline Quin’s study echoes these findings. Most of 
those who were not interested in self-testing did not want to assume responsibility 
for self-testing, or felt that anticoagulation monitoring was best undertaken by a 
healthcare professional. This finding challenges the assumption of policy-makers 
that patients will embrace self-management. On this basis, it would appear prudent 
to gauge patient demand before establishing an OAT patient self-monitoring 
service. The likely reality is that some patients may not be prepared to take the 
plunge, and ways of encouraging patients to self-test will need to be considered. 
One option, to be explored in the patient self-testing pilot, may be to offer patients 
an opportunity to try it for six months, with no obligation to continue self-testing 
after this trial period.  
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The requirement to purchase a coagulometer represents a significant barrier to 
patient self-monitoring oral anticoagulation in our clinic population, and finding a 
way to facilitate provision of these machines may be a necessary intervention to 
increase uptake of the service. Although 53% of survey respondents indicated that 
they would be willing to self-monitor their oral anticoagulation, when those who 
would be willing to self-monitor AND purchase a coagulometer were considered 
this proportion dropped to 15%. At £399, the price of a coagulometer is not 
insignificant, and currently is not funded by the NHS. There may be ways to ease 
this financial burden – for example, one of the coagulometer manufacturers has 
offered a scheme whereby the patient pays for the machine over several months. 
However, two problems of a more philosophical and ethical nature remain. Firstly, 
the necessity for the patient to fund the machine goes against the principle of the 
NHS being free at the point of care. Secondly, the cost of the machine may exclude 
the less affluent members of the clinic population, leading to an inequitable service.  
 
Ironically, when introducing a patient self-monitoring service, the anticoagulation 
clinic could be a victim of its own success. Satisfaction with the current service has 
been cited as a reason for patients not participating in self-monitoring clinical trials28 
and has been found to be a reason for not wanting to self-test.160 However, in this 
patient survey, levels of satisfaction with the current service did not have a 
significant effect on the potential willingness to self-test. 
 
5.5.3 Challenges to OAT patient self-monitoring 
 
Two key service requirements, centred on education and support, were derived 
from the challenges arose facing the establishment of an OAT patient self-
monitoring service: 
 
STRUCTURE – Develop an anticoagulation educational programme for patients 
PROCESS – Deliver an anticoagulation educational programme for patients; 
Provide education and support for dose adjustment by patients (PSM only) 
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The need for adequate educational preparation was echoed by many study 
participants, although views were mixed as to the content of any educational 
package. Whilst guidance on how to test the INR was thought to be very important, 
there was less agreement on whether patients needed theoretical knowledge of INR.  
 
In addition to preparatory education, a need for support was voiced. This support 
could come from more than one source – healthcare professional, family and peers 
– and take the form of ongoing support and regular review. 
 
Self-monitoring OAT was felt not to be suitable for all, with a need to identify those 
who would be eligible for this model of care. 
 
Finally, some patients had concerns about the way in which self-monitoring would 
be introduced. They felt reluctant to completely sever their ties with the service they 
currently use. Whilst they welcomed the independence and flexibility that self-
monitoring could bring, they wanted assurance that they would still retain contact 
with the service.  
 
There was also the question of how quickly a patient self-testing service should be 
introduced, with some favouring a phased introduction. The accepted wisdom is 
that service redesign should be manageable and testing incremental changes is a safe 
way to learn about redesign and foster a more receptive culture.164 This is the 
approach that has historically been adopted by the Whittington Anticoagulation 
Monitoring and Stroke Prevention Service, with incremental improvements in 
service reflecting increasing levels of empowerment, from the hospital consultant 
through to the anticoagulation nurse specialist to the community pharmacist or 
practice nurse.  
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Giving the patient the opportunity to assume greater responsibility for their oral 
anticoagulation is the next step on this journey. Nevertheless, this has to be 
implemented in a controlled manner, and it may be prudent to introduce a patient 
self-testing service initially with a view to “progressing” to self-management subject 
to the patient and clinician agreeing they are ready.  Although a detailed discussion 
on service reorganisation is outside of the scope of this thesis, support for patient 
self-monitoring will need to be integrated into the current service, with resultant 
potential changes in workflow and staff roles. A preliminary exploration of the 
requirements for a patient self-testing service will be made through the pilot PST 
study. 
 
In conclusion, this research described in this chapter has explored the perspectives 
of patients to identify the drivers, benefits, barriers and challenges to OAT patient 
self-monitoring, and a set of candidate service requirements has been derived. The 
other main stakeholders are the clinicians supporting self-monitoring patients, and 
those commissioning this model of care. The next chapter describes how the views 
of these healthcare professionals and managers were evaluated. 
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CHAPTER 6: EXPLORING THE VIEWS OF 
HEALTHCARE STAFF ON PATIENT SELF-
MONITORING OF ORAL ANTICOAGULATION: A 
FOCUS GROUP STUDY 
 
In the last chapter, the views of patients about self-monitoring of oral 
anticoagulation were explored. The convenience of self-testing, liberating the patient 
from regular anticoagulant clinic visits, was the main motivating factor for self-
monitoring. The main barrier to patient uptake was the requirement to buy the 
coagulometer. Challenges included adequate educational preparation, and 
introduction and integration of PST / PSM into the anticoagulation monitoring 
service. However, ultimately, some patients may not have the confidence of 
willingness to self-monitor their OAT. 
 
As this research was seeking to establish the requirements for a service to support 
patient self-testing and patient self-management, it was important to understand the 
views of those who would be supporting, commissioning and managing such a 
service. 
 
Thomas Kuhn defined a paradigm as a worldview that is essentially an interrelated 
collection of beliefs shared by scientists (or healthcare professionals).165 
Traditionally, healthcare professionals have been wedded to a paradigm derived 
from the treatment of acute illness, which has been the focus of their professional 
education.166 The healthcare professional’s view of the management of oral 
anticoagulation may differ from those taking warfarin. Whilst this may not 
necessarily present problems, difficulties may arise when the goals and expectations 
of each group do not match. 
 
In recent years, the NHS has moved towards a system that is highly dependent on 
the effective commissioning of services by primary care trusts (PCTs). At the time 
of conducting this study (September 2009), PCTs were responsible for 
commissioning services from secondary care. In effect PCTs were responsible for 
ensuring that patients received the support they need; this would include self-care 
support. 
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From a financial perspective, the support of commissioners and hospital managers 
is essential. The PCT will need to be assured that OAT self-monitoring represents 
the best use of finite resources to meet the needs of their local population. From the 
point of view of hospital managers, the establishment of an OAT self-monitoring 
service should be a cost-effective way to increase service capacity without incurring 
loss of revenue to the organisation. 
 
As discussed earlier (3.8), the views of all of these stakeholders – healthcare 
professionals, commissioners and hospital managers - have not been systematically 
studied. Therefore, the aim of this part of the research was to explore clinicians’ and 
managers’ views on patients self-monitoring their oral anticoagulation. From 
establishing the drivers, benefits, barriers and challenges of OAT patient self-
monitoring from the perspectives of healthcare personnel, it was hoped to derive a 
set of suggested, or ‘candidate’ requirements of a service designed to support OAT 
patient self-monitoring. 
 
 This was done through two focus group meetings. The rationale underlying the 
choice of this methodology has been previously described in Chapter 3 (4.4.2).  
 
The design of this focus group study is summarised in Figure 20. 
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Figure 20: Evaluating the perspectives of healthcare staff on OAT patient self-
monitoring: Study design 
 
This chapter describes how these focus group meetings were conducted and their 
findings. 
 
6.1 Aim and Objectives 
 
The aim of this part of the research was to explore the perspectives of clinicians and 
healthcare managers on warfarin patient self-testing and self-management.  
 
Within this aim, there were two objectives: 
i. To identify the key drivers, benefits, barriers and challenges of OAT patient 
self-monitoring from the perspectives of clinicians and healthcare managers 
 
ii. To derive a set of candidate requirements for a service to support OAT 
patient self-monitoring from the perspectives of clinicians and healthcare 
managers 
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6.2 Recruitment of sample 
 
Twelve individuals who were delivering, or who had managerial responsibility for, 
anticoagulation monitoring, or who were responsible for commissioning these 
services were identified by the author or colleagues working in the Whittington 
Anticoagulation Monitoring and Stroke Prevention Service. These were individuals 
that were known to the author and colleagues; they had either collaborated with 
them to develop anticoagulation monitoring services, and / or were thought to have 
valuable insights into OAT patient self-monitoring. A mixture of purposive and 
convenience sampling was used. Purposive sampling in that the sample was selected 
to represent the views of different stakeholders from both sides of the healthcare 
interface (secondary and primary care). Convenience sampling in that these 
participants were near to hand, easy to recruit and were likely to respond. 
 
The aim was to hold two focus groups of six individuals; focus groups typically have 
between six and twelve participants.139 As many researchers advocate homogeneity 
within each group,143 two separate meetings were held - one group with healthcare 
professionals and the other with managers - as opposed to one meeting with all 
participants: 
 
Group One with healthcare professionals, comprising hospital doctors, general 
practitioners (GPs), hospital nurse specialists, practice nurses, community 
pharmacists and hospital pharmacists. 
 
Group Two comprising healthcare managers, including representatives from 
primary care, clinical governance and general hospital management.  
 
Written invitations were sent out by email to twelve healthcare staff in August 2009, 
along with an information sheet for the study. The invitation letter and study 
information sheet can be found in Appendix 9. The author asked potential 
participants whether they are willing to be involved; once a positive response was 
received, the author contacted the participants with the dates of the focus groups 
and sent the consent form for them to read. 
 
 194  
Local Research and Ethics approval was granted for this study. Relevant 
correspondence is in Appendix 10. 
 
6.3 Method 
 
The methodological and data analysis approach to this study is summarised below. 
 
FG1 meeting themes 
reported
Initial themes for 
FG1 identified by 
author 
Focus group 
meeting with 
healthcare 
professionals (FG1)
Topic guide developed from the findings of 
the patient studies and from the literature
Initial themes for 
FG1 identified by 
another researcher 
Agreement reached on 
consensus themes and FG1 
transcript re-coded using 
these themes
Themes from two focus 
group meetings triangulated 
and reported
Focus group 
meetings audiotaped 
and transcribed in 
full
Focus group 
meeting with 
healthcare 
managers (FG2)
Initial themes for 
FG2 identified by 
author 
Initial themes for 
FG2 identified by 
another researcher 
Agreement reached on 
consensus themes and FG2 
transcript re-coded using 
these themes
FG2 meeting themes 
reported
 
 
Figure 21: Focus group study with healthcare staff: Methodological and data 
analysis approach 
 
6.3.1 Development of focus group topic guide 
 
A topic guide was developed with the aim of generating discussion about topics of 
interest. The overall aim was to identify the drivers, benefits, barriers and challenges 
to setting up and delivering an OAT patient self-monitoring service. The topic guide 
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was developed from two main sources: emergent themes from the patient-centred 
studies and the published literature. 
 
The first source was the list of emergent themes from the patient-centred studies 
reported in the last chapter. These were used in one of two ways; either in the 
construction of the question itself, or to generate response prompts. The 
construction of these questions and response prompts is summarised in  
Table 32. 
 
Further topics were identified from the published literature. As described in section 
3.8, one published study was located exploring the barriers to OAT patient self-
monitoring from the point of view of American anticoagulant practioners.95 As the 
main barriers identified were financial ones, additional prompts relating to service 
funding were included. 
 
Further insight was gained from published studies of healthcare professionals’ 
perspectives of patient self-management of long-term conditions.167 A reluctance to 
embrace sharing care with patients emerged from this work. Therefore two 
questions exploring sharing responsibility with patients were included. 
 
Finally as there is currently a lack of clarity around accountability for self-
management, a question to explore managing any extra risk incurred with OAT 
patient self-monitoring was included. 
 
The topic guide can be found in Appendix 11. 
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Use in focus group topic guide 
Study 
objective 
Emergent themes 
from triangulated 
results from patient 
studies 
Interview question Response prompts 
(where provided) 
Drivers for 
OAT patient 
self-
monitoring 
 
Availability of 
support 
Participants asked for 
their views on how to 
support self-monitoring 
patients 
Check up on patients 
regularly 
 
Make it easy for patients 
to contact the clinic if 
they have concerns 
    
Participants asked if they 
thought their patient 
population was ready to 
self-monitor. 
The proportion of patients 
who would be interested 
in PST or PSM 
Patient acceptability 
Patient engagement Participants asked for 
their views on the 
barriers to implementing 
a self-monitoring service 
Cost of the coagulometer 
Participants asked if they 
thought their patient 
population was ready to 
self-monitor 
The proportion of patients 
who would be able to buy 
a coagulometer 
The need for the 
patient to purchase the 
coagulometer 
Participants asked for 
their views on how to 
support self-monitoring 
patients 
Provide patients with the 
coagulometer 
Lack of confidence in 
testing INR 
Participants asked if they 
thought their patient 
population was ready to 
self-monitor 
The proportion of patients 
who would be able to test 
their INR 
Participants asked how 
patients who wished to 
self-monitor should 
demonstrated 
competency 
 
Barriers to 
OAT patient 
self-
monitoring 
Patient eligibility 
Participants asked which 
types of patients would 
benefit from self-
monitoring 
Exclusion criteria? 
Criteria for PST different 
from PSM 
    
Participants asked for 
their views on how to 
support self-monitoring 
patients 
Provide more information 
or education about 
warfarin 
Educating self-
monitoring patients 
Participants asked for 
specific educational 
requirements to prepare 
a patient for self-
monitoring 
 
Challenges of 
OAT patient 
self-
monitoring 
 
Adjusting dose of 
warfarin 
Participants asked if they 
thought their patient 
population was ready to 
self-monitor 
The proportion of patients 
who would be able to 
adjust their dose of 
warfarin 
 
Table 32: Focus group study with healthcare staff:Construction of topic guide from 
emergent themes from patient-centred studies 
 
 197  
 
 
6.3.2 Conducting the focus group meetings 
 
Two focus meetings, with six people per group, were held in a private room in the 
pharmacy department at the Whittington Hospital in September 2009. Meetings 
were audiotaped with the subjects’ permission. Each group had two facilitators; the 
author leading the discussion using the topic guide, and one other making 
contemporaneous field notes. Before the discussion commenced, participants were 
asked for written consent and given a brief information sheet about self-monitoring 
of oral anticoagulation to read. This information sheet can be found in Appendix 
12. 
 
6.4 Analysis 
 
Discussions from the two focus group meetings were transcribed verbatim by the 
author. Transcriptions were anonymised, both in the transcription of the tape 
recordings and in written field recordings. Data were read to identify an initial list of 
themes and subthemes. The transcripts were then re-read and the audiotapes 
listened to a second time to refine these themes.  As small numbers of subjects were 
involved, themes were inputted manually in a spreadsheet.  
 
Using the same methodology, another researcher with expertise in qualitative 
analysis (JM) independently read the transcriptions to identify themes and sub-
themes. The author and JM then compared their analyses and, after discussion, a 
consensus was reached on a common set of themes. The focus group transcripts 
were then re-coded using this set of consensus themes. 
 
The focus groups observers’ notes were also reviewed to take into account their 
observations, especially non-verbal cues and their perceptions of the reactions and 
interactions of the participants. 
 
Finally, the results from the two focus groups were triangulated. The approach to 
triangulation of results has been previously described in Chapter 4 (4.5.4). 
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6.5 Results: Focus Group One – Healthcare Professionals 
 
6.5.1 Sample 
 
All six healthcare professionals invited agreed to participate in this focus group. The 
composition of the focus group is summarised in Table 33. The participant code 
comprises the participants’ sex and identifying number (e.g. M1 refers to the first 
male participant in the study). 
 
Participant 
code 
Job title Role Location 
M1 Consultant 
Cardiologist  
Clinical Lead for 
Anticoagulation Monitoring 
Services 
Acute Trust 
M2 Consultant 
Haematologist  
Clinical Lead for 
Anticoagulation Monitoring 
Services. Involved in a patient 
advocacy group for OAT self-
monitoring on national level. 
Acute Trust 
F1 General 
Practitioner 
General Practitioner Primary Care 
M3 Specialist 
Anticoagulation 
Pharmacist 
Formally managed a large 
anticoagulation monitoring 
service. 
Acute Trust 
M4 Community 
Pharmacist  
Commissioned to provide 
Anticoagulation Monitoring 
Service 
Primary Care 
F2 Clinical Nurse 
Specialist, 
Diabetes 
Supports self-monitoring 
diabetic patients in primary 
and secondary care 
Acute Trust 
 
Table 33: Focus group study with healthcare staff: Healthcare professionals 
participating in Focus Group One 
 
 
6.5.2 Data collection 
 
The focus group meeting took place over 50 minutes. All subjects gave written 
consent. 
 
All topics on the focus group guide were covered in the order on the guide. All of 
the group were very engaged and vocal. This generated an enthusiastic discussion, 
limiting the scope or need for the moderator to interject. 
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6.5.3 Themes 
 
The main themes and sub-themes arising from the meeting are summarised in Table 
34. 
Main theme Sub-themes 
Raised awareness of OAT patient self-
monitoring 
Theme 1 Drivers for OAT patient 
self-monitoring 
Healthcare provider drivers 
Financial barriers 
Patient readiness 
Theme 2 Barriers to OAT patient 
self-monitoring 
Impact on primary care 
Areas of risk 
Accountability 
Theme 3 Risk management 
Patient – clinician relationship 
Patient self-management of other long-term 
conditions 
Theme 4 Learning lessons from 
others 
Patient self-monitoring of OAT in other 
countries 
Options appraisal for delivering self-
monitoring 
Alternative models of INR monitoring 
PST or PSM? 
Theme 5 Service redesign 
Coagulometer provision 
Patient selection criteria 
Education 
Ongoing support 
Establish agreed channels of communication  
Manage risk 
Define arrangements for quality assurance of 
coagulometers 
Theme 6 Requirements for an OAT 
patient self-monitoring 
service 
Ethical considerations 
 
Table 34: Focus group study with healthcare staff: Main themes and sub-themes 
arising from meeting of Focus Group One (Healthcare Professionals) 
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6.5.3.1 Theme 1: Drivers for OAT patient self-monitoring 
 
Identification of the drivers for OAT patient self-monitoring is important as these 
not only provide justification for establishing a self-monitoring service, but also give 
an insight into the anticipated benefits of patient self-monitoring. The group 
anticipated that a growing awareness of, and interest in, self-monitoring amongst 
anticoagulated patients would act as a driver for uptake of OAT self-monitoring. 
This growing awareness is likely to come through three main routes: 
 
i. Marketing of technology 
ii. Seeing other patients with personal coagulometers 
iii. Patient advocacy groups 
 
Roche has marketed their CoaguChek™ machine directly to patients using a variety 
of media, including daily newspapers (Daily Telegraph, Daily Mail), Saga magazine, 
Easy Jet in-flight magazine and posters on the London Underground. Patients 
subsequently purchasing machines and then expecting clinics to support them in 
self-monitoring has created problems: 
 
“So they’d paid £199, and picked up a device and now wanted to know what to 
do with it, which wasn’t of course part of the Roche promotional campaign” 
(M3) 
 
Discounts offered by Roche on coagulometers may persuade patients to purchase 
machines. However, the group considered that the two biggest drivers for patients 
making that commitment was the potential timesaving benefit, and avoidance of 
time away from work. 
 
From the point of view of secondary care, patient self-monitoring represented a 
means to ease congested clinics. Primary care participants felt that offering a 
financial incentive to GPs to support self-monitoring patients would increase its 
uptake. Nevertheless, there was a joint commitment across the interface to both 
shared decision-making between healthcare professionals and patients, and to 
increasing patient empowerment.   
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6.5.3.2 Theme 2: Barriers to OAT patient self-monitoring 
 
The group identified two main financial barriers to OAT patient self-monitoring. 
Firstly, the issue of payment for those supporting OAT patient self-monitoring was 
raised, more particularly in terms of training patients. Although the National 
Enhanced Service  (NES) element of the General Medical Services (GMS) 
contract168 offers a mechanism for commissioning self-monitoring services in 
primary care, the reimbursement for anticoagulant services does not take into 
account the costs of training. Consequently, it was felt that clarity around 
reimbursement for those training self-monitoring patients was needed. 
 
Secondly, echoing the results from the patient study, there was the cost to the 
patient of the coagulometer. Not only did the patient have to pay for the machine 
but also, by doing so, is in effect paying for a proportion of their healthcare, 
contrary to the fundamental ethos of the NHS as care delivered free at the point of 
delivery.  
 
“I wonder whether because the NHS is seen as being free at the point of 
delivery that has made patients in this country a little bit more … well, less 
willing to take on aspects of their own management, whereas in Germany or 
France where it’s a split system there might be a different approach to that” 
(M3) 
 
It was suggested that supplying coagulometers on private prescription – in effect, 
exempting them from VAT – would partially ease this financial burden. 
This topic generated further discussion about the economic model used by the 
manufacturers of the coagulometers. In stark comparison to coagulometers, the 
blood glucose testing machines are often given out free to patients, and the 
manufacturers make their money through the sale of consumables. 
 
However, aside from the cost of the coagulometer, there was a fear that some 
patients were not ready to embrace self-monitoring, either through a lack of 
confidence or a lack of ability. This supported the views of some of the participants 
in the patient study. 
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The potential impact of OAT patient self-monitoring on primary care invoked 
strong feelings. Although it was felt that self-monitoring was too large a leap from a 
secondary care monitoring service, supporting a patient self-monitoring service 
from primary care left staff vulnerable to excessive workload and potential litigation. 
Self-monitoring patients may have high expectations of their GP supporting them, 
but there was not confidence in the GP having the knowledge to do so. 
 
“It’s embarrassing when you don’t know anything compared to your patient.” 
(F1) 
 
Therefore, GPs may need to build expertise to support this group of patients.  
 
6.5.3.3 Theme 3: Risk management 
 
As discussed earlier in this thesis (3.6), under trial conditions OAT patient self-
monitoring is at least as safe as routine management. However, because of 
warfarin’s narrow therapeutic range, its complex pharmacokinetics and its adverse 
effects profile, monitoring of OAT by any method can be challenging.169 It is 
essential that the introduction of an OAT patient self-monitoring service should not 
introduce new risks. 
 
The risks identified by the group included potential additional risks to the patient 
incurred through self-monitoring, but also risks to the professional, particularly 
around issues of accountability. Managing the potential risks to the professional 
invoked intense debate within the group. However, all of the participants concurred 
on the uncertainty around the medicolegal position and the potentially destructive 
effect of litigation on all concerned. A number of areas of risk were identified and 
are listed in Table 35.  
 
PST Compliance with testing 
  Patients faking INR results 
  Over-testing  
  Offers patients the ability to play around with dose 
    
PSM Dose adjustment 
    
Increased patient anxiety levels Through closer attention to monitoring and medical 
condition 
 
Table 35: Focus Group One: OAT patient self-monitoring - areas of risk  
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Most participants felt that the area of greatest risk was a patient adjusting their dose 
of warfarin when fully self-managing.  
 
“There’s a big step between self-testing and self-management. A really big step. 
And that’s where everything could go wrong.”(F2) 
 
Adverse events could arise from the patient misinterpreting their INR or over-
reacting to one reading. Unlike self-monitoring of blood glucose (SMBG), the INR 
does not represent an instant phenomenon, and the group felt that patients needed 
to understand this concept before self-managing their OAT. 
 
However, one participant challenged the group view that PSM is inherently more 
hazardous, and contended that in PST, where there is a gap between a patient 
testing their INR and receiving advice from their anticoagulation practitioner, there 
is a significant organisational risk. 
 
Issues of accountability invoked strong feeling in the group. The medicolegal 
position is unclear, with legislation lagging behind practice. Litigious action was a 
big concern: 
 
“And, of course, you’ve got the criminal court and the civil court and so, yes, 
you may not be prosecuted but you may well be sued or as an individual outside 
the Trust” (M3) 
 
A mismatch between the professional framework suggested by the General Medical 
Council (GMC) and encouraging the patient to take more responsibility for their 
care was identified.  
 
“But there are two courts aren’t there? There’s the legal courts – and the 
[question of whether] you’ve been negligent and whether you’re going to be 
paid out – and then there’s the GMC, I think has a very big influence.” (F1) 
 
Where responsibility sits provoked debate amongst the group, with some feeling 
that it rested with the clinician and others contending that the patient should bear 
responsibility. The accountability of pharmacists operating in an extended role was 
felt to be even more unclear. 
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“I think I would see it as still accountability resting with the [] physician and I 
would, as a pharmacist, fit in somewhere in between. So I very much see 
accountability lying with us other than the patient and the self-testing scenario” 
(M3) 
 
Patient self-monitoring of oral anticoagulation forms part of the continuum of 
shared decision-making, and an underlying conflict between the current medico-
legal framework and the concept of shared decision-making was identified: 
 
“There’s an analogy between shared decision making and this sort of self-
management. And the problem is that the medico-legal framework that I 
perceive myself as working in as a doctor, and certainly my GP colleagues 
perceive themselves working in, is a paternalistic one where we have 
responsibility for the patient well being.” (F1) 
 
Patient self-monitoring was also felt to be vulnerable to less tangible risks through 
changes to the patient – clinician relationship, largely through the loss of benefits of 
a face-to-face interaction. For instance, there was less opportunity for behaviour 
modification: 
 
“What self-testing doesn’t do, it doesn’t give them a slap on the wrist, that’s the 
trouble.” (M4) 
 
The nature of the role of both the patient and the healthcare professional within a 
self-monitoring model was also questioned, and there was a fear that a self-
monitoring patient will be less compliant and take more risks. 
 
6.5.3.4 Theme 4: Learning lessons from others 
 
The group felt care was needed in extrapolating experiences with self-care of other 
long-tem conditions (LTCs) to self-monitoring of OAT. 
 
Self-care of diabetes, hypertension, and asthma may provide valuable insight into 
setting up an OAT patient self-monitoring service. 
 
“Why not use the same model that we use for all other illnesses?” (F1) 
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However, the group felt that important differences between OAT patient self-
monitoring and self-care of some LTCs needed to be considered.  A few of these 
points have been touched upon earlier. Although self-care of asthma and diabetes 
also involve dose titration, the test result on which a dose is based reflects an 
immediate phenomenon unlike an INR which may reflect an event that happened 
two or more days earlier. Similarly, a blood glucose measurement or a peak flow 
provides immediate feedback to a diabetic or asthmatic patient if something is going 
wrong. 
 
A diabetic patient may monitor their blood glucose many times a day, whereas an 
anticoagulated patient should test their INR at a maximum frequency of once a 
week. In addition, the cost to the patient of the technology to monitor their INR is 
comparatively more expensive. 
 
Whilst it is important to acknowledge these differences, the group felt that lessons 
could still be learnt. For example, adopting the “train-the-trainer” approach used to 
educate those about to self-monitor their blood glucose, may prepare those wishing 
to self-monitor their OAT. Indeed, this approach has been adopted in one area of 
the UK as described earlier. 
 
In Chapter Two, an international perspective on OAT patient self-monitoring was 
given. The group felt that a greater understanding of the success factors for 
adoption of OAT patient self-monitoring may come from examining the differences 
between the UK and Germany, where this model of monitoring is more 
widespread.  
 
“The health system, you know, in Germany is different and the uptake there is 
75% so there must be something …. financial must be one but all these issues 
we have mentioned … it must be the health system, the system as a whole” (M2) 
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The group identified financial and cultural factors that may contribute to the 
successful uptake of OAT patient self-monitoring in Germany: 
 
i. Healthcare not free at point of delivery (split system) 
ii. A long history of SMBG 
iii. SMBG is a health insurance requirement 
iv. Patient self-monitoring is a cultural norm 
 
“I wonder whether because the NHS is seen as being free at the point of 
delivery that has made patients in this country a little bit more … well, less 
willing to take on aspects of their own management, whereas in Germany of 
France where it’s a split system there might be a different approach to that.” 
(M3) 
 
6.5.3.5 Theme 5: Service redesign 
 
In order for the service to change to one that involves an element of OAT patient 
self-monitoring, consideration needs to be given as to how the service will change 
and the options for service redesign. Before introducing a new service it is necessary 
to compare the options for its delivery. This group felt strongly that there needed to 
be a ‘halfway house’ between management by the secondary care clinic and patient 
self-monitoring, and that there was merit in adopting a similar model to long-term 
conditions by training primary care professionals - GPs, practice nurses and 
pharmacists - to manage self-monitoring patients. 
“But then why not use the same model that we use for all other illnesses? Which 
is blood pressure being the classic example, you know, for the straightforward  
train primary care including pharmacists and practice nurses and GPs to 
manage.” (F1) 
 
Again, there was concern that GPs would not be able to build sufficient expertise to 
support this group of patients, and if they were to do so patients should be 
requested to phone them at specified times when the GP would be able to access 
specialist advice.  
 
There was strong support for community pharmacists supporting this service 
delivery, including the option of siting publicly available coagulometers in 
pharmacies. 
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“There’s some very interesting literature in terms of patient behaviour and a 
patient tends to be monogamous with their pharmacist but they’re not 
monogamous with their GP”(M1) 
 
A domiciliary service, where the patient has their blood tested at home by a 
healthcare professional, is an alternative to the patient attending an anticoagulation 
clinic or testing their INR at home. However, there was disagreement within the 
group as to who was best placed to provide this service, a practice nurse or district 
nurse. 
 
Within a self-monitoring service, there is the option for the patient to self-test or 
self-manage. As discussed earlier, the majority of the group felt that self-
management carried the greater risk and, for this reason PST was the preferred 
model. Dose adjustment was felt to be challenging for healthcare professionals and 
patients alike. 
 
“We don’t understand how to do it, we don’t understand the algorithms and we 
think it’s specialised and dangerous … Now if GPs are feeling like that I 
suspect patients may have a bit of difficulty unless the algorithms are very 
straightforward and that’s the bit that worries me.” (F1) 
 
However, it was questioned whether one can separate self-testing and self-dosing 
once the patient has a machine, with an acknowledgement that there is likely to be 
some ‘unofficial’ self-management. 
 
The requirement for the patient to purchase a coagulometer had been identified as a 
potential barrier, and the group felt that the availability of a loan machine might 
allow patients to ‘try before they buy’.  
 
6.5.3.6 Theme 6: Service requirements 
 
Finally, the group considered the requirements for an anticoagulation monitoring 
service to support patient self-monitoring.  
 
It was felt essential to define patient inclusion and excluision criteria. Patient 
selection criteria published in consensus guidelines are broad36;52, but this group 
agreed upon a relatively narrow set of criteria. These are summarised in Table 36. 
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Inclusion criteria Exclusion criteria 
Long-term indication for OAT Psychotic illness 
Ability to buy coagulometer Mental impairment 
Sufficient dexterity  
Able to demonstrate ‘understanding’  
 
Table 36: Focus Group One: Inclusion and exclusion criteria for OAT patient self-
monitoring  
 
It was not clear how a patient’s understanding of OAT would be demonstrated. 
There was also some support to establish the service with ‘super-selected’ patients, 
who may be a cohort of healthcare professionals on warfarin. 
 
In addition to identifying inclusion and exclusion criteria, the group felt that it was 
important to define the action to be taken when someone who is deemed unsuitable 
to self-monitor turns up at the clinic with a machine. 
 
“You can’t stop them from buying their own machine. However, you can stop … 
you can refuse to help them. And it’s a tricky one. Withdrawal of co-operation. 
But then there is a duty of care” (M1) 
 
Education was required for both patients and healthcare professionals. Although 
the content of these programmes was not defined, a longitudinal approach to 
patient education was desirable: 
 
“It [patient education] has to be done over time – an hour of education, you’ll 
only remember the first 10 minutes if you’re lucky” (M1) 
 
In addition to initial education, ongoing support for both patients and the GPs 
supporting them was needed. Although the GP representative of the group did not 
feel that she had to be an expert in OAT management, she needed to know who to 
call for advice and for them to be available at specified times. 
 
“You’d have to look at how you run [the self-testing] service. So you might only 
run it on certain days when you know you could get through to somebody who 
would, you know be available right then. But then your patient would only be 
able to come on those certain days. But then it would save them coming up 
here.” (F2) 
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GPs’ requirement for timely access to expert advice, and a robust system to ensure 
that a self-testing patient received prompt advice in response to a self-reported INR 
were also felt to be essential. 
 
In terms of managing the additional risks associated with OAT patient self-
monitoring, the group identified the following requirements: 
 
i. Patient signs a written agreement  
ii. Clear dosing algorithms – for PSM but also to aid non-specialist clinicians 
to advise patients who are self-testing 
iii. Clarity on what constitutes negligence under self-care 
iv. Professional bodies (GMC) to carry out a review of self-care 
 
 
Lastly, there was the dilemma of how to deal with potential inequities of a service 
that is partially predicated on a patient’s ability to pay for some of their care. 
 
6.6 Results: Focus Group Two 
 
6.6.1 Sample 
 
All six healthcare professionals managers invited agreed to participate in this focus 
group. The composition of the focus group is summarised in Table 37. As before, 
the participant code comprises the participant’s sex and identifying number (e.g. M1 
F3 refers to the first third female participant in the study). 
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Participant 
code 
Job title Role Location 
F3 Deputy Director of 
Nursing  
Clinical Governance & 
educational lead in Trust.  
Ex warfarin patient 
Acute Trust 
F4 Assistant Director of 
Finance 
Assistant Director of 
Finance 
Acute Trust 
M5 Commissioner, Primary 
Care Trust 
Commissions primary care 
anticoagulation monitoring 
services 
Primary Care 
F5 Deputy head of 
Medicines Management, 
Primary Care Trust 
Commissions primary care 
anticoagulation monitoring 
services 
Primary Care 
F6 Director of Integrated 
Care 
Remit for patient care 
across the interface 
Acute Trust 
F7 Specialist 
Anticoagulation 
Pharmacist 
Manages patients attending 
anticoagulation monitoring 
service 
Acute Trust 
 
Table 37: Focus group study with healthcare staff: Healthcare Managers 
participating in Focus Group Two 
 
 
6.6.2 Data collection 
 
The focus group meeting took place over 50 minutes. All subjects gave written 
consent. 
 
All topics on the focus group guide were covered in the order on the guide. There 
was a heated but amicable discussion, largely driven by two participants (M5 and 
F5). Two participants (F3 and F4) were more reticent and needed to be actively 
drawn in to the discussion by the moderator. In comparison to the first focus 
group, there was lots of overlapping conversation and interruptions, and many 
questions about a potential warfarin patient self-monitoring service to the 
moderator. 
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6.6.3 Themes 
 
The main themes and sub-themes arising from the meeting are summarised in Table 
38. 
 
Main theme Sub-themes 
Patient drivers 
Healthcare provider drivers 
Theme 1 Drivers for OAT patient 
self-monitoring 
Department of Health policy drivers 
Financial barriers 
Patient readiness 
Clinical risk 
Loss of "value-added" service through reduced 
contact between professional & patient 
Alternative models of INR monitoring 
The technology facilitating OAT self-
monitoring 
Theme 2 Barriers to OAT patient 
self-monitoring 
Ethical concerns 
Areas of risk 
Accountability 
Theme 3 Demonstrating feasibility 
Patient – clinician relationship 
Theme 4 Learning lessons from 
others 
Patient self-management of other long-term 
conditions 
Options appraisal for delivering self-
monitoring 
Theme 5 Service redesign 
Skill mix to deliver a self-monitoring service 
Patient selection criteria 
Education 
Ongoing support 
Establish agreed channels of communication  
Manage risk 
Define arrangements for quality assurance of 
coagulometers 
Theme 6 Requirements for an OAT 
patient self-monitoring 
service 
Ethical considerations 
 
Table 38: Focus group study with healthcare staff: Main themes and sub-themes 
arising from meeting of Focus Group Two (Healthcare Managers) 
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6.6.3.1 Theme 1: Drivers for OAT patient self-monitoring 
 
Supporting the results of the patient study, the group felt that the avoidance of 
clinic visits with the advantages that brings – easier childcare arrangements and 
avoiding time out of work were cited as examples – and the convenience of testing 
INR when travelling were important in persuading patients to self-monitor. 
 
In addition to increasing capacity, OAT patient self-monitoring was felt to be the 
“direction of travel”, not only reflecting Department of Health (DH) policy, but 
also fitting with changes in the healthcare landscape: 
 
“The other bit for me [is] the development of poly-systems, but you know …the 
changes in system around North Central London and needing to reconfigure 
acute Trusts and all that sort of stuff and pushing however many centres of 
outpatients into the community might actually really happen over the next 3 – 5 
years.” (F6) 
 
“I think in the future, you know, the way the system is changing, GP practices 
are going to have to shift their… the way they work, in terms of their workforce, 
and they are going to need to explore things which are much more about self-
monitoring as well.” (F6) 
 
Although there was consensus that OAT patient self-monitoring fitted with DH 
policy, it was felt that there was no robust evidence that it would work in practice, 
or that it was the model of care that patients want, and there was some criticism that 
policy did not always consider the affordability of service changes. 
 
6.6.3.2 Theme 2: Barriers to OAT patient self-monitoring 
 
The barriers to OAT patient self-monitoring, especially concerning the potential 
cost-burden and clinical risk, generated lively and extensive discussion. 
There was strong agreement that financial issues needed to be resolved before 
establishing an OAT patient self-monitoring service. The main concern of the 
commissioners was the affordability of a self-monitoring service to the PCT.  
 
“Because, you know, let’s be serious about this … it is cost at the end of the 
day, it’s not a PCT who’s struggling. It’s all very good the Government saying 
this is the policy and everything else, we’ve always got to do affordability 
models and if, at the end of the day, we can’t afford it, we can’t afford it. I 
mean, this is pushed through ‘til there’s nothing left to give.” (M5) 
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It was unclear who would pay for the machines and testing strips, and not all PCTs 
would be happy to fund this service especially if patient numbers increased. A clear 
business case at the outset was felt to be essential, with a guaranteed financial 
payback: 
 
“If it’s not paying back you’re going to struggle getting it off the ground … 
seriously.”(M5) 
 
Financial disincentives from a secondary care viewpoint were also identified. INR 
monitoring outpatient visits generate valuable income for the acute Trust, and there 
may be a reluctance to relinquish this income stream.  
 
“You don’t want to lose money at the hospital. We don’t want to lose money at 
the PCT.” (M5) 
 
Or in the words of the Trust’s Assistant Director of Finance: 
 
“Don’t do it!” (F4) 
 
A recurring theme in both the patient and healthcare staff studies was the ability and 
willingness of patients to buy the coagulometer. Again, this group doubted that 
many patients were able to buy a coagulometer and would be prepared to assume 
the extra responsibility of OAT self-monitoring. 
 
Fear of litigation was identified as another obstacle to the uptake of OAT patient 
self-monitoring, with clarity lacking. Mismanagement of self-monitoring may also 
result in financial risk: 
 
“Can I just ask if anybody has spoken to the NHS Litigation Authority? Because 
if a patient screws up on their testing and dies, would we get sued? The 
Litigation Authority would do the court case but would our [hospital insurance] 
premiums go up because we were doing this.” (F4) 
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Support from the acute Trusts for GPs supporting this service was considered 
essential: 
 
“You know, the PCT … certainly the clinical people will not take on a clinical 
risk if they don’t feel they’re supported … I think there has to be some real 
clinical engagement and honesty about who’s responsible and, yes, we’re going 
to carry on supporting you, we’re not just leave you out there in the 
wilderness.” (M5) 
 
The group felt that primary and secondary care needed to share clinical risk, and the 
governance arrangements for a patient self-monitoring service needed to be defined, 
especially to cover patients moving between primary and secondary care: 
 
“It can become very complicated, especially when you talk about clinical 
ownership. At what point is it your patient? When I ring you up and say ‘Mr 
Jones is coming now’  and you say ‘Right. I’ll expect him’ Have you now taken 
clinical responsibility? That’s the question that’s asked all the time. What’s the 
stage … if that patient … if something happens to that patient between leaving 
the GP practice and coming to you, who … who’s taking clinical 
responsibility?” (M5) 
 
These governance arrangements should also include the respective responsibilities 
of the patient and healthcare professional.  
 
“There definitely has to be something  and the patient has to sign up to that 
contract to say this is your responsibility… I think there has to be something 
where the patient takes clinical ownership or responsibility for their actions and 
what they’re doing.” (M5) 
 
“I think there has to be some ownership by the patient of responsibility. That’s 
the thing. I think we’re all happy saying it somebody else’s  but I think if a 
patient takes this, by implication, they’re taking on some of the responsibility” 
(M5) 
 
In addition to clarifying lines of accountability and persuading the patient to take 
some ownership, shared care with patients on oral anticoagulation presents other 
challenges. There is the risk that patients will not comply with testing, or wilfully 
misreport INRs, and that they will not view their condition seriously: 
 
“Is there is a danger that if it moves to self-testing, patients are offered self-
testing they start to think ‘Ooh. Well it can’t be that bad if I can just do this at 
home’?” (F4) 
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OAT monitoring is not merely dose adjustment, and the group felt that the patients 
would lose other elements of care, such as health screening and opportunities for 
behaviour modification, through reduced contact with a healthcare professional. 
There was also a danger that patients may perceive self-monitoring as a reduced 
level of care: 
 
“People like … I mean, that’s why people come to hospital because they like to 
be seen by a person and go to a building and feel they’re being treated. I just 
wonder if they do it home, they feel the same level of … of care” (F3) 
 
Patients may feel that alternative primary care INR monitoring models are more 
attractive than self-monitoring: 
 
“But more important, would the patient …. if we provided something more local 
would they be more than happy with that and not bother about self-testing? Or 
are they saying because at the moment there’s nothing, it’s either hospital or 
nothing they’ll take self-testing?” (F5) 
 
Therefore it might be premature to embrace self-monitoring as a solution to an 
overstretched hospital INR monitoring service until all options are mapped out. 
 
At the time of the focus group meeting, there were two, identically priced, 
coagulometers marketed for patient use. This lack of competition in the 
coagulometer market, leading to the relatively high cost of the machines, was felt in 
itself to be a barrier to uptake of self-monitoring. However, if patient self-
monitoring was to become more widespread, an increase in demand for these 
machines may persuade other diagnostic manufacturers to enter the market: 
 
“It’ll be like generics really. Once people start using a lot of them, someone 
else will come on the market and prices will eventually fall.” (F5) 
 
Although the group had an expectation that the price of coagulometers would 
eventually fall, there would still be a potential need to replace machines that are 
broken, adding to the financial burden.  
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On ethical grounds, some in the group were uncomfortable about an OAT self-
monitoring service that excludes those who cannot afford a coagulometer: 
 
“Is that not ethical?” (F3) 
 
Overall, the group felt that it was far from certain that an OAT self-monitoring 
service could be established and managed successfully. Whilst a small pilot of 50 
patients may be feasible, it was unclear if this could then be scaled up to 1000 
patients. 
 
6.6.3.3 Theme 3: Demonstrating feasibility 
 
The group believed that there were two ways of demonstrating the feasibility of a 
large-scale INR patient self-monitoring service; by building a business case and 
establishing a pilot service. 
 
The PCT representatives wanted a business model that would demonstrate that 
INR patient self-monitoring is cost-effective, with a return on investment required 
within the first financial year. The aspiration was that the cost of the patient self-
monitoring service would be partially offset by a reduction in inpatient episodes. 
The financial risk for both primary and secondary care was felt to be significant, 
creating tensions within the group. 
 
A meaningful pilot was felt to be key to demonstrating feasibility of an INR patient 
self-monitoring service. Essential elements identified by the group are listed below: 
 
¾ Use a cross section of people (e.g. different age groups, different genders) 
¾ Enrol 10- 20% of patient population 
¾ Evaluate financial impact, inpatient / outpatient activity, patient 
acceptability and impact on Trust productivity 
¾ Confine to one PCT, ideally around an emerging polysystem local to 
hospital 
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6.6.3.4 Theme 4: Learning lessons from others 
 
The group felt that important differences between OAT patient self-monitoring and 
SMBG in diabetes needed to be considered. There was a view that the required high 
frequency of blood glucose tests has driven self-testing in diabetes:  
 
“In fairness, diabetes is not something you can say come back in 6 weeks and 
we’ll test you again it’s got to be a daily thing. So I think the condition has 
driven self-testing. Whereas this, you can leave it 4 or 5 weeks, test in between, 
so it’s not an everyday sort of occurrence, it’s not … for a lot of patients it’s not 
that inconvenient to come every 6 to 8 weeks.” (M5) 
 
In contrast to the high cost to the patient of the technology to monitor their INR, 
diabetic patients are either given glucometer from the diabetes outpatient clinic or 
purchase them cheaply.  
 
In the early days of patient self-care of asthma, there were also concerns about its 
safety: 
 
“As a practice nurse … I was just thinking when we are getting into self-
management of asthma, there was the same sort of worry and concerns.” (F6) 
 
 
6.6.3.5 Theme 5: Service redesign 
 
There was some discussion about redesign of the anticoagulation monitoring service 
to include patient self-monitoring, largely centred on service delivery options and 
where a self-monitoirng service should be run from. Although there was some 
support for a publicly sited coagulometer, not all of the group agreed that this was a 
good option: 
 
“But that’s similar to what we have now though? Isn’t it similar?” (F5) 
 
There was more support for setting up a patient network, where patients own and 
share a machine: 
 
“I like that idea though. I think if you did that as a self-help group almost where 
people met and did their own thing maybe that would be more palatable.” (M5) 
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There opposing views as to where a patient self-monitoring service should be 
established. Although a few members of the group felt that self-monitoring patients 
should be supported from the acute Trust, others contended that this could be done 
in primary care: 
 
“Once they’re stable, I think they can then move to the next level down where a 
GP or a pharmacist or somebody else could do it. It doesn’t need to be the 
hospital.” (M5) 
 
However, this generated accusations that primary care would be “cherry-picking” 
the more stable patients, with the following note of caution: 
 
“You can’t ever cherry pick just good, stable patients because everybody will 
destabilise at some point.” (F7) 
 
However, there was a counter-view that those with poor INR control would be 
more motivated and would benefit from self-monitoring: 
 
“Some of the poorer controlled patients actually want to self-test because they 
want to stop coming to hospital each week.” (F7) 
 
6.6.3.6 Theme 6: Requirements for an OAT self-monitoring service 
 
In contrast to the first focus group, there was no detailed discussion on patient 
selection criteria for self-monitoring. Instead, the group felt that individual risk 
assessments to decide if patients would be suitable to self-monitoring would be of 
benefit. 
 
Education, as well as ongoing support, was needed to prepare patients for self-
monitoring. Regular patient reviews would also satisfy the requirement for regular 
quality assurance of the coagulometers: 
 
“We need to give people a lot of education and I think we need to be seeing 
them or we need to, you know, validate their machines probably twice a year.” 
(F7) 
 
But ongoing support was not just confined to patients. If patient self-monitoring is 
to be supported in primary care, staff will need support also: 
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“Even though … even though we’d be happy to take it on, I think, clinically in 
the PCT, it’d still be nice to know that the higher level of clinical ability in the 
hospital is still there supporting us and hasn’t just walked away and said ‘It’s 
yours’ and forget about it.” (M5) 
 
Establishing agreed channels of communication was felt to be essential, both 
between patient and healthcare professional and between primary and secondary 
care. Lines of communication must be structured to accommodate patients moving 
between providers and sectors. 
 
Managing risk was a thread that ran throughout the meeting. As well as recognising 
the areas of risk, the group felt that there must be ways of assessing and mitigating 
against these risks from the outset. Their suggestions are listed below: 
 
i. Establish a formal shared care agreement 
ii. Define where clinical responsibility lies 
iii. Agree protocols between PCT and hospital re: patient transfer 
iv. Elaborate ethical / legal framework 
 
 
As discussed earlier, there was much debate over the financial aspects of moving to 
OAT patient self-monitoring, and there was a need to ensure that a self-monitoring 
service would be financially viable (6.6.3.3).   
 
There was a fear that patients would not want to self-monitor, and that the service 
needed to canvass their views to gauge demand before going further: 
 
“I know it’s the direction of travel but I’m still not convinced that we’ve 
actually asked the end user what they really want.” (M5) 
 
It was felt that other options for OAT monitoring should be explored and evaluated 
in the context of a full options appraisal, also discussed in Focus Group One.  
 
The need for policies to manage risk associated with shared care and patient transfer 
has already been identified. Additionally, the group felt strongly that there should be 
an overarching corporate strategy drawn up before demand for patient self-
monitoring grows, setting out how to manage a fully operational service. This was 
necessary to both foster partnerships between primary and secondary care, and also 
to review and revise the financial model to enable shared care. 
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6.7 Summary of healthcare staff’s perspectives on OAT patient 
self-monitoring 
 
The findings from these three studies are summarised in Table 39. 
 
The approach taken is consistent with that adopted for the patient-centred studies. 
There are four distinct sections to this table – drivers, benefits, barriers and 
challenges to OAT patient self-monitoring - derived from the perspectives of these 
healthcare professionals. Sub-themes within these broad themes are described, with 
a summary of supporting evidence from each of the studies where available. Finally, 
suggested, or ‘candidate’, service requirements are derived from these sub-themes, 
and these are then mapped to Donabedian’s framework.
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Table 39: Summary of healthcare staff’s perceptions of OAT self-monitoring (drivers) 
 
Perspectives of healthcare staff Drivers 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Patient convenience Potentially timesaving benefit and 
avoids time away from work 
Potentially timesaving benefit, 
avoids time away from work and 
convenient when travelling 
  
Increasing service 
capacity 
Ease congested clinics Ease congested clinics   
DH policy  Development reflects DH policy 
and changes in healthcare 
landscape 
  
Awareness of OAT 
self-monitoring 
A growing awareness of self-
monitoring amongst anticoagulated 
patients will act as a driver for uptake 
 Promote the self-
monitoring service to 
patients 
Structure 
 
Table 39 (cont): Summary of healthcare staff’s perceptions of OAT self-monitoring (benefits) 
 
Perspectives of healthcare staff Benefits 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Patient convenience Potentially timesaving benefit and 
avoids time away from work 
Potentially timesaving benefit, 
avoids time away from work and 
convenient when travelling 
Self-monitoring service is 
acceptable to patients 
Outcome 
Increasing service 
capacity 
Ease congested clinics Ease congested clinics   
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Table 39(cont): Summary of healthcare staff’s perceptions of OAT self-monitoring (barriers) 
 
Perspectives of healthcare staff Barriers 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Provision of the 
coagulometer 
Cost of coagulometer may deter 
patients from self-monitoring 
 
Make a loan machine available 
Cost of coagulometer may deter 
patients from self-monitoring 
 
Lack of competition in market 
pushes up prices of coagulometers 
Facilitate provision of the 
coagulometer 
Structure 
Financial barriers  Reimbursement will be required for 
supporting self-monitoring 
 
Offering financial incentives to GPs 
could increase uptake 
Affordability to PCTs 
 
 
Loss of income stream to acute 
Trust 
 
 
 
Ensure engagement from 
those delivering and 
commissioning OAT 
monitoring 
 
Establish financial feasibility 
 
Self-monitoring service is 
cost-effective 
Structure 
 
 
 
 
Structure 
 
Outcome 
Lack of patient 
confidence in testing 
INR 
Patients may lack confidence to self-
monitor 
Patients may lack confidence to 
self-monitor 
Provide patient training in 
self-testing and using the 
coagulometer 
Process 
Confidence in the 
accuracy of the 
coagulometer 
Define QA arrangements for 
coagulometer  
Define QA arrangements for 
coagulometer 
Establish process for quality 
assurance (QA) of 
coagulometer 
Structure 
Patient preference for 
alternative models of 
care 
Canvass patients’ views Patients may feel that other ways 
of monitoring INR more attractive 
Gauge patient demand 
 
Structure 
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Table 39 (cont): Summary of healthcare staff’s perceptions of OAT self-monitoring (barriers)  
 
Perspectives of healthcare staff Barriers 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Patient eligibility Patients may lack ability to self-
monitor 
 
Consensus reached on eligibility 
criteria 
Inclusion criteria - Long-term 
indication for OAT; ability to buy 
coagulometer; sufficient dexterity; 
able to demonstrate ‘understanding’  
Exclusion criteria - Psychotic illness; 
mental impairment  
 
Establish the service with ‘super-
selected’ patients  
 
Define action to be taken when 
someone who is deemed unsuitable 
to self-monitor purchases a machine 
 
Patients may lack ability to self-
monitor 
 
No consensus reached on 
eligibility criteria 
 
Debate over whether those with 
poor INR control should be 
excluded  
 
Risk assess patients  
 
Construct eligibility criteria Structure 
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Table 39 (cont): Summary of healthcare staff’s perceptions of OAT self-monitoring (barriers) 
 
Perspectives of healthcare staff Barriers 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Lack of clarity on 
accountability 
Medicolegal framework not keeping 
pace with shared decision-making 
 
Elaborate Ethical / legal framework 
including clarity on what constitutes 
negligence under self-care 
 
 
Professional bodies (GMC) to carry 
out a review of self-care 
 
Fear of litigation 
 
Primary care staff vulnerable to 
litigation 
Define where clinical 
responsibility lies 
 
 
 
Elaborate Ethical / legal 
framework including clarity on 
what constitutes negligence under 
self-care  
 
Professional bodies (GMC) to 
carry out a review of self-care  
 
Clarify issues of 
accountability and clinical 
responsibility 
Structure 
Ethical  A service predicated on patient’s 
ability to pay (for coagulometer) is 
inequitable 
Facilitate provision of the 
coagulometer 
 
Address potential inequities 
in the service 
Structure 
 
 
Structure 
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Table 39 (cont): Summary of healthcare staff’s perceptions of OAT self-monitoring (challenges)  
 
Perspectives of healthcare staff Challenges 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Adjusting dose of 
warfarin (PSM) 
Dose adjustment in PSM is an area of 
potential risk 
 
Make available dosing algorithms 
 Provide education and 
support for dose adjustment 
by patients (PSM) 
Process 
Educating self-
monitoring patients 
Education required for patients  Education required for patients Develop and deliver an 
educational programme for 
patients 
Structure 
Process 
Educating healthcare 
professionals 
Education required for healthcare 
professionals 
 
GPs’ knowledge may not meet 
patients’ expectations 
 Develop and deliver an 
educational programme for 
primary care staff supporting 
self-monitoring patients 
Structure 
Process 
Availability of support 
for patients 
Required for patients  Required for patients  Provide ongoing support for 
patients (regular review and 
ad-hoc support) 
Process 
Supporting primary 
care staff 
Ongoing support required for 
primary care staff supporting self-
monitoring patients 
Ongoing support required for 
primary care staff supporting self-
monitoring patients 
Provide ongoing support for 
primary care staff supporting 
self-monitoring patients 
Process 
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Table 39 (cont): Summary of healthcare staff’s perceptions of OAT self-monitoring (challenges)  
 
Perspectives of healthcare staff Challenges 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Redesigning the service Operate from primary care 
 
 
 
 
Use community pharmacists and site 
public coagulometers in community 
pharmacies 
 
Domiciliary service offers an 
alternative to self-monitoring 
 
PST preferred model 
No consensus on whether a self-
monitoring service should be 
operated from primary or 
secondary.  Support for PST team 
 
Mixed views on siting public 
coagulometers in community 
pharmacies 
 
 
Set up patient networks 
 
 
Conduct options appraisal Structure 
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Table 39 (cont): Summary of healthcare staff’s perceptions of OAT self-monitoring (challenges) 
 
Perspectives of healthcare staff Challenges 
Focus group 1 
(Professionals) 
Focus group 2 
(Managers) 
Derived service 
requirement 
Donabedian 
framework element 
Managing financial risk  Need to build business case to 
demonstrate that self-monitoring is 
cost-effective 
 
Meaningful pilot to demonstrate 
feasibility 
Establish financial feasibility 
 
 
Structure 
 
 
Managing clinical risk Risk of patient non-compliance with 
self-testing 
 
Robust system to ensure that a self-
testing patient receives prompt 
advice in response to INR essential 
 
Patient to sign a written agreement 
 
Define governance arrangements for 
primary and secondary care to share 
care, and for responsibilities of 
patients and staff 
 
 
 
 
Loss of intangible benefits of face-to-
face interaction – e.g. behaviour 
modification 
Risk of patient non-compliance 
with self-testing 
 
Robust system to ensure that a 
self-testing patient receives 
prompt advice in response to INR 
essential 
 
 
Agree protocols between PCT and 
hospital with respect to patient 
transfer  
 
Agreed channels of 
communication between primary 
and secondary care 
 
Loss of intangible benefits of face-
to-face interaction – e.g. behaviour 
modification 
Establish a formal shared-
care agreement between 
patient and clinician 
 
 
 
 
 
 
Establish a formal shared-
care agreement between 
primary care and secondary 
care 
 
Self-monitoring service is 
safe 
 
 
Structure 
 
 
 
 
 
 
 
 
Structure 
 
 
 
 
Outcome 
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6.7.1 Summary list of candidate service requirements from focus group 
meetings with healthcare staff 
 
 
STRUCTURE 
¾ Gauge patient demand for OAT self-monitoring 
¾ Conduct an options appraisal (i.e. explore other methods of OAT 
monitoring / define delivery of OAT self-monitoring service) 
¾ Establish financial feasibility of service 
¾ Ensure engagement of those delivering and commissioning OAT 
monitoring 
¾ Promote the self-monitoring service to patients 
¾ Facilitate the provision of coagulometers ( e.g. by funding coagulometer) 
¾ Construct patient eligibility and assessment criteria 
¾ Develop an educational programme for patients 
¾ Develop an educational programme for primary care staff supporting self-
monitoring patients 
¾ Establish a formal shared-care agreement between patient and clinician 
¾ Establish a formal shared-care agreement between primary care and 
secondary care 
¾ Establish a process for quality assurance (QA) of coagulometers 
¾ Establish an OAT self-monitoring policy 
¾ Clarify issues of accountability and clinical responsibility 
¾ Address the potential inequities of the service 
 
PROCESS 
¾ Provide patient training in self-testing and using the coagulometer 
¾ Deliver an educational programme to patients 
¾ Develop an educational programme to primary care staff supporting self-
monitoring patients 
¾ Provide education and support for dose adjustment by patients (PSM) 
¾ Provide ongoing support to self-monitoring patients (regular review and ad-
hoc support) 
¾ Provide ongoing support to primary care staff supporting self-monitoring 
patients 
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OUTCOME 
¾ Self-monitoring service is safe 
¾ Self-monitoring service is acceptable to patients 
¾ Self-monitoring service is cost-effective 
 
6.8 Discussion 
 
This study has explored how those delivering, managing and commissioning oral 
anticoagulation monitoring services view patient self-monitoring. Service 
requirements for an OAT patient self-monitoring service have been derived from 
their perceptions, and these requirements have been mapped to Donabedian’s 
framework. 
 
In terms of outcomes, the self-monitoring service should be acceptable to patients, 
safe and cost-effective. However, the majority of the derived service requirements 
were structural elements – i.e. the context for the service, including the 
organisational framework and the resources required to deliver the service. In 
particular, broad agreement between the two groups lent strong support for the 
following candidate service requirements: 
 
¾ Gauge patient demand 
¾ Address potential inequities in the service 
¾ Facilitate provision of the coagulometer 
¾ Construct patient eligibility and assessment criteria 
¾ Establish a formal shared-care agreement between patient and clinician 
¾ Establish a formal shared-care agreement between primary and secondary 
care 
¾ Clarify issues of accountability and clinical responsibility 
¾ Establish financial feasibility 
 
These requirements will now be briefly discussed. 
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OAT patient self-monitoring was thought to have benefits for both the healthcare 
provider and the patient. At a time when anticoagulation monitoring clinics are 
overstretched, self-monitoring was an attractive alternative service delivery option to 
increase capacity. Echoing the results of the patient-centred studies, patients may 
find self-monitoring more convenient. However, other methods of INR monitoring 
may be more attractive to patients – for example, going to a GP clinic – or they may 
simply prefer to continue attending a secondary care clinic. Therefore, it was 
thought necessary to gauge the patient demand for a self-monitoring service before 
implementation. 
 
The requirement for the patient to purchase their coagulometer was a significant 
issue for both groups. Uptake of self-monitoring by patients is threatened by their 
ability to purchase a coagulometer. As described earlier in this thesis, although 53% 
of patient survey respondents indicated that they would be willing to self-monitor 
their oral anticoagulation, when those who would be willing to self-monitor AND 
purchase a coagulometer were considered this proportion dropped to 15%.  
 
This raises an ethical dilemma: should a service that it predicated on the patient’s 
ability and willingness to pay be introduced? More philosophically, in paying for the 
machine, in effect, the patient is paying for a proportion of their healthcare, contrary 
to the fundamental ethos of the NHS as care delivered free at the point of delivery. 
Siting public coagulometers in community pharmacies was suggested as a way to 
make them available to patients who wish to self-monitor. However, this produced 
a mixed response, and some participants felt that this option negated the benefit of 
the patient being able to test the INR in their own home.  
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Both groups felt it was essential to define those who would be able to self-monitor, 
either by agreeing selection criteria, or by carrying out individual risk assessments on 
patients. With the current model of anticoagulation monitoring, education is 
provided to the patient, and then an assessment is made of their understanding of 
anticoagulation and their ability to comply with both treatment and INR testing. In 
essence they are ‘risk-assessed’. Introducing patient self-monitoring entails greater 
partnership working with  patients, and a confidence that they will take warfarin and 
test their INR in the manner agreed. Therefore, there is a continuing need to ensure 
that the patient understands their treatment, and will comply with treatment and 
testing. At the Whittington, a structured tool is being developed to assess how 
patients on warfarin will comply with treatment and testing. This tool could be 
adapted for use to risk-assess those wishing to self-monitor.   
 
Managing any potential new risks generated lively discussion in both groups. With 
the introduction of OAT patient self-monitoring, care would be shared in two ways: 
between primary and secondary care providers (as with the current models of 
service delivery), but also an increased sharing of care between patient and 
healthcare professional.  
 
There was a need to define the governance arrangements for this shared care. This 
included establishing a formal shared-care protocol between primary and secondary 
care, which would include protocols for patient transfer between GP and hospital in 
the event of the patient becoming clinically unstable. The respective roles and 
responsibilities of patient and healthcare professional will also need to be clearly 
defined, and a form signed by both parties may form be part of this agreement 
 
There was great unease in both groups about the lack of clarity around 
accountability and what constitutes negligence under self-care. It is clear that 
legislation lags behind practice and policy. Although out of the scope of local 
implementation, both groups felt that the following were necessary steps: 
 
i. Elaboration of the legal framework to clarify what constitutes negligence 
under self-care 
ii. A review of self-care conducted by the professional bodies (e.g. the GMC)  
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There was no consensus across the two groups where the patient self-monitoring 
service should be delivered - in primary or secondary care.  
 
This study highlighted tensions between primary and secondary care over sharing 
financial risk. The economic implications of introducing in primary care are 
complex. There is a financial risk to secondary care in terms of loss of income from 
anticoagulant outpatient clinic visits. As discussed earlier in this thesis (3.14), the 
cost-effectiveness of OAT patient self-monitoring is unproven at best. Therefore, 
implementation of this service may also incur financial risks for the commissioners. 
The view from the second focus group of commissioners and managers is that, 
similar to sharing clinical risk, any financial risk should also be shared. 
 
In Chapter Two, the situation in Germany and USA, where there has been greater 
uptake of OAT patient self-monitoring, was discussed along, with factors in these 
countries that may have facilitated this model of care. The focus group of healthcare 
professionals agreed that there were important cultural and healthcare funding 
differences between Germany and the UK that limit the transferability of the 
German model to the UK. Self-management is a cultural norm in Germany, and 
healthcare is not free at the point of delivery. Germany also has a long history of 
self-monitoring of blood glucose (SMBG), and patient engagement in SMBG is an 
insurance requirement. 
 
In the next chapter, the candidate service requirements from this chapter and the 
patient-centred studies will be triangulated to present a combined set of candidate 
requirements for an OAT patient self-monitoring service. This combined set of 
candidate service requirements will then be incorporated into the design of a PST 
pilot service, which will then be implemented and evaluated at the Whittington 
Hospital. 
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6.9 Limitations 
 
The main limitation of this study was its size and scope – just twelve participants 
recruited from one locality. However, they provided a valuable and unique insight 
into the perspectives of those delivering, managing and commissioning 
anticoagulation monitoring services on OAT patient self-monitoring.  
 
These focus groups, especially the second one, were potentially limited by the views 
of the more vocal participants dominating those of the rest of the group. The 
moderator attempted to counteract this by actively drawing the quieter members of 
the group into the discussion. 
 
Also, as with any focus group, it cannot be assumed that individuals in a focus 
group are expressing their definitive individual view. They are speaking in a specific 
context and the nature of the group discussion may discourage some people from 
trusting others with sensitive information. Ideally, if time and resources had 
permitted, these focus groups would have been followed up by one-to-one 
interviews. 
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CHAPTER 7: A VALIDATION OF A SET OF 
CANDIDATE REQUIREMENTS FOR AN ORAL 
ANTICOAGULATION PATIENT SELF-
MONITORING SERVICE 
 
The last two chapters have described the empirical work undertaken to establish a 
multi-stakeholder perspective of patient self-monitoring of oral anticoagulation. 
From the perspectives of these stakeholders - anticoagulated patients, professionals 
and managers - candidate requirements for a service model to support the 
successful adoption of OAT patient self-monitoring have been derived.  
 
The perspectives of these stakeholders and the derived candidate service 
requirements have been previously summarised, for each group, in Table 31 and 
Table 39 respectively.  
 
In Table 40, these results are triangulated to present a combined set of candidate 
requirements for an OAT patient self-monitoring service within the framework of 
Donabedian’s triad of structure, process and outcome.  This framework has been 
previously described (1.3.2). In summary, structure is the set of elements that will 
enable care to be given to those self-monitoring their oral anticoagulation. Process 
relates to the activities required to provide care to this group of patients. The 
structure needs to be in place for the process to occur. For example: 
 
¾ The financial feasibility of the service needs to be established to allow it to 
be delivered 
¾ An educational programme for patients needs to be developed before 
education can be delivered 
 
Finally, outcomes refer to both individual patient clinical outcomes and to service 
outcomes, including those related to finance. 
 
This chapter describes how these candidate service requirements were validated 
through a pilot oral anticoagulation patient self-testing service – the pilot PST 
service - at the Whittington Hospital.  
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Table 40: Candidate requirements for an OAT patient self-monitoring service 
 
Derivation of service requirement Candidate service requirement 
Studies with patients  
(Table 31) 
Studies with 
healthcare personnel 
(Table 39) 
STRUCTURE 
Gauge patient demand √ √ 
Conduct service options appraisal  √ 
Establish financial feasibility of service √ √ 
Ensure engagement from those delivering and commissioning OAT management  √ 
Promote the self-monitoring service to patients √ √ 
Facilitate provision of coagulometer √ √ 
Construct patient eligibility and assessment criteria √ √ 
Develop an educational programme for patients √ √ 
Develop an educational programme for primary care staff supporting patients  √ 
Establish a formal shared-care agreement between patient and clinician  √ 
Establish a formal shared-care agreement between primary care and secondary care  √ 
Establish process for quality assurance (QA) of coagulometer √ √ 
Establish an OAT self-monitoring policy  √ 
Clarify issues of accountability and clinical responsibility  √ 
Address potential inequities in the service  √ 
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Table 40 (cont): Candidate requirements for an OAT patient self-monitoring service  
 
Derivation of service requirement Candidate service requirement 
Studies with patients  
(Table 31) 
Studies with 
healthcare personnel 
(Table 39) 
PROCESS 
Provide patient training in self-testing and using the coagulometer √ √ 
Deliver anticoagulant education for self-monitoring patients  √  
Provide education and support for dose adjustment by patients (PSM) √ √ 
Deliver anticoagulant education for primary care staff supporting patients  √ 
Provide ongoing support to patients √ √ 
Provide ongoing support to primary care staff supporting self-monitoring patients  √ 
   
OUTCOME 
Self-monitoring service is safe √ √ 
Self-monitoring service is acceptable to patients √ √ 
Self-monitoring service is cost-effective  √ 
 
The design of the pilot PST study is summarised in Figure 22. 
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Figure 22: Validating candidate service requirements for an OAT patient self-
monitoring service – study design 
 
There were two main stages to this study: the operational stage and the evaluation 
of the pilot. These will be described in the remainder of this chapter. 
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7.1 Aims and objectives 
 
The aim of the PST pilot was to validate a set of candidate requirements for a 
service to support patient self-monitoring of oral anticoagulation. 
 
Within this there were the following objectives: 
 
i. To determine whether a cohort of Whittington clinic patients could achieve 
therapeutic INR values through self-testing 
ii. To determine patients’ motivations for, and expectations of, self-testing 
iii. To determine patients’ experiences of self-testing 
iv. To determine clinic staff’s experiences of supporting self-testing 
 
7.2 Operational methodology 
 
The establishment and operation of the PST service is summarised in Figure 23. 
 
The Chair of the Local Research and Ethics Committee was consulted prior to 
starting this pilot. As the pilot was considered to be a service development, as 
opposed to pure research, ethical approval was not required. 
 
 
. 
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Discussion among key clinical staff Site visit to self-testing service at Barts & The London
Draft set of operational requirements
Standard 
operating 
procedure written
Invitation letters 
sent to potential 
participants
Educational 
material compiled
Participants attend 
introductory 
session
Receive 
education
Receive machine 
and strips
Sign patient 
agreement
Capillary INR 
compared with 
venous INR
Participants attend 
follow-up visit at 
time of next INR 
test
Self-testing technique 
checked
Participants practise 
self-testing at home
Participants 
continue self-
testing at home
Letters sent to 
participants’ GPs
 
Figure 23: Establishing and operating the PST pilot service 
 
 
The five main stages of this study were as follows: 
 
i. Establishing operational requirements 
ii. Operating the pilot 
iii. Determining patients’ motivations, expectations and experiences 
iv. Determining the safety of the service 
v. Determining clinic staff’s experiences  
 
The stages to this study will now be discussed. 
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7.2.1 Establishing the operational requirements for the PST pilot 
 
This pilot PST service was set up by two senior anticoagulation pharmacists (SD 
and FA) under the guidance of the author. A series of discussions to map out how 
the service should be delivered took place between these three individuals, with 
input from the clinical lead for the Whittington Oral Anticoagulation Monitoring & 
Stroke Prevention Service in the autumn of 2009.  
 
Two sources were used to inform the key operational requirements for the PST 
pilot: 
 
i. Experiences of those working with self-testing patients at Barts and The 
London Hospital 
ii. Candidate service requirements derived from the empirical work with 
patients, healthcare professionals and managers 
 
Using the published literature and information from colleagues both within the 
NHS and the pharmaceutical industry, the author identified that Barts and The 
London Hospital had a well-established OAT patient self-testing service. The 
author contacted this service and was granted an interview and permission to 
conduct a site visit. Therefore, in September 2009, the author and FA paid a visit to 
their anticoagulation nurse specialist to see if lessons could be learnt from their 
experience. 
 
As the aim of this study was to validate a set of candidate requirements for an OAT 
patient self-monitoring service derived from the earlier empirical work described in 
this thesis, it was important to incorporate these requirements into the design of the 
PST pilot service.  
 
The sources of the key operational decisions for the PST pilot are summarised in 
Table 41. 
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Derivation of decision 
 
Key operational decision 
Candidate service requirement Barts & 
London 
Patient self-testing service option selected Conduct service options appraisal Yes 
Engage key stakeholders 
1. Ensure that GP is happy to prescribe 
the INR testing strips 
Ensure engagement from those 
delivering and commissioning OAT 
management 
Yes 
2. Seek position of PCTs around 
provision of testing strips 
Ensure engagement from those 
delivering and commissioning OAT 
management 
 
Establish financial feasibility of 
service 
 
3. Inform key hospital clinicians and 
managers informed about PST pilot 
Ensure engagement from those 
delivering and commissioning OAT 
management 
 
Make a loan machine available Facilitate provision of coagulometer  
Relatively inclusive patient selection criteria 
used 
Construct patient eligibility and 
assessment criteria 
 
Pre-screen patients with respect to NPT  
 
Yes 
Develop and deliver a patient education 
programme 
Develop an education programme for 
patients 
 
Deliver an education programme for 
patients 
 
Establish a process for QA of coagulometer  Establish a process for QA of 
coagulometer 
Yes 
Establish a formal agreement between patient 
and anticoagulant service (patient agreement 
form) 
Establish a formal shared-care 
agreement between patient and 
clinician 
Yes 
Develop a standard operating procedure Establish an OAT self-monitoring 
policy 
Yes 
Support self-testing patients throughout pilot Provide ongoing support to patients  
 
Table 41: Derivation of key operational decisions taken when establishing the PST 
pilot 
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However, for operational, logistical or ethical reasons it was not possible to include 
all of the (triangulated) candidate requirements listed at the beginning of this 
chapter. This PST pilot was established for service as well as research reasons. Prior 
to its implementation, a number of patients had expressed an interest in self-testing, 
and some had gone a step further and purchased a coagulometer. At that time, the 
service was not configured to support these patients, and there were concerns about 
them self-testing without this support. Establishing a means to support these 
patients became a priority for the Whittington Anticoagulation Monitoring and 
Stroke Prevention Service.  
 
Consequently, time did not permit a thorough service options appraisal and, to 
expedite implementation, the service was delivered within existing resources and 
directly from secondary care. As a result of this decision, most of the requirements 
relating to an OAT patient self-monitoring service if it were being delivered from 
primary care – for example, education and supporting primary care staff – could not 
be validated. Selection of a PST model, as opposed to PSM or a mixed model, 
meant that it was not appropriate to provide advice on warfarin dosing to patients. 
 
The financial feasibility of the service was also not assessed prior to service. 
Participants at the second focus group meeting felt that to assess the feasibility of a 
scaled up service, it was essential to enrol at least 10% of the clinic population into a 
pilot (6.6.3.3). As this pilot enrolled fourteen patients, it was felt that assessing 
financial feasibility would not produce meaningful and useable data for such an 
evaluation. 
 
As the likely demand for a patient self-testing service had been assessed in the 
earlier survey of Whittington clinic patients, demand for a PST service was not 
assessed again. Time constraints also precluded a detailed consideration of the 
potential inequities of the service. 
 
Aside from the research agenda, this was a pilot service to establish if it was possible 
to support those who wished to self-test their OAT from the Whittington 
anticoagulant clinic. Therefore, as the future of the service was not guaranteed, it 
was felt unethical to promote it widely to patients. 
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Table 42 summarises which of the candidate service requirements were included in 
the pilot, and the reasons for excluding the rest of the requirements. 
 
Candidate requirement 
included in pilot 
 Candidate requirement 
excluded from pilot 
Reason for 
exclusion 
STRUCTURE    
Conduct service options 
appraisal (limited) 
 Establish financial feasibility of 
service 
Relevance and 
value unclear 
Ensure engagement from those 
delivering and commissioning 
OAT management 
 Gauge patient demand Likely patient 
uptake estimated in 
earlier empirical 
work 
Facilitate provision of 
coagulometer 
 Promote the self-monitoring 
service to patients 
Unethical 
Construct patient eligibility 
criteria 
 Develop an educational 
programme for primary care 
staff supporting patients 
Develop an educational 
programme for patients 
 Establish a formal shared-care 
agreement between primary 
care and secondary care 
Pilot service not 
delivered from 
primary care 
Establish a formal shared-care 
agreement between patient and 
clinician 
 Address potential inequities in 
the service 
Beyond constraints 
of time 
Establish process for quality 
assurance (QA) of coagulometer 
   
Draft an OAT self-monitoring 
policy 
   
Clarify issues of accountability 
and clinical responsibility 
(partially) 
   
    
PROCESS    
Provide patient training in self-
testing and using the 
coagulometer 
 Provide education and support 
for dose adjustment by patients 
(PSM) 
Not a PSM service 
Deliver anticoagulant education 
for self-monitoring patients  
 Deliver anticoagulant education 
for primary care staff 
supporting patients 
Provide ongoing support to 
patients 
 Provide ongoing support to 
primary care staff supporting 
self-monitoring patients 
Pilot service not 
delivered from 
primary care 
    
OUTCOME    
Self-monitoring service is safe  Self-monitoring service is cost-
effective 
Relevance and 
value unclear 
Self-monitoring service is 
acceptable to patients 
   
 
Table 42: Inclusion and exclusion of candidate service requirements in the PST 
pilot 
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The next section describes how each of the key operational decisions was made. 
 
7.2.1.1 Patient self-testing service option selected 
 
In setting up an OAT patient self-monitoring service, the different variables of the 
self-monitoring process need to be defined and decisions taken on how this service 
will be delivered. As discussed in earlier chapters, patient self-monitoring of oral 
anticoagulation can comprise patient self-testing or patient self-management. 
Therefore, there were three main options for the pilot service: 
 
i. Patient self-testing only 
ii. Patient self-testing and patient self-management (mixed model) 
iii. Patient self-management only  
 
It was decided to start with a self-testing service with the option of extending this 
into a self-management service at a later stage. Barts and The London Hospital 
operates only a self-testing service.  
 
The reasons for this were three-fold. Firstly, as the clinic still bore responsibility for 
adjusting the patient’s dose of warfarin a self-testing model was felt to carry the 
lowest risk, a view endorsed by the healthcare professionals and managers 
interviewed earlier in this research. Secondly, a gradual “progression” from self-
testing to self-management was in keeping with the ethos of the service, which 
favours a cautious implementation of service developments. Finally, although the 
patient educational requirements for OAT patient self-testing and self-management 
are not entirely clear, preparing patients for self-testing was felt to require less 
educational investment.  
 
7.2.1.2 Engage key stakeholders 
 
The results of the empirical work highlighted the need to ensure the support of key 
stakeholders at an early stage. To comply with this requirement, GPs, 
commissioners and key hospital staff were engaged at an early stage.  
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Confirmation from the patient’s GP that they were happy to prescribe the INR 
testing strips was needed before the patient was allowed to start self-testing. Whilst 
the clinic provided strips for the duration of the pilot period, participants’ GPs were 
asked if they would be prepared to supply these strips after the pilot. This was 
included in a standard letter sent to the GP at the start of the pilot. 
 
Although supply of testing strips was not raised as an issue during the earlier focus 
group meetings with healthcare personnel, or through interviews with self-
monitoring patients, this is not reflective of the experiences of some patients in the 
UK.170 
   
The position of commissioners on provision of testing strips was also sought by 
email. As this was a pilot service, at this stage there was no broader discussion about 
funding a scaled-up service. 
 
Key hospital staff – consultant haematologists and haematology laboratory manager 
- were also informed of the pilot via email. 
 
7.2.1.3 Make a loan coagulometer available 
 
The requirement for the patient to purchase the coagulometer was identified as a 
barrier to uptake of OAT patient self-monitoring in both the patient and healthcare 
personnel studies. Financial constraints meant that the anticoagulation service was 
not able to provide a machine to those who were eligible for self-testing. 
 
As a compromise, to allow patients to ‘try before they buy’, funding was made 
available to provide a loan coagulometer for the duration of the pilot if required. 
However, it was made clear to participants that coagulometers were given to them 
by the clinic for the duration of the pilot only. If they wished to continue testing at 
home after this six-month period, they would be expected to purchase their own 
machine. 
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7.2.1.4 Relatively inclusive patient selection criteria 
 
The challenge of identifying those patients who are suitable for self-testing has been 
previously discussed in section 3.11. Empirical work, presented in Chapter 5, found 
that some Whittington warfarin patients had concerns that not all patients would be 
able to self-test, particularly those who are elderly or have complex medical 
problems. Although there was some debate as to whether those with poor INR 
control should be included, healthcare professionals and managers felt that 
inclusion criteria should be as broad as possible, perhaps starting with those patients 
who are “self-selecting” and hence highly motivated. This inclusive approach was 
adopted in this pilot and is described further in 7.2.2. 
 
Barts and the London suggested an additional screening criterion after initial 
enrollment into the pilot – ensuring that the coagulometer is able to deliver an 
accurate INR reading for the patient. In a minority of patients, the coagulometer is 
unable to deliver an accurate INR. For example, the presence of anti-phospholipid 
antibodies (APAs) such as Lupus antibodies (LA), and a high haematocrit value can 
potentially lead to elevated INR values. Therefore, to ensure that the coagulometer 
will deliver an accurate reading, before self-testing starts two contemporaneous 
patient blood samples – a capillary sample measured on the coagulometer and a 
venous sample measured in the hospital haematology laboratory – should be within 
0.4 INR units of each other.  
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7.2.1.5 Develop an educational programme 
 
All stakeholder groups identified the need for adequate educational preparation for 
OAT patient self-monitoring.  
 
The education of those wishing to undertake self-monitoring has been previously 
discussed in section 3.12.1. In summary, there is no standardised educational 
package for OAT self-testing patients in the UK. There is insufficient detail in the 
published literature to define the length and content of the educational session. 
More data are available for educational support for OAT self-managing patents. 
However, it is unclear if a lower intensity of training would be required for self-
testing (duration of training described for self-management varied from 3 hours to 
16 hours). 
 
The main challenge of developing an educational programme to support those 
wishing to self-test is the diversity of information needs in this group of people, as 
evidenced by the results of the patient interviews and survey conducted earlier in 
this research. However, although there was variation in both the type and depth of 
information needed, the more ‘practical’ skills – for example, use of the 
coagulometer - were the ones for which many patients felt they would need support 
if they were to self-test. 
 
Therefore, although some more didactic underpinning material was included, the 
educational session was designed to be very much ‘hands on’. The structure and 
content of the session was developed by the senior anticoagulation pharmacists (SD 
and FA) under the guidance of the author. In the first instance, they obtained the 
names of anticoagulation monitoring services that were supporting self-testing from 
the author and from the medical representative of Roche (the manufacturer of the 
coagulometer). They then contacted a number of centres, including Barts and The 
London, Nottingham University NHS Trust, South Manchester University NHS 
Trust and Birmingham, known to be operating a PST service. The content of their 
education sessions was reviewed, with a view to an aspiration that the session was as 
practical as possible, and a culmination used a template for the PST programme at 
The Whittington.   
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The aims and objectives of the session, in terms of what the participants were 
expected to be able to describe at the end of the educational session, are listed 
below: 
 
¾ The theory of blood coagulation and how warfarin works  
¾ Indications for oral anticoagulation and target INRs 
¾ Why regular monitoring is needed  
¾ The influence of diet and lifestyle and of other medicines on INR readings 
¾ The concept of self-testing of INR 
¾ How to test the INR 
¾ Quality control of INR tests 
¾ The necessary health and safety measures associated with carrying out an 
INR test 
 
Participants were also required to perform at least one satisfactory INR test using 
the coagulometer. 
 
7.2.1.6 Establish a formal agreement between patient and anticoagulant 
service 
 
Liability for patient self-testing was a concern expressed by clinicians and managers 
in the focus groups. Although it is far from clear where accountability rests, the 
respective responsibilities of both the patient and the clinic should be understood 
and documented at the start of self-testing. Therefore, a written agreement between 
the patient and the anticoagulant clinic, similar to one used at Barts and The 
London, was drawn up and signed by both patient and a member of the clinic staff.   
This agreement can be found in Appendix 13. 
 
Although this is not a contract in strict legal terms, it does set out respective 
responsibilities. One copy was kept by the patient; a copy retained by the clinic; and 
a third copy sent to the patient’s GP. 
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7.2.1.7 Establish a process for QA of coagulometer 
 
The CoaguChek™ XS machine was selected for this pilot. The Whittington 
Anticoagulation Monitoring and Stroke Prevention Service has a long history of 
working with CoaguChek™ machines, and staff felt confident that they would be 
able to support patients in their use. And, in accordance with consensus guidelines, 
this device has had a positive evaluation from the Centre for Evidence Based 
Purchasing (formerly the MHRA and MDA).171  
 
As discussed in earlier chapters, to ensure accuracy of INR readings, the 
coagulometer needs to be regularly quality assured. This is mandated in consensus 
guidelines,36;52 and was required by both patients and healthcare personnel in this 
body of research. Two options that complied with this requirement were identified: 
 
i. Two contemporaneous capillary samples; one measured on the patient’s 
machine the other on the clinic’s coagulometer which has been subject to 
external quality assurance. 
 
ii. One capillary sample measured on the patient’s machine; one 
contemporaneous venous sample measured in the hospital haematology 
laboratory. 
 
There is no consensus as to the best method of QA. The second method was 
selected to provide patients with the reassurance that the CoaguChek™ was “as 
good” as the hospital INR tests they were accustomed to. 
 
7.2.1.8 Develop a standard operating procedure  
 
An operational plan for managing a PST service was identified as a requirement by 
the healthcare personnel attending the focus group meetings. This need was met by 
a standard operating procedure, developed by the senior anticoagulation 
pharmacists (SD and FA) under the guidance of the author, drawing on the 
experiences of the PST service at Barts and The London.  
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A standard operating procedure (SOP) has been defined as “a written set of 
instructions that someone should follow to complete a job safely, with no adverse 
effect on personal health or the environment, and in a way that maximizes 
operational and production efficiency.”172 An SOP was felt to be essential to 
describe the steps and activities of the service, to ensure that it operated in a 
consistent manner, so promoting a quality service. The contents of the SOP are 
summarised in Table 43. 
 
¾ Aim of SOP 
¾ Criteria for accepting patients to self-test 
¾ Patient training 
¾ GP notification 
¾ Procedure for patient self-testing 
¾ Quality control 
¾ Maintenance of CoaguChek™ machine 
¾ Disposal of waste 
¾ Six-month clinic review 
Appendix 1 Initial assessment sheet for home monitoring of INR 
Appendix 2 Questions to be asked by clinic staff when self-testing patient 
communicates INR 
Appendix 3 Procedure for communicating INR results 
 
Table 43: Contents of the Whittington OAT patient self-testing standard operating 
procedure 
 
7.2.1.9 Support patients throughout the pilot 
 
In addition to providing dosing advice in response to patient-measured INRs, the 
empirical work identified two type of support that might be needed by self-testing 
patients: regular review and ad-hoc advice. Although the time span of the pilot 
would not permit a regular review, clinic staff would need to respond to patients’ 
INRs and to ad-hoc requests for advice.  
 
All stakeholder groups felt that a reliable means of communication was essential to 
foster support provision, especially with communication of INR results. As clinic 
staff felt that more than one method would provide more flexibility for the patient, 
both a dedicated telephone line and an email address were set up. 
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The rationale behind the key operational decisions has been described. The next 
section outlines how the PST pilot was operated. 
 
7.2.2 Recruitment of sample to PST pilot 
 
Eligible patients were Whittington clinic patients who had previously expressed a 
desire to self-test to clinic staff or to the author. Clinic staff and the author assessed 
these patients for suitability for self-testing using the criteria presented in Figure 24.  
 
On lifelong oral anticoagulation 
Good command of English (or a carer or family member available who can 
translate) 
Good manual dexterity (or a carer or family member available who can assist with 
testing). 
 
Figure 24: Patient inclusion criteria for the warfarin PST pilot 
 
No other assumptions were made about the patient’s ability to self-test; the most 
important selection criterion was an expressed desire to self-test. Previous poor 
compliance, either in terms of medication or clinic visits, and poor INR control 
were not regarded as exclusion criteria. The Whittington Anticoagulation 
Monitoring and Stroke Prevention Service does not manage children so, by default, 
all patients were > 18 years old. 
 
Invitation letters were sent to 21 patients in March 2010, along with an information 
sheet about patient self-testing. The letter included a form, which the patient was 
asked to complete and return, indicating their intent to participate in the pilot. This 
letter and information sheet can be found in Appendix 14. 
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7.2.3 Delivery of educational programme for patients participating in the 
PST pilot 
 
After receiving their written agreement to participate in the pilot, self-testing 
patients were invited to attend an educational session.  
 
The education session was held in the Pharmacy Department at The Whittington 
Hospital and was delivered by one or both of the senior anticoagulation 
pharmacists. There were approximately six patients in each group; the session lasted 
for three hours. The content of the educational material is summarised in Table 44. 
 
¾ Self-testing of oral anticoagulation, including advantages and 
responsibilities of patient and healthcare professional 
¾ Point of care INR testing vs. laboratory INR testing 
¾ Blood coagulation and warfarin 
¾ Indications for warfarin 
¾ Effects of medication, diet and lifestyle on INR 
¾ Practical session on self-testing technique 
 
Table 44: PST pilot: Summary of content of the patient educational session 
 
Before arriving at the session, each patient had an INR measured in the laboratory 
from a venous sample of blood. This was then compared with a reading taken from 
a capillary sample measured on the CoaguChek™ XS machine. If the INR readings 
were within 0.4 units agreement, the patient was allowed to continue with the pilot. 
In the event of readings with a divergence of greater than 0.4 INR units, a repeat 
comparison and discussion with the Consultant Haematologist were required. 
 
At the end of the session, patients signed the agreement between them and the 
clinic (as discussed earlier), and took their machine and a starter pack of test strips 
home. A record was kept of the lot number of patients’ CoaguChek™ XS machines 
(in case of a recall), batch numbers of test strips and comparative INR readings.  
 
On completion of training the senior anticoagulation pharmacists notified the 
patient’s GP that the patient had demonstrated that they could self-test their INR 
using a CoaguChek™ XS machine. A copy of the patient agreement was also faxed 
to the GP.  
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7.2.4 Implementation of patient self-testing pilot 
 
Pilot patients were advised to practise testing their INR before attending the clinic 
for their next INR check as normal. At this follow-up visit, the patient’s self-testing 
technique was assessed by the senior anticoagulation pharmacist (FA or SD). Once 
they were confident that the patient’s technique was satisfactory, the patient was 
instructed to perform their next scheduled INR test at home on the CoaguChek™ 
XS, and to inform the clinic of the result via the dedicated phone line, or via email, 
before 1pm on the day of testing. Clinic staff would then advise on the subsequent 
dose and testing interval. Patients were issued with a box of testing strips. 
 
These patients then tested their INR at home for the six-month pilot period. 
Patients telephoned or emailed their results to the clinic and staff then recorded 
these results in the patients record in the clinic’s electronic advisory system. They 
then advised the patient on the dose of warfarin, and on when to check their INR 
again. The length of time between tests was dependent on the INR result; i.e. if a 
result was not in the patient’s target INR range they would be required to perform 
an INR test sooner than if the INR was in range. Patients were also encouraged to 
report any signs of bleeding of thrombosis when they contacted the clinic.  
 
The next section describes with how the pilot was evaluated. 
 
7.3 Evaluation methods 
 
There were four strands to the evaluation of this PST pilot: 
 
i. Auditing INR control of self-testing patients 
ii. Determining patients’ motivations for, and expectations of, anticoagulation 
self-testing 
iii. Determining patients’ experiences of anticoagulation self-testing  
iv. Determining clinic staff’s experiences of patient self-testing 
 
These will now be described. 
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7.3.1 Auditing INR control of self-testing patients 
 
In order to validate the candidate requirements, safety of the PST service had to be 
demonstrated. Options for assessing the safety of anticoagulation control have been 
discussed previously (3.6.1). In this pilot, safety was assessed by patients’ INR 
control during the pilot compared with the pre-pilot period.  
 
Using their electronic anticoagulant record, INR readings during the pilot period 
and for the six months prior to the pilot were collected for each patient. 
Additionally, the patient’s electronic anticoagulant record was searched for entries 
relating to bleeding or thrombotic episodes. As it is thought that more frequent 
testing may contribute to improvement in INR control,75 the median time between 
INR tests was also calculated for pre and post pilot periods. 
 
Patients who were not taking warfarin prior to self-testing were omitted from these 
analyses. 
 
7.3.2 Determining patients’ motivations for, and expectations of, 
anticoagulation self-testing 
 
One objective of this study was to determine patients’ motivations for, and 
expectations of, self-testing.  Exploring these patients’ views was important for two 
reasons. Firstly, it was hoped that their perspectives would help to validate some of 
the candidate requirements. But also, one of the overarching aims of this research 
was to explore the perspectives of patients on self-monitoring of oral 
anticoagulation.   
 
7.3.2.1 Developing the pre-pilot patient questionnaire to measure patients’ 
motivation for, and expectations of, self-testing 
 
Although two published PST studies included an assessment of patient acceptability 
of self-testing,76;118 an extensive literature search did not find any research exploring 
the expectations and perspectives of self-testing patients. Therefore, a preliminary 
set of questions was developed by the author, building on the empirical work 
described in this thesis with a focus on patients’ motivation for PST, anticipated 
benefits, concerns and anticipated support for self-testing.  
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As the wording of a questionnaire is fundamental to both the validity and reliability 
of a study, this set of questions was sent to two experts – a qualitative researcher 
and an anticoagulation practitioner - for comments. Minor modifications in wording 
were made as a result of their feedback.  
 
The final questionnaire was a 12-point instrument, and can be found in Appendix 
15. 
 
7.3.2.2 Administering the questionnaire 
 
Patients participating in the self-testing pilot were asked to complete the 
questionnaire at their initial educational session. A covering letter was also provided 
and can also be found in Appendix 15. 
 
7.3.3 Determining patients’ experiences of anticoagulation self-testing 
 
Another objective of this study was to determine patients’ experiences of self-
testing, in particular if their experience of self-testing matched their expectations. As 
with the pre-pilot questionnaire, these were studied to help validate the candidate 
service requirements and to fulfil one of the overarching aims of the research.  
 
7.3.3.1 Developing the post-pilot patient questionnaire 
 
A set of questions for the post-pilot questionnaire was developed by the author. As 
the objective was to determine the patients’ experiences of self-testing, many of the 
questions were similar to those  included in the pre-pilot questionnaire with 
appropriate changes of wording. For example, “What benefits do you think you will 
get from self-testing” became “ What benefits (if any) do you think you have got 
from self-testing”. 
 
Another measure of the success of the PST pilot was its acceptability by patients. 
Therefore questions were included to determine patient acceptability and any 
derived benefits. Additional questions to validate specific candidate requirements – 
for example, education and support and willingness and ability to purchase a 
coagulometer - were also included.  
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7.3.3.2 Administering the post-pilot questionnaire 
 
A questionnaire, along with a covering letter and postage paid envelope, was posted 
to each patient completing the pilot at the end of the pilot period. The questionnaire 
and covering letter can be found in Appendix 16. 
 
7.3.4 Determining clinic staff’s experiences of patient self-testing 
 
In addition to having a safe service that is acceptable to patients, a successful PST 
service must be acceptable to clinic staff, and integrate delivery into the existing 
clinic structure. Although published evidence is available to demonstrate the safety 
of patient self-testing, no studies were found that explored clinic staff’s experiences 
of establishing and supporting a self-testing service.  
 
The author had regular – at least two-weekly – oral progress updates with staff 
supporting the service, and recorded key issues and problems discussed on a 
spreadsheet. Additionally, the author reviewed the electronic anticoagulant record of 
each patient on a weekly basis and recorded any relevant narrative in the same 
spreadsheet. 
 
One of the senior anticoagulation pharmacists (SD) had earlier participated in one 
of the focus groups. At the end of the pilot period she was asked to verify the 
emergent themes from the focus group meeting she attended in the light of her 
experiences of the pilot. Field notes were made by the author during the interview. 
However, the interview was not audiotaped, to allow SD to speak more freely about 
her experiences.  
 
The question guide used for this interview can be found in Appendix 17. 
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7.4 Analysis of results 
 
This section describes how data from the PST pilot were analysed. All statistical 
analyses were performed using SPSS 17.0. 
 
7.4.1 Auditing INR control of self-testing patients 
 
The safety of the pilot service was evaluated by retrospective audit of the 
participants’ INR results. 
 
Percentage time in therapeutic range (TIR) was used to assess INR control in this 
study. The rationale for using this method has been previously discussed (4.5.3). 
 
For each patient, percentage TTR for the pilot period, and for the six months prior 
to the pilot, was calculated using the method of linear interpolation described by 
Rosendaal et al.146 Median percentage TRR values for these two testing periods were 
then calculated and compared using a Wilcoxon test. The interquartile range (IQR) 
for both median values was calculated to measure the extent of the spread of values. 
Median times between tests for the pilot period and the pre-pilot period were also 
compared using a Wilcoxon test.  
 
Where given, statistical significance was defined as p < 0.05. 
 
7.4.2 Determining patients’ expectations of anticoagulation self-testing 
 
Patients’  responses to these questions were summarised into categories, with 
illustrative quotations used where appropriate. For the few questions that had a 
fixed response, the median value, with the interquartile range, was used to measure 
the central tendency where necessary. These coded data were entered on SPSS, 
which was used to generate the statistics.  
 
Data were tagged with participants’ sex and identifying number (e.g. M1 refers to 
the first sequential male respondent). 
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7.4.3 Determining patients’ experiences of anticoagulation self-testing 
 
As before, this questionnaire comprised mostly open-ended free-text questions and 
the responses were also categorised as before. For the few questions that had a fixed 
response, the median value, with its associated interquartile range, was used to 
measure the central tendency where necessary.  
 
Coded data from the returned questionnaires were entered into SPSS 17.0. 
  
7.4.4 Determining clinic staff’s experiences of patient self-testing 
 
Data collected from the verbal updates with clinic staff and from the patients’ 
electronic anticoagulation records were organised by topics and themes. As small 
numbers of subjects are involved, this was done manually using a simple 
spreadsheet. 
 
Similarly, data from the interview with SD were organised by themes. 
 
7.5 Results 
 
7.5.1 Sample 
 
Twenty-one patients were invited to participate in the PST pilot; fourteen patients 
accepted, five declined and no response was received from two patients. Where 
stated, the reasons for declining to participate were satisfaction with current service; 
new diagnosis of breast cancer; lack of confidence. The demographics of patients 
accepted into the self-testing pilot are summarised in Table 45. 
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                                                                  Number or mean value 
Male (n) 12 
Female (n) 2 
Median age (years) (IQR) 60.5 (51 – 67.8) 
Indication for anticoagulation 
Atrial fibrillation 4 
Replacement heart valve 4 
Venous thromboemboli 1 
Other 5 
Target INR 
2.5 10 
3.5 4 
 
Table 45: PST pilot: Patient demographics (n=14) 
 
Eleven patients used the loan coagulometers provided by the hospital; three patients 
purchased their own machines. 
 
One patient dropped out after the initial training session as, despite repeated 
attempts, he was unable to get a satisfactory capillary blood sample. He declined 
offers of further training. Therefore, in total, thirteen patients completed the pilot. 
 
Two patients were aided by carers, and these carers participated in the initial 
training. 
 
7.5.2 Patient recruitment  
 
There was a staged recruitment of these fourteen patients into the PST pilot. The 
first six patients attended an education session in March 2010; a second cohort of 
four patients attended a session in April 2010. The remaining four patients were 
trained either in pairs or on a one-to-one basis in June and July 2010. With the 
exception of one patient who was managed by the thalassaemia clinic, all 
participants attended a follow-up appointment at the anticoagulant clinic within a 
month of their education session. 
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7.5.3 INR audit data 
 
INR data for the six-month pilot period and for the six-months immediately prior 
to the pilot were collected for eleven patients completing the pilot. As two patients 
started self-testing soon after starting warfarin, pre-audit INR data were not 
available. Hence, they were excluded from this analysis.  
 
The median percentage time in therapeutic range (%TIR) was significantly higher in 
the pilot period than the pre-pilot period (75.8% vs 63.4%, p = 0.03) (Table 46) 
 
% Time in therapeutic range (TIR)  
Pilot period Pre-pilot period 
Median 75.8 63.4 
IQR 72.5 – 85.0 49.8 – 80.7 
Minimum 59.5 32.3 
Maximum 100.0 94.2 
 
Table 46: PST pilot: Percentage time in therapeutic range - Self-testing pilot period 
vs pre-pilot period (n=11) 
 
There was no significant increase in frequency of testing between the two groups. 
The median number of days between INR tests in the self-testing pilot period was 
22.5; the median time interval was 28.0 days in the pre-pilot period (p = 0.05). 
 
One patient had an INR < 1.5 (1.3) and another had one INR >5 (5.5) in the self-
testing pilot period. The low INR was a consequence of the patient stopping 
warfarin on his doctor’s instruction; he subsequently restarted it. There was no clear 
reason recorded for the high INR.  
 
There were no INRs <1.5 and one INR >5 (5.5) in the pre-pilot period. It was likely 
this high INR was the result of a course of antibiotics and antifungals. 
 
There were two pilot patients that were not included in this analysis as they had no 
INR results in the six months prior to the pilot. They achieved a median TRR 
during the pilot period of 76.4% and 86.5%. 
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7.5.4 Adverse events 
 
No bleeding or thromboembolic events were reported during the pilot. 
 
7.5.5 Patients’ expectations of self-testing 
 
Questionnaires were given to all pilot patients (n=14) at their introductory training 
session. All patients completed the questionnaire.  
 
7.5.5.1 Themes from the pre-pilot questionnaire: patients’ expectations of 
self-testing 
 
Source of information about self-testing 
 
As the majority of the pilot patients had approached the clinic about self-testing – in 
effect, self-referring – it was of interest to know where they had heard of warfarin 
PST. One of the candidate service requirements was to promote the self-monitoring 
service to patients, and therefore information about suitable forums for this might 
be useful. 
 
Half of these patients had heard about self-testing through the Whittington 
Hospital. The results are summarised in Table 47.   
 
Source of information about warfarin PST Number of patients 
Whittington anticoagulant clinic 4 
Whittington Hospital (unspecified location) 3 
GP surgery 2 
Hospital consultant 2 
Newspaper 1 
Charitable foundation 1 
(London) Heart Hospital 1 
 
Table 47: PST pilot: Source of pilot patients' initial information about warfarin 
PST 
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Motivations for self-testing 
 
Similarly, to tailor any future promotional activity, a knowledge of patients’ 
motivations for self-testing might prove useful. Patients were asked to rank the 
difficulty they had in deciding to participate in the pilot on a 5-point Likert scale 
from 1 = “no difficulty” to 5 = “ a lot of internal debate”. Almost all of the patients 
(n=13) had no difficulty in reaching this decision; median score was 1 (IQR = 1 to 
1). As these patients were essentially self-referring, this was an unsurprising result. 
 
Although there were a number of different reasons for the pilot patients expressing 
a desire to self-test (summarised in Table 48), the dominant factor was the 
convenience afforded by self-testing whilst travelling, either for work or leisure. 
 
Motivating factor Number of patients 
Travel 6 
Avoidance of hospital visits 4 
Wish to self-care 2 
Convenience 2 
Reassurance 1 
Time saving 1 
Recommendations from medical colleagues 1 
Increase stability of INR 1 
Difficulty with venepuncture 1 
 
Table 48: PST pilot: Motivating reasons for warfarin self-testing amongst 
participants 
 
Amongst this group, avoidance of hospital visits was also a frequently cited reason, 
especially in terms of travelling to the hospital and finding parking once there. 
 
One of the pilot patients had thalassaemia and, by necessity, had to attend the 
hospital regularly. Therefore, there was a debate amongst clinic staff when recruiting 
for the pilot as to any potential benefits he may achieve. However, he expressed 
desire to have a greater role in self-care (one of two patients stating this motivation), 
which is an equally strong potential benefit of self-testing.  
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The availability of a loan coagulometer was a deciding factor for participation in the 
pilot for seven of the eleven patients who were given a machine for the duration of 
the pilot. The education and support provided by the service were also strong 
factors.  
Benefits of self-testing 
 
The pilot patients’ anticipated benefits largely mirrored their motivations for trying 
self-testing and are summarised in Table 49. 
 
Anticipated benefits of self-testing Number of patients 
Convenience (including avoiding travelling to hospital) 5 
Time saving 3 
Better INR control 3 
Reassurance 2 
Independence / more autonomy 2 
None 1 
Step towards PSM 1 
Unsure 1 
 
Table 49: PST pilot: Participants’ anticipated benefits of self-testing 
 
Concerns about self-testing 
 
The majority of the pilot patients (n=10) had no concerns about self-testing. For 
the remainder of patients concerns focused on their ability to perform an INR test 
and the accuracy of the coagulometer: 
 
“Previous machine correlated poorly with venous blood so I have a lingering 
doubt about not having a venous test regularly” (M4) 
 
Reassurance about the accuracy of coagulometers, which could be provided through 
education, support and quality assurance, was also important to some of the patients 
interviewed earlier in this research. Their concerns were partly predicted on past 
experiences, either with coagulometers or glucometers.  
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However, it is important at this point to note another important difference in 
monitoring blood glucose and INR. Although it is essential that the accuracy of 
both of these types of machines is assured, it can be argued that this is more critical 
in the case of coagulometers. In contrast to blood glucose control, there are often 
no signs that the INR is not therapeutic, and the only means of assessment is the 
coagulometer.  
 
Support for self-testing 
 
Patients were asked for their requirements both in terms of education prior to 
starting PST, and also ongoing support whilst self-testing. 
 
Very little was required from this group of patients in terms of clinical information 
about warfarin. Where stated, educational requirements centred on the more 
technical aspects of patient self-testing and use of the coagulometer. One patient 
stated that he needed no educational support and three felt that minimal input was 
needed. The results are summarised in Table 50. 
 
Educational element required before self-testing Number of patients 
Coagulometer use and INR testing 6 
Overview / background to PST 2 
"Top-up" education 2 
Problem solving 1 
 
Table 50: PST pilot: Educational requirements of participants prior to self-testing 
 
This pilot group had modest expectations of support from the anticoagulant clinic 
whilst self-testing. Over half of the group (n=8) expected the clinic to recommend 
the dose of warfarin in response to the self-measured INR. Other requests centred 
on technical support for the coagulometer. 
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Sustainability of pilot 
 
Patients were asked about two issues that may have an impact on them continuing 
self-testing once the pilot had finished. 
 
Earlier stages of this research, identified patients’ reluctance or inability to purchase 
a coagulometer as a potential barrier to its uptake. Using a 5-point Likert scale, from 
1 – “very unlikely” to 5 = “very likely”,  patients were asked how likely they were to 
buy a coagulometer once the pilot had ended. As four patients had already 
purchased a coagulometer, this question was not applicable to them. For the 
remaining ten patients who responded to this question, the median response was 4 
= “likely” (IQR = 2.5 to 5). 
 
The reluctance of GPs to prescribe INR test strips has also been earlier identified as 
a potential barrier to warfarin PST (2.5.3). Whilst eight of these patients’ GPs were 
happy to prescribe strips, the remaining six patients were unsure of how their GP 
would react, largely because they had not discussed the issue with the GP.  
 
Two of the four patients who had purchased a machine had not discussed test strip 
prescriptions with their GP. One of this group of patients stated that her GP had 
overcome an initial reluctance to prescribe: 
 
“My GP now prescribes my test strips. Two years ago he was not happy with 
self-testing. So I’m not sure if he is happy about it or not, but as he now 
prescribes the strips maybe he is growing more comfortable with self-testing” 
(F2) 
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7.5.6 Patients’ experiences of self-testing 
 
Questionnaires were posted to all patients completing the pilot (n=13); eight 
patients returned their questionnaires.    
 
7.5.6.1 The post-pilot questionnaire: patients’ experiences of self-testing  
 
The post-pilot questionnaire was divided into four sections; experiences during the 
pilot (which included benefits and difficulties) support for self-testing, feasibility of 
continuing self-testing and final thoughts. These will now be discussed. 
 
Experiences during the pilot 
 
All respondents rated their experience as ‘very positive’; median score was 1 (IQR = 
1 to 1) 
 
Patient-reported benefits of self-testing centred around two main themes; 
convenience and reassurance. The ability to test the INR whilst away from home 
and the avoidance of hospital visits, with the associated traveling, meant that the 
benefit that half of this group of patients derived from self-testing was convenience. 
Additionally, over half of this group embraced the greater control they achieved 
through testing their INR when they felt it was necessary, and the reassurance this 
brought: 
 
“The security of knowing that if I feel unwell and suspect my INR may be very 
out of range, I can test it to find out as soon as possible whether my guess that it 
is out of range is correct” (F2) 
 
“The ability to monitor the effect of my daily intake has on my blood gives me 
unmeasurable (sic) peace of mind. I can see this in my own home. Wao!” (M1) 
 
There were no unanticipated benefits reported. 
 
Where reported, patients had difficulties with either getting a large enough blood 
sample, or with applying this blood sample to the test strip. This affected over half 
of this patient group, and sometimes resulted in wasted test strips. 
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“At the start a problem with obtaining enough blood. This solved when I was 
shown how to adjust the 'size' of the lancet blade - No problem now.” (M5) 
 
Some of these difficulties may be circumvented by education and training.  
 
“I used to waste a few strips - but I waste fewer now since I was shown, on the 
pharmacists self testing training session at the beginning of this pilot, a better 
way to apply the blood to the strip. Before that I was doing it the way I was 
shown on the Roche self testing DVD that came with the machine.” (F2) 
 
Supporting self-testing 
 
The majority of respondents did not feel that any changes to the educational 
programme provided by the clinic were necessary. 
 
“Any more (education) would have been counter productive. You have to try to 
learn from your mistakes.” (M3) 
 
However, a few patients felt that extra practice with self-testing and a more robust 
assessment of patients’ technique may be beneficial. No changes to other aspects of 
the educational programme were suggested. 
 
Most patients felt that the support provided during the pilot was ‘great’ or ‘excellent’ 
 
“The support is excellent. Full marks.” (F2) 
 
No suggestions for improvement were received. 
Continuing self-testing 
 
All eight patients who returned the post-pilot questionnaire wished to continue self-
testing after the pilot. The overwhelming reason for wanting to do this was 
convenience. 
 
“Being able to self-test gives you freedom in looking after your INR results 
without going to hospital to do this and for holidays.” (F2) 
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However, some patients may find it difficult to buy a machine. 
 
All patients who answered the question – there was one missing response – stated 
that they would be ‘very willing’ to purchase a coagulometer at the end of the pilot; 
median score was 1 (IQR 1 to 1). However, when questioned about ability to buy a 
coagulometer the median score dropped to 2 with a greater variation in score (IQR 
1 to 3.5). 
 
For three patients, the ability to purchase a coagulometer was contingent on 
acquiring the means to do so:   
 
“I will pay through my benefit” (M1) 
 
“(I) will have to borrow the money” (M3) 
 
“Should my machine break it would be difficult to afford another. But I seem to 
remember Roche told me that you can pay in instalments and that would be 
possible.” (F2) 
 
Endnote 
 
Seven patients would recommend warfarin PST to a friend; one respondent did not 
answer this question. Again, convenience was the overwhelming reason for 
advocating self-testing. 
 
“The freedom and control of looking after your health at a time and place 
convenient to you. Thanks for the chance to try this out.” (M3) 
 
However, control was also cited as a reason for recommendation by three 
respondents. 
 
“A feeling of being in control. Ability to respond quickly to changes in INR.” 
(M4) 
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7.5.7 Anticoagulant clinic staff’s experiences of patient self-testing 
 
7.5.7.1 Themes from formal oral progress updates with staff and their entries 
in the pilot patients’ anticoagulation records 
 
Data from the progress updates with clinic staff (SD and FA) running the PST pilot, 
and analysis of the content they had entered into the pilot patients’ electronic 
anticoagulation record were categorized into six broad themes (Table 51) 
 
INR testing 
Communication of INR results 
Patient selection 
Self-management 
Feasibility of PST 
Marketing of coagulometers 
 
Table 51: PST pilot: Themes emerging from discussion with staff  
 
These will now be discussed. 
 
Theme 1: INR testing 
 
INR testing can be broken down in three sub-themes: patient capability, 
concordance between venous and capillary samples and patient confidence in 
readings. These will now be considered. 
 
Some patients had initial difficulties in obtaining an adequate sample of capillary 
blood on which to perform an INR test. Although two of these patients also 
measured their blood glucose at home, they still found measuring their INR a 
challenge. Specific problems included using the correct depth setting on the lancet, 
positioning the finger over the testing strip and incorrect technique, including 
stabbing or squeezing the finger. Some of these problems were compounded by 
nervousness and one patient had commented that if the prescribed gap between 
INR tests was long, he forgot how to test his INR. 
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As discussed earlier (7.2.1.4), concordance between capillary and venous samples is 
a pre-requisite for patient self-testing. This created difficulties during the pilot in 
two ways. Firstly, two patients were reluctant to return to the clinic for a second 
comparative test. Secondly, there were initial difficulties in getting matching INRs 
from another patient; further management advice was sought from the consultant 
hematologist and the patient was allowed to continue with the pilot once 
concordant samples were obtained. 
 
There was a perception amongst clinic staff that many patients did not trust the 
INR result generated by the coagulometer, which has been borne out by the 
comments of some of the pilot patients. However, this distrust was not confined to 
self-testing but extended to use of the coagulometer for INR monitoring in primary 
care (i.e. when used by primary care staff for community based clinics). 
 
Theme 2: Communication of INR results 
 
Regular INR tests are essential to the safe management of oral anticoagulation, to 
ensure that the patient is not at risk of bleeding or thrombosis.14 One of the 
responsibilities of the self-testing patient was to perform the INR test at the 
mutually agreed time interval, and inform the anticoagulant clinic of the result by 
1pm on the day of testing. 
 
Reliable communication of INR results by patients to the clinic staff caused 
considerable problems during the pilot. These problems were related to patient 
compliance and staff engagement. 
 
Two patients emailed their results to the clinic; the remainder used the telephone. 
However, the dedicated telephone was not always used, which risked results not 
being picked up in a timely manner. Equally, the dedicated email account was not 
used by patients, risking communication of results to a person who was on annual 
leave. 
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Clinic staff had to put considerable effort into following up patients who had not 
communicated their INR results at the prescribed time. At one stage in the pilot, 
over half of those enrolled were not communicating their results at the correct time. 
At one point, a patient who spends much of his time in Nigeria was six weeks 
overdue with his INR test result and uncontactable, raising serious safety concerns. 
Another patient headed off to Thailand with his coagulometer and the clinic did not 
hear from him for over three months. 
 
Non-compliance with testing may be addressed by education. There was an initial 
perception amongst some patients that if their INR was within range they did not 
need to contact the clinic. One patient started a course of antibiotics during the 
pilot and deferred his INR test until he felt better. 
 
Engagement from clinic staff is equally important and initially one of the clinic staff 
was resistant to this service development and not passing on patients’ messages. 
However, as the pilot progressed she became more engaged, and the feeling of 
those running the pilot was that there was a lack of understanding which might have 
been prevented by involving her in the development of the pilot service at an early 
stage. 
 
Theme 3: Patient selection 
 
Issues surrounding patient selection came up through discussions with clinic staff. 
Acceptance (or refusal) of patients for self-testing created some ethical dilemmas. 
There was a potential referral for a stroke patient, who was a candidate for oral 
anticoagulation but for whom self-testing, with the assistance of her daughter, was 
the only option for monitoring. Denying her the opportunity to self-test would have 
been denying her an effective treatment. However, the patient’s prognosis was poor 
and anticoagulating her may not have improved her quality of life, and may have 
denied another patient the chance to self-test. 
 
There were concerns over the equity of the service. Three of the pilot patients were 
retired doctors, and there was a fear that self-testing was the preserve of the 
knowledgeable few. 
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Clinic staff were keen to accept one patient into the pilot as he was “difficult”, and 
his self-testing would potentially reduce contact with him! 
 
One patient accepted on to the pilot was new to oral anticoagulation and self-testing 
from the start of treatment did not pose any problems. 
 
Theme 4: Self-management 
 
There was not only a desire expressed by some patients at the start of the pilot to 
adjust their own dose of warfarin, but also three patients admitted to self-managing 
during the pilot. The quote below is taken from the electronic record of one of the 
pilot patients: 
 
“Just returned from trip to Africa. No change to meds but diet and lifestyle have 
been different while away. Going to Bangkok tomorrow for 3 weeks. INR from 
self-testing yesterday. Has taken an extra day of 3mg instead of 4mg as INR 
high” 
 
By the end of the pilot, another patient was reaching a consensual decision with 
clinic staff on dose. He had steadily grown in confidence during the pilot, from 
being initially non-compliant with self-testing to phoning in INR results on time and 
offering dosing suggestions for discussion; clinic staff described this as a “complete 
turn-around”. 
 
Theme 5: Feasibility of PST 
 
Concerns were expressed over the feasibility of patient self-testing of OAT, 
especially in the early days of the pilot. It was felt that operating the pilot was 
labour-intensive, particularly in terms of educating patients and performing 
comparative blood samples, and there were doubts that this investment would reap 
few rewards.  
 
A few logistical issues were raised during the pilot. 
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The operation of the pilot was underpinned by a standard operating procedure. But 
it was felt that this needed to be expanded to better support the clinic nurse 
specialist and administrator, especially to guide them when patients phone in INR 
results. 
 
It was felt essential that local PCTs were consulted at the start of the pilot. Although 
Camden and Haringey were happy for their GPs to prescribe testing strips, the 
position of Islington and Barnet PCTs remained unclear. 
 
Theme 6: Marketing of coagulometers 
 
Towards the end of the pilot period, Roche invested in a more intensive marketing 
campaign for its CoaguChek™ XS machine for self-testing. This strategy included a 
temporary price reduction for the CoaguChek™ XS (to £299), implementation of 
support to anticoagulant clinics from a dedicated nurse, awareness evenings and 
advertising directly to patients in daily newspapers and on the London 
Underground. However, much of the campaign’s resources were directed towards 
primary care, including visits to GP practices and advertisements placed in GP’s 
magazines. 
 
This resulted in a small surge of interest from patients. In August 2010, seven 
patients approached the clinic; six of these were male. Although it was decided not 
to include these patients in the PST pilot, two of them went ahead and purchased 
machines and the clinic staff felt compelled to train and support them. 
 
7.5.7.2 Themes from post-pilot interview with clinic staff 
 
One of the anticoagulation pharmacists running the pilot (SD) was interviewed after 
the pilot was completed. The interview took 40 minutes and took place in a private 
room in the Pharmacy department at the Whittington Hospital.  
 
The interview with SD centered around four themes that emerged from the focus 
group that she attended – concerns; risk; feasibility and service redesign. A fifth 
theme – benefits – emerged from this interview. These will now be described. 
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Theme 1: Concerns about self-testing 
 
Concerns about self-testing related to timely communication of results between the 
patient and anticoagulation clinic and patient selection criteria. 
 
During the pilot, four patients needed to be contacted every time for their INR 
results. However, the remaining patients were more “organised, conscientious or 
scientific”, reflecting the group as a microcosm for the “spread of humanity”. The 
reasons for patients not communicating their INR results were multifaceted. 
However, SD did offer this insight: 
 
“A few times we’ve had to chase results but people are testing … they’re just 
choosing not to communicate their results. But I think that’s their little bit of 
rebellion. I can be a patient but I don’t have to be in a hospital” 
 
Although reported INR results during the pilot appeared better than those achieved 
pre-pilot, SD felt that this was not so much better results per se, but instead the 
reporting of better results. There was some evidence that patients were either 
measuring their INR only when they felt the results would be good, or testing more 
often than asked to but not reporting the additional results. 
 
There has been debate in the literature, and within the focus group discussion, over 
whether those with a history of poor INR control should be considered for PST. 
SD felt strongly that those with poor INR control should be offered the chance to 
self-test: 
 
“Some patients feel frustrated with anticoag and feel frustrated that they have 
to come into hospital when they feel quite healthy …. They don’t like someone 
else managing it and rebel against it” 
 
These patients were likely to be, but not exclusively, young or middle-aged men and 
SD had already identified a small number who “might pick up if they are given the 
responsibility to do it themselves”. 
 
However, SD felt that the overriding priority is that a PST service should be 
inclusive, and that potential inequity presented more difficulty: 
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“(the) worst problem with this service is that it’s impossible to make it 
equitable” 
 
As the service has limited resources and a large number of patients, funding 
coagulometers is impossible. Therefore, PST becomes the preserve of those who 
are able to buy a machine. In SD’s words: 
 
“(It is) difficult to be inclusive when there is a financial cost associated with it” 
 
But it is not only the financially disadvantaged who are excluded; language barriers 
may also exclude ethnic minorities. 
 
For the duration of the pilot, patients were given a loan machine to “try before they 
buy”, on the condition that this is returned to the hospital at the end of the pilot 
period. However, SD felt that this was not a workable proposal in the future. In 
addition to potential difficulties in persuading patients to relinquish the loan 
machines, SD felt that it was wrong to raise people’s expectations by giving them a 
machine if they were not ultimately in a position to purchase one of their own. By 
doing this, there is a risk, at best, of disaffection, but also of the patient dropping 
out of the anticoagulation monitoring service. 
 
Theme 2: Risk management 
 
Risk management centred around shared responsibility; between patient and 
anticoagulation practitioner and between anticoagulation practitioners in primary 
and secondary care. 
 
Before patients were enrolled on the pilot, they signed a patient agreement form 
which outlined the respective responsibilities of the self-testing patient and clinic. 
SD felt that a signed agreement of this nature was essential to protect the clinic 
from liability, and to clarify the relationship between the patient and clinic. The PST 
service represents… 
 
“… a remodelling of the relationship that has to be formalised” 
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A focus group concern that patients who are self-testing are less likely to take their 
medical condition seriously was not borne out in this pilot. Although patients were 
less dependent on the clinic - and some quite blasé about contacting the clinic - they 
did not devalue either their condition or medication. 
 
To mitigate potential risks, the focus group felt that an evaluation of patient 
competence was undertaken, at least on an annual basis. The pilot patients were 
assessed on use of the coagulometer at their initial training session and again at their 
follow-up clinic session. SD agreed that this was necessary, as was six-monthly QC 
of the patient’s coagulometer. Whilst she stopped short of endorsing top-up 
educational sessions, she also felt there was merit in re-enforcement of educational 
messages through a newsletter. However, she felt that a formal re-evaluation should 
be reserved for those patients about whom the clinic staff had concerns. 
 
The focus group also identified a need to have an agreed protocol between the 
hospital clinic and primary care in the event of patient transfer. Anticoagulated 
patients are often well for a long time, but can become suddenly unwell, or need to 
have a procedure, and will then require more intensive monitoring. But whilst it was 
acknowledged that a formalised agreement was necessary, there could be difficulties 
in accommodating all patients’ needs. 
 
“(all patients) are individuals with different care needs so one model doesn’t 
really fit all”  
 
SD concurred with the view of the focus group that there was a risk that the self-
testing patient could lose “value-added” service through reduced contact with their 
healthcare professional. She confessed that is “quite easy to be casual” when a 
patient phones in their INR results and that they were not always subject to the 
same scrutiny as in a face-to-face contact. However, the same argument can be 
applied to those patients who are on the clinic’s mailing list. 
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Theme 3: Feasibility of patient self-testing service 
 
SD felt that, in the current climate, a larger scale PST service was not feasible. There 
are too many patients, and consideration needed to be given to the time required to 
train patients and also to the acquisition cost of the coagulometers. The attention 
that needed to be devoted to preparing and supporting an individual to self-test was 
arguably disproportionate to that given to the anticoagulated population at large; the 
needs of the one outweighing the needs of the many. 
 
Before considering scaling-up the pilot, two things needed to happen; extra 
resources in  terms of personnel, and an assurance from the PCTs that test strips 
would be funded.  
 
Theme 4: Service redesign 
 
If a larger scale patient self-testing service were enabled, some thought would need 
to be given to the best way of operating this service. SD felt that there were three 
options: 
 
i. Include a PST strand in the service’s existing clinical governance framework 
to allow PST to be initiated and supported in both primary and secondary 
care. 
 
ii. Manage all  PST patients at one centralised service.  
 
iii. Management by the patient’s GP  
 
On balance it was felt that the third option was the better one as the patient was 
likely to be attending the GP’s surgery regularly, and also the INR results would go 
directly to the GP (as the prescriber). However, SD identified a potential training 
need of primary care practitioners: 
 
“Community practitioners are not as well informed as hospital practitioners” 
 
Regardless of where, and by whom, the self-testing patient is supported, quality of 
the service in terms of both INR control and QC of coagulometers must be 
ensured. 
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At the healthcare professional focus group meeting, it was proposed that patients 
could set up networks where they could avail of a shared coagulometer. However, 
SD felt that this approach had a number of drawbacks. There were potential health 
and safety risks in the use of blood testing equipment, and safeguards would need to 
be put in place to ensure the machines were quality controlled and that the strips 
and solutions were stored correctly.  
 
Changes to the skill mix within the anticoagulation monitoring service may be 
needed to support PST. Although SD felt that skill mix does not matter, the 
linchpin was the clinic administrator, who has an important role highlighting when 
people are not reporting tests. She felt that higher grades of staff are not needed to 
run a PST service provided there are good guidelines. 
 
Theme 5: Benefits of PST 
 
SD felt that there was a need to offer patient self-testing as an option for the 
Whittington clinic patients. The current method of monitoring does not meet the 
needs of a proportion of the population, and within an increasing clinic population 
it is necessary to accommodate the different needs. There should be an emphasis on 
improving services and meeting individual patient needs: 
 
“Because it’s a long term relationship you have to facilitate it” 
 
In her view, the main problem with traditional anticoagulation clinics is that they 
can be time consuming and difficult to access: 
 
“A young working man with a family to support shouldn’t have to spend three 
hours of his week, two weeks a month in an ac clinic” 
 
In addition to providing a more patient-centred and convenient service, PST may 
improve safety through increased frequency of testing, although this brings 
increased financial pressure.  But benefits may not only be conferred on the patient, 
but also on society: 
  
“Financial benefit to society might offset any increased costs to ac services” 
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7.6 Validation of candidate service requirements 
 
This PST pilot was a success in terms of being safe and acceptable to patients. From 
an operational point of view, anticoagulant clinic staff were able to support these 
patients and felt that it had clear benefits for some patients. However, they had 
concerns about the equity of the service and its scalability from a pilot, and they 
experienced problems with timely communication of INR results from patients. 
 
The aim of this PST pilot was to validate the candidate requirements for an OAT 
patient self-monitoring service, derived from the empirical work described earlier in 
this thesis. For operational reasons, not all of these candidate requirements could be 
validated, and this has been discussed earlier. But, where possible, the candidate 
service requirements identified from these studies were incorporated into the design 
of this pilot. 
 
Table 52 summarises the outcome of validating these candidate service 
requirements. Some elements could not be fully validated in a PST pilot. It was 
essential that this research was ethical, adhering to the core principle of ‘doing no 
harm’ to study participants.27 For example, it would be have been unethical to offer 
some patients education and none to others. Thus, as it is not known if the pilot 
would have been successful in the absence of educational support, this candidate 
requirement could only be partially validated. 
 
The same ethical consideration applies to providing self-testing training and ongoing 
support to patients. However, these requirements could be validated using measures 
other than the success of the pilot. Pilot patients emphasised the importance of 
being trained on how to self-test and to use the coagulometer, and felt that initial 
difficulties with self-testing could have been avoided if greater attention had been 
paid to this in the initial educational session. The provision of support was an 
important factor in persuading patients to participate in the pilot, and positive 
feedback was received for the support given. 
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Service options were appraised in the early stages of the development of the pilot. 
Building on the findings of the focus group meetings, a PST model was selected and 
was found to be safe. However, in the absence of a direct comparison with a PSM 
service, it is not possible to conclude that this is the preferred model of care for this 
group of patients. The next stage of development of this service – ‘progressing’ 
some of these patients to PSM – might help answer this question.  
 
Although, for operational reasons, the pilot service was delivered from secondary 
care, clinic staff felt that primary care might be the best place from which to support 
PST. This assertion broadly supports the discussions in the focus group meeting. 
Therefore, further development of the service may be to engage general 
practitioners, currently delivering the primary care anticoagulation monitoring 
clinics, in supporting self-testing patients. 
 
Engagement of all Whittington anticoagulant clinic staff was found to be essential. 
The anticoagulant nurse specialist and clinic administrator were not involved early in 
the process, an oversight that resulted in their initial resistance to the pilot. Two 
strategies might have avoided this. Firstly, earlier engagement with these individuals, 
involving them at the developmental stage of the pilot. Secondly, whilst the standard 
operating procedure (SOP) used in the pilot was felt to be beneficial and an essential 
requirement, in future it should incorporate the roles of all clinic staff. 
 
The empirical work suggested that two formalised shared care agreements were 
needed: one between primary and secondary care, and another between patient and 
clinician. As this pilot service was run from secondary care, the first shared care 
agreement could not be tested. However, through the insight gained by supporting 
self-testing patients, clinic staff felt that some form of agreement between primary 
and secondary care was needed, although there were doubts that this could 
accommodate the needs of all patients. Therefore, if a shared care agreement 
between primary and secondary care is to be tested in future, consideration may 
need to be given to making it as broad as possible to embrace different patient 
needs. 
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The shared-care agreement between patient and clinician was the patient agreement 
form signed by both parties at the start of self-testing. Although this set out the 
respective responsibilities, it was felt that some patients did not fully comply, 
particularly around timely communication of INR results. Nonetheless, clinic staff 
felt that this form was an essential requirement of the service, to both define the 
relationship between patient and clinician and to protect the clinic from liability.  
 
There are ways to persuade the patient to report their INRs in a timely fashion. 
Firstly, the importance of complying with this requirement should be given more 
emphasis at the educational session and the risks of non-compliance outlined. 
Research commissioned by the National Patient Safety Agency found that some 
patients do not understand the meaning of INR readings.169 Secondly, stronger 
wording could be employed in the patient agreement form. Although flexibility in 
communication methods with the clinic was already built into the service, with the 
option of providing results by telephone or email, the facility to provide INRs by 
text could be explored.  
 
However, it needs to be accepted that, regardless of additional measures put in 
place, there may always be some patients who are less compliant with testing. 
Relatively inclusive eligibility criteria were used in the pilot, and this is discussed 
further in Chapter 9. However, to mitigate the risk of non-compliance with INR 
testing, those with a history of continually not attending the anticoagulant clinic on 
the agreed appointment date may need to excluded from self-testing in the future. 
There is no evidence that those who are non-compliant with clinic visits for INR 
monitoring will fail to communicate their self-measured INR values in a timely 
fashion, and there is a possibility that the empowerment that may come from self-
monitoring will encourage them to self-test at the prescribed intervals. Nonetheless, 
this is a gamble, and one that has to be traded against managing the risk of non-
compliance with INR testing.  
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Although, the pilot did not set out to test the candidate requirement to promote the 
service to patients, Roche embarked on an intensive marketing strategy for the 
CoaguChek™ machine during the lifetime of the pilot. This resulted in a surge of 
interest in self-testing from patients, so much so that it became problematic for 
clinic staff to deal with requests for support. This not only emphasised the impact 
of increased awareness of self-testing, but also the need to have a process to deal 
with the patient interest that this generates. 
 
Validating the findings from empirical work with patients and healthcare personnel, 
the requirement for the patient to purchase a coagulometer was again found to be a 
significant barrier to the uptake of OAT patient self-monitoring. Although the 
availability of a loan machine was a strong motivating factor for patient participation 
in this pilot, its sustainability needs to be ensured. Since the end of the pilot there 
have been difficulties in persuading patients to relinquish their machines. There is 
also the potential of raising people’s expectations by giving them a machine if they 
were not ultimately in a position to purchase one of their own.  
 
There are ways to circumvent these problems. Firstly, as has happened at Barts and 
The London, patients could be asked for a deposit when they are issued with the 
machine, refundable on its return. Secondly, patients may be asked to sign a 
statement on the patient agreement form that they are willing and able to purchase a 
coagulometer at the end of the loan period. 
 
This section has discussed the validation of the candidate service requirements that 
could be included in this PST pilot. Further validation of these requirements, and 
validation of the requirements that needed to be excluded from this pilot service 
model, is a fertile ground for future research. Some of these options have already 
been outlined in this section; for example, engaging GPs to provide a patient self-
testing service. Other options will be described at the end of the Chapter 9. 
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Table 52: Validation of OAT patient self-monitoring candidate service 
requirements derived from earlier empirical work 
 
Candidate service 
requirement 
Validated by 
pilot? 
Supporting evidence from pilot 
STRUCTURE 
Establish financial 
feasibility of service 
No  
Gauge patient demand No Validation through pilot not required as demand had 
been assessed through patient survey. 
Conduct service options 
appraisal 
Yes Service options appraisal conducted at developmental 
stage.  
 
PST model selected safe and well accepted by patients. 
However, in the absence of a direct comparison, cannot 
assert that PST is better than PSM 
 
For operational reasons, the pilot service was delivered 
from secondary care. However, clinic staff felt that 
primary care might be the best place from which to 
support PST. 
Ensure engagement from 
those delivering and 
commissioning OAT 
management 
Yes Lack of involvement of all clinic staff in the development 
of the PST pilot was felt to be a reason for their initial 
resistance to the pilot 
 
The SOP should be extended to include the clinic 
administrator and nurse specialist 
 
Agreement from clinic staff that PCTs need to be 
consulted at start of process to ensure provision of testing 
strips. 
Promote the self-
monitoring service to 
patients 
Yes There was a surge of interest in self-testing from patients 
following a more intensive marketing strategy by Roche 
Facilitate provision of 
coagulometer 
Yes The availability of a loan machine was a deciding factor 
for participating in the pilot for over half of this group of 
patients. However, clinic staff felt that this was not a 
workable solution in the future. 
 
Although patients were ‘very willing’ to buy a 
coagulometer at the end of the pilot period, three out of 
the eight respondents indicated that they would have 
difficulty in doing so. 
Construct patient 
eligibility and assessment 
criteria 
Yes The PST service was safe. Relatively inclusive selection 
criteria constructed based on the results from the 
empirical work. 
 
For those with historic poor INR control, time in 
therapeutic range significantly improved during the pilot.
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Table 52 (cont): Validation of OAT patient self-monitoring candidate service 
requirements derived from earlier empirical work 
Candidate service 
requirement 
Validated by 
pilot? 
Supporting evidence from pilot 
Develop an educational 
programme for patients 
Partially Pilot patients achieved good therapeutic control after an 
educational session. Although it is not known how these 
patients would have fared in the absence of educational 
preparation, the education offered was an important 
factor for some deciding to participate in the pilot. 
 
The content of the programme delivered felt to be 
optimal by most patients. 
 
Clinic staff felt that education may address potential non-
compliance with testing 
Develop an educational 
programme for primary 
care staff supporting 
patients 
No  
Establish a formal shared-
care agreement between 
primary care and 
secondary care 
Partially Although clinic staff felt that an agreement was needed 
there were misgivings that this could accommodate the 
many needs of all patients. 
Establish a formal shared-
care agreement between 
patient and clinician 
Yes PST pilot was safe. However, despite a variety of 
methods available, there was a lack of timely 
communication of INR results from some patients. 
 
Patient agreement form felt to be an essential 
requirement by clinic staff. 
 
All patients signed this form. However, many patients 
did not comply with all the listed responsibilities, 
particularly around communication of INR results. 
Establish process for 
quality assurance (QA) of 
coagulometer 
Yes Some patients (n=4) had concerns about the accuracy of 
the coagulometer at the start of the pilot 
 
Perception amongst clinic staff that many patients did not 
trust the INR result generated by the coagulometer.  
 
Clinic staff felt that six-monthly QC of the coagulometer 
is an essential quality requirement of the PST service. 
Establish an OAT self-
monitoring policy 
Yes Develop a standard operating procedure 
 
PST was safe. However, the SOP may need to broadened 
to include other clinic staff supporting the service 
 
The SOP was felt to be essential to support clinic staff 
supporting the PST service  
Clarify issues of 
accountability and clinical 
responsibility 
Yes A signed agreement between patient and clinic (patient 
agreement form) felt to be essential to protect the clinic, 
and individuals, from liability 
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Table 52 (cont): Validation of OAT patient self-monitoring candidate service 
requirements derived from earlier empirical work 
 
Candidate service 
requirement 
Validated by 
pilot? 
Supporting evidence from pilot 
Address potential 
inequities in the service 
Yes Clinic staff interviewed had concerns about the equity of 
the service.Three of the pilot patients were retired 
doctors, and there was a fear that self-testing was the 
preserve of the knowledgeable few. 
 
   
PROCESS 
Provide patient training in 
self-testing and using the 
coagulometer 
Yes Educational requirements of many of this group of 
patients (n=6) focused on self-testing and the use of the 
coagulometer 
 
Initial difficulties with self-testing with some patients 
 
Although most patients felt that the content of the 
educational programme to be optimal, a few patients felt 
that more attention should have been paid to self-testing 
technique. 
Deliver anticoagulant 
education for self-
monitoring patients  
Partially Pilot patients achieved good therapeutic control after an 
educational session. Although it is not known how these 
patients would have fared in the absence of educational 
preparation, the education offered was an important 
factor for some deciding to participate in the pilot. 
 
Clinic staff felt that education might address potential 
non-compliance with testing. 
Provide education and 
support for dose 
adjustment by patients 
(PSM) 
No  
Deliver anticoagulant 
education for primary care 
staff supporting patients 
No  
Provide ongoing support 
to patients 
Yes Support offered was an important factor for some 
deciding to participate in the pilot. However, 
expectations of support were modest. As a minimum 
requirement, the majority of patients (n=8) needed 
support in terms of dosing recommendations. Other 
requests centred on technical support for coagulometer. 
 
Positive feedback from patients for support provided 
during pilot with no suggestions for improvement. 
Provide ongoing support 
to primary care staff 
supporting self-
monitoring patients 
No  
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Table 52 (cont): Validation of OAT patient self-monitoring candidate service 
requirements derived from earlier empirical work 
 
Candidate service 
requirement 
Validated by 
pilot? 
Supporting evidence from pilot 
OUTCOME   
Self-monitoring service is 
cost-effective 
No  
Self-monitoring service is 
safe 
Yes Quality of the service needs to be ensured in terms of 
INR control 
 
No bleeding or thromboembolic events were reported 
during the pilot period. However, as the time period was 
short and the numbers of patient few, the likelihood of 
these events occurring was low. 
 
PST resulted in a statistically significant improvement in 
INR control. However, clinic staff felt that improved 
INR results may have been a result of selective reporting 
by patients than better results per se. 
Self-monitoring service is 
acceptable to patients 
Yes All patients wished to continue with self-testing at the 
end of the pilot period 
 
Half of the group of patients responding to the post-pilot 
questionnaire reported that self-testing was convenient. 
Over half of this group felt reassured through the 
improved INR control that PST brought 
 
 
7.7 Conclusion 
 
This pilot has demonstrated that it is feasible to support a small group OAT self-
testing patients from the Whittington Hospital Anticoagulation and Stroke 
Monitoring Service. Candidate service requirements derived from the earlier 
empirical work with patients and healthcare staff were incorporated into the design 
of this pilot, and many of these requirements could be validated.  
 
Patient experiences were positive, and they welcomed the convenience, reassurance 
and greater personal control that self-testing afforded. A minority of patients 
admitted to limited self-dosing during the pilot, and the next stage of this service 
development will be to offer self-management to some patients. 
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Although clinic staff operating the service felt that the anticoagulation monitoring 
service should support those who wished to self-test, they had concerns. Some 
patients were not conscientious about communicating their results to the clinic, 
which entailed considerable effort in follow-up. The necessity to purchase the 
coagulometer may place self-testing out of reach for many patient, resulting in an 
inequitable service.  
 
Although a small group of patients enthusiastically embraced this model of care, 
scaling-up the service from a pilot to a larger group of patients may not be feasible 
without extra resources and assurances from PCTs that test strips will be funded. 
 
7.8 Limitations 
 
Steps were taken during this study to increase its reliability and validity. The first 
patient questionnaire was sent to two experts to ensure that questions were 
unambiguous and were likely to yield accurate information. Ideally, both 
questionnaires should have been piloted on a small number of patients before its 
use. However, the total patient numbers were small (n=14), and piloting the 
questionnaire would have reduced this number further.   
 
As the first questionnaire was completed at the educational session, there was a 
100% response rate. However, the second questionnaire was posted out to PST 
patients, risking accentuating response bias. With hindsight, a reminder and second 
questionnaires should have been used to increase the response rate.  
 
Reliability in questionnaire studies relates to their reproducibility; that is ability of 
the instrument to produce the same results if it were tested it many times over. 
However, this is difficult to demonstrate in practice. If time had permitted, test-
retest, a statistical method used to determine an instrument’s reliability, could have 
been performed.139 This would have entailed testing the questionnaire on a small 
number of the study sample twice, several weeks apart, and performing statistical 
tests to measure correlation. Although opinion is divided on which statistical tests 
are the best measure of correlation, Cohen’s kappa coefficient (nominal data), 
weighted kappa (ordinal data) or Pearson’s coefficient (interval data) are generally 
used. 
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However, the main limitations to this study were its size and scope.  
 
This was a small pilot study, set up primarily to meet the needs of a small group of 
patients in North London and to validate some candidate service requirements of an 
OAT patient self-monitoring service identified in earlier chapters. Therefore, its 
generalisability to a wider population is limited. 
 
To gain a more comprehensive view of the operational requirements of a PST 
service, it would have been desirable to conduct site visits and interviews with other 
centres, both nationally and internationally, offering this service. However, lack of 
resources did not permit this and, instead, an established UK service, recommended 
by the coagulometer manufacturer, was chosen as an exemplar site.  
 
There are plans for further validation of the candidate service requirements. Some 
of these have been described earlier in this chapter. Other proposed plans will be 
discussed in Chapter 9. 
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CHAPTER 8: THE REQUIREMENTS FOR AN ORAL 
ANTICOAGULATION PATIENT SELF-
MONITORING SERVICE 
 
Through identification of the drivers, benefits, barriers and challenges, this 
investigation set out to derive a service model that would foster the successful 
adoption of patient self-monitoring of oral anticoagulation. A set of candidate 
service requirements was derived from evaluating the perspectives of key 
stakeholders. The majority of these requirements were then tested in the context of 
developing and implementing a pilot PST service. 
 
The investigation was divided into three main studies: 
 
i. Patient perspectives of self-monitoring of OAT 
ii. Healthcare provider perspectives of patient self-monitoring of OAT 
iii. Validation of a set of candidate requirements for an OAT patient self-
monitoring service through a pilot patient self-testing service 
 
In this chapter the results of these three studies, and key findings from the literature 
where pertinent, are triangulated to produce a blueprint of the service requirements 
to enable the establishment of a successful OAT patient self-monitoring service.  
 
These service requirements are presented within Donabedian’s framework in two 
sections:  
 
i. Validated service requirements  
ii. Unvalidated service requirements  
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Each requirement of the service model is accompanied by a short description if 
required. Following this, in boxed text, is a summary of the evidence for its 
derivation, including published literature where this is pertinent, followed by the 
source of this evidence.   
 
Evidence sources are coded as summarised in Table 53. 
 
Lit = Literature 
EP = Expert Patient interview 
PI = Patient interview 
PS = Patient survey 
G1 = Focus Group 1 (healthcare professionals) 
G2 = Focus Group 2 (healthcare managers) 
Pilot = PST Pilot 
 
Table 53: Evidence sources for service requirements 
 
8.1 Validated requirements for an OAT patient self-monitoring 
service 
 
Service requirements were validated in one of two ways, and are summarised in 
Table 54. 
 
Firstly, as discussed in the last chapter, candidate requirements could be validated 
through testing in the PST pilot service. 
 
However, the PST pilot is not the only method of validation. For operational, 
logistical or ethical reasons it was not possible to test all of the candidate service 
requirements through the PST pilot. Therefore, candidate requirements that could 
not be included in the PST pilot were considered to be validated if consensus was 
reached across the stakeholder groups, or if one stakeholder group asserted the 
requirement very strongly i.e. it was almost a unanimous opinion amongst those 
stakeholders. 
 
 
291  
 
 
STRUCTURE METHOD OF 
VALIDATION 
¾ Gauge patient demand for OAT self-monitoring Pilot 
¾ Conduct an options appraisal (i.e. explore other methods 
of OAT monitoring / define delivery of OAT self-
monitoring service) 
Pilot 
¾ Establish financial feasibility of service Strength of 
assertion 
¾ Ensure engagement of those delivering and 
commissioning OAT monitoring 
Pilot 
¾ Promote the self-monitoring service to patients Pilot 
¾ Facilitate the provision of coagulometers ( e.g. by funding 
coagulometer) 
Pilot 
¾ Construct patient eligibility and assessment criteria  Pilot 
¾ Develop an educational programme for patients Consensus view 
¾ Establish a formal shared-care agreement between patient 
and clinician 
Pilot 
¾ Establish a formal shared-care agreement between 
primary care and secondary care 
Strength of 
assertion 
¾ Establish a process for quality assurance (QA) of 
coagulometers 
Pilot 
¾ Establish an OAT self-monitoring policy Pilot 
¾ Clarify issues of accountability and clinical responsibility Pilot 
¾ Address the potential inequities of the service  Pilot 
  
PROCESS  
¾ Provide patient training in self-testing and using the 
coagulometer 
Pilot 
¾ Deliver an educational programme to patients Consensus view 
¾ Provide education and support for dose adjustment by 
patients (PSM) 
Consensus view 
¾ Provide ongoing support to self-monitoring patients  Pilot 
  
OUTCOME  
¾ Self-monitoring service is safe Pilot 
¾ Self-monitoring service is acceptable to patients Pilot 
¾ Self-monitoring service is cost-effective Strength of 
assertion 
 
Table 54: Validation of service requirements for an OAT patient self-monitoring 
service 
 
These requirements will now be described further. 
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STRUCTURE 
 
Gauge patient demand  
 
Although in recent years there has been a gradual move away from the traditional, 
paternalistic model of healthcare, some patients may be reluctant to assume more 
responsibility for their health.  
 
A 2010 meta-analysis of 14 OAT patient self-monitoring (both PST and 
PSM) trials found that, on average, 68% of eligible people would not or 
could not take part.  
Lit91 
Some patients prefer to leave OAT monitoring to healthcare 
professionals 
Lit160, 
PS 
Although 53% of local patients surveyed indicated that they would be 
willing to self-test or self-manage their OAT, a small number of patients 
expressed a strong preference not to self-monitor. Younger, better-
educated patients were more likely to be prepared to monitor their own 
OAT. 
PS 
Some patients are not ready to embrace self-monitoring G1, G2 
Patients’ views should be sought to gauge demand before establishing a 
self-monitoring service. 
G1 
Patients may feel that other ways of monitoring INR more attractive G2 
 
Recommended requirement: 
To elicit the views of the potential end users to confirm demand before developing 
an OAT patient self-monitoring service. 
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Conduct an options appraisal 
 
In setting up an OAT patient self-monitoring service, an options appraisal can be 
thought of in two broad contexts. Firstly, the different variables of the self-
monitoring process need to be defined and decisions taken on how this service will 
be delivered. Secondly,  it is also necessary to establish whether other methods of 
OAT monitoring would be as attractive, or more attractive, to patients (e.g. 
attending an OAT monitoring clinic at a GP surgery). 
 
A preference for another method of monitoring is one of the reasons for 
attrition in OAT patient self-monitoring trials.  
Lit104 
Although 53% of sample indicated that they would be willing to self-test, 
a small number of patients expressed a strong preference to continue 
with current service model 
PS 
Alternative ways of delivering OAT monitoring need to be explored in 
the context of a full options appraisal. Other services in primary care may 
be more attractive to patients. 
G1, G2 
Service options appraisal conducted at developmental stage of a 
successful pilot. 
Pilot 
 
Recommended requirement: 
To conduct an options appraisal before establishing an OAT patient self-monitoring 
service, which should include a consideration of alternative ways of service delivery. 
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Establish financial feasibility of service 
 
NHS resources are finite and the feasibility of any new service needs to be 
established before implementation. The financial impact is likely to be felt across the 
healthcare interface.  Primary care is commissioning, and hence paying for, care. 
However, the movement of patients away from the traditional outpatient setting 
could represent a substantial loss of revenue for an acute hospital Trust.  
 
A cost-effectiveness analysis UK-specific data has estimated that 
wide adoption of OAT patient self-monitoring would cost the UK 
an extra £8 – 14.3 million per year. 
Lit28 
Clarity needed over who will pay for the machines and strips G2 
Clarity around reimbursement for those training and supporting self-
monitoring patients needed.  
G1 
Build a business case and run a meaningful pilot service to establish 
feasibility 
G2 
 
Recommended requirement: 
Financial feasibility needs to be demonstrated from the point of view of both 
primary and secondary care 
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Ensure engagement of those delivering and commissioning OAT monitoring  
 
Engagement is not confined to patients. Buy-in from healthcare professionals, clinic 
support staff and commissioners is also essential. 
 
Clinicians’ poor attitude is cited as a barrier to uptake of self-management 
of long-term conditions. 108;109 
Lit105-109 
Support from healthcare professionals is likely to be a key factor in 
increasing uptake of patient self-management.  
Lit97 
Reimbursement will be required for supporting self-monitoring G1 
Consult PCTs before setting up service Pilot 
Ensure all staff supporting self-testing patients are informed and engaged. 
Lack of involvement of all clinic staff in the development of the PST 
pilot was felt to be instrumental in initial resistance to the pilot.  
Pilot 
 
Recommended requirement: 
To engage healthcare providers, managers and commissioners at an early stage of 
the development of a patient self-monitoring service.  
 
Promote the self-monitoring service to patients 
 
Increasing the awareness of self-monitoring amongst patients may act as a driver for 
its uptake. 
 
Patients who were aware of self-testing before the survey were 
significantly more willing to self-monitor 
PS 
A growing awareness of self-monitoring amongst anticoagulated patients 
will act as a driver for uptake 
G1 
During the course of the pilot, there was a surge of interest in self-testing 
from patients following a more intensive marketing strategy by Roche 
Pilot 
 
Recommended requirement: 
To promote the self-monitoring service directly to patients.
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Facilitate provision of coagulometers 
 
It is necessary for the patient to have a personal coagulometer for them to test their 
INR at home. The cost of the coagulometer - £399 (ex. VAT) at the time of writing 
this thesis – is currently borne by the patient.  
 
The cost of the coagulometer initially deterred patients from self-
monitoring 
EP 
Although 53% of local patients said that they would be willing to self-test 
or self-manage their OAT, only 15% of the sample surveyed indicated they 
would be willing to self-monitor AND purchase a coagulometer. 
PS 
Patients considered that it was “very important” (median score) that the 
clinic provided their coagulometer. 
PS 
The cost of the coagulometer is a barrier to self-monitoring, especially in 
certain sectors of the population 
PI, 
G1, 
G2 
A service predicated on patient’s ability to pay (for coagulometer) is 
inequitable 
G2 
The availability of a loan machine was a deciding factor for participating in 
the pilot for over half of this group of patients.  
Pilot 
Although patients were ‘very willing’ to buy a coagulometer at the end of 
the pilot period, three out of the eight respondents indicated that they 
would have difficulty in doing so. 
Pilot 
 
Recommended requirement: 
To facilitate the no-cost or low-cost provision of coagulometers to encourage wide 
adoption of patient self-monitoring. 
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 Construct patient eligibility and assessment criteria 
 
There are no clearly defined selection criteria for OAT patient self-monitoring with 
most of the published trials using highly selected groups of patients.  
 
Lack of evidence as to which patients are suitable for OAT patient self-
monitoring. Consensual recommendations for inclusion and exclusion 
criteria made in national and international guidelines are broad. 
Lit36;52  
Concerns over the ability of some patients to monitor their OAT and a 
need to agree on selection criteria. 
PI, G1, 
G2 
Require a formal method to assess patients’ competence to self-monitor; 
this may include a risk-assessment of each patient. This should include 
demonstration of competence to perform an INR test.52;173 In the case of 
PSM, patients need to demonstrate that they can correctly interpret an 
INR test.52 Competency should be reassessed at regular intervals.36  
Lit, G2, 
Pilot 
Selecting relatively inclusive selection criteria constructed on the basis of 
the results from the empirical work, the PST pilot service was safe. This 
included patients with historically poor INR control.  
Pilot 
 
Recommended requirement: 
To reach local consensus on patient inclusion and exclusion criteria for OAT self-
monitoring, and on a method to assess competence.  
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Develop an educational programme for patients 
 
Although there is a national programme in Germany, there is no standardised 
educational programme in the UK to prepare patients for OAT self-monitoring. 
 
Education is a requirement to prepare patients for self-monitoring.  Lit,36 PI, 
PS, G1, 
G2 
Although there is no evidence to guide the intensity of this training, 
and standardisation of training is thought to be a “pressing 
requirement”.  
Lit174 
Patients thought that providing education for those undertaking OAT 
self-monitoring was “very important” (median score).  
PS 
The education offered was an important factor for some patients in 
deciding to participate in the PST pilot 
Pilot 
Pilot patients achieved good therapeutic control after an educational 
session. However, it is not known how these patients would have fared 
in the absence of educational preparation. 
Pilot 
Clinic staff felt that education might address potential non-compliance 
with testing. 
Pilot 
 
Recommended requirement: 
To develop an educational programme to prepare patients to self-monitor their 
OAT.  
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Establish a formal shared-care agreement between patient and clinician 
 
Sharing care entails redefining the relationship between patient and clinician, with a 
clarification of respective responsibilities. As with shared care agreements, 
traditionally used to allow the seamless transfer of patient treatment from the 
secondary care to general practice, a shared-care agreement between patient and 
clinician will foster sharing responsibility for anticoagulation monitoring.  
 
In line with the Midlands Therapeutic Advisory Committee’s Policy on Effective 
Shared Care Agreement175, this should be consensual, and include clear definitions 
of respective responsibilities and communication networks. Accurate, timely 
information flow is essential to any anticoagulation monitoring service and self-
testing patients will need a means to communicate their results to their healthcare 
provider, and the provider will be required to respond back to them in a timely 
fashion. 
 
Both patients and practitioners should maintain documentation of 
communication with each other. 
Lit173 
Patients need a reliable, mutually agreeable method (or methods) 
to communicate their INR results to their anticoagulation 
practitioner. 
Lit173, G2, Pilot
Healthcare professionals need to be responsive to patient-
reported INRs 
Lit173, G1, G2 
There is a risk of patient non-compliance with self-testing G1,G2 
Establish a formal shared care agreement between healthcare 
provider and patient. 
Lit52;173;173, G1  
A formal shared care agreement between patient and clinic 
(patient agreement form) felt to be essential to protect the clinic, 
and individuals, from liability 
Pilot 
 
Recommended requirement: 
To establish a shared-care agreement between patient and clinician to define 
respective responsibilities and to clarify lines of communication. 
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Establish a formal shared-care agreement between primary care and 
secondary care 
 
A shared-care agreement will be needed to allow the seamless transfer of care from 
primary care to secondary care in the event of the patient’s INR control becoming 
unstable, and back to primary care once they have stabilised. This should include 
respective responsibilities and communication networks. 
 
Agree protocols for patient transfer between primary and 
secondary care 
G2, Pilot 
Need robust lines of communication between primary and 
secondary care to facilitate patient movement across the interface 
G2 
Define governance arrangements for primary and secondary care 
to share care 
G1 
 
Recommended requirement: 
Establish a formal shared-care agreement between primary care and secondary care 
including procedures for escalating concerns urgently.
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Establish a process for quality assurance (QA) of coagulometers 
 
Providing assurance of the accuracy of the coagulometer is important for two 
reasons. Firstly, this is needed to foster patient confidence in the machine. Secondly, 
it is essential that the accuracy of the coagulometer is assured to operate a safe self-
monitoring service. Although most devices automatically run an internal quality 
control (IQC) each time the machine is used, they also need to be externally quality 
controlled (EQC) at regular pre-defined intervals.  
 
Discuss the potential use of coagulometers with the local point-of-
care committee (or haematologist). Local procurement policy 
should be adhered to. 
Lit174 
Reassurance about the accuracy of the coagulometer was 
important to some patients 
PI, Pilot 
Concerns about QA of the coagulometer expressed PS 
Establish robust procedures for QA of machines. Detailed 
guidance is provided in the UK consensus guideline.  
Lit174, G1, G2, 
Pilot 
Perception amongst clinic staff that many patients did not trust 
the INR result generated by the coagulometer 
Pilot 
 
Recommended requirement: 
Establish a process for quality assurance of coagulometers. 
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Establish an OAT patient self-monitoring policy 
 
A policy is needed to ensure the safe operation of the service on a day-to-day basis. 
If this policy is sufficiently broad, it may also foster partnership between primary 
and secondary care. 
 
Corporate strategy needs to be drawn up before demand for patient self-
monitoring grows, setting out how to manage a fully operational service.  
G2 
A standard operating procedure supported the PST pilot. This was felt by 
clinic staff to be an essential requirement. 
Pilot 
 
Recommended requirement: 
To establish a policy to manage an OAT patient self-monitoring service. This 
should encompass as many stakeholders as feasible. 
 
Clarify issues of accountability and clinical responsibility 
 
Moving from a paternalistic model of care to one that shares care with patients may 
introduce new risks. Where accountability sits is unclear. 
 
Define where clinical responsibility lies before launching service G2 
Clarification on what constitutes negligence in self-care G1, G2 
Elaboration of the existing legal framework to consider self-care G1, G2 
Review of the legal aspects of self-care by the professional bodies 
(e.g. GMC) 
G1 
A signed agreement between patient and clinic (patient agreement 
form) felt to be essential to protect the clinic, and individuals, from 
liability 
Pilot 
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Recommended requirement: 
To clarify issues of accountability and clinical responsibility. Whilst clinical 
responsibilities of those delivering the service may be defined prior to service 
launch, much of this clarification is outside the direct control of the anticoagulant 
service provider.  (It may be necessary to lobby professional bodies and defence 
bodies to develop national guidance on this vital issue) 
 
Address the potential inequities of the service 
 
As discussed earlier, currently participation in self-monitoring is predicated on the 
patient’s ability to purchase a coagulometer. However, language barriers may also 
prevent some ethnic groups from participating. Firstly, coagulometers deliver their 
messages to users in English only. Secondly, extra resources will be needed to 
deliver educational material and support to those for whom English is not their first 
languages.  
 
Establish a way to deal with a potentially inequitable service. This 
may involve facilitating provision of the coagulometer as discussed 
earlier or the availability of resources in languages other than 
English. 
G2, Pilot 
 
Recommended requirement: 
To address the potential inequities resulting from the introduction of an OAT 
patient self-monitoring service, for example by providing multi-lingual educational 
resources. 
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PROCESS 
 
Provide patient training in self-testing and using the coagulometer 
 
Acquiring a good capillary blood sample and using the coagulometer to generate an 
INR are core tasks for patients assuming responsibility for self-monitoring INR. 
Patients’ confidence in their ability to perform these tasks appears pivotal to the 
success of OAT self-testing. 
 
One participant had initial difficulties in testing INR EP 
Many participants stated that instruction on using the coagulometer 
was a prerequisite for its use 
PI 
Patients were significantly more willing to self-monitor if they were 
confident in their ability to test their INR 
PS 
Patients may lack confidence to test INR G1, G2 
There is a need, both perceived and actual, for training in how to use 
the coagulometer. 
PI, PS, 
Pilot 
There were initial difficulties with self-testing with some PST pilot 
patients 
Pilot 
Some of the PST pilot patients felt that more attention should have 
been paid to self-testing technique during the educational session. 
Pilot 
 
Recommended requirement: 
To train all patients undertaking OAT self-monitoring on self-testing and on the use 
of the coagulometer. 
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Deliver an educational programme to self-monitoring patients 
 
As discussed earlier, there is no standardisation of the content of an educational 
programme in the UK to prepare patients for OAT self-monitoring.  
 
Education is a requirement to prepare patients for self-monitoring.  Lit,36 PI, 
PS, G1, 
G2 
Although there is no evidence to guide the intensity of this training, 
and standardisation of training is thought to be a “pressing 
requirement”.  
Lit174 
Patients thought that providing education for those undertaking OAT 
self-monitoring was “very important” (median score).  
PS 
The education offered was an important factor for some patients in 
deciding to participate in the PST pilot 
Pilot 
Pilot patients achieved good therapeutic control after an educational 
session. However, it is not known how these patients would have fared 
in the absence of educational preparation. 
Pilot 
Clinic staff felt that education might address potential non-compliance 
with testing. 
Pilot 
 
Recommended requirement: 
To provide the resources and facilities to deliver an educational programme to 
prepare patients to self-monitor their OAT.  
 
 
 
306  
 
Provide education and support for dose adjustment by patients (PSM) 
 
If a patient is self-managing their OAT, they are both testing their INR and 
adjusting the dose of warfarin. They may need assistance to help them decide an 
appropriate dose. 
 
Self-managing patients had different ways of adjusting warfarin doses EP 
Anxiety expressed at the prospect of adjusting the dose of warfarin in 
PSM 
PI 
There was a perceived need for training in dose adjustment skills. PI, PS 
Make clear dosing algorithms available for patients who are self-
managing, and to aid primary care practitioners supporting self-testing 
patients. 
G1, Lit52 
Dose adjustment in PSM is an area of potential risk G1 
 
Recommended requirement: 
To provide education and support in dose adjustment for patients who are self-
managing their OAT.  
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Provide ongoing support for self-monitoring patients 
 
Patients require ongoing support throughout their OAT self-monitoring journey. 
Three types of support were identified through the course of this research 
 
i. Provision of dosing advice in response to patient-reported INRs 
ii. Regular review 
iii. Provision of ad-hoc advice 
 
Regular (at least yearly) reviews are required. Lit52;173, G2
Healthcare professionals need to be responsive to patient-reported 
INRs 
Lit173, G1, 
G2 
The support of healthcare professionals was important when starting 
to self-monitor. 
EP 
Ability to access advice and for the clinic to provide regular reviews 
was important 
PI 
Patients thought it was “very important” (median score) that they 
received regular clinic check-ups 
PS 
Patients considered making it easy for them to contact the clinic when 
self-monitoring to be “very important” (median score). 
PS 
Ongoing support is required for self-monitoring patients G1, G2,  
Support offered was an important factor for some deciding to 
participate in the pilot. Positive feedback from patients for support 
provided during pilot with no suggestions for improvement. 
Pilot 
 
Recommended requirement: 
To establish a clinical support and a communications infrastructure to support self-
monitoring patients. This needs to include clearly specified communications 
channels for urgent patient concerns. 
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OUTCOME 
 
Self-monitoring service is safe 
 
For patient self-monitoring of OAT to be considered feasible it must be at least as 
safe as usual care. Safety can be measured in terms of hard clinical endpoints - i.e. 
incidence of bleeding and thromboembolism – and INR control. 
  
Patient self-monitoring may improve INR control PI 
Potential additional risks incurred by patient self-monitoring need to 
be managed 
G1,G2 
Quality of the service needs to be ensured through audit of INR 
results 
Pilot 
No bleeding or thromboembolic events were reported during the pilot 
period. However, as the time period was short and the numbers of 
patient few, the likelihood of these events occurring was low. 
Pilot 
INR control during pilot period was at least as good as that achieved 
in the six months prior to the pilot 
Pilot 
 
Recommended requirement: 
To conduct regular audits of a patient self-monitoring service to ensure its safety, 
examining both INR control and the incidence of treatment complications. 
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Self-monitoring service is acceptable to patients 
 
Safety of the service is not the only outcome measure. For the service to be 
successful, it needs to be acceptable to patients. 
 
Convenience cited as a perceived and actual patient benefit of OAT 
self-monitoring 
EP, PI, PS
The reassurance of being to able to test the INR at home when desired 
was a potential benefit 
PI 
All patients wished to continue with self-testing at the end of the pilot 
period 
Pilot 
 
Recommended requirement: 
To conduct regular patient reviews to ensure that PST / PSM remains the preferred 
method of monitoring. 
 
Self-monitoring service is cost effective 
 
The quality of a clinical service is not only measured on its safety and acceptability 
by patients; it also has to make good use of precious NHS resources. Published 
analyses have suggested that patient self-monitoring is unlikely to be cost-effective 
in the UK128 
 
Need to build business case to demonstrate that patient self-
monitoring is cost-effective 
G2 
Affordability to PCTs and the potential loss of income for the acute 
Trust need to be considered 
G2 
 
Recommended requirement: 
To develop a business case for a patient self-monitoring service and conduct 
periodic financial audits to ensure that the patient self-monitoring service is cost-
effective to all stakeholders. 
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8.2 Unvalidated requirements for an OAT patient self-
monitoring service 
 
As discussed earlier, it was not possible to validate all of the candidate requirements 
in this investigation. This section lists these unvalidated requirements, which are 
summarised in Table 55.  
 
STRUCTURE 
¾ Develop an educational programme for healthcare 
professionals supporting self-monitoring patients 
 
PROCESS 
¾ Deliver an educational programme primary care staff 
supporting self-monitoring patients 
¾ Provide ongoing support to primary care staff supporting self-
monitoring patients 
 
Table 55: Unvalidated candidate service requirements for an OAT patient self-
monitoring service 
 
STRUCTURE 
 
Develop an educational programme for healthcare professionals supporting 
self-monitoring patients 
 
Educational preparation may not only be confined to patients. If a patient self-
testing service is to be delivered in primary care, practitioners may not have the 
requisite warfarin management skills and confidence to support patients. In 
addition, some healthcare professionals may be personally committed to a 
paternalistic paradigm, and may therefore need to develop new skills if they are to 
work in partnership in patients.   
 
To achieve successful patient education, those training patients should 
themselves be trained.  
Lit36 
Healthcare professionals will also need education to prepare them to 
support self-monitoring patients. 
G1 
GPs’ knowledge may not meet patients’ expectations G1 
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Recommended requirement: 
To develop an educational programme to prepare healthcare professionals to 
support self-monitoring patients.  
 
PROCESS 
 
Deliver an educational programme to primary care staff supporting self-
monitoring patients 
 
As discussed above, primary care practitioners may need educational support. 
  
To achieve successful patient education, those training patients should 
themselves be trained.  
Lit36 
Healthcare professionals will also need education to prepare them to 
support self-monitoring patients. 
G1 
GPs’ knowledge may not meet patients’ expectations G1 
 
Recommended requirement: 
To deliver an educational programme to prepare healthcare professionals to support 
self-monitoring patients. Additional peer support activities may be required to help 
convince/reassure those who are reluctant to endorse self-monitoring. 
 
Provide ongoing support to primary care staff supporting self-monitoring 
patients 
 
As with patients, if a self-monitoring service is to be delivered in primary care, 
healthcare staff may require expert support. 
 
Support from hospital clinic required for GPs and practice nurses if 
patient self-monitoring is to be delivered in primary care 
G1, G2 
Support should be from clearly identified individuals available at pre-
specified times 
G1 
Recommended requirement: 
To establish expertise to support those delivering care to self-monitoring patients. 
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8.3 Conclusion 
 
This chapter has summarised the requirements for a service to successfully support 
patient self-monitoring of OAT, presented within Donabedian’s framework of 
structure, process and outcome. It has considered both the requirements that could 
be validated through the course of this empirical work, and those that could not be 
validated.  
 
In the next chapter, the key findings from this investigation will be discussed, the 
limitations of this research considered and options for future work, including 
options for further validation of these requirements, suggested. 
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CHAPTER 9: DISCUSSION 
 
9.1 Introduction 
 
Patient self-management is increasingly recognised as a way of responding to the 
considerable challenge of providing care for those with a long-term condition, and, 
as such, is enshrined in Governmental policy. However, it has not yet achieved 
widespread penetration across the NHS, and the reasons for this are unclear.  
 
This research has focused on one area of patient self-management – self-monitoring 
of oral anticoagulation therapy – and has investigated the requirements for the wide-
scale uptake of an OAT patient self-monitoring service that would be well accepted 
by patients and healthcare providers. Relevant literature pertaining to patient self-
monitoring of OAT, and self-management of long-term conditions in general, was 
reviewed. A combination of qualitative and quantitative methodological approaches 
was adopted to engage with the key stakeholder groups who would most directly be 
involved in commissioning, delivering and receiving such a service (patients, 
healthcare professionals, and healthcare managers). Through these groups, this 
research has identified the drivers for, principal benefits and challenges of, and the 
barriers to, establishing a patient self-monitoring service from a multi-stakeholder 
perspective. From these perspectives, candidate requirements for an OAT patient 
self-monitoring service were derived, which were then tested through a patient self-
testing pilot. An overarching goal of any clinical service should be the provision of 
high quality care. Donabedian's structure-process-outcome triad, more traditionally 
used to document a clinical service from a quality perspective, was used as a 
framework to categorise these requirements. 
 
The last chapter presented the requirements for establishing and delivering an OAT 
patient self-monitoring service, placing them within Donabedian’s framework, and 
mapped these to the evidence that supports each recommendation. In this 
penultimate chapter, the key findings from the empirical work will be summarised, 
and the key challenges in establishing an OAT patient self-monitoring service 
described. Then, the requirements for an oral anticoagulation patient self-
monitoring service, discussed in the preceding chapter, will be summarised, the 
appropriateness of using Donabedian’s framework considered and thought given to 
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the generalisability of these requirements to self-management of long-term 
conditions. Finally, the limitations to this research and opportunities for future work 
will be discussed. 
 
9.2 Summary of findings 
 
The empirical work in this thesis evaluated the views of three stakeholder groups: 
 
i. Patients – eliciting the views of expert patients and the broader clinic 
population using interviews and a survey 
ii. Healthcare professionals - using focus group methodology and interviews 
iii. Healthcare managers – using focus group methodology  
 
For each of these three stakeholder groups, the key drivers and barriers to OAT 
patient self-monitoring, and the factors that would incentivise these groups to 
embrace self-monitoring will be discussed.  
 
9.2.1 Key findings from empirical work with patients 
 
Overwhelmingly, increased convenience was an important driver for, and a 
perceived potential benefit of, patient self-monitoring of oral anticoagulation. 
Although the first set of interviews with those who were already self-monitoring 
involved small numbers, all of these patients stated that convenience was a driver 
for wishing to embrace OAT self-monitoring. For some this gave them the freedom 
to travel or spend lengthy periods overseas. For others it simply liberated them from 
attending the anticoagulant clinic.  
 
These views were supported by interviews with the group of patients who were not 
self-monitoring, who felt that self-monitoring would be more convenient for them. 
Other drivers identified were the potential to improve INR control – an advantage 
borne out in the PST pilot – and a desire for greater personal control over their 
health.  
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Although over half of the patients surveyed indicated that they would be interested 
in self-monitoring their OAT, a lack of confidence in their ability to self-test and to 
take more responsibility for their treatment was expressed by around 6% of 
patients, with a third of these patients explicitly stating that they would prefer to  
“leave it (OAT monitoring) to the expert”. In the initial stages of the pilot, over half 
of those recruited found it difficult to self-test but both confidence and ability grew 
as the pilot progressed. 
 
However, the most significant barrier to patients undertaking OAT self-monitoring 
was the requirement for them to fund the coagulometer. Only 17% of survey 
respondents felt that they would be able to buy the coagulometer; the proportion of 
those who were content to fund the machine was lower still (15%). The Whittington 
Hospital population includes pockets of considerable social deprivation, and 
objections to patient self-monitoring were mostly on the grounds of affordability. If 
a clinic population in another area was surveyed, this objection may not have been 
so strong. However, the patient interviews also uncovered a few objections on a 
more philosophical level – i.e. if a patient is part-funding their care NHS treatment 
is no longer free at the point of care. 
 
Therefore, subsidising or providing a coagulometer may persuade patients to 
embrace OAT self-monitoring. This is discussed further in 9.3.4 
 
9.2.2 Key findings from empirical work with healthcare professionals 
 
Those delivering anticoagulation monitoring services viewed a self-care model as a 
means to increase clinic capacity. Continued growth in the use of oral 
anticoagulation has lead service providers to consider options for relieving pressure 
on already overcrowded secondary care clinics. Locally, this has resulted in the 
formation of a distributed service with commissioned clinics in GP surgeries and 
community pharmacies in addition to the traditional hospital clinic. A patient self-
monitoring service presents an attractive option for increasing capacity yet further. 
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However, healthcare professionals were not comfortable about the increased clinical 
risk arising from patients not complying with testing or mismanaging dose 
adjustment. Uncertainty around the medicolegal position compounded their 
anxieties. Primary-care health professionals also had concerns that they would not 
have the skills to support a self-monitoring patient if the service was delivered from 
there rather than secondary care. 
 
The necessary incentives centred on preparing and supporting primary-care 
practitioners to deliver OAT patient self-monitoring services. This was both in 
terms of initial education to prepare them for their new role, and ongoing access to 
defined expert support thereafter. 
 
9.2.3  Key findings from empirical work with healthcare managers 
 
Like their healthcare practitioner colleagues, managers viewed OAT patient self-
monitoring as a way to increase clinic capacity. But there was more discussion about 
how developing a patient self-monitoring service was a necessary step in aligning the 
service to changes in the healthcare landscape.  
 
Again, there was anxiety over the clinical risk that may result from a patient self-
monitoring service, with concerns of potential litigation and the lack of clarity of the 
medicolegal position. But their anxieties did not stop with clinical risk. It was also 
felt that there was considerable financial risk, both in primary care through 
commissioning a patient self-monitoring service and also in the acute Trust through 
loss of income. 
 
To mitigate both of these types of risk, and to ensure commissioning of a patient 
self-monitoring service, two actions were desired. Firstly, a robust business case was 
needed to support financial feasibility. But, perhaps, the more challenging task was 
to define where clinical responsibilities and accountabilities lie. 
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9.3 The key challenges in establishing an OAT patient self-
monitoring service 
 
This research has established strong drivers for establishing an OAT patient self-
monitoring service. It fits with the direction of travel in the NHS and seems to offer 
a solution to the capacity issue. It affords patients greater convenience and 
empowerment and may improve INR control. However, the rate of adoption in the 
UK is low and this research has sought to identify what is needed to make patient 
self-monitoring acceptable to patients, clinicians and managers. 
 
Some of the barriers to OAT patient self-monitoring – financial, clinical and legal – 
have been summarised in the last section, as have the measures that should be 
considered to encourage adoption of a self-monitoring model of care. However, 
some specific challenges identified through this empirical work – risk management, 
education and support, patient selection and service funding  - warrant further 
consideration. These will now be discussed. 
 
9.3.1 Managing the risks of sharing care with patients 
 
Anticoagulation therapy is inherently high risk with errors involving anticoagulants 
in the top ten causes of claims against NHS Trusts.169 Although sharing the 
responsibility for anticoagulation monitoring with patients may bring benefits, it is 
also essential to ensure that clinical care remains safe.  
 
Therefore, from the outset, it is important to identify where new risks may be 
introduced and to set up systems to avoid these risks. Through the course of this 
research, such areas of new potential risk were identified and these are summarised 
in Table 56. 
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Patient selection, education and assessment 
Patient incorrectly deemed suitable for self-management 
Incorrect patient selection criteria used 
Inadequate education 
Patient incorrectly assessed as competent to self-manage 
Measuring INR 
Coagulometer inaccurate (failure of QC) 
Reads coagulometer incorrectly 
Capillary sampling incorrect 
Patients not testing INR at prescribed intervals 
Reporting INRS 
Patients misreporting INRS (PST only) 
Unclear communication of INRs or doses 
Dose adjustment 
Patients ‘unofficially’ adjusting doses of warfarin (PST) 
Misreads algorithm (PSM) 
Fails to use algorithm (PSM) 
Does not contact clinic out of range of algorithm (PSM) 
Review 
No regular review / inadequate review 
 
Table 56: Potential risks arising from patient self-monitoring or oral 
anticoagulation 
 
The importance of appropriate patient selection, patient education and quality 
assurance of coagulometers to mitigate some of these risks have been previously 
discussed. However, even if these measures were put into place to minimise those 
risks, OAT self-monitoring could still result in harm to the patient. As discussed 
earlier in the thesis (3.15), legislation has not kept pace with practice, and it is 
unclear where accountability lies within this new shared-care model.  
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Although a patient agreement form setting out respective responsibilities was used 
in the PST pilot, this was not a contract as such and it is not known if this would 
bear any legal weight to defend a clinician if mistakes were made that could be 
attributed to the patient. The SMART trial, conducted in Birmingham, was the 
pivotal UK-based evaluation of patient self-management of oral anticoagulation.49 
Of note, only 65 of the 193 patients completing the trial continued self-managing 
outside of trial conditions. The reason given was a lack of GP support, largely 
because of their fear of litigation.176 
  
Similarities (and differences) to self-monitoring of blood glucose (SMBG) in 
diabetes have been described throughout this thesis. Both have been made possible 
through a combination of combination of medical & social forces. Electronic 
miniaturisation has made home testing suitable for use by lay people, and treatment 
management involves adjusting the dose of a drug in response to testing a drop of 
capillary blood. 
 
No test cases involving SMBG were found. However, a review of potential liability 
of the clinician in diabetes self-care considered that five legal theories are likely to be 
raised if a patient is injured by self-care treatment.177 These are summarised in Table 
57, along with ways to mitigate these risks. 
 
Legal theory Mitigation 
Failure to provide adequate education Well designed educational programme  
Failure to determine patient’s 
suitability for self-care, or to review 
competence at regular intervals 
Robust selection criteria 
Regular reviews 
Offer retraining at regular intervals 
Unrealistic promises from clinician of 
benefits of self-care (breach of 
contract) 
Provide clear, evidence-based 
information at start of self-monitoring 
Injury caused to patient by carer 
participating in programme (imputed 
negligence) 
If carer to be involved in self-care, they 
must educated and assessed as 
competent 
Failure to inform patient of risks (lack 
of informed consent) 
Informed consent to be formally sought 
and granted 
 
Table 57: Legal theories likely to be raised if a patient is injured by self-care 
treatment and ways of mitigating against them 
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In the words of the author of this review: 
 
“The most likely approach to litigation would be to predicate a malpractice 
action on the failure of clinician to comply with proper standard of care in 
providing self-care education” 
 
9.3.2 Education, support and communication 
 
This research identified the need for patient education, and also for ongoing patient 
support.   
 
As discussed earlier, there is no standardised educational programme in the UK for 
those wishing to self-monitor their oral anticoagulation. Certainly, training on how 
to get a good capillary blood sample and then generating an INR is essential: many 
patients in the PST pilot had initial difficulty in using the coagulometer. Diabetes 
literature suggests that that self-monitoring may be of no therapeutic benefit if 
patients receive insufficient education or lack the confidence or support to respond 
to their results.178  
 
The Whittington Anticoagulation Monitoring and Stroke Prevention Service has an 
established training and accreditation programme, which has been described in 
Chapter Two. There may be scope to develop this to suit the needs of the self-
monitoring patient.  
 
Although there is a significant initial time commitment to delivering this education 
and training, providing ongoing support presents more challenges. An infrastructure 
to support self-monitoring patients needs to be established. Although it remains 
unclear where this should be delivered, there was more support from the healthcare 
professionals and managers that this should come from primary care. However, 
questions remain as to who should support these patients and whether this support 
can be integrated into current community anticoagulation monitoring services 
(where they exist). 
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Computers may also offer opportunities to educate and support those self-
monitoring their OAT. There is evidence that educated and well-motivated patients 
can make good use of web portals to their electronic health record (EHR), to view 
test results and to access linked educational materials.97 There is a limited evidence 
base evaluating the use of the use of computers in supporting OAT self-
monitoring,179-181 and in self-management of long-term conditions.182 
 
Although a randomised controlled study of patients with heart failure accessing their 
on-line healthcare record suggested modest benefits,183 importantly, this study did 
demonstrate a trend towards improvement in patient satisfaction with doctor-
patient communication. Good communication is vital in the safe management of 
chronic disease, and particularly in the management of oral anticoagulation. If this 
potential benefit were borne out in the anticoagulated patient population, this would 
be a significant advance.184;185 
 
However support is not confined to patients. Healthcare professionals interviewed 
during the course of this research felt that expert support would be essential for 
them to deliver a patient self-monitoring service. They also need to be equipped 
with the skills to allow them to work in partnership with patients. To this end, the 
Co-Creating Health programme may be of help. Since 2007, this programme has 
aimed to embed self- management support within UK health services.186 It does this 
by developing the skills and attitudes of both people with long term conditions and 
clinicians, and ensuring systems and services are designed to support and facilitate 
patient self-management. 
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9.3.3 Patient selection 
 
There is no accurate, standardised way to predict who will be competent at self-
monitoring, nor is there a level of benefit from self-monitoring at which it is 
recommended, or level of harm at which it is not recommended.  
 
The inclusion and exclusion criteria used in published trials have been summarised 
previously in Table 16. Additionally, the largest PST study – The Home INR Study 
(THINRS) –  included a multivariate logistic model to identify which patient 
characteristics are predictors of competency status.93 Three characteristics were 
significantly associated with a failure to perform PST: age, prior stroke and poor 
manual dexterity. 
 
All of the stakeholder groups expressed concern that not all patients would be able 
to monitor their OAT, and that selection criteria are needed. However, the 
challenge is selecting the correct criteria. This is illustrated by the lack of consensus 
in this empirical work. The findings from each of the stakeholder groups are 
summarised in Table 58. 
 
Stakeholder Inclusion criteria Exclusion criteria 
Patient 
None identified Elderly 
Those with complex 
medical problems 
Long-term indication for OAT 
 
 
Psychotic illness 
 
Ability to buy coagulometer Mental impairment 
Able to demonstrate 
‘understanding’ 
 
Healthcare 
professional 
Sufficient dexterity  
Healthcare 
manager 
Consensus not reached.  
Disagreement as to whether to exclude those with poor INR 
control  
 
Table 58: Summary of patient selection criteria for OAT self-monitoring identified 
by the empirical work 
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With the existing need for the patient to purchase a coagulometer, currently self-
monitoring patients are essentially self-selecting. That it, those that can afford the 
coagulometer and are sufficiently motivated and informed put themselves forward 
for self-monitoring. This is not an inclusive service and, therefore, far from 
satisfactory. 
 
The inclusion of only those who have a long-term indication for oral 
anticoagulation is pragmatic. It would not be a prudent investment to include those 
on short-term treatment, both in terms of the patient purchasing the coagulometer 
and also the resources required to educate the patient. 
 
The inclusion of those with historical poor INR control generated much discussion 
and debate amongst the healthcare staff. In terms of risk avoidance, conventional 
wisdom suggests that this group of patients should be excluded. However, 
conversely, INR control may improve if the patient is empowered to take more 
control over their care. The results of the SMART trial suggest the latter is true.49 
Self-managed patients with poor control before the study showed an improvement 
of control (between 15 and 20%) not seen in the routine care group. 
 
This was also borne out in the PST pilot, and, as a result, the case for including 
those with poor control was strongly supported by the healthcare professionals 
managing the pilot. However, those with a history of frequently not attending the 
anticoagulant clinic on the agreed appointment date may need to excluded from 
self-testing in the future. 
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9.3.4 Funding the service 
 
The financial challenges facing establishing an OAT patient self-monitoring service 
are significant. 
 
To make the service available for all who would be able and willing to self-monitor, 
the provision of coagulometers must be facilitated. A number of options were 
identified through the course of this research and these are summarised in Table 59. 
 
Option Source
Supply coagulometers on private prescription to exempt them from 
VAT 
G1 
Making a publicly-sited coagulometer available for self-monitoring 
patients to use (e.g. in a community pharmacy) (Mixed views) 
PI, G1, G2
Set up a patient network where patients own and share a machine G2 
Making loan machines available for patients to “try before they buy” PI, G1 
Clinic should provide or part-fund the coagulometer PS, PI 
Need to engage with the diagnostics industry to reduce cost of 
coagulometer and extend guarantee 
G2, PI 
 
Table 59: Options for facilitating the provision of coagulometers to patients 
 
(Code: PI = patient interview; PS = patient survey; G1 = focus group 1; G2 = 
focus group 2) 
 
A sensitivity analysis conducted by Roche, suggests that £199 is the lowest price at 
which their CoaguChek™ machine could be sold.187 It is not be possible to adopt 
the economic model used for glucometers. Although glucometers are cheaper to 
manufacture (at ~ £70) they sell for a lot less than this. However, as many more 
strips would be used in contract to INR testing strips, much more money can be 
clawed back on consumables. 
 
Over the past year, Roche has offered a £100 discount as part of its marketing 
campaign for its CoaguChek™ machine (Figure 25), bringing the cost of the 
machine down to £299.  
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Figure 25: Advertisement for CoaguChek™ XS, Daily Telegraph, May 21st 2010 
 
Another way of providing machine is through charitable donations through bodies 
such as The Children’s Heart Foundation, Anticoagulation Europe and The British 
Heart Foundation. However, there are waiting lists for such support.176  
 
The cost of the machine is not the only financial consideration. Published analyses 
have suggested that patient self-monitoring is unlikely to be cost-effective in the 
UK28;128, and the empirical work in this investigation suggests that commissioners 
will  need persuading to fund a patient self-monitoring service and the strips.  
 
As this thesis was being finalised (April 2012), two new oral anticoagulants -
dabigatran and rivoroxaban - had gained marketing authorisation for stroke 
prevention in those with atrial fibrillation. More selective than existing vitamin K 
antagonists – dabigatran is a direct thrombin inhibitor and rivoroxaban inhibits 
Factor Xa – they are leading the vanguard of new anticoagulant agents, including 
apixiban.   
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Unlike existing OAT, these oral agents do not require routine monitoring of 
coagulation, and this may help ease the pressures on overstretched anticoagulation 
monitoring services. However, despite their initial promise, some are urging caution 
with these new agents.188  
 
They are not without clinical risk. As with warfarin, these agents are associated with 
haemorrhagic risk and reports of bleeding continue to emerge, especially in those 
with renal impairment. Unlike warfarin, there is currently no antidote. Another 
concern centres on those who are poorly compliant with treatment. Whilst the INR 
provides an objective measure that a person taking warfarin is optimally 
anticoagulated, there is no such quantifiable test with the new agents. 
 
There is also a financial risk. Although the new agents will compete for the attention 
of those commissioning anticoagulation monitoring services, they will come at a 
cost with dabigatran priced at approximately £66 per month. The position of the 
commissioners is currently unclear.  
 
Although evidence to support the use of the new agents is emerging, they are 
unlikely to be granted marketing authorisation for use in those with metal heart 
valve replacement in the near future.  
 
Therefore, it is too soon to consign warfarin to the pharmaceutical rubbish bin, and 
anticoagulation monitoring services will need to continue to develop to meet 
capacity needs and the expectations of patients. Initial indications are that the new 
agents may be reserved for those intolerant of warfarin, or for those with labile 
INRs in the absence of compliance issues. Although their introduction may be 
limited, these new agents are likely to impact on the structure and delivery of 
anticoagulation monitoring services. Thus, for these services to remain relevant and 
viable, they will need to take into consideration the needs of patients taking the new 
agents as part of their continuing development. 
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9.4 Validated requirements for establishing and delivering an 
OAT patient self-monitoring service  
 
In the last chapter, the service requirements for a patient self-monitoring model of 
care were described. The validated elements of this model – the blueprint for the 
service - are summarised in Figure 26. 
 
STRUCTURE 
¾ Gauge patient demand for OAT self-monitoring 
¾ Conduct an options appraisal (i.e. explore other methods of OAT monitoring / 
define delivery of OAT self-monitoring service) 
¾ Ensure financial feasibility of service 
¾ Ensure engagement of those delivering and commissioning OAT monitoring 
¾ Promote the self-monitoring service to patients 
¾ Facilitate the provision of coagulometers ( e.g. by funding coagulometer) 
¾ Construct patient eligibility and assessment criteria  
¾ Develop an educational programme for patients 
¾ Establish a formal shared-care agreement between patient and clinician 
¾ Establish a formal shared-care agreement between primary care and secondary care 
¾ Establish a process for quality assurance (QA) of coagulometers 
¾ Establish an OAT self-monitoring policy 
¾ Clarify issues of accountability and clinical responsibility 
¾ Address the potential inequities of the service  
 
PROCESS 
¾ Provide patient training in self-testing and using the coagulometer 
¾ Deliver an educational programme to patients 
¾ Provide education and support for dose adjustment by patients (PSM) 
¾ Provide ongoing support to self-monitoring patients  
 
OUTCOME 
¾ Self-monitoring service is safe 
¾ Self-monitoring service is acceptable to patients 
¾ Self-monitoring service is cost-effective 
 
Figure 26: Validated requirements for an oral anticoagulation self-monitoring 
service 
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Throughout this thesis, Donabedian’s triad has been used as a framework to 
categorise these service requirements. As an OAT patient self-monitoring service 
would need to be of high quality, conceptual frameworks to describe quality were 
reviewed in Chapter 1 and Donabedian’s triad of structure, process and outcome 
was proposed as the most suitable framework for this research. Was Donabedian’s 
triad, therefore, a suitable framework into which to place the requirements for an 
OAT patient self-monitoring service? 
 
To recap, the framework selected aimed to meet five objectives: 
 
To support the design of the service 
The design of this service was reflected in the structural elements of the service, 
which include the patients who are self-monitoring and the professionals who are 
supporting them. The structure also includes the service elements in place to 
support these individuals and to enable them to undertake the necessary healthcare 
processes: for example the establishment of formal shared-care agreements. 
 
To specify the processes that will support implementation of the service 
These are reflected in the process elements that enable the activities that must be 
undertaken to provide care to this group of patients; for example, providing 
ongoing clinical advisory support to self-monitoring patients. 
 
To establish the measures used to assess the quality of the service 
Finally, outcomes are the desired outcomes of the service. These can be considered 
at a system level – for example, that the service is cost-effective – or at an individual 
level: for example that the service is safe. 
 
Although this framework meets these first three objectives, arguably the final two 
objectives arguably provide more compelling support for the use of Donabedian’s 
framework, and for the engagement of the main stakeholders, in this research. 
These will now be considered. 
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To cultivate a shared view of the service across the stakeholder groups 
The service requirements were derived from the perspectives of the main 
stakeholders, and placed within a formal framework. Most of the service 
requirements defined as structural and process elements in this framework are 
derived mainly from the barriers and challenges they identified in establishing and 
implementing an OAT patient self-monitoring service – that is, the design of the 
service and the way that it is conducted aim to both overcome the barriers of 
patient self-monitoring, and to meet its challenges. By contrast, outcomes are 
derived from the professionals and patients perceptions of the service’s benefits, 
including its drivers. These outcomes can also be viewed as a means of measuring 
the success of overcoming the financial and clinical risks perceived by professionals 
to be associated with the service. 
 
To define and connect components of the service 
Many of the OAT service requirements identified for OAT could be mapped to a 
discrete category within the triad. However, the framework did not prove a perfect 
fit for all service elements. For example, some elements within the structure of the 
service –establishing a process for QA of coagulometers and establishing a formal 
shared-care agreement between patient and clinician – overlap with the outcome of 
a safe OAT patient self-monitoring service. This is not necessarily a failing of the 
model as one would expect the structure and processes of the service model to 
engender the desired outcome. Indeed, in this service model, structure is related to 
process and outcome, and process is related to outcome. This is represented in 
Figure 27 below. 
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STRUCTURE
Individuals
System factors
PROCESS
Service delivery
OUTCOME
Individual level
System level
 
 
Figure 27: Relationship between structure, process and outcome elements of an 
anticoagulation patient self-monitoring service model (Adapted from Kunkel et 
al189) 
 
Structure is related to process characteristics; for example, an educational 
programme for patients needs to developed before it can be delivered. Structure is 
also related to outcome characteristics; for example, establishment of formal shared-
care agreements to foster safer anticoagulation management. But if, for example, 
ongoing support is not given to patients, the resulting service may not be a safe one. 
Thus, process is also related to outcome. This suggests that although structural 
elements are important in providing a high quality service, activities undertaken to 
deliver service also contribute to service quality. 
 
In addition to the conceptual overlap described, the line between structure and 
process can be blurred. It could be argued that some of the structural elements are 
also, in themselves, processes. For example: although an assessment of patient 
demand needs to be put in place before the service itself is implemented, the act of 
gauging that demand could be viewed as a process element.  
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In conclusion, this research suggests that Donabedian’s triad is an appropriate 
framework to categorise the requirements of an OAT patient self-monitoring 
service, although not a perfect fit for every requirement. It is also apparent that the 
structure, process and outcome service elements are often closely inter-related. 
 
9.4.1 Requirements for establishing and delivering a service to support self-
management of long-term conditions 
 
At the start of this investigation oral anticoagulation was considered as an example 
of a long-term condition. Treatment is often lifelong, and clinical expertise is needed 
to adjust its dose.  
 
There was initially an expectation that many of the recommendations made in this 
thesis may be applicable to other self-care of long-term conditions. Diabetes, 
asthma, hypertension and arthritis have been most extensively evaluated in the 
context of patient self-management, and the key elements of these interventions are 
compared with patient self-monitoring of OAT in Table 60. 
 
There are some generic key elements. Self-management of all of these long-term 
conditions necessitates the patient assuming greater responsibility for their 
healthcare, with decisions shared between patient and clinician. This new way of 
working requires both patients and healthcare staff to acquire new skills to enable 
shared decision-making. The risks of patient self-management will need to be 
assessed and mitigated, and the service will need to be funded and integrated into 
healthcare system. Most of the interventions involve titrating the dose of a drug to a 
pre-specified endpoint, and still more have clear therapy goals.  
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Table 60: Key elements of self-management interventions in OAT, diabetes, 
asthma, hypertension and arthritis. 
 
Equally there are tasks that are specific to self-management of each long-term 
condition. Additionally, patient self-monitoring  of OAT requires the patient to 
purchase a relatively expensive machine. Therefore this derived service model for an 
OAT patient self-monitoring service is unlikely to be generalisable to self-
management of other long-term conditions. Each disease state requires different 
interventions, and the requirements for need to be mapped out on a case-by-case 
basis.  
 
Condition Aim Key elements 
To maintain the INR within the prescribed 
therapeutic range to prevent bleeding 
and thromboembolic episodes 
Adjusting dose of drug in response to blood 
test 
Clear therapy goal (INR) 
Responding to signs of under-
anticoagulation 
Assuming greater responsibility for 
healthcare 
OAT 
  
  
  
  
  
Responding to signs of over-anticoagulation
To maintain day-to-day control of blood 
glucose, detect hypoglycaemia and 
assess control during any illness. 
Adjusting dose of drug in response to blood 
test 
 Clear therapy goal (BG / HbA1C) 
 Management of eating behaviours 
 Management of depression 
Diabetes 
  
  
  
  
  Integration of complex regimen into lifestyle 
To prevent acute exacerbations through 
avoidance of triggers, monitor symptoms 
and consequent adjustment of treatment 
and improve treatment adherence 
Self-care of trigger factors 
 Monitor disease activity 
 Adjust treatment to peak flow results 
 Relaxation techniques 
 Adjusting treatment to written action plan 
Asthma 
  
  
  
  
  
  Adjusting treatment to symptoms 
To maintain blood pressure within 
acceptable limits 
Clear therapy goal (BP) 
 Relaxation response 
Hypertension 
  
  
  Anxiety management 
Arthritis To reduce pain and improve physical and 
psychological functioning 
Improve coping 
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9.5 Limitations of this research 
 
Individual study limitations have been described in the relevant chapters. There 
were also some general limitations to this research. 
 
The first part of this study – the interviews with self-monitoring patients - was 
limited by its size; just three patients who were self-managing their oral 
anticoagulation were interviewed. These were very motivated, self-monitoring 
patients and, as such, were not representative of the general patient population. 
Recognising this, these interviews were used only to provide an early insight into the 
characteristics of these “early-adopters.” Methodologically,  the purpose of these 
interviews was to get a feel for the main issues associated with OAT patient self-
monitoring to inform the subsequent stage of the study. A larger group of patients 
were then interviewed using a more comprehensive interview guide, which in turn 
was used to develop a questionnaire. This questionnaire was then distributed to a 
much larger group of patients.  
 
The next stage of the investigation elicited the views of healthcare professionals and 
managers gathered into focus groups. Resource constraints limited this to a small 
and geographically local (north London) group. Because of the significant emerging 
issue of funding of coagulometers, a representative from the diagnostics industry 
may have added a valuable perspective. However, during the course of the research 
the author had informal discussions with these representatives, and also attended 
meetings and seminars organised by Roche to keep abreast of current and future 
developments.  
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The main limitations of this research are its size and scope. It is not certain how 
generalisable the results of this research are to other clinical settings or patient 
populations. The setting for this research is a single anticoagulation monitoring 
service at a British District General Hospital (DGH), and it would have also been 
desirable to have spoken with those involved with anticoagulation care outside of 
the immediate locality. Although the author visited the anticoagulant clinic at Barts 
& The London, a broader perspective would have been gained by visiting more 
centres, including those overseas, especially in Germany where patient self-
monitoring is prevalent. Nonetheless, it is believed that the methods used to 
investigate requirements in this setting would be applicable to other Trusts. 
 
The PST pilot involved small numbers – just fourteen patients. However, the 
number of patients self-testing continues to grow and some are going on to self-
manage and may form the basis of future work. 
 
9.6 Future work 
 
 
This research has identified several opportunities for future work. 
 
For operational, logistical or ethical reasons it was not possible to include all of the 
candidate requirements in the PST pilot. A larger pilot to validate all of the results is 
desirable, and this may expose other requirements not previously identified. 
 
The feasibility of conducting further work is largely dependent on resources – time 
and money.  Within Europe, there is a growing interest in enriched patient 
engagement with long-term conditions. Money is following this interest, and an 
opportunity that could be explored is to seek an EU project grant to continue 
research. I would recommend four specific areas for such research. 
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Firstly, as risk aversion by healthcare professionals and managers was a major 
barrier to establishing an OAT patient self-monitoring service, establishing the areas 
of risk should be a priority. In Chapter 6, the need to risk-assess patients wishing to 
undertake self-monitoring was discussed. However, the person approach is only one 
way to view human error. James Reason has established that most incidents are a 
result of systemic failures.190 He holds that most systems will have a number of 
defensive layers, but these layers are like Swiss cheese, with each layer having a 
number of holes that are continually shifting location.  
 
The presence of these holes in any one "slice" does not normally cause a bad 
outcome. However, if the holes in each defensive layer are aligned, this sets up an 
opportunity for error. Reason suggests that the holes in the defences arise as a result 
of active failures and latent conditions. Active failures are the unsafe acts committed 
by people who are in direct contact with the patient or system, in the form of slips, 
lapses, fumbles, mistakes and procedural violations. Latent conditions are “resident 
pathogens” within the system, arising from decisions by those who have designed 
the system.  
 
The Whittington Anticoagulation Monitoring and Stroke Prevention Service has an 
existing programme of Root Cause Analysis (RCA) to identify both active failures 
and latent conditions in response to reported errors and near-misses in the service. 
Root Cause Analysis is a systematic method of trying to find out more about 
incidents and near-misses, and involves a multidisciplinary group including clinicians 
and risk-management academic staff.  
 
In contrast to active failures, latent conditions can be identified and remedied before 
an adverse event occurs. As with RCA, Failure Mode and Effect Analysis (FMEA) 
uses a multidisciplinary team, but it is a prospective methodology that proactively 
identifies failure modes that pose the greatest risk in a system of process. Therefore, 
it is proposed that the existing Root Cause Analysis programme is extended to use 
FMEA to identify the latent conditions of a patient self-monitoring service, using 
hypothetical scenarios. 
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Secondly, there is a pressing need for a more informed view of the legal implications 
of patient self-monitoring of OAT, and of self-care of long-term conditions in 
general. I would recommend consulting with key stakeholders – healthcare 
professionals, managers, legal professionals and representatives from the 
professional bodies – with feedback on hypothetical scenarios, to establish a 
consensus view. 
 
Thirdly, further validation of the requirements for an OAT patient self-monitoring 
services could be achieved by involving patients, healthcare professionals and 
managers outside of London – the needs of a rural community may differ from an 
urban one – and outside of the UK. There are two main options for doing this. The 
methodology and instruments used in this research could be applied to these 
different populations. However, whilst providing further validation of the 
instruments used, this approach would be relatively time and resource intensive. 
More importantly, there are some candidate requirements that cannot be fully 
validated in the context of a PST pilot. For example, it would be unethical to 
provide support to some patients but not to others. 
 
Therefore, an alternative method could be considered such as a Delphi survey. This 
is a method to obtain group consensus on key issues, through an iterative cycle, via 
email.143 As there are no geographic boundaries, international perspectives can be 
gained.  
 
Lastly, the web-based information management system supporting the Whittington 
Anticoagulation and Stroke Prevention Service has been previously described, and 
from 2012, it will be technically possible for Whittington patients to access their 
electronic healthcare record (EHR) embedded in this system, and also to use the 
decision support it offers for warfarin dose adjustment. Because practitioners can 
also access these records to review their patients’ progress, patients could use the 
system to manage their anticoagulation independently but not in isolation. The 
potential benefits of this are compelling – to empower, engage, support and educate 
the patient – but are yet to be proven, and present an exciting future research 
opportunity.  
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CHAPTER 10: CONCLUSION 
 
The UK has been slow to embrace patient self-monitoring of oral anticoagulation 
and, prior to this research, there was no work undertaken to establish the reasons 
behind this. Using a methodological approach, this research has explored the 
perspectives of the key stakeholders to gain a better understanding of what should 
be included in a service model that would foster the successful development and 
delivery of an OAT patient self-monitoring service.  
 
This investigation has resulted in an in-depth understanding of the issues of 
establishing and delivering an OAT patient self-monitoring service. The main 
concerns of the three stakeholder groups are identified in Table 61, and are mapped 
to service requirements. 
 
Stakeholder 
group 
Key concern Service requirement 
Patient The need to purchase 
the coagulometer 
 
Facilitate provision of the coagulometer 
 
Healthcare 
professional
Increased clinical 
risk and fear of 
litigation 
Construct patient eligibility and assessment 
criteria 
Establish a formal shared-care agreement 
between patient and clinician 
Provide ongoing support to self-monitoring 
patients 
Establish a process for quality assurance (QA) of 
coagulometers 
Clarify issues of accountability and clinical 
responsibility 
 
Healthcare 
manager 
Financial risk Establish financial feasibility of service  
 
Table 61: The key concerns of stakeholder groups mapped to service requirements 
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The ability and willingness of patients to purchase a coagulometer cannot be 
underestimated. Patients may be more willing to purchase a coagulometer if they 
can realise the benefits associated with self-monitoring. To this end, a loan 
coagulometer could allow them to ‘try before you buy’. However, the 
anticoagulation service may need to acquire funding for some machines to allow a 
larger sub-section of the clinic population the opportunity to self-monitor.  
 
Steps need to be taken to ensure that the introduction of patient self-monitoring 
does not introduce new risks. Clinical staff will need to feel confident about change, 
and may need education, training and support to prepare them for a new role. There 
are likely to be implications in terms of their patterns of work, their workloads, and 
their relationships with self-monitoring patients and their responsibilities.  
 
Finally, the service must not incur financial risk to either to the commissioners or to 
secondary care. For a service model whose cost-effectiveness is unproven at best, 
this is challenging in the current economic climate. 
 
However, the principal aim of this research was to derive a set of requirements for a 
service to support OAT patient self-monitoring. These requirements are presented 
as a conceptual model below. 
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STRUCTURE
SERVICE APPRAISAL AND FACILTATION
- Gauge patient demand
- Conduct options appraisal
- Establish financial feasibility of service
- Ensure engagement of those delivering and commissioning OAT monitoring
- Facilitate provision of coagulometers
PATIENT FACTORS SERVICE DELIVERY
- Promote the self-monitoring service to 
patients
- Construct patient eligibility and assessment 
criteria
- Develop a patient education programme
- Establish a process for QA of 
coagulometers
- Establish an OAT self-monitoring policy
SHARED CARE
- Establish formal shared-care agreement between patient and clinician
- Establish formal shared-care agreement between primary and secondary care
ETHICO-LEGAL
- Clarify issues of accountability and responsibility
- Address potential inequities
PROCESS
PATIENT TRAINING PATIENT SUPPORT
- Provide training on using the coagulometer
- Deliver an educational programme
- Provide education for dose adjustment (PSM)
- Provide ongoing support
- Provide support for dose adjustment (PSM)
OUTCOME
Service is safe
Service is acceptable to patients
Service is cost-effective
PATIENT PLUS FAMILY AND 
CARERS
ANTICOAGULANT 
CLINIC STAFF
GPs,  PRACTICE 
NURSES AND 
COMMUNITY 
PHARMACISTS
SHARED CARE
 
 
Figure 28: A conceptual model of the requirements for an oral anticoagulation self- 
monitoring service
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Although this model is unlikely to be generalisable to self-management of other 
long-term conditions, the method of investigation used in this research could be 
applied to derive a set of specific service requirements for other conditions. This 
method of deriving service requirements from the perspectives of key stakeholders 
is pertinent when considered against the background of the future model of NHS 
services. 
 
Policy makers are emphasising the need for integrated care.191 Greater integration of 
care inevitably involves multiple stakeholders, and future services will need to be 
developed to accommodate all of their needs. Integration can occur between health 
and social care (horizontal integration) or across primary, community and secondary 
care providers  (vertical integration). In April 2011, the author’s employing NHS 
Trust vertically integrated with the provider arm of two PCTs to form an integrated 
care organisation (ICO). This may offer exciting new opportunities for more holistic 
integration. 
 
 
 
 
341  
 
REFERENCES  
 
1.  Department of Health. Ten things you need to know about long term 
conditions. 2008. www.dh.gov.uk. Last accessed 04-11-2011 
 
2.  Department of Health. Supporting people with long term conditions to self 
care: A guide to developing local strategies and good practice. 2006. 
www.dh.gov.uk. Last accessed 10-11-2006 
 
3.  Department of Health. The NHS improvement plan. 2004. www.dh.gov.uk. 
Last accessed 04-03-2006 
 
4.  Department of Health. Saving lives: our healthier nation.2009.  
www.dh.gov.uk. Last accessed 17-10-2010 
 
5.  Department of Health. Self care - a real choice. Self-care support - A 
practical option. 2005. www.dh.gov.uk. Last accessed 24-01-2010 
 
6.  Norris S, Engelgau M, Narayan K. Effectiveness of self-management 
training in type 2 diabetes. Diabetes Care 2001;24:561-87. 
 
7.  Moss J. Roche Diagnostics - Uptake of patient self-testing of oral 
anticoagulation. Personal Communication 16-09-2010 
  
8.  Institute of Medicine. Crossing the Quality Chasm: A New Health System 
for the 21st Century. 2001. www.iom.edu. Last accessed 17-10-2011 
 
9.  Leatherman S and Sutherland K. The quest for quality in the NHS. A 
midterm evaluation of the ten-year quality agenda. 2003. www.nuffieldtrust.org.uk. 
Last accessed 17-10-2011 
 
10.  Kelley E and Hurst J. Health care quality indicators project. Conceptual 
framework paper.  2006.  Organisation for Economic Co-operation and 
Development. www.oecd.org. Last accessed 18-10-2011 
 
 
342  
 
 
 
11.  Donabedian A. Evaluating the Quality of Medical Care. Milbank Memorial 
Fund Quarterly: Health and Society 1966;44:166-203. 
 
12.  Cott C, Devitt R, Wong R, Soever L, MacKay C. A client-centred health 
service model of primary health care and rehabilitation for arthritis.  2011.  Arthritis 
Community Research and Evaluation Unit (ACREU). www.acreu.ca. Last accessed 
07-01-2012 
 
13. Coleman B, Patterson D, Long M, Farrell J. Setting quality standards for a 
community pharmacist-led anticoagulant clinic.  Pharm J 2003;270:308-11. 
 
14.        National Patient Safety Agency. Actions that can make oral anticoagulant 
therapy safer: Information for patients and carers. 2007. www.npsa.nhs.uk. Last 
accessed 14-01-2012 
  
15.  Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation 
(warfarin): third edition - 2005 update. British Journal of Haematology 2006;132:277-85. 
 
16.  The Pharmaceutical Press. Martindale: The Complete Drug Reference. 
London,2010. 
 
17.  Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of 
anticoagulant treatment. Chest 1992;102:352S-363. 
 
18.  Landefeld C,.Beyth RJ. Anticoagulant-realted bleeding - clinical 
epidemiology, prediction and prevention. Am J Med 1993;95:315-28. 
 
19.  Linkins LA, Choi PT, Douketis JD. Clinical Impact of Bleeding in Patients 
Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-
Analysis. Annals of Internal Medicine 2003;139:893-900. 
 
 
 
343  
 
20.  Hirsh J. Oral anticoagulant drugs. New England Journal of Medicine 
1991;324:1865-75. 
 
21.  National Research Register. Variability in response to warfarin: a prospective 
analysis of pharmacogenetic and environmental factors. National Research Register. 
www.nihr.ac.uk. Last accessed 19-01-2012 
 
22.  Breckenridge A. Interindividual differences in the response to oral 
anticoagulants. Drugs 1977;14:367-75. 
 
23.  American Society of Health System Pharmacists. AHFS Drug Information. 
Bethesda, MD:ASHP, 2006. 
 
24.  Rang H, Dale M, Ritter J. Pharmacology. Edinburgh: Churchill Livingstone, 
2000. 
 
25.   Therapeutic Drugs. Edinburgh: Churchill Livingstone, 1999. 
 
26.  Haemostasis and Thrombosis Task Force for the BCSH. Guidelines on oral 
anticoagulation: third edition. Br J Haem 1998;101:274-387. 
 
27.  Charles C, Whelan T, Gafni A. What do we mean by partnership in making 
decisions about treatment? BMJ 1999;319. 
 
28.  Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, 
Song F. Clinical effectiveness and cost-effectiveness of different models of 
managing long-term oral anticoagulation: a systematic review and economic 
modelling. Health Technology Assessment 11(38). 2007. www.hta.ac.uk. 
  
29.  Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of 
antithrombotic therapt in atrial fibrillation: Analysis of pooled data from five 
randomised controlled trials. Arch Intern Med 1994;154:1449-57. 
 
 
 
344  
 
30.  York M, Agarwal A, Ezekowitz M. Physicians' attitudes and the use of oral 
anticoagulants: surveying the present and envisioning future. J Thromb Thrombolysis 
2003;16:33-7. 
 
31.   Are the UK's anticoagulation clinics at breaking point? INReview 2005;6-7. 
 
32.  Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A 
et al. Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the 
Anticoagulation Forum. Ann Pharmacother 2008;42:979-88. 
 
33.  Kost G. Guidelines for point-of-care testing: improving patient outcomes. 
Am J Clin Pathol 1995; 104:S111-S127. 
 
34.  Yang D, Robetorye R, Rodgers G. Home Prothrombin Time monitoring: A 
literature analysis. American Journal of Hematology 2004;77:177-86. 
 
35.  Lucas F, Duncan A, Jay R. A novel whole blood capillary technique for 
measuring prothrombin time. Am J Clin Pathol 1987;88:442-6. 
 
36.  Ansell J, Jacobson A, Levy J, Voller H, Hasenkam JM. Guidelines for 
implementation of patient self-testing and patient self-management of oral 
anticoagulation. International consensus guidelines prepared by International Self-
Monitoring Association for Oral Anticoagulation. International Journal of Cardiology 
2005;99:37-45. 
 
37.  Jacobson A. Patient self-management of oral anticoagulant therapy: An 
international update. J Thromb Thrombolysis 1998;5:25-8. 
 
38.  White R, McCurdy S, von Marensdorff H, Woodruff D, Leftgoff P. Home 
prothrombin time monitoring after the initiation of warfarin therapy. Ann Intern Med 
1989;111:730-6. 
 
 
 
345  
 
39.  Ansell J, Holden A, Knapic N. Patient self-management of oral 
anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. 
Arch Intern Med 1989;149:2509-11. 
 
40.  Ansell J, Patel N, Ostrovsky D. Long-term patient self -management of oral 
anticoagulation. Arch Intern Med 1995;155:2185-9. 
 
41.  Bernardo A. Experience with patient self-management of oral 
anticoagulation. J Thromb Thrombolysis 1996;2:321-5. 
 
42.  Horskotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring 
and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb 
Thrombolysis 1998;5:S19-S24. 
 
43.  Sawicki P. A structured teaching and self-management program for patients 
receiving oral anticoagulation: a randomised controlled trial: Working Group for the 
Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999;281:145-50. 
 
44.  Cromheecke M, Levi M, Colly L, de Mol B, Prins M, Hutten B et al. Oral 
anticoagulation self-management and management by a specialist anticoagulation 
clinic: a randomised cross-over comparison. Lancet 2000;356:97-102 
 
45.  Gadisseur A, Breukink-Engbers W, van der Meer F, van den Besselaar A, 
Sturk A, Rosendaal F. Comparison of the quality of oral anticoagulant therapy 
through patient self-mnangement and management by specialized anticoagulation 
clinics in the Netherlands. Arch Intern Med 2003;163:2639-46. 
 
46.  Sidhu P, O'Kane HO. Self-managed anticoagulation: results from a two-year 
prospective randomized trial with heart valve patients. Ann Thorac Surg 
2001;72:1523-7. 
 
47.  Braddock A.. PST / PSM: Roche Diagnostics. Personal Communication  
14-07-2011.  
 
 
 
346  
 
48.  Medicare to Now Cover INR Self Testing for Patients on Anticoagulants 
for Chronic Atrial Fibrillation and Venous Thromboembolism. 2008. 
www.hemosense.com. Last accessed 10-11-2008. 
 
49.  Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S 
et al. Self management of oral anticoagulation: randomised trial. BMJ 2005;331:1057. 
 
50.  Department of Health. Equity and excellence: Liberating the NHS. 2010. 
www.dh.gov.uk. Last accessed 27-01-2012. 
  
51.  Roche Diagnostics. Annual Report 2010. www.roche.com. Last accessed 14-
09-2011. 
 
52.  Fitzmaurice DA, Gardiner C, Kitchen S, Mackie I, Murray ET, Machin SJ. 
An evidence-based review and guidelines for patient self-testing and management of 
oral anticoagulation. British Journal of Haematology 2005;131:156-65. 
 
53.  Department of Health. National Enhanced Service: Anticoagulation 
Monitoring. 2006. www.dh.gov.uk. Last accessed 17-09-2011. 
  
54.  NHS Hertfordshire. Local Enhanced Service for Anti-coagulation 
monitoring. 2011/12 Service Level Agreement. 2011. www.hertfordshire.nhs.uk. 
Last accessed 27-11-2011. 
 
55.  Eysenbach G. Recent advances: Consumer health informatics. BMJ 
2000;320:1713-6. 
  
56.  Coulter A, Parsons S, Askham J. Where are the patients in decision-making 
about their own care?  2008. Copenhagen, World Health Organisation. 
www.who.int. Last accessed 02-12-2011. 
 
57.  Department of Health. Pharmacy in the Future - Implementing the NHS 
Plan. 2000. www.dh.gov.uk. Last accessed 23-06-2010. 
 
 
 
347  
 
58.  Wyness M. Evaluation of an educational programme for patients taking 
warfarin. Journal of Advanced Nursing 1990;15:1052-63. 
 
59.  Morsdorf S, Erdlenbruch W, Taborski U. Training of patients for self-
management of oral anticoagulant therapy: standards, patient suitability, and clinical 
aspects. Semin Thromb Hemost 1999;25:109-16. 
 
60.  Knowlton CH, Thomas OV, Williamson A, Gammaitoni AR, Kirchain WR, 
Buttaro ML et al. Establishing community pharmacy-based anticoagulation 
education and monitoring programs. JAPhA 1999;39:368-74. 
 
61.  Scalley R, Kearney E, Jakobs E. Interdisciplinary inpatient warfarin 
education program. Am J Hosp Pharm 1979;36:219-20. 
 
62.  Creer T, Renne C, Christian W. Behavioural contributions to rehabilitation 
and childhood asthma. Rehabilitation Literature 1976;37:232 
 
63.  Lorig KR,.Holman HR. Self-management education: History, Definitions, 
Outcomes and Mechanisms. Ann Behav Med 2003;26:1-7. 
 
64.  Taylor C, Farquhar J, Nelson E, Agras S. Relaxation therapy and high blood 
pressure. Arch Gen Psychiatry 1977;34:339-42. 
 
65.  Corben S, Rosen R. Self-management for long-term conditions. Patients' 
perspectives on the way ahead. London: King's Fund, 2005. www.kingsfund.org.uk. 
Last accessed 23-11-2011. 
 
66.  Consumers' Association. The patient journey: Information. 2003 (1) 55-57.  
 
67.  Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management 
approaches for people with chronic conditions: a review. Patient Education and 
Counseling 2002;48:177-87. 
 
 
 
348  
 
68.  Department of Health. Supporting people with long-term conditions. An 
NHS and social care model to support local innovation and integration. 2005. 
www.dh.gov.uk. Last accessed 12-10-2010. 
 
69.  Warsi A, Wang P, LaValley M, Avorn J, Solomon D. Self-management 
education programs in chronic disease. Arch Intern Med 2004;164:1641-9. 
 
70.  Chodosh J, Morton SC, Mojica W, Maglione M, Suttorp MJ, Hilton L et al. 
Meta-Analysis: Chronic Disease Self-Management Programs for Older Adults. 
Annals of Internal Medicine 2005;143:427-38. 
 
71.  Newman S, Steed L, Mulligan K. Self-management interventions for chronic 
illness. Lancet 2004;364:1523-37. 
 
72.  Monninkhof E, Effing T, van der Valk P, Walters E, van der Palen J. Self-
management education for patients with chronic obstructive pulmonary disease. 
Cochrane Database of Systematic Reviews  2007. 
 
73.  Powell H,.Gibson P. Options for self-management education for adults with 
asthma. Cochrane Database of Systematic Reviews 2003. 
 
74.  Welschen L, Blomendal E, Nijpels G, Dekker J. Self-monitoring of blood 
glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database 
of Systematic Reviews 2005. 
 
75.  Samsa G,.Matchar D. Relationship between test frequency and outcomes of 
anticoagulation: A literature review and commentary  with implications for the 
design of randomized trials of patient self-management. J Thromb Thrombolysis 
2000;9:283-92. 
 
76.  Gardiner C, Williams K, Mackie I, Machin S, Cohen H. Patient self-testing is 
a reliable and acceptable alternative to laboratory INR monitoring. BJH 
2004;128:242-7. 
 
 
 
349  
 
77.  Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS et al. 
Effect of Home Testing of International Normalized Ratio on Clinical Events. New 
England Journal of Medicine 2010;363:1608-20. 
 
78.  Kortke H,.Korfer R. International normalized ratio self-management after 
mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 
2001;72 :44-8. 
 
79.  Beyth R, Quinn L, Landefield C. A multicomponent intervention to prevent 
major bleeding complications in older patients receiving warfarin: a randomized 
controlled trial. Ann Intern Med 2000;133:687-95. 
 
80.  Khan T, Kamali F, Kesteven P, Avery P, Wynne H. The value of education 
and self-monitoring in the management of warfarin therapy in older patients with 
instable control of anticoagulation. Br J Haem 2004;126:557-64. 
 
81.  Fitzmaurice DA, Murray ET, Gee KM, Hobbs FDR. A randomised 
controlled trial of patient self management of oral anticoagulation treatment 
compared with primary care management. J Clin Pathol 2002;55:845-9. 
 
82.  Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-
management of oral anticoagulation in the elderly: Rationale, design, baselines and 
oral anticoagulation control after one year of follow-up. Thromb Haemost 
2007;97:408-16. 
 
83.  Menendez-Jandula B, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I 
et al. Comparing Self-Management of Oral Anticoagulant Therapy with Clinic 
Management: A Randomized Trial. Annals of Internal Medicine 2005;142:1-10. 
 
84.  Watzke H, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B. A 
prospective controlled trial comparing weekly self-testing and self-dosing with the 
standard management of patients on stable oral anticoagulation. Thromb Haemost 
2000;83:661-5. 
 
 
 
350  
 
85.  Sunderji R, Gin K, Shalansky K. A randomized trial of patient self-managed 
versus physician-managed oral anticoagulation.  Can J Cardiol 2004;20:1117-23. 
 
86.  Gardiner C, Longair I, Pescott MA, Erwin H, Hills J, Machin SJ et al. Self-
monitoring of oral anticoagulation: does it work outside trial conditions? Journal of 
Clinical Pathology 2009;62:168-71. 
 
87.  Gadisseur APA, Kaptein AA, Breukink-Engbers WGM, Van Der Meer 
FJM, Rosendaal R. Patient self-management of oral anticoagulant care vs. 
management by specialized anticoagulation clinics: positive effects on quality of life. 
Journal of Thrombosis and Haemostasis 2004;2:584-91. 
 
88.  Gardiner C, Williams K, Longair I, Mackie IJ, Machin SJ, Cohen H. A 
randomised control trial of patient self-management of oral anticoagulation 
compared with patient self-testing. British Journal of Haematology 2006;132:598-603. 
 
89.  Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-
management of oral anticoagulation reduces major outcomes in the elderly. A 
randomized controlled trial. Thromb Haemost 2008;100:1089-98. 
 
90.  Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, 
Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-
analysis. The Lancet 2006;367:404-11. 
 
91.  Garcia-Alamino J, Ward A, Alonso-Coello P, Perera R, Bankhead C, 
Fitzmaurice D et al. Self-monitoring and self-management of oral anticoagulation 
(Review). Cochrane Database of Systematic Reviews 2010;4. 
 
92.  Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I et al. 
Meta-analysis: Effect of Patient Self-testing and Self-management of Long-Term 
Anticoagulation on Major Clinical Outcomes. Annals of Internal Medicine 
2011;154:472-82. 
 
 
 
351  
 
93.  United States Department of Veterans Affairs. The Home International 
Normalized Ratio (INR) Monitor Study (THINRS). 2007. 
www.herc.research.va.gov. Last accessed on 01-10-2010. 
 
94.  Bandura A. Health functioning: Self-efficacy - the exercise of control. New 
York: W.H. Freeman and Company, 1997. 
 
95.  Wittkowsky A, Sekreta C, Nutescu E, Ansell J. Barriers to self-testing of 
prothrombin time: national survey of anticoagulation practitioners. Pharmacotherapy 
2005;25:265-9. 
 
96.  Jones A, Pill R, Adams S. Qualitative study of views of health professionals 
and patients on guided self management plans for asthma. BMJ 2000;321:1507-10. 
 
97.  Department of Health. Public Attitudes to Self-Care - A Baseline Survey. 
2005. www.dh.gov.uk. Last accessed on 17-01-2012. 
 
98.  General Medical Council. Good Medical Practice. 2006. www.gmc-uk.org. 
Last accessed on 14-10-2011.  
 
99.  British Medical Association. Improved self-care by people with long-term 
conditions through self-management education programmes. 2007. 
www.bma.org.uk. Last accessed on 14-10-2011.  
 
 
100.  British Medical Association. Enabling people with long-term conditions to 
self-manage their health: a resource for GPs. 2007. www.bma.org.uk. Last accessed 
on 14-10-2011.  
 
 
 
 
  
   
 
 
352  
 
101.  Royal College of General Practitioners. The future direction of general 
practice. A roadmap. 2007. www.rcgp.org.uk. Last accessed on 14-10-2011.  
 
102.  Royal Pharmaceutical Society of Great Britain. The self-care challenge: A 
strategy for pharmacists in England. 2007. www.rpsgb.org.uk.  Last accessed on 14-
10-2011.  
 
103.  Bungard TJ, Koshman SL, Tsuyuki RT. Patient preferences for ongoing 
warfarin management after receiving care by an anticoagulation management 
service. American Journal of Health-System Pharmacy 2008;65:1498. 
 
104.  Heneghan C, Perera R, Ward A, Fitzmaurice D, Meats E, Glasziou P. 
Assessing differential attrition in clinical trials: self-monitoring of oral 
anticoagulation and type II diabetes. BMC Medical Research Methodology 2007;7:18. 
 
105.  Jerant AF, Friederichs-Fitzwater MM, Moore M. Patients' perceived barriers 
to active self-management of chronic conditions. Patient Education and Counseling 
2005;57:300-7. 
 
106.  Bayliss EA, Steiner JF, Fernald DH, Crane LA, Main DS. Descriptions of 
barriers to self-care by persons with comorbid chronic diseases. Annals of Family 
Medicine 2003;1:15-21. 
 
107.  Lansbury G. Chronic pain management: a qualitative study of elderly 
people's preferred coping strategies and barriers to management. Disability and 
Rehabilitation 2000;22:2-14. 
 
108.  Patterson B. Myth of empowerment in chronic illness. J Adv Nurs 
2001;13:259-67. 
 
109.  Riegel B,.Carlson B. Facilitators and barriers to heart failure self-care. Patient 
Education and Counseling 2002;46:287-95. 
 
 
 
353  
 
110.  Sidhu P,.O'Kane H. Self-managed anticoagulation for heart valve patients: a 
one year experience. Ann Thoracic Surgery 2001;72:1523-7. 
 
111.  Voller H, Dovifat C, Glatz J, Koertke H, Taborski U, Wegscheider K. Self 
management of oral anticoagulation with the IN Ratio system: impact of a 
structured teaching program on patients' knowldege of medical background and 
procedures. Eur J Cardiovasc Prev Rehabil 2004;11:442-7. 
 
112.  Koertke H, Zitterman A, Mommertz S, El-Arousy M, Litmathe J, Koerfer 
R. The Bad Oeynhausen concept of INR self-management. J Thromb Thrombolysis 
2005;19:25-31. 
 
113.  Voller H, Dovifat C, Glatz J. Home management of anticoagulation. Eur 
Heart J Suppl 2001;3:Q44-Q49. 
 
114.  The National Collaborating Centre for Primary Care. Medicines adherence: 
involving patients in decsions about prescribed medicines and supporting 
adherence.  2009.  
 
115.  North London Cancer Network. North London Cancer Network: 
Population profile. 2006. www.whittington.nhs.uk  
 
116.  McCahon D, Fitzmaurice D, Murray E, Fuller C, Hobbs R, Allan T et al. 
SMART: Self-Management of Anticoagulation, a Randomised Trial 
[ISRCTN19313375]. BMC Family Practice 2003;4:11. 
 
117.  Murray E, Fitzmaurice D, McCahon D, Fuller C, Sandhur H. Training for 
patients in a randomised controlled trial of self management of warfarin treatment. 
BMJ 2004;328:437-8. 
 
118.  Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin 
time monitor for home use by patients who require long-term oral anticoagulant 
therapy. Archives of Internal Medicine 1993;153:1441-7. 
 
 
 
354  
 
119.  Oral Anticoagulation Monitoring Study Group. Point-of-care prothrombin 
time measurement for professional and patient self-testing use. A multicenter 
clinical experience. Am J Clin Pathol 2001;115:288-96. 
 
120.  Oral Anticoagulation Monitoring Study Group. Prothrombin management 
using a patient self-testing system. Am J Clin Pathol 2001;115:280-7. 
 
121.  Cosmi B, Palareti G, Moia M, Carpenedo M, Pengo V, Biasiolo A et al. 
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter 
study on home use of a portable prothrombin time monitor (COAGUCHECK). 
Haematologica 2000;85:826-31. 
 
122.  Christensen TD, Andersen NT, Attermann J, Hjortdal VE, Maegaard M, 
Hasenkam JM. Mechanical heart valve patients can manage oral anticoagulant 
therapy themselves. European Journal of Cardio-Thoracic Surgery 2003;23:292-8. 
 
123.  Voller H, Taborski U, Dovifat C, Hartwig I, Kadar JG, Wegscheider K et al. 
ProTime self-management yielding improvement of fluency and quality of life. 
Thrombosis and Haemostasis 2007;98:889-95. 
 
124.  Norris SL, Engelgau MM, Venkat Narayan KM. Effectiveness of Self-
Management Training in Type 2 Diabetes. Diabetes Care 2001;24:561-87. 
 
125.  Day JL, Coles C, Walford S. Self-management in diabetes: training 
implications for professional carers. Clinical Medicine 2003;3:338-41. 
 
126.  Gutierres SL,.Welty TE. Point-of-Care Testing: An Introduction. Ann 
Pharmacother 2004;38:119-25. 
 
127.  Information Centre for Health and Social Care. Prescription Cost Analaysis 
- England 2010. www.ic.nhs.uk/statistics-and-data-collections. Last accessed on 10-
08-2011. 
  
 
 
 
355  
 
  
128.  Jowett S, Bryan S, Murray E, McCahon D, Raftery J, Richard Hobbs FD et 
al. Patient self-management of anticoagulation therapy: a trial-based cost-
effectiveness analysis. British Journal of Haematology 2006;134:632-9. 
 
129.  National Institute for Health and Clinical Excellence. Measuring 
effectiveness and cost effectiveness: the QALY. 2010. www.nice.org.uk. Last 
accessed on 03-08-2011. 
 
130.  Lafata JE, Martin SA, Kaatz S, Ward RE. The Cost-Effectiveness of 
Different Management Strategies for Patients on Chronic Warfarin Therapy. Journal 
of General Internal Medicine 2000;15:31-7. 
 
131.  Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of 
self-managed versus physician-managed oral anticoagulation therapy. CMAJ 
2006;174:1847-52. 
 
132.  Taborski U, Wittstamm F, Bernardo A. Cost-effectiveness of self-managed 
anticoagulant therapy in Germany. Semin Thromb Hemost 1999;25:103-7. 
 
133.  Richardson G. Cost-effectiveness of interventions to support self-care: a 
systematic review. International Journal of Technology Assessment in Health Care 
2005;21:423-32. 
 
134.  Department of Health. The new NHS: modern, dependable. 1997.  
www.dh.org.uk. Last accessed on 22-04-2011.  
 
135.  Emanuel EJ,.Emanuel LL. What Is Accountability in Health Care? Annals of 
Internal Medicine 1996;124:229-39. 
 
136.   Medicine in contemporary society. London: Kings Fund, 1987. 
 
137.  Redman BK. Responsibility for control; ethics of patient preparation for 
self-management of chronic disease. Bioethics 2007;21:243-50. 
 
 
356  
 
 
138.  Redman BK. Accountability for patient self-management of chronic 
conditions; ethical analysis and a proposal. Chronic Illness 2007;3:88-95. 
 
139.  Bowling A. Research Methods in Health. Buckingham: Open University 
Press, 1997. 
 
140.  Kravitz RL. Measuring Patients' Expectations and Requests. Annals of 
Internal Medicine 2001;134:881-8. 
 
141.  Dawn A, Lee P. Patient expectations for medical and surgical care: A 
Review of the literature and applications to ophthalmology. Survey of Ophthalmology 
2004;49 :513-24. 
 
142.  Jenkinson C, Coulter A, Bruster S. The Picker Patient Experience 
Questionnaire: development and validation using data from in-patient surveys in 
five countries. International Journal for Quality in Health Care 2002;14:353-8. 
 
143.  Pope C, Mays N. Qualitatitve Research in Health Care. Oxford: Blackwell, 
2006. 
 
144.  Green J, Thorogood N. Qualitative methods in health research. London: 
Sage, 2009. 
 
145.  Glaser B, Strauss A. The discovery of grounded theory: Strategies for 
qualitative research. New York: Aldine, 1967. 
 
146.  Rosendaal F, Cannegieter S, Van Der Meer FJM. A method to determine 
the optimal intensity of oral anticoagulant therapy.  Thromb Haemost 1993;69:236-9. 
 
147.  Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS et al. 
Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage 
among Patients Taking Warfarin for Atrial Fibrillation. Annals of Internal Medicine 
2004;141:745-52. 
 
 
357  
 
 
148.  Whittington Hospital NHS Trust. 2006. www.whittington.nhs.uk. Last 
accessed on 20-10-2006 
 
149.  National Health Service. North London Cancer Network: Population 
profile. 2006. www.ncln.nhs.uk. Last accessed on 24-10-2006 
 
150.  National Statistics. Census 2001. www.statistics.gov.uk. Last accessed on 24-
10-2006 
 
151  Coleman B, Martin C, Barber N, Patterson D. An evaluation of the safety 
and acceptability of an anticoagulation clinic in a community pharmacy setting - a 
pilot study. Pharm J 2004;273:822-4. 
 
152  Vahder BD, Patterson DLH, Leaning MS. Comparison of oral anticoagulant 
control by a nurse-practitioner using a computer decision-support system with that 
by clinicians. Clin.Lab.Haem. 1997;19:203-7. 
 
153  Vahder BD, Patterson DLH, Leaning MS. Validation of an algorithm for 
oral anticoagulant dosing and appointment scheduling. Clin.Lab.Haem. 1995;17:339-
45. 
 
154. Vahder BD, Patterson DLH, Leaning MS. Evaluation of a decision support 
system for initiation and control of oral anticoagulation in a randomised trial. BMJ 
1997;314:1252-6. 
 
155.  Samsa G, Matchar D, Dolor R, Wiklund I, Hedner E, Wygant G et al. A new 
instrument for measuring anticoagulation-related quality of life: development and 
preliminary validation. Health and Quality of Life Outcomes 2004;2:22. 
 
156.  Barcellona D, Contu P, Sorano G, Pengo V, Marongiu F. The management 
of oral anticoagulant therapy: The patient's point of view. Thromb Haemost 
2000;83:49-53. 
 
 
 
358  
 
157.  Dantas G, Thompson B, Manson J, Tracy CS, Upshur R. Patients' 
perspectives on taking warfarin: qualitative study in family practice. BMC Family 
Practice 2004;5:15. 
 
158.  Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, 
Hughes RA et al. The impact of long-term warfarin therapy on quality of life. 
Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial 
Fibrillation Investigators. Archives of Internal Medicine 1991;151:1944-9. 
 
159.  Patterson B. The shifting perspective model of chronic illness. Journal of 
Nursing Scholarship 2001;First quarter:21-6. 
 
160.  Quin J, Markwell S, Rogers LQ, McLafferty R, Reinersman M, Hazelrigg S. 
Home Anticoagulation Testing: Predictors of Rural Patient Interest. Journal of 
Surgical Research 2006;136:232-7. 
 
161.  Day JL. Diabetic patient education: determinants of success. Diabetes / 
Metabolism Research and Reviews 2000;16:S70-S74. 
 
162.  Ajzen. From intentions to actions: a theory of planned behaviour. In Kuhl J, 
Beckham J, eds. Action Control: From Cognition to Behaviour, New York: Springer-
Verlag, 1985. 
 
163.  Gatt S,.Sammut R. An exploratory study of predictors of self-care behaviour 
in persons with type 2 diabetes. International Journal of Nursing Studies 2008;45:1525-
33. 
 
164.  Locock L. Healthcare redesign: meaning, origins and application. Qual Saf 
Health Care 2003;12:53-8. 
 
165.  Kuhn T. The Structure of Scientific Revolutions. Chicago, IL.: University of 
Chicago Press., 1962. 
 
 
 
359  
 
166.  Anderson RM,.Funnell MM. Patient empowerment: reflections on the 
challenge of fostering the adoption of a new paradigm. Patient Education and 
Counseling 2005;57:153-7. 
 
167.  Blakeman T, Macdonald W, Bower P, Gately C, Chew-Graham C. A 
qualitative study of GPs' attitudes to self-management of chronic disease. British 
Journal of General Practice 2006;56:407-14. 
 
168.  BMA. Focus on enhanced services. 2007. www.bma.org.uk. Last accessed 
on 20-10-2011. 
 
169.  National Patient Safety Agency. Risk assessment of anticoagulant therapy. 
2006. www.npsa.nhs.uk. Last accessed 21-09-2011. 
 
170.  Oral Anticoagulation Testing Strips: A Resource Pack. Anticoagulation 
Europe .2009. www.anticoagulationeurope.org. Last accessed 01-12-2011. 
 
171.  Centre for Evidence Based Purchasing. Roche Diagnostics CoaguChek™ 
XS. 2006. http://nhscep.useconnect.co.uk. Last accessed 17-05-2007.  
 
172.  Bedi S, Behera S, Ayra S, Singh S. Standard operating procedures in hospital 
- a reality check. Journal of the Academy of Hospital Administration 2006;18:1-12. 
 
173.  Burgwinkle P, Dice G, Fintel D, Ezekowitz M, Franke C, Frazier T et al. 
Oral anticoagulation patient self-testing: Consensus guidelines for practical 
implementation. Supplement to Managed Care 2008;1. 
 
174.  McCahon D, Murray E, Fitzmaurice D. Guidelines for patient self-testing 
and self-management of oral anticoagulation. Thrombus 2004;8. 
 
175.  Department of Health. Shared care guidelines. 2011. www.dh.gov.uk. Last 
accessed 04-01-2012. 
 
 
 
360  
 
176.  Murray, E. Oral anticoagulation patient self-monitoring update. Personal 
Communication. 16-09- 2010.  
 
177.  Kabel J. Diabetes Self-Care. Potential liability of the treating physician. The 
Journal of Legal Medicine 1984;5:253-93. 
 
178   Self-monitoring of blood glucose in diabetes. DTB 2007;45:65-70. 
 
179.  Gardiner C, Williams K, Mackie I, Machin SJ, Cohen H. Can oral 
anticoagulation be managed using telemedicine and patient self-testing? A pilot 
study. Clin.Lab.Haem. 2006;28:122-5. 
 
180.  Lamminen H, Niiranen S, Niemi K, Mattila H, Kalli S. Personal health care 
and the new media in anticoagulant treatment. Scandinavian Journal of Primary Health 
Care 2002;20:123-5. 
 
181.   Internet used to link warfarin patients to pharmacist anticoagulation 
management. Pharmaceutical Journal 2008;280:343. 
 
182.  Lewis D. Computer-based approaches to patient education. JAMIA 
1999;6:272-82. 
 
183.  Ross SE, Moore LA, Earnest MA, Wittevrongel L, Lin C-T. Providing a 
Web-based Online Medical Record with Electronic Communication Capabilities to 
Patients With Congestive Heart Failure: Randomized Trial. J Med Internet Res 
2004;6:e12. 
 
184.  Turnin M, Beddock R, Clottes J. Telematic expert Diabeto: new tool for diet 
self-monitoring for diabetic patients. Diabetes Care 1992;15:204-12. 
 
185.  Wantland D, Portillo CJ, Holzemer WL, Slaughter R, McGhee EM. The 
Effectiveness of Web-Based vs. Non-Web-Based Interventions: A Meta-Analysis of 
Behavioral Change Outcomes. J Med Internet Res 2004;6:e40. 
 
 
 
361  
 
186.  The Health Foundation. Co-creating Health. 2010. www.health.org.uk. Last 
accessed 16-07-2011.  
 
187.  Moss, Jeremy. Roche Diagnostics. Coagunation forum, Oxford. 06-06-2007. 
 
188.  Wood P, Brill D, Skilton N. More caution urged for dabigatran as focus 
shifts to at-risk groups. www.cardiologyupdate.com. 17-4-0012. Last accesssed 30-4-
2012.  
 
189.  Kunkel S, Rosenqvist U, Westerling R. The structure of quality systems is 
important to the process and outcome, an empirical study of 386 hospital 
departments in Sweden. BMC Health Serv Res  2007;7:104-11. 
 
190.  Reason J. Human error: models and management. BMJ 2000;320:768-70. 
 
191.  Department of Health. Our NHS Our Future: NHS Next Stage Review - 
Leading Local Change. 2008.  www.dh.gov.uk . Last accessed 10-04-2011.  
 
 
 
 
 
 
 
 
362  
 
APPENDIX 1: SAMPLE PAGES FROM THE 
WORKBOOK USED IN EDUCATIONAL 
PROGRAMME FOR ANTICOAGULATION 
PRACTITIONERS 
 
CLINICAL USE OF WARFARIN   
 
 
PHARMACOKINETICS AND METABOLISM 
 
Knowledge of the pharmacokinetics of warfarin is essential to 
understanding the response to therapy.  
Warfarin is a racemic mixture of stereoisomers, which are 99 
percent bound to albumin. However, because of redistribution 
of the displaced drug throughout the body, administration of 
another drug that displaces warfarin from its binding site (e.g. 
NSAIDs), or uraemia, does not lead to an enhanced drug effect. 
However, there may be a temporary increase in anticoagulant 
response until a new steady-state is established. 
Warfarin is almost completely absorbed from the GI tract and 
can be detected in the plasma one hour after oral administration. 
However, the relationship between plasma concentration of 
warfarin and its effect is complex. As warfarin’s effect on vitamin 
K clotting factors is a function of both their synthesis rate and 
degradation rates, there is no simple correlation between plasma 
concentration and therapeutic effect. 
The mean plasma half-life is approximately 40 hours, and the 
duration of effect is two to five days. When starting warfarin 
treatment, it would normally take about 5 half-lives (i.e. 8 days) 
to reach constant plasma concentration (steady state). 
Therefore, when initiating Warfarin therapy loading doses are 
used to bring the steady state forward. Because of warfarin’s 
long half-life, it takes at least 48 hours to see the maximum 
effect of a change in dose.  
The drug is eliminated almost entirely by metabolism in the 
liver to inactive metabolites that are excreted in the urine and 
stool. Therefore, liver dysfunction can potential the response to 
Warfarin both through impaired synthesis of clotting factors and 
decreased Warfarin metabolism. 
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A number of factors account for the marked variability in warfarin 
dose requirement between individuals; 10- or 20-fold differences are 
not uncommon! These include: 
 
¾ Genetically determined differences in liver enzyme activity – leads to 
marked differences in clearance. Other drugs also affect the activity of 
these enzymes 
¾ Variation in vitamin K availability 
¾ Variation in clotting factor turnover 
¾ Differences in the extent of plasma protein binding 
 
 
Warfarin crosses the placenta, and is not given in the initial or latter 
stages of pregnancy. The drug is teratogenic (6 – 14 weeks is the 
critical period), and causes intracranial haemorrhage in the baby during 
delivery. 
 
 
In summary: 
 
 
Oral absorption > 95% 
 
Plasma protein binding Strongly bound to plasma albumin  
 
Metabolism Extensive metabolism in liver by 
cytochrome P450 enzymes, of which 
CYP2C9 is most important 
 
Half-life Highly variable. Usually around 40 hours. 
 
 
 
 
Initial onset of action 
 
5 days 
Time for dose change to take effect 
 
2 days 
Time for INR to return to normal after stopping 
treatment 
 
>5 days 
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MONITORING WARFARIN 
 
 
The effect of warfarin is measured by measuring the prothrombin time 
(PT) which is then expressed as an International Normalised Ratio (INR). 
  
The prothrombin time is the time taken for citrated plasma to clot after 
the addition of calcium and tissue thromboplastin. The INR is then 
expressed as the ratio of the PT of the patient to the PT of a pool of 
plasma from healthy subjects on no medication. 
 
However, thromboplastins are not standardised among manufacturers or 
between batches from the same manufacturer. This can lead to 
significant variability in PT results for warfarinised patients. To overcome 
this, all commercially available thromboplastins are compared to an 
international reference thromboplastin and assigned an International 
Sensitivity Index (ISI). This value is used to mathematically convert the 
PT to the INR as follows: 
 
INR = (PT patient / PT mean normal)ISI  
 
The aim of the INR system, approved by the WHO in 1983, is to provide 
a more uniform and safe oral anticoagulation therapy.  
 
TARGET INR 
 
Warfarin treatment is managed to keep the patient’s INR at an optimum 
level – the target INR. The target INR is that which reduces the risk of 
thromboembolic events without producing an unacceptable risk of 
haemorrhage, and this value varies according to the condition being 
treated. This can be expressed as a range of values (e.g. 2.0 – 3.0) or, 
increasingly, as a single value (e.g. 2.5). The British Haematological 
Society guidelines advise on the target INR and duration of treatment. 
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APPENDIX 2: AN EXPLORATION OF THE 
EXPERIENCES OF SELF-MONITORING PATIENTS 
– INTERVIEW PROMPTS 
 
 
Introductory questions 
 
Do you self-test or self-manage? 
 
 
How long have you been doing this for? 
 
 
How long were you on warfarin before you started self-monitoring? 
 
 
Starting out 
 
Do you remember how you first heard about self-monitoring? 
 
 
What was your initial reaction? 
 
 
Did anything out you off doing it? 
 
 
What was your main motivation to “give it a go”? 
 
 
What other factors would have persuaded you to try it out? 
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Information needs at the beginning 
 
Where did you seek out further information? 
 
 
What information were you given? 
 
Support 
 
Who supported you in self-monitoring? 
 
The journey 
 
What has become easier as you have become more used to self-monitoring? 
 
Has anything become more difficult? 
 
Were there any points where you would have given up? 
 
What factors tipped the balance? 
 
 
Information needs through the journey 
 
Is there any information that you were not given at the outset that, with hindsight, 
would have been useful? 
 
 
 
And finally … 
 
Do you have any pearls of wisdom for those thinking of self-monitoring? 
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APPENDIX 3: INTERVIEWS WITH LOCAL 
ANTICOAGULANT CLINIC PATIENTS -  STUDY 
INVITATION LETTER AND PATIENT 
INFORMATION SHEET 
 
 
 
 
 
 
[Insert date]     Bridget Coleman 
[Insert patient name]    Anticoagulation Monitoring & 
[Insert patient address]   Stroke Prevention Service 
C/o Pharmacy Department 
Whittington Hospital 
Magdala Avenue 
London 
N19 5NF 
 
Re: Patients’ views on developing the anticoagulant service 
 
Dear [insert patient name] 
 
I am writing to you, as a patient taking warfarin, to see if you would be interested 
in taking part in a small research study. 
 
It is now possible for people to play a greater role in looking after their warfarin 
treatment by measuring their own blood INR at home on a small handheld 
machine. With education and support some patients may also be able to adjust 
the dose of warfarin by themselves. However, we are not sure if this is something 
that patients would want to do, and what type of education and support patients 
might need to take on this greater role.  
 
As part of an MPhil / PhD degree in Health Informatics, I am trying to find out if 
patients taking warfarin would be willing to take a greater role in managing their 
treatment, and what support they might need to do this. I hope to send out a 
questionnaire to find out what patients feel about this, and about their 
experiences of taking warfarin and attending the anticoagulant clinic. However, 
before doing so I need to “test out” this questionnaire on a small number of 
patients to check that I am asking the right questions in the right way. 
 
Therefore, I am inviting you to test out this questionnaire by going through the 
questions with me in the form of an interview. This can take place either at the 
Whittington, or in your own home, and will last for no more than 45 minutes. All 
information obtained will be treated confidentially. 
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Full details are on the enclosed information sheet and I ask that you read this 
carefully. If you would like to take part, please either phone me (020 7288 5726), 
email me (bridget.coleman@whittington.nhs.uk) or alternatively return the 
reply page in the stamped addressed envelope provided. I can then arrange the 
interview for a mutually convenient time and place. You will be asked to sign a 
consent form on the day of the interview. Please do not hesitate to contact me by 
phone or email if you need further information before making a decision. 
 
Thank you for taking the time to read this letter, and I hope to get the opportunity 
to interview you. 
 
Yours sincerely, 
 
 
 
Bridget Coleman 
Pharmacist, Anticoagulant Monitoring & Stroke Prevention Service 
 
  
Re: Patients’ views on developing the anticoagulant service 
 
 
I would like to be interviewed to test out the patient questionnaire 
 
 
Name:  
 
 
 
Preferred way to contact: [please give telephone number, address or email 
address] 
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Patient Information Sheet 
 
Patients’ views on developing the anticoagulant service 
 
 
You are being invited to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss 
it with friends, relatives and your GP if you wish.  Ask us if there is anything that 
is not clear, or if you would like more information.  Take time to decide whether 
or not you wish to take part. 
 
What is the purpose of the study? 
 
The aim of this study is to find out how we can help people to play a greater role 
in looking after their warfarin treatment. It is now technically possible to 
measure your own blood INR at home on a small handheld machine. With 
education and support some patients may also be able to adjust the dose of 
warfarin by themselves. Clinical studies have shown that this is a safe way of 
monitoring warfarin treatment. 
 
However, there has been little research to show what type of education and 
support patients might need to take on this greater role. Also, we are not sure if 
this is something that patients would want to do. 
 
This is a good opportunity to explore these issues with you, and also to find out 
what you feel about taking warfarin and attending the anticoagulation clinic. We 
are doing this by sending out a questionnaire to seek the views of a large group 
of patients. But before doing this we need to “test out” the questionnaire on a 
small group of patients to make sure that we are asking the right questions. 
 
Why have I been chosen? 
 
You have been invited to take part because you are taking warfarin and attend 
one the Whittington anticoagulant clinics for blood monitoring. Once this 
questionnaire has been tested out with eight other patients, it will be sent out to 
another 400 patients. 
 
Do I have to take part? 
 
No. It is entirely up to you whether or not to take part. If you do decide to take 
part you will be given this information sheet to keep and will be asked to sign a 
consent form. If you wish to withdraw from the study you may do so at any time 
and without giving reason. If you decide not to take part in the study, this will not 
affect the standard of care that you receive. 
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What will happen to me if I take part? 
 
If you agree to take part, you will be invited to attend an interview. This will take 
part at a convenient time and location – either in the anticoagulant clinic or in 
your own home if desired – and should take no longer than 45 minutes. The 
interview will be with Bridget Coleman, and you will be asked to share your 
views on taking warfarin, your experiences of attending the anticoagulant clinic, 
your views on playing a greater role in monitoring your treatment and what type 
of education and support you would need to do this.  
 
With your permission, the discussion will be audio-taped, and this will then be 
transcribed onto a paper document at a later stage. Both the tapes and the paper 
documents will be kept in a locked cupboard. We will look at the responses to 
find out which topics are important to you, and will use these in the questionnaire 
that will be sent out to a larger group of patients. Things that you say during the 
interview may be quoted in reports, publications or presentations arising from 
this research. However, all quotations will be anonymous. 
 
What do I have to do? 
 
If you accept this invitation to be interviewed, we would like you to turn up for 
the interview at the agreed time. There will be no change to the management of 
your warfarin treatment. 
 
What are the possible disadvantages and risks in taking part in this study? 
 
There are no risks to you taking part in this study and we do not anticipate that 
the interview will cause any distress. 
 
What are the possible benefits of taking part? 
 
The information that we get from this study may help us to develop your 
anticoagulation service. You will have a direct input into this process. 
 
What happens when the research study stops? 
 
Management of your warfarin treatment and your clinic visits will remain 
unchanged.  
 
What if there is a problem? 
 
If you have any concerns about the study, or any complaint about the way that 
you have been dealt with during the study, you should speak to Bridget Coleman 
on tel: 020 7288 5726, or Dr David Patterson on tel:020 7288 5310 who will try 
to deal with your concerns.  If you remain unhappy, you can complain formally 
through the NHS Complaints Procedure. Details are available from the 
Whittington Hospital Patient Advocacy & Liaison Service (PALS) on tel: 020 
7288 5784 
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Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of this research will 
be kept strictly confidential. Any information about you that leaves the hospital 
will have your name and address removed so that you cannot be recognized from 
it. We would like to let your GP know that you are taking part in this study, but 
will only do so if you agree to this. 
 
What will happen to the results of the research study? 
 
The results will be included in a dissertation to be written by Bridget Coleman 
for an MPhil / PhD in Health Informatics with the Centre for Health Informatics 
& Multiprofessional Education (CHIME) at University College London. It is 
hoped to present the results at relevant local, national and international meetings 
and to submit a written report for publication in medical or health informatics 
journals. The results will also be made available to all patients attending the 
anticoagulant clinic by posting them on the patient information board in the 
clinic area. 
 
But ultimately, it is hoped that the results of the study will help us to develop our 
anticoagulation service. 
 
Who is organizing and funding this study? 
 
This study is being organised by Bridget Coleman (Pharmacy Department & 
Anticoagulant Clinic, Whittington Hospital), in collaboration with Jeannette 
Murphy (CHIME, University College London). This study is not being 
financially sponsored. 
 
Who has reviewed the study? 
 
The Moorfields & Whittington Research Ethics Committee Hospital has 
reviewed this study. 
 
Contact for further information 
 
If you would like any further information please contact Ian Man, Lead 
Pharmacist - Anticoagulant Service on tel: 020 7288 3516  
 
 
Thank you for reading this sheet 
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APPENDIX 4: ETHICAL APPROVAL LETTER FOR 
PATIENT-CENTRED STUDIES 
 
Moorfields & Whittington Research Ethics Committee 
South House, Block A 
Royal Free Hospital 
Pond Street 
London 
NW3 2QG 
 
Telephone: 020 7794 0552  
Facsimile: 020 7794 0714 
 
Miss Bridget Coleman 
Medicines Management Pharmacist 
Whittington Hospital 
Magdala Avenue 
London,  N19 5NF 
 
11 July 2007 
 
Dear Miss Coleman 
 
Full title of study: The role of information in empowering patients to monitor 
their oral anticoagulation treatment 
REC reference number: 07/Q0504/48 
 
Thank you for your letter of 25 June 2007, responding to the Committee’s 
request for further information on the above research and submitting revised 
documentation. 
 
The further information has been considered on behalf of the Committee by the 
Vice-Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion 
for the above research on the basis described in the application form, protocol 
and supporting documentation as revised. 
 
Ethical review of research sites 
 
The Committee has designated this study as exempt from site-specific 
assessment (SSA.  There is no requirement for [other] Local Research Ethics 
Committees to be informed or for site-specific assessment to be carried out at 
each site. 
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Conditions of approval 
 
The favourable opinion is given provided that you comply with the conditions set 
out in the attached document.  You are advised to study the conditions carefully. 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as 
follows: 
  
Document    Version    Date    
Application    02 May 2007  
Investigator CV    01 May 2007  
Protocol  2.0  01 April 2007  
Covering Letter    02 May 2007  
Questionnaire  6.0  04 June 2007  
Letter of invitation to participant  1.1 pilot  01 May 2007  
Letter of invitation to participant  2.1 Main 
survey  
01 May 2007  
GP/Consultant Information Sheets  1.0  25 June 2007  
Participant Information Sheet: Main survey  2.2  04 June 2007  
Participant Information Sheet: Pilot  1.2  04 June 2007  
Participant Consent Form  2.0  04 June 2007  
Response to Request for Further Information    25 June 2007  
Supervisor CV    30 April 2007  
 
R&D approval 
 
All researchers and research collaborators who will be participating in the 
research at NHS sites should apply for R&D approval from the relevant care 
organisation, if they have not yet done so.  R&D approval is required, whether or 
not the study is exempt from SSA.  You should advise researchers and local 
collaborators accordingly.  Guidance on applying for R&D approval is available 
from http://www.rdforum.nhs.uk/rdform.htm. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees (July 2001) and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK. 
 
Feedback on the application process 
 
Now that you have completed the application process you are invited to give 
your view of the service you received from the National Research Ethics Service.  
If you wish to make your views known please use the feedback form available on 
the NRES website at: 
 
https://www.nresform.org.uk/AppForm/Modules/Feedback/EthicalReview.aspx 
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We value your views and comments and will use them to inform the operational 
process and further improve our service. 
 
07/Q0504/48 Please quote this number on all 
correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
Linda Ficker 
Vice-Chair 
 
Email: katherine.clark@royalfree.nhs.uk 
 
Enclosures: Standard approval  
 
Copy to: R&D Office, Whittington Hospital NHS Trust  
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APPENDIX 5: INTERVIEWS WITH LOCAL 
ANTICOAGULANT CLINIC PATIENTS -  
PRELIMINARY INTERVIEW GUIDE  
 
WHITTINGTON HOSPITAL 
ANTICOAGULATION AND STROKE 
PREVENTION SERVICE 
 
 
HELPING US TO DEVELOP YOUR ANTICOAGULANT SERVICE 
 
 
PATIENT QUESTIONNAIRE
 
 
 
IMPORTANT: Your answers to these questions will remain 
confidential 
 
 
Please answer the questions as completely as possible. There are no 
right or wrong answers. We are interested only in your personal 
views, so please tell us what you feel and not what you think we may 
want to hear. 
 
PLEASE RETURN YOUR COMPLETED 
QUESTIONNAIRE IN THE POSTAGE-PAID 
ENVELOPE PROVIDED 
 
Thank you very much for taking part in this survey 
 
Bridget Coleman 
Anticoagulation & Stroke Prevention Service, Whittington Hospital  
June 2007 
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SECTION A: YOUR WARFARIN TREATMENT 
 
The following questions relate to your Warfarin treatment and how you manage it. Please answer 
by ticking the relevant box. 
 
1. Can you tell me how long have you been taking warfarin? 
 
1- 6 
months 
 7 months to 
1 year 
 13 months to 5 
years 
 More than 
5 years 
 I don’t know  
 
 
2. 
 
Can you tell me why you are taking warfarin? You may need to tick more than one box. 
 
Atrial Fibrillation (Irregular 
heartbeat) 
   Metal heart valve   
       
Deep Vein Thrombosis (Clot 
in leg) 
   I don’t know 
 
  
       
Pulmonary embolism (clot in 
lung) 
   Other (please state)   
 
3.  Does someone help you manage your 
warfarin at home? 
       YES      NO   
 
4. If someone helps you with your warfarin, can you tell me who this is? 
 
Husband / wife / partner 
 
   Friend / neighbour   
       
Son / daughter 
 
   Healthcare professional 
 
  
       
Other family member    Other (please state who)   
 
 
5.  Do you feel that being on warfarin has had an 
impact on your life? 
 YES        NO   
 
6. Would you like to make any further comments? 
  
 
 
 
7.  Has your warfarin ever caused any bleeding 
 
       YES      NO   
 
8. Would you like to make any further comments? 
  
 
 
 
9.  Do you ever feel anxious about your warfarin?    YES 
 
     NO   
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10. Would you like to make any further comments? 
  
 
 
 
 
11. 
 
What do you feel is the worst thing about taking warfarin?  Please tick just one box. 
 
Having to watch what I eat 
 
   Having to attend the clinic for frequent 
blood tests 
  
       
Having to watch what other 
medicines I take 
   There is nothing bad about taking 
warfarin 
  
       
Living with the risk of 
bleeding 
   Other (please state what this is)   
 
 
12.       How would you describe your current health? 
 
 Excellent 
 
           Good         Not very good                Terrible      
 
13.   Can you tell me (roughly) how many different medicines (other than warfarin) you 
take each day? 
 
  More 
than 6 
              3 - 5              1 - 2                             None   
 
 
SECTION B: ATTENDING THE  WARFARIN CLINIC 
 
The following questions relate to your warfarin clinic visits and how you feel about them.  Please 
answer by ticking the relevant box. 
 
14.    Where do you usually have your warfarin treatment monitored? 
 
  At the 
Whittington 
    At a GP’s    
surgery 
          At a community 
        pharmacy  
        At home   
 
15. If you attend the warfarin clinic at the Whittington, are you on the mailing list (that is, you 
don’t wait to see the staff in the clinic after you have your blood taken but have your results 
posted to you) 
 
 YES 
 
   NO    
 
16.   Can you estimate how many times you have been to the warfarin clinic in the last six 
months? 
 
  More 
than 6 
         3 - 5          1 - 2                           None   
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17. How do you usually travel to the warfarin clinic? 
 
By car 
 
   By hospital transport   
       
I walk 
 
   By taxi 
 
  
       
By bus    Other (please state)   
 
18.      Can you tell me how long this journey usually takes you? 
 
  Less than 15 
minutes 
  15 – 29 
minutes 
   30 – 60 
minutes       
  More than 1 
hour 
  
 
19.   Can you estimate the time you usually spend in the warfarin clinic (from walking in the 
door to walking out)? 
 
  Less than 15 
minutes 
  15 – 29 
minutes 
   30 – 60 
minutes       
  More than 1 
hour 
  
 
20. Now think about your clinic visits? Please tick a box to show how much you agree with each 
of the following statements. 
 5  4  3  2  1 
 Strongly 
agree 
 Agree  Uncertain  Disagree  Strongly 
disagree 
I find it easy to plan my 
life around my Warfarin 
clinic visits 
         
          
I have complete trust in 
the Warfarin clinic staff 
 
         
          
I have complete trust in 
the computer used in the 
Warfarin clinic 
         
          
I find my Warfarin clinic 
visits disrupt my life 
 
         
 
21.  Have you heard of patients “self-testing” or 
“self-managing” their warfarin? 
       YES      NO   
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22. Now think about what would you like to change about your warfarin treatment & 
monitoring. Please tick a box to show which of these options are most attractive. You may 
tick more than one box. 
 
Less frequent clinic visits 
 
   An alternative to warfarin that does not 
need monitoring 
 
  
       
Spending more time with 
clinic staff 
   Testing my INR (blood level) at home 
and phoning the clinic for advice on my 
dose 
  
       
Spending less time with clinic 
staff 
   Testing my INR (blood level) at home 
and adjusting the dose of Warfarin 
myself 
  
 
23. 
 
Please write any other suggestions in the space below 
 (narrative) 
 
 
 
SECTION C: SELF-MONITORING WARFARIN 
 
The following questions relate to patients taking a greater role in managing their warfarin 
treatment. Please answer by ticking the relevant box. 
 
PLEASE READ THE ENLCOSED INFORMATION SHEET “A” ON WARFARIN SELF-
TESTING. 
 
 
24. Now think about testing your own INR (“self-testing”). Please tick a box to show how much 
you agree with each of the following statements. 
 
 Strongly 
agree 
 Agree  Uncertain  Disagree  Strongly 
disagree 
I would be able to prick my 
finger to get a blood sample 
         
          
I would be able to test my blood 
on the machine 
         
          
I would be able to buy a machine 
 
         
          
I would be happy to buy a 
machine 
         
          
I would miss the other patients 
attending the anticoagulant clinic 
         
          
I would like to have more control 
over my warfarin treatment 
         
 
25. We might be able to set up a programme where we could support patients who would like 
to test their own blood INR at home. If this were to happen would you be interested? 
 
 YES    NO    
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PLEASE READ THE ENLCOSED INFORMATION SHEET “B” ON WARFARIN SELF-MANAGEMENT 
  
26. Now think about testing your own INR and adjusting the Warfarin dose yourself (“self-
managing”). Please tick a box to show how much you agree with each of the following 
statements. 
 
 Strongly 
agree 
 Agree  Uncertain  Disagree  Strongly 
disagree 
I would be able to prick my finger 
to get a blood sample 
         
          
I would be able to test my blood 
on the machine 
         
          
I would be able to buy a machine 
 
         
          
I would be happy to buy a 
machine 
         
          
I would miss the other patients 
attending the anticoagulant clinic 
         
          
I would miss the regular contact 
with the clinic staff 
         
          
I would be able to adjust my dose 
of Warfarin 
         
          
I would like to have more control 
over my warfarin treatment 
         
 
 
27. We might be able to set up a programme where we could support patients who would like 
to test their own blood INR and adjust their dose of warfarin at home. If this were to 
happen would you be interested? 
 
 YES    NO    
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28. If we were to set up these “self-testing” and “self-management” programmes, there are a 
number of ways we could support you. Wehave listed some of these below. Please could you 
indicate how important these would be if you were self-testing or self-managing your 
warfarin treatment. 
 
Give you more information / education 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
 
 
      
 
Make it easy for you to contact the clinic if you have any concerns 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
 
 
      
 
Provide the machine to measure your blood INR 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
 
 
      
 
Check up on you regularly? 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
 
 
      
  
29. There may be other ways that the clinic could support patients who decide to self-test or 
self-manage their Warfarin treatment. If you can think of any, please write your 
suggestions in the space below. 
  
 
 
 
 
 
SECTION D: WARFARIN INFORMATION NEEDS 
 
The following questions relate to the types of information or skills that you might need to take a 
greater role in managing your warfarin treatment. Please answer by ticking the relevant box. 
 
 
30. Did someone talk to you about your warfarin when you first started treatment? 
 
 YES 
 
   NO    I CANNOT 
REMEMBER 
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31. Now imagine that you have decided to either test your own blood INR at home with the 
anticoagulant clinic still adjusting your dose of warfarin (“self-test”), or that you are going 
to test your own blood INR and adjust your dose of  warfarin at home (“self-manage”). 
Listed below are some examples of information or skills that you might find useful. Please 
could you tick a box to show which of these you would need. You may tick more than one 
box. 
 
 I would need to know this if I was 
“self-testing” – i.e. testing my own 
blood INR at home but the clinic staff 
still adjusting the dose of my warfarin  
I would need to know this if I was “self-
managing” – i.e. testing my own blood 
INR and adjusting my dose of warfarin at 
home  
   
How to prick my finger to get a 
blood sample 
      
       
How to use the blood INR testing 
machine 
      
       
How Warfarin works 
 
      
       
Side effects of Warfarin 
 
      
       
How Warfarin interacts with other 
medicines 
      
       
How to deal with bleeding  
 
      
       
How to communicate with 
healthcare staff (e.g. doctors, 
nurses, pharmacists) 
      
       
How to solve problems 
 
      
       
How to tell if my INR (blood test) 
is too high 
      
       
How to tell if my INR (blood test) 
is too low 
      
       
How to manage my diet whilst on 
warfarin 
      
       
Other (please specify in the space 
below) 
      
 
 
 
 
 
383  
 
 
SECTION E: EXPERIENCES WITH USING COMPUTERS 
 
The following questions relate to your experiences with using computers Please answer by ticking 
the relevant box. 
 
32.  Do you have access to the Internet? 
 
       YES      NO   
 
If the answer to this question is “no”, please skip ahead to question 36. If the answer is 
“yes” please carry on. 
 
33. Where do you use the Internet most of the time? 
 
At home 
 
   In an internet cafe   
       
At work    Other (please state where in the space 
below) 
  
       
In a public library       
 
34. If we made Warfarin information available on the Internet would you look at it?? 
 
 YES    NO    MAYBE    
 
35.  Have you ever used an Internet chat room?        YES      NO   
 
36.  Do you use email?        YES      NO   
 
37.     If you do use email, could you tell me how happy would you be to communicate with 
the anticoagulant clinic by email? 
 
  Very happy 
 
   Happy              Not very happy   Unhappy          
 
38. Please add any other comments you would like to make about using the Internet and email for 
warfarin information and communication with the clinic 
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SECTION E: ABOUT YOU 
 
Finally, to help us classify your answers and make our statistical comparisons, would you mind 
answering the following few questions? 
 
39.    Please could you indicate your age 
 
  18 – 40 yrs      41 – 55 yrs        56 – 65 yrs   Older than 65 yrs   
        
40.  Please could you indicate your sex        MALE     FEMALE   
 
41. 
 
Which ethnic group would you say you belong to? 
 
White (British) 
 
   Asian (or Asian British)   
       
White (Irish) 
 
   Chinese 
 
  
       
White (other)    Mixed race   
       
Black (or Black British)    Other (please state which)   
 
42. What is your first language? 
 
  
 
 
 
43. 
 
How would you describe your educational background? (please indicate highest level) 
 
No formal qualifications 
 
   Diploma / NVQ level   
       
Passed GCSE / O Levels / 
CSEs 
   Degree level and above 
 
  
       
Passed A levels    Rather not say   
 
44. We may want to ask for your help again in the near future. Please could you tick the relevant 
box to indicate if you would be happy to take part.  
 
 YES 
 
       NO    
 
 
45. Please add any further comments in the space below. 
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46. Finally, please add your name in the space below. Unless you have indicated that you 
would be happy to take part in a follow-up study, we will destroy this sheet as soon as 
we have let your GP know that you have completed this questionnaire. Please be 
assured that your replies to these questions will remain confidential. 
 
  
 
 
 
 
 
 
Thank you for your help in completing this questionnaire! 
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APPENDIX 6: INTERVIEWS WITH LOCAL 
ANTICOAGULANT CLINIC PATIENTS -  PATIENT 
INFORMATION SHEETS A AND B 
INFORMATION SHEET A 
Warfarin self-testing 
 
What is warfarin self-testing? 
Warfarin self-testing is when you test your blood INR at home, but then contact the 
anticoagulant clinic to adjust your dose of warfarin.  
 
How would I test my own INR? 
You place a testing strip in a small, handheld machine. Then you prick your finger and 
place a small drop of blood onto the strip. The machine will then tell you what your INR 
is within a couple of minutes. Currently, there are two self-testing monitors for use by 
patients; the CoaguChek™ XS by Roche Diagnostics and the INRatio by Sysmex. Here 
are pictures of these machines: 
 
  
CoaguChek™ XS                                                                                           INratio 
 
How often would I need to test my INR?           
The clinic staff will advise you on when you should test your INR. 
 
Is this a safe way of managing my warfarin? 
Studies have shown that people who self-test their own warfarin therapy are at the 
correct INR at least as often as those who have their blood tested in an anticoagulant 
clinic. 
 
What would happen if I had problems with measuring my blood INR? 
In these circumstances you would contact the anticoagulant clinic for advice 
 
Are the testing strips available on prescription? 
Yes 
 
Are these machines available on prescription? 
No. You would need to buy them yourself. 
 
How much do these machines cost? 
Both of these machines cost £399. 
 
How accurate are these machines? 
Both of these machines have been passed by the regulatory authorities in the UK. We 
use the CoaguChek™ machine in our GP and community pharmacy clinics. 
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INFORMATION SHEET B 
 
Warfarin self-management 
 
What is warfarin self-management? 
Warfarin self-management is when you test your blood INR at home, and then adjust 
your own warfarin dosage within limits set by the anticoagulant clinic. 
 
How would I test my own INR? 
You place a testing strip in a small, handheld machine. Then you prick your finger and 
place a small drop of blood onto the strip. The machine will then tell you what your INR 
is within a couple of minutes. Currently, there are two self-testing monitors for use by 
patients; the CoaguChek™ XS by Roche Diagnostics and the INRatio by Sysmex. Here 
are pictures of these machines: 
 
  
CoaguChek™ XS                                                                                           INratio 
 
How often would I need to test my INR?           
The clinic staff will advise as to how often you should test your INR  
 
Is this a safe way of managing my warfarin? 
Studies have shown that people who manage their own warfarin therapy are at the 
correct INR at least as often as those who have their warfarin managed by a doctor, 
nurse of pharmacist. 
 
What would happen if my INR was very high or very low, or if I had any problems 
with adjusting my warfarin? 
In these circumstances you would contact the anticoagulant clinic for advice 
 
Would the clinic check up on how I was getting on? 
Yes. The clinic would like to review your warfarin treatment at least once a year 
 
Are the testing strips available on prescription? 
Yes 
 
Are these machines available on prescription? 
No. You would need to buy them yourself. 
 
How much do these machines cost? 
Both of these machines cost £399. 
 
How accurate are these machines? 
Both of these machines have been passed by the regulatory authorities in the UK. We 
use the CoaguChek™ machine in our GP and community pharmacy clinics. 
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APPENDIX 7: A SURVEY OF LOCAL 
ANTICOAGULANT CLINIC PATIENTS – STUDY 
INFORMATION SHEET, STUDY INVITATION 
LETTER AND REMINDER LETTER 
 
 
 
 
 
Patient Information Sheet 
 
Patients’ views on developing the anticoagulant service 
 
You are being invited to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss 
it with friends, relatives and your GP if you wish.  Ask us if there is anything that 
is not clear, or if you would like more information.  Take time to decide whether 
or not you wish to take part. 
 
What is the purpose of the study? 
 
The aim of this study is to find out how we can help people to play a greater role 
in looking after their warfarin treatment. It is now technically possible to 
measure your own blood INR at home on a small handheld machine. With 
education and support some patients may also be able to adjust the dose of 
warfarin by themselves. Clinical studies have shown that this is a safe way of 
monitoring warfarin treatment. 
 
However, there has been little research to show what type of education and 
support patients might need to take on this greater role. Also, we are not sure if 
this is something that patients would want to do. 
 
This is a good opportunity to explore these issues with you, and also to find out 
what you feel about taking warfarin and attending the anticoagulation clinic. We 
are doing this by sending out a questionnaire to seek the views of a large group 
of patients.  
 
Why have I been chosen? 
 
You have been invited to take part because you are taking warfarin and attend 
one the Whittington anticoagulant clinics for blood monitoring. This 
questionnaire has been sent out to over 600 patients. 
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Do I have to take part? 
 
No. It is entirely up to you whether or not to take part. We have no way of 
knowing if you have decided not to take part in the study, and this decision will 
not affect the standard of care that you receive. 
 
What do I have to do? 
 
If you decide to take part, simply complete the enclosed questionnaire and return 
it to us in the enclosed reply-paid envelope.  
 
What are the possible disadvantages and risks in taking part in this study? 
 
There are no risks to you taking part in this study. The only disadvantage is the 
time it will take you to complete the questionnaire. 
 
 
What are the possible benefits of taking part? 
 
The information that we get from this study may help us to develop your 
anticoagulation service. You will have a direct input into this process. 
 
What happens when the research study stops? 
 
Management of your warfarin treatment and your clinic visits will remain 
unchanged.  
 
What if there is a problem? 
 
If you have any concerns about the study, or any complaint about the way that 
you have been dealt with during the study, you should speak to Bridget Coleman 
on tel: 020 7288 5726, or Professor David Patterson on tel: 020 7288 5310   who 
will try to deal with your concerns.  If you remain unhappy, you can complain 
formally through the NHS Complaints Procedure. Details are available from the 
Whittington Hospital Patient Advocacy & Liaison Service (PALS) on tel: 020 
7288 5784 
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Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of this research will 
be kept strictly confidential. Any information about you that leaves the hospital 
will have your name and address removed so that you cannot be recognized from 
it. We would like to let your GP know that you are taking part in this study, but 
will only do so if you agree to this. 
 
What will happen to the results of the research study? 
 
The results will be included in a dissertation to be written by Bridget Coleman 
for an MPhil / PhD in Health Informatics with the Centre for Health Informatics 
& Multiprofessional Education (CHIME) at University College London. It is 
hoped to present the results at relevant local, national and international meetings 
and to submit a written report for publication in medical or health informatics 
journals. The results will also be made available to all patients attending the 
anticoagulant clinic by posting them on the patient information board in the 
clinic area. 
 
But ultimately, it is hoped that the results of the study will help us to develop our 
anticoagulation service. 
 
Who is organizing and funding this study? 
 
This study is being organised by Bridget Coleman (Pharmacy Department & 
Anticoagulant Clinic, Whittington Hospital), in collaboration with Jeannette 
Murphy (CHIME, University College London). This study is not being 
financially sponsored. 
 
Who has reviewed the study? 
 
The Moorfields & Whittington Hospital Research Ethics Committee has 
reviewed this study. 
 
Contact for further information 
If you would like any further information please contact Ian Man, Lead 
Pharmacist - Anticoagulant Service on tel: 020 7288 3516  
 
Thank you for reading this sheet 
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[Insert date]     Bridget Coleman 
[Insert patient name]   Anticoagulation Monitoring & 
[Insert address]    Stroke Prevention Service 
C/o Pharmacy Department 
Whittington Hospital 
Magdala Avenue 
London  
N19 5NF 
 
Re: Patients’ views on developing the anticoagulant service 
 
Dear [insert patient name] 
 
I am writing to you, as a patient taking warfarin, to see if you would be interested 
in taking part in a small research study. 
 
It is now possible for people to play a greater role in looking after their warfarin 
treatment by measuring their own blood INR at home on a small handheld 
machine. With education and support some patients may also be able to adjust 
the dose of warfarin by themselves. However, we are not sure if this is something 
that patients would want to do, and what type of education and support patients 
might need to take on this greater role.  
 
As part of an MPhil / PhD degree in Health Informatics, I am trying to find out if 
patients taking warfarin would be willing to take a greater role in managing their 
treatment, and what support they might need to do this. Today, you have been 
chosen at random to receive a questionnaire to find out what you think about this, 
and to ask you about your experiences of taking warfarin and attending the 
anticoagulant clinic.  
 
Your views are important.  The Anticoagulation & Stroke Prevention Service is 
committed to ongoing service development. However, we need to be sure that 
these developments are what our patients want, and that we are able to support 
them in a relevant way. The results of the questionnaires will be used to tell us if 
the service should be developed to support patients who are willing to play a 
greater role in managing their oral anticoagulation, and how we can help them do 
this. 
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Your participation is entirely voluntary, and your answers to the questions are 
strictly confidential. The questionnaire should take no longer than 30 minutes to 
complete. Full details are on the enclosed information sheet and I ask that you 
read this carefully. If you have any questions about this survey please either 
phone me (020 7288 5726), email me (bridget.coleman@whittington.nhs.uk). If 
you decide to complete this questionnaire please return it to me in the stamped 
addressed envelope provided. 
 
Thank you for taking the time to read this letter. 
 
 
 
Yours sincerely, 
 
 
 
Bridget Coleman 
Pharmacist, Anticoagulant Monitoring & Stroke Prevention Service
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<Clinical & Academic Department of Cardiovascular Medicine  
 
 
 
January 2008 
 
 
Patients’ views on developing the anticoagulant service 
 
 
A questionnaire about developing our anticoagulation monitoring service was 
recently posted to you. If you have already returned your questionnaire, thank 
you and please accept my apologies for bothering you. 
 
It is entirely up to you whether or not to take part in this survey. However, your 
views are important and I would like to hear from you. But if you do not wish to 
take part, you do not need to give a reason and the care you receive from us will 
not be affected.  
 
If you have any comments or questions about the questionnaire, or need help 
with completing it, please do not hesitate to contact me on 020 7288 5726 or via 
email (bridget.coleman@whittington.nhs.uk). The phone line is open 10.30 to 
5.00, Tuesday to Friday. I will do my best to answer any questions you might 
have. 
 
Thank you for your time 
 
 
 
 
 
 
 
 
 
 
Bridget Coleman, BSc, MSc, MRPharmS  
Senior Pharmacist, Anticoagulation Monitoring & Stroke Prevention Service, 
Whittington Hospital 
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APPENDIX 8: A SURVEY OF LOCAL 
ANTICOAGULANT CLINIC PATIENTS –  STUDY 
QUESTIONNAIRE AND PATIENT INFORMATION 
SHEET A 
 
 
WHITTINGTON HOSPITAL 
ANTICOAGULATION MONITORING AND 
STROKE PREVENTION SERVICE 
 
 
HELPING US TO DEVELOP YOUR ANTICOAGULANT SERVICE 
 
PATIENT QUESTIONNAIRE 
 
 
 
IMPORTANT: Your answers to these questions will remain confidential 
 
Please answer the questions as completely as possible. There are no right or 
wrong answers. We are interested only in your personal views, so please tell 
us what you feel and not what you think we may want to hear. It should take 
you about 15 – 20 minutes to complete this questionnaire. 
 
PLEASE RETURN YOUR COMPLETED 
QUESTIONNAIRE IN THE POSTAGE-PAID 
ENVELOPE PROVIDED 
 
Thank you very much for taking part in this survey 
 
Bridget Coleman, BSc, MSc, MRPharmS  
Senior Pharmacist, Anticoagulation & Stroke Prevention Service, Whittington 
Hospital  
January 2008  
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SECTION A: ABOUT YOUR WARFARIN TREATMENT 
 
The following questions relate to your warfarin treatment and how you manage it. Please answer 
by ticking the relevant box. 
 
1. Can you tell me how long have you been taking warfarin? 
 
1- 6 
months 
 7 months to 
11 months 
 1 year to 5 
years 
 More than 
5 years 
 I can’t 
remember 
 
 
 
2. 
 
Can you tell me why you are taking warfarin? You may need to tick more than one box. 
 
Atrial Fibrillation (Irregular 
heartbeat) 
   Artificial heart valve   
       
Deep Vein Thrombosis (Clot 
in leg) 
   I don’t know 
 
  
       
Other (please give details) Pulmonary embolism (Clot in 
lung) 
     
    
 
  
 
3.  Does someone help you manage your 
warfarin at home? 
       YES      NO   
 
4. If someone helps you with your warfarin, can you tell me who this is? 
 
Husband / wife / partner 
 
   Friend / neighbour   
       
Son / daughter 
 
   Healthcare professional 
 
  
       
Other family member    Other (please state who in the space 
below) 
 
  
       
 
 
5.  Do you feel that being on warfarin has had an 
impact on your life? 
 YES        NO   
 
6. Please add any further comments below 
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7.  Have you had any bleeding or bruising since 
taking warfarin? 
       YES      NO   
 
8. Please add any further comments below 
 
  
 
 
 
 
9.  Do you ever worry about being on warfarin?    YES 
 
     NO   
 
10. Please add any further comments below 
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11. 
 
What do you feel is the worst thing about taking warfarin?  Please tick just one box. 
 
Having to watch what I eat 
 
   Having to attend the clinic for frequent 
blood tests 
  
       
Having to watch what other 
medicines I take 
   Living with the risk of bleeding   
       
 Other (please give details below)  Having to watch how much alcohol 
I drink 
 
 
 
 
 
 
   
 
12.       How would you describe your current health? 
 
 Excellent 
 
           Good         Not very good                Poor                
 
13.   Can you tell me (roughly) how many different medicines (other than warfarin) you 
take each day? 
 
  6 or 
more 
              3 - 5              1 - 2                            None   
 
 
SECTION B: ABOUT ATTENDING THE  WARFARIN CLINIC 
 
The following questions relate to your warfarin clinic visits and how you feel about them.  Please 
answer by ticking the relevant box. 
 
14.    Where do you usually have your warfarin treatment monitored? 
 
  At the 
Whittington 
    At a GP’s    
surgery 
          At a community 
        pharmacy  
        At home   
 
15. If you go to the warfarin clinic at the Whittington, are you on the mailing list? That is, you 
go home after your blood is taken and someone from the clinic posts your results to you or 
phones you. 
 
 YES 
 
   NO    
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16.   Can you tell me how many times (roughly) you have been to the warfarin clinic in the 
last six months? 
 
6 or more          3 - 5          1 - 2                           None   
 
17. How do you usually travel to the warfarin clinic? 
 
By car 
 
   By hospital transport   
       
I walk 
 
   By taxi 
 
  
       
By bus    Other (please give details in space 
below) 
  
       
 
18.      Can you tell me how long this journey usually takes you? 
 
  Less than 15 
minutes 
  15 – 29 
minutes 
   30 – 60 
minutes       
  More than 1 
hour 
  
 
19.   Can you estimate the length of time you usually spend in the warfarin clinic? (from 
arriving at the hospital / pharmacy /GP surgery to leaving) 
 
  Less than 15 
minutes 
  15 – 29 
minutes 
   30 – 60 
minutes       
  More than 1 
hour 
  
 
 
20. Now think about your clinic visits. Please tick a box to show how much you agree with each 
of the following statements. 
 
 Strongly 
agree 
 Agree  Uncertain  Disagree  Strongly 
disagree 
I find it easy to plan my 
life around my Warfarin 
clinic visits 
         
          
I have complete trust in 
the Warfarin clinic staff 
 
         
          
I have complete trust in 
the computer used in the 
Warfarin clinic 
         
          
I find my Warfarin clinic 
visits disrupt my life 
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21.  Have you heard of patients “self-testing” or 
“self-managing” their warfarin? 
       YES      NO   
 
 
22. If you have heard of patient “self-testing” or “self-managing” their warfarin, can you tell me 
where you heard of this? 
 
  
 
 
 
SECTION C: ABOUT TESTING YOUR BLOOD INR AT HOME 
 
The following questions relate to patients taking a greater role in managing their warfarin 
treatment. Please answer by ticking the relevant box. 
 
FIRST, PLEASE READ THE ENCLOSED INFORMATION SHEET “A” ON TESTING YOUR 
BLOOD INR AT HOME. 
 
 
23. Now imagine you are going to test your own INR at home, but to adjust your dose of 
warfarin you will contact the anticoagulant clinic (“self-testing”). Please tick a box to show 
how much you agree with each of the following statements. 
 
 Strongly 
agree 
 
 Agree  Uncertain  Disagree  Strongly 
disagree 
I would be able to prick my finger 
to get a blood sample 
         
          
I would be able to test my blood 
on the machine 
         
          
I would be able to buy the 
machine 
 
         
          
I would be happy to buy the 
machine 
         
          
I would miss the other patients 
attending the anticoagulant clinic 
         
          
I would like to have more control 
over my warfarin treatment 
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24. We might be able to set up a programme where we could support patients who would like 
to test their own blood INR at home. If we could do this would you be interested in taking 
part? 
 
 YES    NO    
 
25. Now imagine that you are going to test your own INR and adjust your warfarin dose 
yourself (“self-managing”). Please tick a box to show how much you agree with the 
following statements. 
 
 Strongly 
agree 
 
 Agree  Uncertain  Disagree  Strongly 
disagree 
I would miss the regular contact 
with the clinic staff 
         
          
With training, I would be able to 
adjust my dose of warfarin 
         
 
26. We might be able to set up a programme where we could support patients who would like 
to test their own blood INR and adjust their dose of warfarin at home. If we could do this 
would you be interested in taking part? 
 
 YES    NO    
 
 
27. There are a number of ways we could support you in testing your blood INR at home. We 
have listed some of these below. Please could you indicate how important you think these 
would be. 
Give you more information / education about warfarin 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
 
 
      
 
Make it easy for you to contact the clinic if you have any concerns 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
 
 
      
 
The clinic to provide the machine to measure your blood INR 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
 
 
      
 
The clinic to check up on you regularly (e.g. once every six months) 
 
Very 
important 
 Quite 
important 
 Not very 
important 
 Not 
important 
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28. There may be other ways that the clinic could support patients who decide test their blood 
INR at home. If you can think of any, please write your suggestions in the space below. 
 
  
 
 
 
 
 
SECTION D: ABOUT WARFARIN INFORMATION  
 
The next question relates to the types of information or skills that you might need to take a 
greater role in managing your warfarin treatment.  
 
29. Firstly, did someone give you information about warfarin (written information or verbal 
information) when you first started treatment? 
 
 YES 
 
   NO    I CANNOT 
REMEMBER 
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30. Now, imagine that you are going to self-manage your Warfarin treatment (that is, test your 
own blood INR and adjust your dose of warfarin at home).  I have listed some pieces of 
information or skills  that may help you do this.  Please could you tick the relevant box to 
show me which of these you would need. You may tick more than one box. 
 
How to prick my finger to get a blood sample 
 
  
   
How to use the blood INR testing machine 
 
  
   
How Warfarin works 
 
  
   
Side effects of Warfarin 
 
  
   
How Warfarin interacts with other medicines 
 
  
   
How to deal with bleeding  
 
  
   
How to work out why my INR is too high or too low 
 
  
   
How to adjust my dose of warfarin if my INR is too high or too low 
 
  
   
   
How to manage my diet whilst on warfarin 
 
 
  
   
Other (please give details in the space below) 
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SECTION E: ABOUT YOUR EXPERIENCES WITH USING COMPUTERS 
 
The following questions relate to your experiences with using computers Please answer by ticking 
the relevant box. 
 
31  Do you have access to the Internet? 
 
       YES      NO   
 
If the answer to this question is “no”, please skip ahead to question 35. If the answer is 
“yes” please carry on. 
 
32 Where do you use the Internet most of the time? 
 
At home 
 
   In an internet cafe   
       
At work    Other (please state where in the space 
below) 
  
       
In a public library     
 
33. If the clinic put warfarin information on the Internet would you look at it? 
 
 YES    NO    MAYBE    
 
34.  Have you ever used an Internet chat room?        YES      NO   
 
35.  Do you use email?        YES      NO   
 
36.     If you do use email, could you tell me how happy would you be to communicate with 
the anticoagulant clinic by email? 
 
  Very happy 
 
   Happy              Not very happy   Unhappy          
 
37. Please add any other comments you would like to make about using the Internet and email for 
warfarin information and communication with the clinic 
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SECTION F: ABOUT YOU 
 
Finally, to help us classify your answers and make our statistical comparisons, would you mind 
answering the following few questions? 
 
38    Please could you indicate your age 
 
  18 – 40 yrs      41 – 55 yrs        56 – 65 yrs   Older than 65 yrs   
        
39.  Please could you indicate your sex 
 
       MALE     FEMALE   
 
40. 
 
Which ethnic group would you say you belong to? 
 
White (British) 
 
   Asian (or Asian British)   
       
White (Irish) 
 
   Chinese 
 
  
       
White (other)    Mixed race   
       
Black (or Black British)    Other (please state which)   
 
41. What is your first language? 
 
  
 
 
 
42. 
 
How would you describe your educational background? (please indicate highest level) 
 
No formal qualifications 
 
   Diploma / NVQ level   
       
GCSE / O Levels / CSEs    Degree level and above 
 
  
       
A levels    Rather not say   
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43. Please add any further comments in the space below. 
 
  
 
 
 
 
 
 
 
44. We may want to ask for your help in this research in the future.  Please could you tick the 
relevant box to indicate if you would be happy to take part.  
 
 YES 
 
       NO    
 
45. Finally, please could you add your name in the space below. Unless you have 
indicated that you would be happy to take part in a follow-up study, we will destroy 
this sheet as soon as we have let your GP know that you have completed this 
questionnaire. Please be assured that your replies to these questions will remain 
confidential. 
 
  
 
 
 
 
 
 
Thank you for your help in completing this questionnaire! 
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Information Sheet A: Testing your blood INR at home 
 
How would I test my own INR? 
You place a testing strip in a small, handheld machine. Then you prick your 
finger and place a small drop of blood onto the strip. The machine will then tell 
you what your INR is within a couple of minutes. Currently, there are two self-
testing monitors for use by patients; the CoaguChek™ XS by Roche Diagnostics 
and the INRatio by Sysmex. Here are pictures of these machines: 
 
  
CoaguChek™ XS                                                                                           INratio 
 
What is warfarin self-testing? 
Warfarin self-testing is when you test your blood INR at home, but then contact the 
anticoagulant clinic to adjust your dose of warfarin. 
 
How often would I need to test my INR?           
The clinic staff will advise you on when you should test your INR. 
 
What would happen if I had problems with measuring my blood INR? 
In these circumstances you would contact the anticoagulant clinic for advice 
 
What is warfarin self-management? 
Warfarin self-management is when you test your blood INR at home, and then adjust 
your own warfarin dosage within limits set by the anticoagulant clinic. 
 
What would happen if my INR was very high or very low, or if I had any problems 
with adjusting my warfarin? 
In these circumstances you would contact the anticoagulant clinic for advice 
 
Would the clinic check up on how I was getting on? 
Yes. The clinic would like to review your warfarin treatment at least once a year 
 
Is testing my own INR a safe way of managing my warfarin? 
Studies have shown that people who monitor their own warfarin therapy are at the 
correct INR at least as often as those who have their blood tested in an anticoagulant 
clinic. 
 
Are the testing strips available on prescription? 
Yes 
 
Are these machines available on prescription? 
No. You would need to buy them. 
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How much do these machines cost? 
Both of these machines cost £399. 
 
How accurate are these machines? 
Both of these machines have been passed by the regulatory authorities in the UK. We 
use the CoaguChek™ machine in our GP and community pharmacy clinics. 
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APPENDIX 9: EXPLORING THE VIEWS OF 
HEALTHCARE PROFESSIONALS – STUDY 
INVITATION LETTER AND INFORMATION SHEET 
 
 
 
 
 
[Date] 
Bridget Coleman 
[Addresee]     Anticoagulation Monitoring &  
      Stroke Prevention Service 
      C/o Pharmacy Department 
Whittington Hospital 
London 
N19 5NF 
 
Re: Views on patient self-monitoring of oral anticoagulation 
 
Dear [name], 
 
I am writing to you, as someone who may have an interest in patients taking oral 
anticoagulants, to invite you to take part in a small research study. 
 
It is now possible for people to play a greater role in looking after their warfarin 
treatment by measuring their own blood INR at home on a small handheld 
machine. With education and support some patients may also be able to adjust 
the dose of warfarin by themselves.  
 
As part of an MPhil / PhD degree in Health Informatics, I am trying to establish 
the barriers to setting up an oral anticoagulation patient self-monitoring service 
and to explore what support patients may require. The first stage of this research 
project, conducted last year, explored our patients’ views on self-monitoring. The 
results indicate that there is a limited demand amongst patients for this method of 
management. However, for self-monitoring of oral anticoagulation to be 
successful the support of healthcare professionals is also essential. There is no 
published research exploring the views of this group of people.  
 
Therefore I am trying to recruit healthcare professionals to attend a focus group, 
to share their views on patient self-monitoring of oral anticoagulation. These will 
take place at the Whittington Hospital, and will last for around 45 minutes. All 
information gathered will be treated confidentially. 
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Further details are on the enclosed study information sheet. If you would like to 
take part please either email me (bridget.coleman@whittington.nhs.uk), phone 
me (020 7288 5672) or return the reply sheet in the stamped addressed envelope 
provided. If you have any questions about this study please feel free to either 
phone or email me. If you decide to participate, I will contact you with the date, 
time and location for the focus group meetings 
 
Thank you for taking the time to read this letter and I hope to see you at one of 
the groups. 
 
Yours sincerely, 
 
 
 
 
Bridget Coleman 
Pharmacist, Anticoagulant Monitoring & Stroke Prevention Service 
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Reply sheet 
 
I would like to volunteer to take part in the patient self-monitoring of oral 
anticoagulation focus group  
 
 
Name: (Please print) 
 
 
 
Best way to contact: (Please provide an email address, telephone number or 
postal address) 
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Study Information Sheet 
 
Healthcare professionals’ views on patient self-monitoring of oral 
anticoagulation 
 
You are being invited to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss 
it with others if you wish.  Ask us if there is anything that is not clear, or if you 
would like more information.  Take time to decide whether or not you wish to 
take part. 
 
What is the purpose of the study? 
 
The aim of this study is to find out what healthcare professionals think about 
patients playing a greater role in looking after their warfarin treatment. It is now 
technically possible for patients to measure their own blood INR at home on a 
small handheld machine (a coagulometer). With education and support some 
patients may also be able to adjust the dose of warfarin by themselves. Clinical 
studies have shown that this is a safe way of monitoring warfarin treatment. 
 
The results of the first stage of this research project, conducted last year, 
explored patients’ views of self-monitoring. The results indicate that there is a 
limited demand amongst patients for this method of monitoring.  
 
However, for self-monitoring of oral anticoagulation to be successful the support 
of healthcare professionals is also essential. There is no published research 
exploring the views of this group of people. Therefore we would like to find out 
what you think about patient self-monitoring of oral anticoagulation. 
 
Why have I been chosen? 
 
You have been invited to take part because you look after patients who are taking 
warfarin, or have an interest in the management of these patients. 
 
What will happen to me if I take part? 
 
If you agree to take part, you will be invited to attend a focus group meeting (6 
people in each group). This will be held in the Whittington Hospital Pharmacy 
Department, which has a private seminar room. There will be two focus groups 
held on separate days. These will be facilitated by Bridget Coleman (Principal 
Pharmacist – Medicines Management) and Ian Man (Lead Pharmacist, 
Anticoagulation). In these groups you will be encouraged to share your views 
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about patient self-monitoring of oral anticoagulation, particularly how we could 
support patients who are self-monitoring, and any barriers to establishing this 
service.  
 
The focus group meeting will last for about 45 minutes. Bridget Coleman will 
facilitate this discussion using a topic guide. But it is important that you express 
whatever views you wish and for the discussion to follow your ideas. Ian Man 
will take written notes on the discussion. With your permission, the discussion 
will also be audiotaped.  
 
At a later stage, Bridget Coleman will transcribe the audiotaped discussion onto a 
paper document. This will then be analysed to pick out themes in the discussion 
which were important to you. 
 
Expenses & payments 
 
As this research is not being funded we will not be able to offer you any payment 
for participating. However, we will provide light refreshments. 
 
 
Do I have to take part? 
 
No. It is entirely up to you whether or not to take part. Things that you say during 
the interview may be quoted in reports, publications or presentations arising from 
this research. However, all quotations will be anonymous. 
 
What do I have to do? 
 
If you decide to take part, simply notify Bridget Coleman by telephone, email or 
post. You will then be contacted with the dates of the focus groups and be sent a 
consent form to read. 
 
What are the possible disadvantages and risks in taking part in this study? 
 
There are no risks to you taking part in this study. The only disadvantage is the 
time it will take you to attend the focus group meeting and to answer any 
subsequent questions. 
 
What are the possible benefits of taking part? 
 
The information that we get from this study may help us to develop the 
anticoagulation monitoring service. You will have a direct input into this process. 
Also, you may learn a little bit more about anticoagulation patient self-
monitoring, and you will hear the views of colleagues. 
 
What happens when the research study stops? 
 
If we come across any points that we do not understand when we are analysing 
the results, we may need to contact you for clarification. Also, once the analysis 
is complete, we may need to get your views on the results. 
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What if there is a problem? 
 
If you have any concerns about the study, or any complaint about the way that 
you have been dealt with during the study, you should speak to Bridget Coleman 
on tel: 020 7288 5672, or Dr David Patterson on tel:  020 7288 5310   who will 
try to deal with your concerns.  If you remain unhappy, you can complain 
formally through the NHS Complaints Procedure. Details are available from the 
Whittington Hospital Patient Advocacy & Liaison Service (PALS) on tel: 020 
7288 5784 
 
Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of this research will 
be kept strictly confidential. Any information about your views that leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  
 
What will happen to the results of the research study? 
 
The results will be included in a dissertation to be written by Bridget Coleman 
for an MPhil / PhD in Health Informatics with the Centre for Health Informatics 
& Multiprofessional Education (CHIME) at University College London. It is 
hoped to present the results at relevant local, national and international meetings 
and to submit a written report for publication in medical or health informatics 
journals.  
 
But ultimately, it is hoped that the results of the study will help us to develop our 
anticoagulation service. 
 
Who is organising and funding this study? 
 
This study is being organised by Bridget Coleman (Pharmacy Department & 
Anticoagulant Clinic, Whittington Hospital), in collaboration with Jeannette 
Murphy (CHIME, University College London). This study is not being 
financially sponsored. 
 
 
Who has reviewed the study? 
 
The Moorfields & Whittington Research Ethics Committee Hospital has 
reviewed this study. 
 
Contact for further information 
 
If you would like any further information please contact Ian Man, Lead 
Pharmacist - Anticoagulation on tel: 020 7288 3516  
 
 
Thank you for reading this sheet 
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APPENDIX 10: EXPLORING THE VIEWS OF 
HEALTHCARE PROFESSIONALS – ETHICAL 
APPROVAL LETTER 
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APPENDIX 11: EXPLORING THE VIEWS OF 
HEALTHCARE PROFESSIONALS – FOCUS GROUP 
TOPIC GUIDE 
 
 
 
 
 
FOCUS GROUP GUIDE 
 
 
THE PURPOSE OF THIS STUDY 
 
Welcome to everyone and thank you for coming. Introductions. 
 
The aim of this group discussion is for you to share your views on patient self-
monitoring of oral anticoagulation. But I would like you to talk more amongst 
yourselves about this than to me. 
 
We would like to audiotape the conversation if that’s OK with you. Ian will take 
some notes in case we need to clarify any points on the tape later that we do not 
understand. 
 
Just a few ground rules before we get started; minimise side conversations; one 
person at a time. Most importantly, it is important that you give us your honest 
views about this. 
 
To start, I am giving you an information sheet about warfarin self-monitoring 
and I would like you to spend a few minutes to read this. Then we will get 
started, firstly going around the group to allow everyone to introduce themselves.  
 
A. YOUR OWN EXPERIENCES OF WARFARIN SELF-TESTING 
 
Firstly, I would like to know about your experience of patients self-testing their 
INR. 
 
1. Have you ever been approached by patients who wish to self-test?  
 
2. Have you supported patients in self-testing their INR? 
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B. THE PATIENT’S VIEW 
 
3. For patient self-testing or self-management to be successful, patient buy-in is 
essential. Do you think our patient population are ready to do this? 
 
Prompts 
What proportion of our patient population would you guess be interested in self-
testing? (50%) 
What proportion of our patient population do you think feel they would be able to 
test their own INR? (57%) 
What proportion of our patient population do you think would be able to buy a 
coagulometer? (16%) 
What proportion of our patient population do you think would be able to adjust 
their dose of warfarin? (53%) 
What proportion of our patient population would you guess be interested in self-
managing their warfarin? (50%) 
 
C. YOUR VIEWS ON SELECTING PATIENTS FOR SELF-TESTING 
 
As yet, there are no clearly defined selection criteria for self-testing and self-
management of oral anticoagulation. It would be useful to get your thoughts on 
which patients would be suitable or unsuitable for this method of management. 
 
4. Which types of warfarin patients do you think would most benefit from self-
testing? 
 
Prompts 
Exclusion criteria? 
Different criteria for self-management 
 
D. SUPPORTING THE SELF-TESTING PATIENT 
 
There are a number of potential ways that we could support patients who are self-
testing and I would like to get your thoughts on this. 
 
5. How do you think we could support patients who would like to self-test their 
warfarin? 
 
Prompts 
Providing more information / education about Warfarin (78%) 
Making it easy for patients to contact the clinic if they have any concerns (82%) 
Providing the coagulometer (76%) 
Checking up on patients regularly (81%) 
 
There is no standardisation of education for anticoagulated patients, including 
those willing to undertake self-monitoring of OAT. Hence, it would be useful to 
obtain your views on what educational support should be given to those self-
testing. 
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6. What should patients be able to demonstrate they know, or can do, before they 
self-test? 
 
Prompts: 
How to take a good finger-prick blood sample 
How to use the coagulometer 
How warfarin works 
Side effects of warfarin  
How warfarin interacts with other medicines 
How to deal with bleeding 
How to manage the diet whilst on warfarin 
 
7. Do you think there would be any additional training requirements to prepare 
the person to self-manage? 
 
Prompts 
How to work out why the INR is too high or too low 
How to adjust the dose of warfarin if the INR is too high or too low 
 
 
E. SHARING RESPONSIBILITY WITH THE PATIENT 
 
If we were to support self-testing, this would result in more collaborative 
working with patients. This, in turn, may lead to a redefining of respective roles 
and responsibilities, and I would find it useful to get your views on this.  
 
8. Do you think the relationship between healthcare professional and patient will 
alter once the patient is self-testing? If yes, how? 
 
 
9. If a patient was to self-test how do you see responsibilities shared between the 
healthcare professional and patient? 
 
For any service development, it is important to have robust clinical governance 
arrangements. However, from a medico-legal viewpoint it is not clear where 
accountability rests when a person is self-testing. 
 
10. What do you consider to be the main risks associated with a self-testing 
service? 
 
 
11. How could we reduce these risks? 
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F. BARRIERS TO IMPLEMENTING SELF-TESTING 
 
Published trials suggest that patients may be reluctant to self-test their INR, with 
reported low participation rates and high attrition rates. The reasons behind a 
reluctance to participate in these trials are unclear. Therefore, I thought it would 
be useful to get your thoughts on potential barriers to implementing a self-testing 
service. 
 
12. What do you feel are the main barriers to developing a self-testing service? 
 
Prompts:  
Patient engagement 
Cost of coagulometer 
Cost of self-testing 
Loss of revenue for the Trust 
Liability concerns 
Attitude of clinicians 
PCT commissioning 
 
13. How can we overcome these barriers?  
 
G. SUMMING UP 
 
 
14. Finally, would you be happy for warfarin self-testing or self-management to 
be introduced at the Whittington? 
 
I would like to thank you all for going along today and for giving your valuable 
time and views. I hope that you have enjoyed taking part. If there are any points 
we need to clarify we may contact you again. We may also send a copy of our 
discussion to some of you, and will ask you to correct any of the points you feel 
we may have got wrong. 
 
Thanks once again 
 
 
419  
 
APPENDIX 12: EXPLORING THE VIEWS OF 
HEALTHCARE PROFESSIONALS – FOCUS GROUP 
INFORMATION SHEET 
 
Wafarin self-monitoring 
 
How is the INR tested at home? 
The patient places a testing strip in a small, handheld machine (the 
coagulometer). Then they prick their finger and place a small drop of blood onto 
the strip. The coagulometer will then tell them what their INR is within a couple 
of minutes. Currently, there are two coagulometers suitable for use by patients; 
the CoaguChek™ XS by Roche Diagnostics and the INRatio by Sysmex. Here 
are pictures of these machines: 
 
  
CoaguChek™ XS                                                                                           INratio 
 
What is warfarin self-testing? 
Warfarin self-testing is when the patient tests their INR at home, but then 
contacts the anticoagulant clinic to adjust their dose of warfarin. 
 
How often would the patient need to test their INR?           
The clinic staff will advise the patient on when they should test their INR. 
 
What would happen if the patient has problems with measuring their INR? 
In these circumstances they would contact the anticoagulant clinic for advice 
 
What is warfarin self-management? 
Warfarin self-management is when the patient tests their INR at home, and then 
adjusts their own warfarin dosage within limits set by the anticoagulant clinic. 
 
What would happen if the patient’s INR was very high or very low, or if 
they had any problems with adjusting their warfarin dose? 
In these circumstances the patient would contact the anticoagulant clinic for 
advice 
 
Is self-monitoring a safe way of managing warfarin treatment? 
Clinical studies have shown that people who monitor their own warfarin therapy 
are at the correct INR at least as often as those who have their blood tested in an 
anticoagulant clinic. 
 
Are the testing strips available on prescription? 
Yes 
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Are these machines available on prescription? 
No. The patient would need to buy them. 
 
How much do these machines cost? 
Both of these machines cost £399. 
 
How accurate are these machines? 
Both of these machines have been passed by the regulatory authorities in the UK. 
We use the CoaguChek™ machine in our GP and community pharmacy clinics. 
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APPENDIX 13: PATIENT SELF-TESTING PILOT – 
SHARED-CARE AGREEMENT BETWEEN 
ANTICOAGULANT CLINIC AND PATIENT 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical, Academic Department  
of Cardiovascular Medicine  < 
& Pharmacy Department  
 
 
 
 
 
 
 
 
 
 
 
 
 
This is an agreement for self testing between The Whittington Hospital 
NHS Trust and: 
 
Patient Details: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anticoagulation Clinic & Patient Agreement 
 
Agreement for the Use of a CoaguChek™® Machine for Self-Testing INR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<Enter patient details here> 
 
 
 
<Enter GP details here> 
Anticoagulant Clinic 
Magdala Avenue, London N19 
5NF 
 
Appointments / Advice and 
Information: 0207 288 3228 
Fax: 0207 288 5010 
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Patient Anticoagulation History: 
 
 
Indication of Anticoagulation: 
 
 
 
Target INR range: 
 
 
 
Type of Anticoagulant/strength: 
 
 
 
Start date of Anticoagulation: 
 
 
 
Start date of self testing: 
 
 
 
 
 
If self testing; the patient is responsible for testing his/her INR. The 
patient is not responsible for dosing. The dosing remains the 
responsibility of the Anticoagulation Clinic. 
 
 
Patient Self-Testing Agreement 
 
Patient Training Record 
 
 
 
 
Patient Name:        
 
 
Trainer Name:        
 
 
 
The training session is being carried out to ensure the correct use of the 
CoaguChek™ monitoring device. Please check off boxes to confirm the 
following information has been given, and sign to confirm this: 
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I confirm that I have received the information on the above criteria from 
the above named trainer. I confirm that I should still read the user manual 
accompanying my CoaguChek™® XS device in conjunction with this 
training. If I require any further technical information I will ring the 
technical support helpline, or refer back to my Anticoagulation 
pharmacist/nurse specialist at the Whittington Hospital NHS Trust.  
 
Date:       
 
Patient Sign:       
  
Trainer Sign:       
Criteria 9
Obtaining a Finger Prick Sample 
Hand washing 
Sites for taking a sample 
Time limits 
Sampling problems 
Recording Results
Anticoagulation Record 
Memory 
Retrieving saved results 
Maintenance & Troubleshooting 
Cleaning meter 
Common error codes 
Technical support 
CoaguChek™ Patient 
 
Care Line: 
 
0808 100 7666 
Criteria 9
Meter Set Up 
Display check 
Date Format 
Date Setting 
Time Format 
Time Setting 
Set Test Measurement 
Beep Tone 
Therapeutic Range 
CoaguChek™ XS Test 
Storage conditions  
Handling test strip  
Calibration Code Chip  
Changing Code Chip  
Onboard Quality Control  
Sample dosing area  
Criteria 9
 Performing a Test
Switch meter on 
Checking screen 
Insertion of test strip 
Confirm code lot number 
Strip warming
Operation lancet  
Device components 
Removal of protective cap 
Priming device 
Depth setting 
Firing lancet 
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Patient Self-Testing Agreement 
Patient Responsibilities 
 
 
 
 
1. I have a CoaguChek™® monitor. To ensure my own safety I agree to 
work in partnership with Whittington Hospitals NHS trust 
Anticoagulation Clinic.  
 
2. I have been trained in the use of the CoaguChek™® XS meter. 
 
3. I will perform INR tests at mutually agreed intervals and will inform the 
Anticoagulation Clinic of the results via the dedicated answer machine 
before 1 pm on the day of testing. I will leave my name; date of birth, 
hospital/NHS number, contact number and INR result on the answer 
machine. 
 
4. I will repeat any test if my INR is less than 1.5 or greater than 5. 
 
5. If my INR is less than 1.8 and I have a mechanical heart valve I will 
contact an anticoagulation pharmacist/nurse specialist via the 
dedicated telephone lines for advice. 
 
6. If my INR is greater than 8 or un-recordable I will inform an 
anticoagulation pharmacist/nurse specialist immediately via the 
dedicated telephone lines. 
 
7. I will act on the advice given by the anticoagulation pharmacist/nurse 
specialist with regard to dosages and test interval. I understand that 
the maximum permitted interval for testing is 12 weeks. 
 
8. I understand that it is my responsibility to order supplies of test strips 
and finger prick lancets from the manufacturer or obtain them from 
clinic, as appropriate. Maintenance of the machine is also my 
responsibility. 
 
9. I will dispose of used lancets, other sharps and contaminated waste 
carefully. 
 
10. I will inform the anticoagulation pharmacist/nurse specialist if starting 
new medications (conventional and unconventional), before and after 
dental and surgical procedures, changes in 
medications/diet/alcohol/herbal remedies, missed doses, recent 
hospital admissions, if unwell/diarrhoea and vomiting. 
 
11. If I do experience any unexplained or excessive bleeding or bruising I 
will contact the Anticoagulation Clinic for advice. 
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12. I will attend the Anticoagulation Clinic for follow up appointments 
every 6 months or sooner if the Anticoagulation Clinic requires. At all 
appointment I will bring my CoaguChek™® machine and test strips 
currently in use, for a comparative venous blood sample. 
 
13. I will inform the Anticoagulation Clinic if I intend to travel abroad and 
self-test. 
 
14. I will inform the Anticoagulation Clinic if I decide to stop self-testing or 
move house to a different area so that arrangements can be made for 
alternative management of my treatment. 
 
15. I will return the CoaguChek™® XS machine back to the clinic once the 
programme is complete. 
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CoaguChek™ Agreement 
  
Anticoagulation Clinic Responsibilities 
 
 
 
1. The Anticoagulation Clinic agrees to support the above named patient 
with his / her self-testing provided that the conditions listed above are 
met.  
 
2. The Anticoagulation pharmacist/nurse specialist will be available 
during normal office hours for help and advice. 
 
3. After the patient has contacted the Anticoagulation Clinic with a result, 
advice on dosing will be given the same day. The patient will be only 
contacted by telephone if there is a dosage change within the next 
three days. This advice will also be confirmed with a single sheet 
therapy record. This will be posted first class to the patient the same 
day and should arrive within 3 working days.  
 
4. The Anticoagulation Clinic will provide an external quality control by 
comparative testing of patient’s capillary blood INR by the patients 
own CoaguChek™® meter and the Anticoagulation Clinic method 
(Venous testing). Patients will be sent an appointment for review 
every 6 months. 
 
5. In the event that conditions are not met; the Anticoagulation Clinic will 
offer the patient a normal clinic service without any regard to self-
testing. 
 
6. The Anticoagulation Clinic will inform the patient’s General Practitioner 
of his/her intentions to start self-testing, stop self-testing or of any 
failure to comply with this agreement. 
 
7. The patient has received appropriate training and has been supplied 
with a CoaguChek™® patient pack. 
 
Contact Telephone Numbers:-  
 
CoaguChek™® (Roche™) patient care line 
0808 100 7666 
 
 
For the Anticoagulation Clinic:- 
020 7288 3228  
 
(Please leave messages on the answer machine before 1pm on weekdays only) 
Anticoagulation Clinic Working Hours: Monday to Thursday 9am – 5:30pm 
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The patient detailed has received the appropriate training and a copy of 
the agreement for self-testing their INR using a CoaguChek™® XS 
monitor. The patient agrees to abide by this agreement. 
 
 
 
Signed on behalf of the Anticoagulation Clinic: 
 
 
Print Name & Sign:        
 
Date:        
 
 
 
 
I have read and understand the self-testing agreement outlined above 
and agree to abide by the terms set out by the Anticoagulation Clinic. I 
understand that if I fail to comply with the above the Anticoagulation Clinic 
cannot support me with self-testing. 
 
 
 
Patient Signature: 
 
 
Print Name & Sign:        
 
Date:        
 
 
 
 
 
 
 
 
 
Anticoagulation Clinic & Patient Agreement 
 
Signatures 
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Patient Self-Testing Agreement 
 
Record of Initial Training & month 6 Reviews 
 
 
 
Review 
Date 
 
Capillary 
INR 
(Patients own 
machine) 
Venous 
INR 
Comments/Issues 
Identified 
Training 
1 
   
 
Training 
2 
   
 
6 month 
review 
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APPENDIX 14: PATIENT SELF-TESTING PILOT – 
INVITATION LETTER AND INFORMATION SHEET 
 
 
 
Dear Mr/Mrs/Miss………………… 
 
 
As part of an ongoing commitment to improving the quality of care we offer, 
the Whittington Hospital Anticoagulation Clinic is developing a new patient 
self-testing service.  This is where those taking warfarin can test their 
International Normalised Ratio (INR) using a machine that they have at 
home instead of attending the hospital for blood tests.  The INR is 
measured by inserting a test strip into the monitoring device, and then 
pricking a finger and putting a small drop of blood on the strip. Staff in clinic 
will advise on the dose of warfarin.  
 
Several studies have shown that this type of anticoagulation monitoring is 
as safe and effective as attending hospitals for INR tests. It also gives more 
flexibility to patients who find it inconvenient to attend the hospital regularly 
for blood tests. Other hospitals that already provide this service include 
Barts and The London NHS Trust, University College London Hospitals 
NHS Trust and the North Middlesex Hospital NHS Trust.   
 
To ensure that we are supporting patient self-testing in the best possible 
way, we are only opening this up small group of people in the first instance, 
and we would like to invite you to take part. As a first step, we will compare 
your INR using the patient-self-testing machine against our hospital INR 
testing machine to ensure that the results are similar. We will then provide 
full training on obtaining a finger-prick blood sample and on using the  
patient self testing machine. If you already own a self-testing machine, we 
may ask you to demonstrate that you can use it before you can self-test. 
We will provide information, and answer any questions that you may have 
about this service and how we will support you.  
 
Clinical & Academic 
Department  
 
 
Anticoagulant Clinic 
Magdala Avenue, London N19 5NF 
 
Appointments: 0207 288 3516  
Advice and Information: 0207 288 
5390 
Fax: 0207 288 5010 
 
e-mail: pst@whittington.nhs.uk
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Following this training, you may start to test your INR at home with support 
from the anticoagulation clinic.  
 
We would like to invite you to take part in this project which will last for 
approximately six months initially.  But before you decide whether you 
would like to participate or not, please could you take a look at the enclosed 
information sheet. Once you have done this, please could you complete the 
attached form and return it to us with your decision as soon as possible so 
that training dates and times can be arranged for all participants. We look 
forward to hearing from you.  
   
 
Best wishes, 
 
 
 
The Anticoagulation Team 
Professor David Patterson (Clinical Director) 
Bridget Coleman, Sister Choi, Faiza Abdow, Sarah Davis,  
 
 
 
 
Registration form for Warfarin Self-Monitoring program starting in 
early 2010 
 
 
 
Please complete this form and send it to the following address: 
 
Anticoagulation Clinic - Clinic 3A Outpatients Block 
Whittington Hospital 
Magdala Avenue 
London 
N19 5NF 
 
 
 
 
 
 
Full Name:   ……………………………………………………………… 
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I have read and understood the information in the letter attached.  I 
understand that self monitoring my own INR increases my responsibilities 
as a patient and that the anticoagulation clinic will continue to be involved in 
monitoring my warfarin.  Please tick one of the following options. 
 
□    I would like to participate in the program and am willing to undertake 
the training involved. 
 
□   I do not wish to participate in this program. 
 
 
Please add any additional comments if you would like 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please sign and date in the box below.  
 
 
Signature: Date: 
 
 
 
 
432  
 
INFORMATION SHEET 
 
 Who will provide the monitoring equipment? 
If you do not have a self-testing machine at home already, the hospital will 
provide one for you with enough supporting equipment for six months. 
However, we cannot guarantee that you will be able to keep this machine 
after this six-month time period. Although the Whittington will not be able to 
supply test strips after the six month project is over, these strips can usually 
be obtained on prescription; but you will need to discuss this with your GP. 
 
What if I already have a self-testing machine? 
If you already have a self-testing machine, you need to obtain test strips 
and other materials from your normal source. This may be from your GP or 
purchasing them privately. You will use your own machine.  
 
Who will advise me about what dosage to take and when I should next 
monitor my INR? 
Experienced anticoagulation clinic staff who are pharmacists, nurses or 
doctors, will continue to give you advice about how much warfarin to take 
and when to measure your next INR. However it will be your responsibility 
to inform us of your results when you measure your INR. This can be over 
the phone or via email. All changes in dosage should be discussed with a 
member of anticoagulation staff.  
 
How will I record my INRs? 
You will be required to keep a record of each INR that you self test in your 
yellow book and your current dosage. You will also be expected to 
communicate your results to the anticoagulation clinic via email or 
telephone.  
 
What will happen at the end of the six months? 
It is likely that the anticoagulation clinic will be able to continue to support 
you self monitoring your INRs at the end of the six month period.  However 
at the moment, we cannot guarantee that we will be able to do this. 
 
Will I need to continue visiting the hospital clinic for anticoagulation 
monitoring? 
You will still need to attend the hospital at the beginning and at the end of 
the six month period to compare your INR taken using your own machine 
against the hospital INR testing machine for quality control purposes. If 
during the six month period you do have a very high INR or an unreadable 
result, we suggest that you contact the anticoagulation clinic during working 
hours, or attend a hospital as soon as possible if this occurs outside of 
anticoagulation clinic hours. 
 
Will I need to give any feedback? 
As this is a new service for the hospital, we will be very keen to hear about 
your experiences and may ask you to fill out questionnaires or keep a diary 
so that we can make any necessary changes based on your views.  
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Will my GP be informed if I decide to take part in this service? 
Your GP will be informed that you have been invited to participate in this 
service.  
 
What happens if I decide that I do not want to continue to take part, or 
I have a problem using the self-testing machine? 
You can choose not to participate at any time and your normal 
anticoagulation clinic will resume responsibility for testing and monitoring 
your INR. If you have any problem using the self-testing machine, the 
anticoagulation clinic will try and help you to resolve it or will ask you to take 
a blood sample at the hospital. 
 
When will this start? 
The exact date has not been confirmed yet, but it is expected to start in 
early 2010 
 
Where do I get more information? 
If you would like to have more information about self-monitoring of warfarin 
before you decide whether or not to take part, please visit 
www.anticoagulationeurope.org if you have internet access, or contact the 
anticoagulation clinic on 0207 2885390 and ask to speak to Faiza Abdow or 
Sarah Davis. Alternatively you can email us on pst@whittington.nhs.uk. 
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APPENDIX 15: PATIENT SELF-TESTING PILOT –  
PRE-PILOT PATIENT QUESTIONNAIRE AND 
COVERING 
LETTER 
 
 
 
 
 
 
WHITTINGTON HOSPITAL 
ANTICOAGULATION MONITORING AND 
STROKE PREVENTION SERVICE 
 
 
 
 
HELPING US TO DEVELOP YOUR ANTICOAGULANT SERVICE 
 
 
 
PATIENT SELF-TESTING 
 
 
 
 
 
IMPORTANT: Your answers to these questions will remain 
confidential 
 
 
 
 
Please answer the questions as completely as possible. There are no 
right or wrong answers. We are interested only in your personal 
views, so please tell us what you feel and not what you think we may 
want to hear. 
 
 
 
Bridget Coleman, BSc, MSc, MRPharmS  
Senior Pharmacist, Anticoagulation & Stroke Prevention Service, Whittington 
Hospital  
April 2010 
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YOUR DETAILS 
 
 
Your name 
 
  
   
Date of training 
 
  
 
 
SECTION B: ABOUT SELF-TESTING YOUR INR 
 
JOINING THE PILOT 
 
 
1. Where did you first hear about patient self-testing? 
 
 
 
 
2. Why were you interested in self-testing? 
 
 
 
 
 
 
 
3. Were there any factors that made you take part in this pilot? (e.g. loan 
machine, education, support) 
 
 
 
 
 
 
4. On a scale of 1 to 5, how much difficulty did you have in reaching a decision 
to take part in this pilot; 1 = no difficulty and 5 = a lot of internal debate? 
 
 
 
 
 
5. Is your GP happy for you to self-test? 
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THE BENEFITS OF SELF-TESTING 
 
6. At this stage, what benefits do you think you will get from self-testing your 
INR? 
 
 
 
 
 
 
 
 
CONCERNS ABOUT SELF-TESTING 
 
 
7. At this stage, do you have any concerns or anxieties about self-testing? 
 
 
 
 
 
 
 
 
 
 
8. On a scale of 1 to 5, how likely are you to purchase a coagulometer once this 
pilot has ended; 1 = very unlikely and 5 = very likely? 
 
 
 
 
SUPPORTING SELF-TESTING 
 
9. What education do you expect to receive before undertaking self-testing? 
 
 
 
 
 
 
 
10. What support do you expect to receive from the clinic staff whilst you are 
self-testing? 
 
 
 
 
 
Thank you for answering these questions!
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April 2010 
 
 
 
The patient self-testing service pilot 
 
 
 
Thank you for taking part in this pilot scheme. 
 
In order to find out how we can best support patient self-testing, I would like to 
ask you a few questions. As one of those participating in the pilot scheme, your 
views are important. But if you do not wish to answer these questions, you do not 
need to give a reason and the care you receive from us will not be affected.  
 
Thank you for your time 
 
 
 
 
 
 
 
 
 
 
Bridget Coleman, BSc, MSc, MRPharmS  
Senior Pharmacist, Anticoagulation Monitoring & Stroke Prevention Service, 
Whittington Hospital 
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APPENDIX 16: PATIENT SELF-TESTING PILOT –  
POST-PILOT PATIENT QUESTIONNAIRE AND 
COVERING LETTER 
 
 
 
WHITTINGTON HOSPITAL 
ANTICOAGULATION MONITORING AND 
STROKE PREVENTION SERVICE 
 
 
 
 
HELPING US TO DEVELOP YOUR ANTICOAGULANT SERVICE 
 
 
 
PATIENT SELF-TESTING 
 
 
 
 
 
IMPORTANT: Your answers to these questions will remain 
confidential 
 
 
 
 
Please answer the questions as completely as possible. There are no 
right or wrong answers. We are interested only in your personal 
views, so please tell us what you feel and not what you think we may 
want to hear. 
 
 
 
 
 
 
Bridget Coleman, BSc, MSc, MRPharmS  
Senior Pharmacist, Anticoagulation & Stroke Prevention Service, Whittington 
Hospital  
February 2011 
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YOUR DETAILS 
 
 
Your name 
 
  
   
Date  
 
  
 
 
SECTION B: ABOUT SELF-TESTING YOUR INR 
 
1. YOUR EXPERIENCES DURING THE PILOT 
 
 
1. On a scale of 1 to 5, how would you rate your experience of self-testing your 
INR; 1 = very positive and 5 = very negative? 
 
 
2. What benefits (if any) do you think you have got from self-testing your INR? 
 
 
 
 
 
 
 
3. Were there any benefits that you thought that you would get from self-testing 
but didn’t happen? 
 
 
 
 
 
 
 
4. What difficulties did you have (if any) with self-testing your INR? 
 
 
 
 
 
 
 
2. SUPPORTING SELF-TESTING 
 
5. Should we consider any changes to the education you received before you 
started self-testing? 
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6. Should we consider any changes to how the clinic staff support you whilst you 
are self-testing? 
 
 
 
 
 
 
 
3. CONTINUING SELF-TESTING 
 
7. Would you like to continue with self-testing after this pilot? 
 
 
8. Are there any specific reasons why you wish to continue / discontinue self-
testing? 
 
 
 
 
 
 
 
9. On a scale of 1 to 5, how willing are you to purchase a coagulometer (cost = 
£399) now that this pilot has ended; 1 = very willing and 5 = very unwilling? 
 
 
10. On a scale of 1 to 5, how able are you to purchase a coagulometer now that 
this pilot has ended; 1 = very able and 5 = completely unable? 
 
 
4. FINAL THOUGHTS 
 
11. Would you recommend self-testing to a friend if he / she was taking 
warfarin? 
 
 
 
12. What reason would you give to your friend for doing self-testing / not doing 
self-testing 
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February 2011 
 
 
 
The patient self-testing service pilot 
 
 
 
Thank you for taking part in this pilot scheme. 
 
It is important for us to learn from your experiences, and I would like to ask you 
a few questions. As one of those participating in the pilot scheme, your views are 
important. But if you do not wish to answer these questions, you do not need to 
give a reason and the care you receive from us will not be affected.  
 
Thank you for your time 
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APPENDIX 17: PATIENT SELF-TESTING PILOT –  
ANTICOAGULANT CLINIC STAFF INTERVIEW 
GUIDE 
 
 
Introduction 
 
Thank you 
 
Purpose = to gauge your level of agreement with the views expressed at the focus group 
meeting, based on your experiences with the PST pilot, and to try to address questions 
posed at this meeting 
 
Section 1: Perceived problems, barriers & risks 
 
1. Shared care with patients – much discussion about this. Questions raised … 
 
Are Pts honest, reliable? If self-test will they lie, misreport results? 
 
Danger of  PST patients not viewing condition seriously? 
 
Must pt take some ownership? How enforce this? Get pt to sign disclaimer? Or use 
consent form 
 
Compliance with testing – a view that the patient needs to agree to certain conditions 
before being admitted to programme  
 
2. Shared responsibility between primary / secondary care 
 
PCT reps felt that clarity on governance arrangements and relative responsibilitities 
needed before they sigend up to this 
 
Must have agreed protocols between PCT and hospital re pt transfer 
 
3. Loss of "value-added" service through reduced contact between professional & 
patients 
 
OAT monitoring not just dose adjustment - lose other elements? 
 
4. Logistical problems from service perspective 
 
Is it possible to scale up from 50 pt to 1,00 or 1,500? Fear of repatriating patients back 
into service 
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Section 2: Service Redesign 
 
5. Options appraisal 
 
One step vs 2 step (from hospital to self testing or hospital to community and then to self 
testing) 
 
Perhaps should not be thinking in first instance in whole sale migration to self-testing. 
Concentrate firstly on moving pts to primary care 
 
Patient networks - share machines. Pt self-help groups – get together, help one another 
with testing; share machines – but would not suit all patients – perhaps best for retirees’ 
 
6. Personnel  
 
Staffing levels / expertise / staff mix 
 
Section 3: Service requirements 
 
7. Patient selection 
 
Initially, do not exclude anyone – rationale – need to see who can/cannot cope – so want 
as broad a group as possible. 
 
Debate: whether pts with poor control should be excluded 
 
8. Evaluation of patient competence 
 
One view – must assess each pt – risk assessment 
 
Yearly or twice yearly re-evaluation of pts (requirement); maybe retraining – part of 
contract (but increases cost) 
 
9. Communication channels 
 
eg phone helpline (?eventually done on line) – could this be automated ? use text 
messaging – answer questions, take readings, give advice on adjusting dose; tell patient 
to see doctor/nurse/pharmacist – complex record keeping system needed – chase up pts – 
need know when to call – what do if cannot track down pt 
 
Must be able to accommodate pts moving back and forth between 
venues/providers/programmes. Eg most may start with hospital – once stable move to 
primary care and then to self-testing 
 
10. Draft strategy / policy 
 
Need to have policy (?local, national) before demand grows – need to know in principle 
whether affordable, scalable. Counter view – could prove a waste of time, resources.  
 
12. Equity 
 
How does one deal with potential inequity of service? 
 
 
